2010

AMERICAN EPILEPSY SOCIETY

64TH ANNUAL MEETING

3rd Biennial North American Regional Epilepsy Congress

SAN ANTONIO, TX

HENRY B. GONZALEZ CONVENTION CENTER

December 3-7, 2010

2010 Annual Meeting

AES2010

DECEMBER 3-7, 2010 ▪ SAN ANTONIO, TX

★ 64TH ANNUAL MEETING ★

AMERICAN EPILEPSY SOCIETY

3rd Biennial North American Regional Epilepsy Congress

PROGRAM BOOK

Learn more at
Booth #501

For the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 4 years and older

Add Powerful Seizure Control To the Lives of Patients with LGS

Powerful efficacy in patients with LGS

In patients inadequately controlled with 1–3 AEDs*:

- 42.5% reduction in tonic-atonic seizures with BANZEL® vs 1.4% increase with placebo ($P<0.0001$)†[1,2]
- 32.7% reduction in total seizures with BANZEL vs 11.7% reduction with placebo ($P<0.002$)†[1,2]
- ≥50% responder rate in tonic-atonic seizures was significantly higher with BANZEL vs placebo (42.5% of patients vs 16.7% of patients, respectively; $P = 0.002$)†[2]
- ≥50% responder rate in total seizures was significantly higher with BANZEL vs placebo (31.1% of patients vs 10.9% of patients, respectively; $P<0.005$)†[2]
- Titration to a maximum dose can be as rapid as 1–2 weeks[1]
- There are risks associated with BANZEL; adverse events seen in clinical trials were mostly mild to moderate and transient[1]

Important Safety Information

- BANZEL is contraindicated in patients with Familial Short QT syndrome.
- AEDs increase the risk of suicidal thoughts or behavior in patients. Patients, their caregivers, and families should be informed of the risk and advised to monitor and report any emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior, or thoughts of self-harm. If these symptoms occur, consider if it may be related to the AED or illness because epilepsy itself can increase these risks.
- Use of BANZEL has been associated with central nervous system–related adverse reactions, such as somnolence or fatigue, coordination abnormalities, dizziness, gait disturbances, and ataxia.
- Formal cardiac ECG studies demonstrated shortening of the QT interval (up to 20 msec) with BANZEL. Caution should be used when administering BANZEL with other drugs that shorten the QT interval.
- Multi-organ hypersensitivity syndrome has been reported in association with BANZEL therapy. In clinical trials, hypersensitivity reactions occurred in children less than 12 years of age and within 4 weeks of starting BANZEL therapy. If this reaction is suspected, BANZEL should be discontinued and alternative treatment started. All patients who develop a rash while taking BANZEL must be closely supervised.
- As with all AEDs, BANZEL should be gradually withdrawn to minimize the risk of increased seizure frequency.
- In all patients with epilepsy treated in double-blind, adjunctive therapy studies, the most commonly observed (10%) adverse reactions with BANZEL vs placebo, respectively, were headache (25% vs 20%), dizziness (17% vs 10%), fatigue (15% vs 9%), somnolence (13% vs 9%), and nausea (11% vs 7%).

Please see the brief summary of Prescribing Information on the following pages.

*AEDs = antiepileptic drugs.
†Results of a 12-week, randomized, double-blind, multicenter, placebo-controlled, parallel-group trial to assess the effectiveness of BANZEL to reduce inadequately controlled seizures associated with LGS in patients (N = 138, intent to treat) being treated with 1–3 concomitant stable-dose AEDs.

References: 1. BANZEL® [package insert]. Woodcliff Lake, NJ: Eisai Inc; 2008. **2.** Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. *Neurology*. 2008;70:1950-1958.

BANZEL® (rufinamide) 200, 400 mg TABLETS
Power. Control. Hope.™

Visit www.BANZEL.com

BANZEL®
(rufinamide) 200, 400 mg TABLETS

Brief Summary of full Prescribing Information: Please consult package insert for full Prescribing Information.

INDICATIONS AND USAGE

BANZEL (rufinamide) is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.

CONTRAINDICATIONS

BANZEL is contraindicated in patients with Familial Short QT syndrome (See PRECAUTIONS, QT Shortening).

WARNINGS

Suicidal Behavior and Ideation

Antiepileptic drugs increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any antiepileptic drug for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different antiepileptic drugs showed that patients randomized to one of the antiepileptic drugs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 antiepileptic drug-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on suicide.

The increased risk of suicidal thoughts or behavior was observed as early as one week after starting drug treatment and persisted for at least 24 weeks. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with antiepileptic drugs of varying mechanisms of action and across a range of indications suggests that the risk applies to all antiepileptic drugs used for any indication. The risk did not vary substantially by age in the clinical trials analyzed.

The following table (Table 1) shows absolute and relative risk of suicidal behavior and ideation by indication.

Table 1: Absolute and Relative Risk of Suicidal Behavior and Ideation

Indication	Placebo Patients with Events Per 1000 Patients	Drug Patients with Events Per 1000 Patients	Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients	Risk Difference: Additional Drug Patients with Events Per 1000 Patients
Epilepsy	1.0	3.4	3.5	2.4
Psychiatric	5.7	8.5	1.5	2.9
Other	1.0	1.8	1.9	0.9
Total	2.4	4.3	1.8	1.9

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar.

Anyone considering prescribing BANZEL or any other antiepileptic drug must balance this risk with the risk of untreated illness. Epilepsy and many other illnesses for which antiepileptics are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

Patients, their caregivers, and families should be informed that antiepileptic drugs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

Central Nervous System Reactions:

Use of BANZEL has been associated with central nervous system–related adverse reactions. The most significant of these can be classified into two general categories:

1) somnolence or fatigue, and 2) coordination abnormalities, dizziness, gait disturbances, and ataxia (see ADVERSE REACTIONS).

PRECAUTIONS

QT Shortening

Formal cardiac ECG studies demonstrated shortening of the QT interval (up to 20 msec) with BANZEL treatment. In a placebo-controlled study of the QT interval, a higher percentage of BANZEL-treated subjects (46% at 2400 mg, 46% at 3200 mg, and 65% at 4800 mg) had a QT shortening of greater than 20 msec at T_{max} compared to placebo (5 – 10%).

Reductions of the QT interval below 300 msec were not observed in the formal QT studies with doses up to 7200 mg/day. Moreover, there was no signal for drug-induced sudden death or ventricular arrhythmias.

The degree of QT shortening induced by BANZEL is without any known clinical risk. Familial Short QT syndrome is associated with an increased risk of sudden death and ventricular arrhythmias, particularly ventricular fibrillation. Such events in this syndrome are believed to occur primarily when the corrected QT interval falls below 300 msec. Nonclinical data also indicate that QT shortening is associated with ventricular fibrillation.

Patients with Familial Short QT syndrome should not be treated with BANZEL (see CONTRAINDICATIONS). Caution should be used when administering BANZEL with other drugs that shorten the QT interval.

Multi-organ Hypersensitivity Reactions

Multi-organ hypersensitivity syndrome, a serious condition sometimes induced by antiepileptic drugs, has occurred in association with BANZEL therapy in clinical trials. One patient experienced rash, urticaria, facial edema, fever, elevated eosinophils, stuporous state, and severe hepatitis, beginning on day 29 of BANZEL therapy and extending over a course of 30 days of continued BANZEL therapy with resolution 11 days after discontinuation. Additional possible cases presented with rash and one or more of the following: fever, elevated liver function studies, hematuria, and lymphadenopathy. These cases occurred in children less than 12 years of age, within four weeks of treatment initiation, and were noted to resolve and/or improve upon BANZEL discontinuation. This syndrome has been reported with other anticonvulsants and typically, although not exclusively, presents with fever and rash associated with other organ system involvement. Because this disorder is variable in its expression, other organ system signs and symptoms not noted here may occur. If this reaction is suspected, BANZEL should be discontinued and alternative treatment started.

All patients who develop a rash while taking BANZEL must be closely supervised.

Withdrawal of AEDs

As with all antiepileptic drugs, BANZEL should be withdrawn gradually to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus. If abrupt discontinuation of the drug is medically necessary, the transition to another AED should be made under close medical supervision. In clinical trials, BANZEL discontinuation was achieved by reducing the dose by approximately 25% every two days.

Status Epilepticus

Estimates of the incidence of treatment emergent status epilepticus among patients treated with BANZEL are difficult because standard definitions were not employed. In a controlled Lennox Gastaut syndrome trial, 3 of 74 (4.1 %) BANZEL-treated patients had episodes that could be described as status epilepticus in the BANZEL-treated patients compared with none of the 64 patients in the placebo-treated patients. In all controlled trials that included patients with different epilepsies, 11 of 1240 (0.9%) BANZEL-treated patients had episodes that could be described as status epilepticus compared with none of 635 patients in the placebo-treated patients.

Information for Patients

Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with BANZEL and should counsel them in its appropriate use. A patient Medication Guide is available for BANZEL. The prescriber or healthcare professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have.

Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking BANZEL.

Suicidal Thinking and Behavior – Patients, their caregivers, and families should be informed that antiepileptic drugs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

Patients should be instructed to take BANZEL only as prescribed.

BANZEL should be taken with food.

As with all centrally acting medications, alcohol in combination with BANZEL may cause additive central nervous system effects.

Patients should be advised about the potential for somnolence or dizziness and advised not to drive or operate machinery until they have gained sufficient experience on BANZEL to gauge whether it adversely affects their mental and/or motor performance.

Female patients of childbearing age should be warned that the concurrent use of BANZEL with hormonal contraceptives may render this method of contraception less effective (see Drug Interactions). Additional non-hormonal forms of contraception are recommended when using BANZEL.

Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. Patients should be advised to notify their physician if they are breast-feeding or intend to breast-feed.

Patients should be advised to notify their physician if they experience a rash associated with fever.

Laboratory Tests

Leucopenia (white cell count < $3X10^9$ L) was more commonly observed in BANZEL-treated patients (43 of 1171, 3.7%) than placebo-treated patients (7 of 579, 1.2%) in all controlled trials.

Drug Interactions

In vitro and in vivo studies have shown that BANZEL is unlikely to be involved in significant pharmacokinetic interactions.

BANZEL can increase plasma concentrations of phenytoin by 21% or more due to non-linear pharmacokinetics.

Valproate can increase BANZEL concentrations up to 70%. Patients stabilized on BANZEL before being prescribed valproate should begin valproate therapy at a low dose, and titrate to a clinically effective dose. Similarly, patients on valproate should begin at a BANZEL dose lower than 400 mg.

Coadministration of BANZEL with ethinyl estradiol and norethindrone can decrease $AUC_{0\text{-}24}$ of these hormonal contraceptives by 22% and 14% and C_{max} by 31% and 18%, respectively. Female patients of childbearing age should be warned that the concurrent use of BANZEL with hormonal contraceptives may render this method of contraception less effective. Additional non-hormonal forms of contraception are recommended when using BANZEL (see Information for Patients).

Drug/Laboratory Test Interactions

There are no known interactions of BANZEL with commonly used laboratory tests.

Antiepileptic Drugs

Effects of BANZEL on other AEDs

Population pharmacokinetic analysis of average concentration at steady state of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, and valproate showed that typical rufinamide C_{avss} levels had little effect on the pharmacokinetics of other AEDs. Any effects, when they occur, have been more marked in the pediatric population.

Effects of Other AEDs on BANZEL

Potent cytochrome P450 enzyme inducers, such as carbamazepine, phenytoin, primidone, and phenobarbital appear to increase the clearance of BANZEL. Given that the majority of clearance of BANZEL is via a non-CYP-dependent route, the observed decreases in blood levels seen with carbamazepine, phenytoin, phenobarbital, and primidone are unlikely to be entirely attributable to induction of a P450 enzyme. Other factors explaining this interaction are not understood.

Any effects, where they occurred were likely to be more marked in the pediatric population.

Valproate: Based on a population pharmacokinetic analysis, rufinamide clearance was decreased by valproate. In children, valproate administration may lead to elevated levels of rufinamide by up to 70%. Patients stabilized on BANZEL before being prescribed valproate should begin valproate therapy at a low dose, and titrate to a clinically effective dose. Similarly, patients on valproate should begin at a BANZEL dose lower than 400 mg.

Effects of BANZEL on other Medications

Hormonal contraceptives: Co-administration of BANZEL (800 mg BID for 14 days) and Ortho-Novum 1/35® resulted in a mean decrease in the ethinyl estradiol $AUC_{0\text{-}24}$ of 22% and C_{max} by 31% and norethindrone $AUC_{0\text{-}24}$ by 14% and C_{max} by 18%, respectively. The clinical significance of this decrease is unknown. Female patients of childbearing age should be warned that the concurrent use of BANZEL with hormonal contraceptives may render this method of contraception less effective. Additional non-hormonal forms of contraception are recommended when using BANZEL (see Information for Patients).

Triazolam: Co-administration and pre-treatment with BANZEL (400 mg bid) resulted in a 37% decrease in AUC and a 23% decrease in C_{max} of triazolam, a CYP 3A4 substrate.

Olanzapine: Co-administration and pre-treatment with BANZEL (400mg bid) resulted in no change in AUC and C_{max} of olanzapine, a CYP 1A2 substrate.

Carcinogenicity, Mutagenicity, Impairment of Fertility

Carcinogenicity: Rufinamide was given in the diet to mice at 40, 120, and 400 mg/kg/day and to rats at 20, 60, and 200 mg/kg/day for two years. The doses in mice were associated with plasma AUCs 0.1 to 1 times the human plasma AUC at the maximum recommended human dose (MRHD, 3200 mg/day). Increased incidences of tumors (benign bone tumors (osteomas) and/or hepatocellular adenomas and carcinomas) were observed in mice at all doses. Increased incidences of thyroid follicular adenomas were observed in rats at all but the low dose; the low dose is <0.1 times the MRHD on a mg/m^2 basis.

Mutagenicity: Rufinamide was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay or the in vitro mammalian cell point mutation assay. Rufinamide was not clastogenic in the in vitro mammalian cell chromosomal aberration assay or the in vivo rat bone marrow micronucleus assay.

Impairment of Fertility: Oral administration of rufinamide (doses of 20, 60, 200, and 600 mg/kg/day) to male and female rats prior to mating and throughout mating, and continuing in females up to day 6 of gestation resulted in impairment of fertility (decreased conception rates and mating and fertility indices; decreased numbers of corpora lutea, implantations, and live embryos; increased preimplantation loss; decreased sperm count and motility) at all doses tested. Therefore, a no-effect dose was not established. The lowest dose tested was associated with a plasma AUC ≈ 0.2 times the human plasma AUC at the MRHD.

PREGNANCY

Pregnancy Category C

Rufinamide produced developmental toxicity when administered orally to pregnant animals at clinically relevant doses.

Rufinamide was administered orally to rats at doses of 20, 100, and 300 mg/kg/day and to rabbits at doses of 30, 200, and 1000 mg/kg/day during the period of organogenesis (implantation to closure of the hard palate); the high doses are associated with plasma AUCs ≈2 times the human plasma AUC at the maximum recommended human dose (MRHD, 3200 mg/day). Decreased fetal weights and increased incidences of fetal skeletal abnormalities were observed in rats at doses associated with maternal toxicity. In rabbits, embryo-fetal death, decreased fetal body weights, and increased incidences of fetal visceral and skeletal abnormalities occurred at all but the low dose. The highest dose tested in rabbits was associated with abortion. The no-effect doses for adverse effects on rat and rabbit embryo-fetal development (20 and 30 mg/kg/day, respectively) were associated with plasma AUCs ≈ 0.2 times that in humans at the MRHD).

In a rat pre- and post-natal development study (dosing from implantation through weaning) conducted at oral doses of 5, 30, and 150 mg/kg/day (associated with plasma AUCs up to ≈1.5 times that in humans at the MRHD), decreased offspring growth and survival were observed at all doses tested. A no-effect dose for adverse effects on pre- and post-natal development was not established. The lowest dose tested was associated with plasma AUC < 0.1 times that in humans at the MRHD.

There are no adequate and well-controlled studies in pregnant women. BANZEL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Labor and Delivery

The effect of BANZEL on labor and delivery in humans is not known.

Nursing Mothers

Rufinamide is likely to be excreted in breast milk. Because of the potential for serious adverse reactions in nursing infants from BANZEL, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Pediatric Use

The safety and effectiveness in patients with Lennox-Gastaut syndrome have not been established in children less than 4 years.

Geriatric Use

Clinical studies of BANZEL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

A study evaluating the pharmacokinetics of rufinamide in elderly subjects showed that there were no significant differences in the plasma and urine pharmacokinetic parameters of rufinamide between the younger and elderly subjects under both single and multiple dose treatments.

ADVERSE REACTIONS

Placebo-controlled double-blind studies were performed in adults and in pediatric patients, down to age of 4, in other forms of epilepsy, in addition to the trial in Lennox-Gastaut syndrome. Data on CNS Reactions (see WARNINGS) from the Lennox-Gastaut study are presented first. Because there is no reason to suspect that adverse reactions would substantially differ between these patient populations, safety data from all of these controlled studies are then presented. Most of these adverse reactions were mild to moderate and transient in nature.

Common central nervous system reactions in the controlled trial of patients 4 years or older with Lennox-Gastaut syndrome treated with BANZEL as adjunctive therapy (see WARNINGS):

Somnolence was reported in 24.3% of BANZEL-treated patients compared to 12.5% of placebo patients and led to study discontinuation in 2.7% of treated patients compared to 0% of placebo patients. Fatigue was reported in 9.5% of BANZEL-treated patients compared to 7.8% of placebo patients. It led to study discontinuation in 1.4% of treated patients and 0% of placebo patients.

Dizziness was reported in 2.7% of BANZEL-treated patients compared to 0% of placebo patients, and did not lead to study discontinuation.

Ataxia and gait disturbance were reported in 5.4% and 1.4% of BANZEL-treated patients, respectively, and in no placebo patients. Balance disorder and abnormal coordination were each reported in 0% of BANZEL-treated patients and 1.6% of placebo patients. None of these reactions led to study discontinuation.

All Adverse Reactions for All Treated Patients with Epilepsy, Double-blind Adjunctive Therapy Studies: The most commonly observed (≥10%) adverse reactions in BANZEL-treated patients, when used as adjunctive therapy at all doses studied (200 to 3200 mg/day) with a higher frequency than in placebo were: headache, dizziness, fatigue, somnolence, and nausea.

At the target dose of 45 mg/kg/day in children, the most commonly observed (≥5%) adverse reactions in BANZEL-treated patients, given as adjunctive therapy, with a higher frequency than placebo were: somnolence, vomiting, headache, fatigue, dizziness, nausea, and convulsion.

At doses up to 3200 mg/day in adults, the most commonly observed (≥5%) adverse reactions in BANZEL-treated patients, given as adjunctive therapy, at all doses studied, with a higher frequency than placebo were: headache, dizziness, fatigue, nausea, somnolence, diplopia, nasopharyngitis, tremor, nystagmus, vision blurred and vomiting.

Table 2 lists treatment-emergent adverse reactions that occurred in at least 3% of pediatric patients with epilepsy treated with BANZEL in controlled adjunctive studies and were numerically more common in patients treated with BANZEL than placebo.

Table 2: Incidence (%) of Treatment-Emergent Adverse Reactions in all Pediatric Double-Blind Adjunctive Trials by Preferred Term at the Recommended Dose of 45 mg/kg/day (Adverse Reactions occurred in at least 3% of BANZEL-treated patients and occurred more frequently than in Placebo Patients)

Preferred Term	BANZEL (N=187) %	Placebo (N=182) %
Somnolence	17	9
Vomiting	17	7
Headache	16	8
Fatigue	9	8
Dizziness	8	6
Nausea	7	3
Influenza	5	4
Nasopharyngitis	5	3
Decreased Appetite	5	2
Rash	4	2
Ataxia	4	1
Diplopia	4	1
Bronchitis	3	2
Sinusitis	3	2
Psychomotor Hyperactivity	3	1
Abdominal Pain Upper	3	2
Aggression	3	2
Ear Infection	3	1
Disturbance in Attention	3	1
Pruritis	3	0

Table 3 lists treatment-emergent adverse reactions that occurred in at least 3% of adult patients with epilepsy treated with BANZEL (up to 3200mg/day) in adjunctive controlled studies and were numerically more common in patients treated with BANZEL than placebo. In these studies, either BANZEL or placebo was added to current AED therapy.

Table 3: Incidence (%) of Treatment-Emergent Adverse Reactions in all Adult Double-Blind Adjunctive Trials (up to 3200mg/day) by Preferred Term (Adverse Reactions occurred in at least 3% of BANZEL-treated patients and occurred more frequently than in Placebo Patients)

Preferred Term	BANZEL (N=823) %	Placebo (N=376) %
Headache	27	26
Dizziness	19	12
Fatigue	16	10
Nausea	12	9
Somnolence	11	9
Diplopia	9	3
Tremor	6	5
Nystagmus	6	5
Vision Blurred	6	2
Vomiting	5	4
Ataxia	4	0
Abdominal Pain Upper	3	2
Anxiety	3	2
Constipation	3	2
Dyspepsia	3	2
Back Pain	3	1
Gait Disturbance	3	1
Vertigo	3	1

Discontinuation in Controlled Clinical Studies

In controlled double-blind adjunctive clinical studies, 9.0% of patients receiving BANZEL as adjunctive therapy and 4.4% receiving placebo discontinued as a result of an adverse reaction. The adverse reactions most commonly leading to discontinuation of BANZEL (>1%) used as adjunctive therapy were generally similar in adults and children.

In pediatric double-blind adjunctive clinical studies, 8.0% of patients receiving BANZEL as adjunctive therapy and 2.2% receiving placebo discontinued as a result of an adverse reaction. The adverse reactions most commonly leading to discontinuation of BANZEL (>1%) used as adjunctive therapy are presented in Table 4.

Table 4: Adverse Reactions Most Commonly Leading to Discontinuation in Double-Blind Adjunctive Trials (At The Recommended Dose of 45mg/kg/day) In Pediatric Patients

Preferred Term	BANZEL (N=187) %	Placebo (N=182) %
Convulsion	2	1
Rash	2	1
Fatigue	2	0
Vomiting	1	0

In adult double-blind adjunctive clinical studies (up to 3200 mg/day), 9.5% of patients receiving BANZEL as adjunctive therapy and 5.9% receiving placebo discontinued as a result of an adverse reaction. The adverse reactions most commonly leading to discontinuation of BANZEL (>1%) used as adjunctive therapy are presented in Table 5.

Table 5: Adverse Reactions Most Commonly Leading to Discontinuation in Double-Blind Adjunctive Trials (up to 3200 mg/day) In Adult Patients

Preferred Term	BANZEL (N=823) %	Placebo (N=376) %
Dizziness	3	1
Fatigue	2	1
Headache	2	1
Nausea	1	0
Ataxia	1	0

Other Adverse Events Observed During Clinical Trials:

BANZEL has been administered to 1978 individuals during all epilepsy clinical trials (placebo-controlled and open-label). Adverse events occurring during these studies were recorded by the investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of patients having adverse events, these events were grouped into standardized categories using the MedDRA dictionary. Adverse events occurring at least three times and considered possibly related to treatment are included in the System Organ Class listings below. Terms not included in the listings are those already included in the tables above, those too general to be informative, those related to procedures, and terms describing events common in the population. Some events occurring fewer than 3 times are also included based on their medical significance. Because the reports include events observed in open label, uncontrolled observations, the role of BANZEL in their causation cannot be reliably determined.

Events are classified by body system and listed in order of decreasing frequency as follows: *frequent adverse events*– those occurring in at least 1/100 patients; *infrequent adverse events*– those occurring in 1/100 to 1/1000 patients; *rare*– those occurring in fewer than 1/1000 patients.

Blood and Lymphatic System Disorders: *Frequent*: anemia. *Infrequent*: lymphadenopathy, leukopenia, neutropenia, iron deficiency anemia, thrombocytopenia.

Cardiac Disorders: *Infrequent*: bundle branch block right, atrioventricular block first degree

Metabolic and Nutritional Disorders: *Frequent*: decreased appetite, increased appetite.

Renal and Urinary Disorders: *Frequent*: pollakiuria. *Infrequent*: urinary incontinence, dysuria, hematuria, nephrolithiasis, polyuria, enuresis, nocturia, incontinence.

DRUG ABUSE AND DEPENDENCE

The abuse and dependence potential of BANZEL has not been evaluated in human studies.

OVERDOSAGE

Because strategies for the management of overdose are continually evolving, it is advisable to contact a Certified Poison Control Center to determine the latest recommendations for the management of an overdose of any drug.

One overdose of 7200 mg/day BANZEL was reported in an adult during the clinical trials. The overdose was associated with no major signs or symptoms, no medical intervention was required, and the patient continued in the study at the target dose.

Treatment or Management of Overdose: There is no specific antidote for overdose with BANZEL. If clinically indicated, elimination of unabsorbed drug should be attempted by induction of emesis or gastric lavage. Usual precautions should be observed to maintain the airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient.

Hemodialysis: Standard hemodialysis procedures may result in limited clearance of rufinamide. Although there is no experience to date in treating overdose with hemodialysis, the procedure may be considered when indicated by the patient's clinical state.

DOSAGE AND ADMINISTRATION

Children four years and older with Lennox-Gastaut syndrome: Treatment should be initiated at a daily dose of approximately 10 mg/kg/day administered in two equally divided doses. The dose should be increased by approximately 10 mg/kg increments every other day to a target dose of 45 mg/kg/day or 3200 mg/day, whichever is less, administered in two equally divided doses. It is not known whether doses lower than the target doses are effective.

Adults with Lennox-Gastaut syndrome: Treatment should be initiated at a daily dose of 400–800 mg/day administered in two equally divided doses. The dose should be increased by 400–800 mg/day every 2 days until a maximum daily dose of 3200 mg/day, administered in two equally divided doses is reached. It is not known whether doses lower than 3200 mg are effective.

BANZEL tablets are scored on both sides and can be cut in half for dosing flexibility. Tablets can be administered whole, as half tablets or crushed.

BANZEL should be given with food.

Patients with Renal Impairment

Renally impaired patients (creatinine clearance less than 30 mL/min) do not require any special dosage change when taking BANZEL.

Patients Undergoing Hemodialysis

Hemodialysis may reduce exposure to a limited (about 30%) extent. Accordingly, adjusting the BANZEL dose during the dialysis process can be considered.

Patients with Hepatic Disease

Use of BANZEL in patients with hepatic impairment has not been studied. Therefore, use in patients with severe hepatic impairment is not recommended. Caution should be exercised in treating patients with mild to moderate hepatic impairment.

HOW SUPPLIED

BANZEL 200 mg tablets (containing 200 mg rufinamide) are pink in color, film-coated, oblong-shape tablets, with a score on both sides, imprinted with "€ 262" on one side. They are available in bottles of 30 (NDC 62856-582-30).

BANZEL 400 mg tablets (containing 400 mg rufinamide) are pink in color, film-coated, oblong-shape tablets, with a score on both sides, imprinted with "€ 263" on one side. They are available in bottles of 120 (NDC 62856-583-52).

Store at 25°C (77°F); excursions permitted to 15° – 30°C (59°F – 86°F). Protect from moisture. Replace cap securely after opening.

Rx Only BANZEL® is a trademark of Novartis Pharma AG, used under license. Manufactured by Eisai Co., Ltd. Marketed by Eisai Inc., Woodcliff Lake, NJ 07677

WELCOME MESSAGE

Welcome to San Antonio and the AES 64th Annual Meeting and 3rd Biennial North American Regional Congress. The AES Annual Meeting and Scientific Program Committees have organized an exciting schedule of educational programs, exhibits, social events and networking opportunities for your participation.

Quality science and education
Here you will find a wide range of quality educational sessions for the diverse interests among professionals dedicated to the study and treatment of epilepsy.

Sessions for junior members
There are activities targeted to Fellows, Postdoctoral Researchers, Instructors and Assistant Professor-level junior faculty at this year's meeting: "Junior Investigator Workshop: Mentoring as an Essential Part of Career Advancement" Monday 9:00 a.m.-10:30 a.m. (Convention Center – Room 006 D). Join the organizers for an exciting, interactive Junior Investigator workshop on Mentoring with pioneers in epilepsy research.
"Mentoring Session for Junior Investigators" Monday, 3:15 p.m.-4:45 p.m. (Convention Center – Room 006 D). Epilepsy professionals at the Associate Professor or Professor level volunteer to serve as mentors for this one-time session. Pre-application is required, so inquire at the registration desk if you are interested and have not signed up.

Poster walking tours
New this year are guided poster walking tours. These tours will be lead by AES senior leadership and occur during the authors present times at Poster Sessions 1, 2 and 3. Approximately 6 – 8 tours will occur each day and they will be topic specific. Poster walking tour details are located on page 12.

Practical new aid to participation
Also new this year is the introduction of TripBuilder's Itinerary Planner. This web-based resource helps you make the most of your time and increase the educational benefit and enjoyment you derive from this meeting. The Itinerary Planner allows you to use your web-enabled mobile phone to create your personalized meeting schedule, including selecting sessions you plan to attend, abstract posters to see, and exhibit booths to visit, plus viewing a list of local restaurants and other city features of possible interest. If you have not yet accessed this resource, go to www.tripbuilder.mobi/aes2010 from your computer or smart phone and build your meeting itinerary. This resource also allows you to receive up-to-date reminders during the meeting.

Expanded networking opportunity
The Saturday evening Social Networking Groups is another new feature this year scheduled in response to the expressed need for SIG, Investigator Workshop, and symposia participants to meet and to continue discussions.

Thank you for joining us. And, please enjoy the meeting!

Jaideep Kapur, M.D., Ph.D.
President, American Epilepsy Society

2010 AES BOARD OF DIRECTORS

PRESIDENT
Jaideep Kapur, M.D., Ph.D.

FIRST VICE PRESIDENT
John M. Pellock, M.D.

SECOND VICE PRESIDENT
Frances E. Jensen, M.D.

TREASURER
Michael D. Privitera, M.D.

PAST PRESIDENT
Steven C. Schachter, M.D.

BOARD MEMBERS
Amy Brooks-Kayal, M.D.
James C. Cloyd, Pharm.D.
William D. Gaillard, M.D.
John Huguenard, Ph.D.
Steven N. Roper, M.D.
Elson L. So, M.D.

EX-OFFICIO
Gregory K. Bergey, M.D.
(*Epilepsy Currents*)
Brandy Fureman, Ph.D. (NINDS Liaison)
David M. Labiner, M.D.
(Director, Council on Education)
Cesare T. Lombroso, M.D., Ph.D.
Page B. Pennell, M.D. (EF PAB Liaison)
Kevin J. Staley, M.D. (Research)
John W. Swann, Ph.D. (ILAE Liaison)
William H. Theodore, M.D. (AAN Liaison)

AMERICAN EPILEPSY SOCIETY

is proud to recognize the following supporters of the 2010 Annual Meeting.

Leader Level

$250,000 – $499,999

Pfizer Inc.
UCB, Inc.

Partner Level

$100,000 – $249,999

GlaxoSmithKline
Sunovion Pharmaceuticals Inc.

Supporter Level

$50,000 – $99,999

Eisai Inc.
Lundbeck

Contributor Level

$25,000 – $49,999

Cyberonics, Inc.
Questcor Pharmaceuticals, Inc.
Nihon Kohden America, Inc.
Medtronic, Inc.

Advocate Level

$10,000 – $24,999

Novartis Pharmaceuticals Corporation
Grass Technologies
Analyze Direct
Care Fusion
Compumedics Limited
Elekta
Natus Medical
Supernus Pharmaceuticals, Inc.

Patron Level

$5,000 – $9,999

PMT Corporation
Ad Tech Medical Instrument Corp.
Blackrock Microsystems
Cadwell Laboratories
Epilepsy Foundation
Electrical Geodesics, Inc.
Optima Neuroscience, Inc.

TABLE OF CONTENTS

Meeting Information

Schedule-at-a-Glance 6
Poster Map and Schedule 8
AES Special Recognition 10
Nurse and Young Investigator Awardees 12
Poster Walking Tours 12
Scientific Exhibits 22
Exhibitors 69
Abstract Author Index 77
General Information 101
Speaker Ready Room and Photos 103

FRIDAY

TopScholar Epilepsy Fellows 15
The National EpiFellows Foundation 15
Advances in the Management of Epilepsy and the Epilepsy Clinic 15
Annual Fundamentals of Epilepsy 15
Spanish Symposium 16
Special Interest Group Meetings 16
Hot Topics Symposium 17

SATURDAY

Hoyer Lecture 19
Special Interest Group Meetings 19
Presidential Symposium 19
Antiepileptic Therapy Symposium 20
Investigators' Workshop 20
Special Interest Group Meetings 20
Social Networking Groups 21
Poster Session 1 23

SUNDAY

Annual Course 33
Investigators' Workshops 34
Special Interest Group Meetings 36
Professionals in Epilepsy Care Symposium 36
Poster Session 2 38

MONDAY

Special Interest Group Meetings 49
Merritt-Putnam Symposium 49
Lennox & Lombroso Lecture 50
Mentoring Session for Junior Investigators 50
Patient Education for Clinicians 50
Investigators' Workshop 50
Special Interest Group Meetings 50
Pediatric Epilepsy Highlights Session 51
Pediatric State of the Art Symposium 51
Platform Sessions 54
Poster Session 3 55

TUESDAY

Special Interest Group Meetings 65
Plenary II 65
International League Against Epilepsy Symposium 66
Special Interest Group Meetings 66

Watch for these 2011 dates!

Annual Meeting Call for Abstracts Available
March 1, 2011

AES Research Recognition and Distinguished Achievement Awards Nominations
August 8, 2011

AES 65th Annual Meeting
December 2-6, 2011
Baltimore, MD



SCHEDULE-AT-A-GLANCE

FRIDAY December 3

8:00 a.m. - 4:30 p.m.	➤ TopScholar Epilepsy Fellows Epilepsy Career Development Seminar *Westin Riverwalk*
8:00 a.m. - 5:00 p.m.	➤ The National Epifellows Foundation 18th Annual Scientific Forum General Session – Morning *Marriott Rivercenter – Grand Ballroom, Salon H/K* Two Workshops – Afternoon *Marriott Rivercenter – Grand Ballroom, Salon H/K* *Marriott Rivercenter – Grand Ballroom, Salon L*
9:00 a.m. - 6:00 p.m.	Registration *Convention Center – Ballroom A*
9:00 a.m. - 4:00 p.m.	Advances in the Management of Epilepsy and the Epilepsy Clinic *Marriott Rivercenter – Grand Ballroom, Salon I/J*
11:00 a.m. - Noon	Lunch – *On Your Own*
Noon - 2:30 p.m.	Annual Fundamentals of Epilepsy: *Psychogenic Nonepileptic Seizures* *Convention Center – Room 103*
2:45 p.m. - 5:15 p.m.	Spanish Symposium: *Status Epilepticus: Novel Concepts in Pathophysiology and Treatment Strategies* *Convention Center – Room 007 C/D*
3:00 p.m. - 4:30 p.m.	Special Interest Group Meetings *Convention Center – See page 16*
5:00 p.m. - 5:30 p.m.	Symposia Break *Marriott Rivercenter – Grand Ballroom Foyer*
5:30 p.m. - 8:00 p.m.	Hot Topics Symposium: *From Headlines to Healthcare* *Marriott Rivercenter – Grand Ballroom Salon E/F*
8:00 p.m. - 9:30 p.m.	➤ Fellows Recognition Gathering *Marriott Rivercenter – Conference Room 17*

SATURDAY December 4

8:00 a.m. - 6:00 p.m.	Registration *Convention Center – Ballroom A*
9:15 a.m. - 11:15 a.m.	Hoyer Lecture *Convention Center – Lila Cockrell Theatre*
9:30 a.m. - 11:00 a.m.	Special Interest Group Meetings *Convention Center – See page 19*
11:30 a.m. - 6:00 p.m.	Exhibit Hall Lunch: 11:30 a.m. - 12:30 p.m. Auction Benefit: Noon *Convention Center – Hall A*
11:30 a.m. - 6:30 p.m.	➤ Poster Session 1 *Convention Center – Hall A*
1:45 p.m. - 4:15 p.m.	Presidential Symposium: *GABAergic Transmission in Epilepsy* *Convention Center – Lila Cockrell Theatre*
4:30 p.m. - 5:00 p.m.	Symposia Break *Convention Center – Hall A*
5:30 p.m. - 7:15 p.m.	Antiepileptic Therapy Symposium: *Channel Surfing: Impact on Treatment Strategies* *Convention Center – Lila Cockrell Theatre*
6:00 p.m. - 8:00 p.m.	➤ Investigators' Workshops *Convention Center – See page 20*
7:30 p.m. - 9:00 p.m.	Special Interest Group Meetings *Marriott Rivercenter – See page 20*
9:00 p.m. - 10:00 p.m.	➤ Social Networking Groups *Marriott Rivercenter – Grand Ballroom, Salon C/D*

SUNDAY December 5

7:30 a.m. - 6:00 p.m.	Registration *Convention Center – Ballroom A*
8:00 a.m. - 5:00 p.m.	Scientific Exhibits *Convention Center – See page 22*
8:00 a.m. - 6:00 p.m.	➤ Poster Session 2 *Convention Center – Hall A*
8:45 a.m. - 5:15 p.m.	Annual Course: *Inflammatory Issues and Infectious Causes of Epilepsy* *Convention Center – Lila Cockrell Theatre*
8:45 a.m. - 5:45 p.m.	➤ Investigators' Workshops IW Posters / Boxed Lunch: Noon - 1:30 p.m. Keynote Speakers: 1:45 p.m. - 2:15 p.m. *Marriott Rivercenter – See page 34*
11:00 a.m. - 6:00 p.m.	Exhibit Hall Lunch: Noon - 1:00 p.m. Auction Benefit: Noon *Convention Center – Hall A*
5:15 p.m. - 6:00 p.m.	Symposia Break *Convention Center – Hall A*
6:00 p.m. - 7:30 p.m.	➤ Investigators' Workshop Poster Session *Marriott Rivercenter – Grand Ballroom, Salon F*
6:00 p.m. - 7:30 p.m.	➤ Special Interest Group Meetings *Convention Center – See page 36*
6:00 p.m. - 8:30 p.m.	PECs Symposium: *How Practitioners Can Use Neuropsychological Testing to Improve Patient Care and Outcomes* *Convention Center – Room 006 A-C*

Breakfast each day is on your own.

Programs listed with this symbol ➤ are for junior attendees

MONDAY December 6

7:30 a.m. - 6:00 p.m.	Registration *Convention Center – Ballroom A*
8:00 a.m. - 5:00 p.m.	Scientific Exhibits *Convention Center – See page 22*
8:00 a.m. - 3:30 p.m.	➤ Poster Session 3 *Convention Center – Hall A*
9:00 a.m. - 10:30 a.m.	➤ Special Interest Group Meetings *Convention Center – See page 49*
9:00 a.m. - Noon	Merritt-Putnam Symposium: *Consequences of Epilepsy Through the Ages: When Is the Die Cast?* *Convention Center – Lila Cockrell Theatre*
11:00 a.m. - 4:00 p.m.	Exhibit Hall Lunch: Noon - 1:00 p.m. Auction Benefit: Noon *Convention Center – Hall A*
2:15 p.m. - 3:00 p.m.	Lennox & Lombroso Lecture: *Looking Forward – Opportunities and Challenges for NINDS* *Convention Center – Lila Cockrell Theatre*
3:15 p.m. - 4:45 p.m.	➤ Mentoring Session for Junior Investigators *Convention Center – Room 006 D*
3:15 p.m. - 4:45 p.m.	Patient Education for Clinicians *Marriott Rivercenter – Grand Ballroom Salon A/B*
3:15 p.m. - 4:45 p.m.	➤ Investigators' Workshop *Convention Center – Room 006 A-C*
3:15 p.m. - 4:45 p.m.	Special Interest Group Meetings *Convention Center – See page 50*
4:00 p.m. - 5:30 p.m.	Pediatric Epilepsy Highlights Session *Convention Center – Lila Cockrell Theatre*
4:00 p.m. - 6:15 p.m.	➤ Platform Sessions: 3 Concurrent Sessions *Convention Center – See page 51*
6:00 p.m. - 6:30 p.m.	Symposia Break *Marriott Rivercenter – Grand Ballroom Foyer*
6:30 p.m. - 8:30 p.m.	Pediatric State of the Art Symposium: *Identifying and Managing the Comorbidities of Pediatric Epilepsy* *Marriott Rivercenter – Grand Ballroom Salon E/F*

TUESDAY December 7

8:30 a.m. - 12:30 p.m.	Registration *Convention Center – Ballroom A*
9:00 a.m. - 10:30 a.m.	Special Interest Group Meetings *Convention Center – See page 65*
9:00 a.m. - 10:30 a.m.	Plenary II: *Neurostimulation in the Treatment of Epilepsy: The Road Traveled and the Road Ahead* *Convention Center – Lila Cockrell Theatre*
10:45 a.m. - 12:15 p.m.	ILAE Symposium: *Epilepsy Treatment in North America and Around the World: Can We Learn From Each Other?* *Convention Center – Lila Cockrell Theatre*
10:45 a.m. - 12:15 p.m.	Special Interest Group Meetings *Convention Center – See page 66*

Please plan to attend

Investigators' Workshop Keynote Speakers
Epilepsy Research Recognition Awardees

Sunday, December 5
1:45 p.m. – 2:15 p.m.
Marriott Rivercenter – Grand Ballroom, Salon H / K

Award for Basic Science
Douglas A. Coulter, Ph.D.

Award for Clinical Science
Tracy A. Glauser, M.D.

see page 10 for award information

Programs listed with this symbol ➤ are for junior attendees

Henry B. Gonzalez Convention Center – Hall A



Poster Walking Tours begin at the **Poster Information** table

Poster Session Entrance is outside **AES Registration**, when Exhibits are closed

Entrance

Questions? Please visit the poster information table in front of the poster area in Hall A.

Saturday, December 4, 2010

Poster Session 1 – 11:30 a.m. – 6:30 p.m. – Convention Center, Hall A *(see pages 23-31)*
Authors Present: Noon - 2:00 p.m. (1.001 – 1.391)
Poster Walking Tours: Noon – 2:00 p.m. *(see page 12 for further details)*

Translational Research	1.001 – 1.060
Clinical Neurophysiology	1.061 – 1.146
Clinical Epilepsy	1.147 – 1.237
Antiepileptic Drugs	1.238 – 1.317A
Neuropsychology / Language / Behavior	1.318 – 1.391

Sunday, December 5, 2010

Poster Session 2 – 8:00 a.m. – 6:00 p.m. – Convention Center, Hall A *(see pages 38-47)*
Authors Present: Noon – 2:00 p.m. (2.001 – 2.393)
Poster Walking Tours: Noon – 2:00 p.m. *(see page 12 for further details)*

Translational Research	2.001 – 2.010
Professionals in Epilepsy Care	2.011 – 2.029
Clinical Neurophysiology	2.030 – 2.096
Neuro-Imaging	2.097 – 2.146
Antiepileptic Drugs	2.147 – 2.209
Non AED / Non Surgical Treatments	2.210 – 2.240
Surgery	2.241 – 2.324
Practice Resources	2.325 – 2.333
Epidemiology	2.334 – 2.354
Public Health	2.355 – 2.365
History of Epilepsy	2.366
Late-Breaking Abstracts	2.367 – 2.394

Investigators' Workshop Lunch Poster Session
Noon – 1:30 p.m. – Marriott Rivercenter, Salon F *(see pages 34-35)*

Investigators' Workshop Poster Session
6:00 p.m. – 7:30 p.m. – Marriott Rivercenter, Salon F *(see page 35)*

Monday, December 6, 2010

Poster Session 3 – 8:00 a.m. – 3:30 p.m. – Convention Center, Hall A *(see pages 55-64)*
Authors Present: Noon – 2:00 p.m. (3.001 – 3.386)
Poster Walking Tours: Noon – 2:00 p.m. *(see page 12 for further details)*

Translational Research	3.001 – 3.073
Clinical Epilepsy	3.074 – 3.155
Neuro-Imaging	3.156 – 3.236
Comorbidities	3.237 – 3.289
Human Genetics	3.290 – 3.322
Health Services	3.323 – 3.338
Neuropathology of Epilepsy	3.339 – 3.366
CAMELICE Posters*	3.367 – 3.386

*Abstracts from the Junior Epileptologist Program from the Mexican Chapter of ILAE (CAMELICE)

Abstract Author Index – see pages 77-92

Epilepsy Research Recognition Awards

Saturday, December 4 – 1:45 p.m., *Convention Center – Lila Cockrell Theatre*
(Immediately preceding the Presidential Symposium)

The American Epilepsy Society Epilepsy Research Recognition Awards are given annually to active scientists and clinicians working in all aspects of epilepsy research. They are designed to recognize professional excellence reflected in a distinguished history of research or important promise for the improved understanding, diagnosis and treatment of epilepsy. The awards of $10,000 each are part of the AES grant and fellowship programs.

Award for Basic Science
Douglas A. Coulter, Ph.D.

Douglas A. Coulter, Ph.D. is Professor of Pediatrics and Neuroscience at the University of Pennsylvania School of Medicine and the Children's Hospital of Philadelphia. He received his doctorate in biology from the Boston University Marine Program at the Marine Biological Laboratories in Woods Hole, Massachusetts and then conducted postdoctoral research in the Department of Neurology and Neurological Sciences, Stanford University School of Medicine. Dr. Coulter first established his independent laboratory at the Virginia Commonwealth School of Medicine, and then moved to the University of Pennsylvania in 1999. He is a recipient of an NINDS Javits Neuroscience Investigator Award and was the Chair of the second Gordon Research Conference on Epilepsy.

Dr. Coulter has made a number of important contributions to understanding the basic mechanisms of epileptogenesis and epilepsy, both in the limbic and thalamocortical systems. His research is multidisciplinary, using diverse techniques and approaches. He has made significant contributions toward understanding neuronal and glial plasticity underlying the enhanced excitability of the epileptic brain, including some of the earliest studies detailing acquired transcriptional channelopathies as a contributory mechanism in epilepsy. He has also identified important cellular actions of several antiepileptic drugs and has identified glial and neurotransmitter transporter contributions to depression of GABA synthesis and function.

Dr. Coulter has been an active participant in AES, including service on the Scientific Program, Investigators' Workshop, Nominations, Education, and Research and Training Committees. He has served as an editor for *Epilepsy Currents*, *Epilepsy Research*, and *Epilepsia*, in addition to several other journals, and is a standing member of NINDS study section. He has attracted a large number of undergraduate, predoctoral, and postdoctoral trainees to his laboratory, where they receive outstanding training in epilepsy-related projects.

Award for Clinical Science
Tracy A. Glauser, M.D.

Tracy A. Glauser, M.D., is Professor of Pediatrics, director of the Comprehensive Epilepsy Center and co-director of the Genetic Pharmacology Service at Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Dr Glauser received his medical degree, cum laude, from Jefferson Medical College in Philadelphia, PA. He completed his residency in pediatrics at the Johns Hopkins Hospital in Baltimore, MD, and fellowship in child neurology at The Children's Hospital of Philadelphia, University of Pennsylvania in Philadelphia, PA. Dr Glauser completed a NINDS research fellowship in pediatric neurology and was a fellow in epilepsy and electroencephalography at St. Louis Children's Hospital, Washington University School of Medicine in St. Louis, MO.

Dr. Glauser's NIH-funded research has focused on improving the care of children with epilepsy through clinical trials and by identifying the genetic and non-heritable factors that underlie the inter-individual variation in response to AEDs. Since 2003, Dr. Glauser has directed the NIH funded Childhood Absence Epilepsy trial. This 32-center, 446-patient double blind randomized comparative trial of three commonly used antiepileptic medications focused on identifying the optimal initial therapy for children with childhood absence epilepsy and the pharmacokinetic, pharmacodynamic, and pharmacogenetic factors that impact upon the inter-individual response to antiepileptic therapy. The short-term results of the clinical trial were published in the *New England Journal of Medicine* in March 2010. The trial is the first Class I study for generalized seizures. The study has recently been renewed for another four years to determine the long-term outcomes of the randomized clinical trial.

In July 2004, Dr. Glauser co-founded and launched the multidisciplinary Genetic Pharmacology Service (www.gps.cchmc.org) at Cincinnati Children's Hospital. His team developed and is testing treatment selection algorithms for medications that incorporate genetic information and drug-drug interactions. He has been the lead principal investigator and first author on three multinational industry-sponsored pediatric epilepsy adjunctive therapy trials and first author on the 2006 ILAE initial monotherapy treatment guidelines. In 2008 he became a standing member of the NINDS NSD-K clinical trials study section. He has authored and coauthored more than 130 articles and book chapters and given over 150 invited lectures throughout the world.

Lennox & Lombroso Lecturer
Monday, December 6
Convention Center – Lila Cockrell Theatre
2:15 p.m.

Story C. Landis, Ph.D.

Story Landis, Ph.D., has been Director of the National Institute for Neurological Disorders and Stroke (NINDS) since 2003. A native of New England, Dr. Landis received her undergraduate degree from Wellesley College (1967) and her Ph.D. from Harvard University (1973). After postdoctoral work at Harvard University, she served on the faculty of the Department of Neurobiology there. In 1985, she joined the faculty of Case Western Reserve University School of Medicine, where she created the Department of Neurosciences which, under her leadership, achieved an international reputation for excellence. Throughout her research career, Dr.Landis has made fundamental contributions to the understanding of nervous system development. She has garnered many honors, is an elected fellow of the Institute of Medicine, the Academy of Arts and Sciences, the American Association for the Advancement of Science and the American Neurological Association, and in 2002 was elected President of the Society for Neuroscience.

Dr. Landis joined the NINDS in 1995 as Scientific Director and worked to re-engineer the Institute's intramural research programs. Between 1999 and 2000, she led the movement, together with the NIMH Scientific Director, to bring a sense of unity and common purpose to 200 neuroscience laboratories from eleven different NIH Institutes. As NINDS Director, Dr. Landis oversees an annual budget of $1.5 billion that supports research by investigators in public and private institutions across the country, as well as by scientists working in its intramural program. Together with NIMH and NIA directors, she co-chairs the NIH Blueprint for Neuroscience Research, a roadmap-like effort to support trans-NIH activities in the brain sciences. In 2007, Dr. Landis was named Chair of the NIH Stem Cell Task Force.

AES Service Award

Saturday, December 4
Convention Center – Lila Cockrell Theatre
9:15 a.m.
(immediately preceding the Hoyer Lecture)

Gregory K. Bergey, M.D.

Dr. Gregory K. Bergey is Professor of Neurology at the Johns Hopkins University School of Medicine in Baltimore, MD, Director of the Johns Hopkins Epilepsy Center and co-director of the Epilepsy Research Laboratory, where their NIH-funded research projects involve studies of seizure dynamics and investigations into computer-simulated neural networks. Other interests and investigations include antiepileptic drug trials, responsive neurostimulation for epilepsy treatment, treatment of primary generalized epilepsy, women and epilepsy, surgical treatment of refractory epilepsy, and the history of neurology and epilepsy.

After graduating from Princeton University and the University of Pennsylvania School of Medicine, he then did residency training in internal medicine at Yale and neurology at Johns Hopkins. He also completed a postdoctoral fellowship in neurophysiology in the Laboratory of Developmental Neurobiology at the NIH.

He has served in a number of capacities for the AES, as a member of the Board of Directors, the Scientific Program Committee (Chair 1994-1995), the Lennox Lecture Committee, the Public Education Committee, the Continuing Medical Education Committee, the Technology Committee (Chair 1996-1999), the Epileptogenesis Task Force, the Research and Training Committee, the Long-Range Planning Committee, the Research Recognition Award Committee, and the Publications Committee.

He is presently Chief Editor for Clinical Science for *Epilepsy Currents*, the journal of the AES, having served as Associate Editor from the time of its inception. He co-chairs the AES Engineering and Epilepsy SIG and has served on and currently chairs the Advisory Board of the National EpiFellows Foundation. Currently a member of the Epilepsy Foundation Research Council, he has been a reviewer for CURE, and has participated on numerous NIH review panels and currently chairs the NINDS NST-1 Study Section. He has served and held office in the Epilepsy Foundation of the Chesapeake Region and is presently a member of the Profession Advisory Board of the Epilepsy Foundation of America.

William G. Lennox Award

Saturday, December 4
Convention Center – Lila Cockrell Theatre
1:45 p.m.
(immediately preceding the Presidential Symposium)

Simon D. Shorvon, M.A., M.D., FRCP

Simon D. Shorvon is Professor of Clinical Neurology, Institute of Neurology, University College London (UCL), Consultant Neurologist National Hospital for Neurology and Neurosurgery (Queen Square, London) and also Clinical Sub-Dean, Institute of Neurology, University College London. His previous posts include: Chairman of University Dept of Neurology, UCL London 1997-2001; Head of the Epilepsy Research Group, Institute of Neurology; and Medical Director, National Society for Epilepsy (at Chalfont UK) 1983-1997. He has been a member of the ILAE Executive Committee for the past 17 years, was previously ILAE Vice-President, and is currently co-Editor-in-Chief of *Epilepsia*. He is recipient of the 2008 European Epileptology Award for lifetime achievement in epileptology.

He has published over 400 peer reviewed articles and chapters, and 20 books, including: *Treatment of Epilepsy.* Shorvon SD, Perucca E, Engel J (eds). 3rd ed. Wiley-Blackwell, New York 2009; *International League Against Epilepsy 1909-2009: a centenary history.* Shorvon S, Weiss G, Avanzini G, Engel J, Meinardi H, Moshe N, Reynolds E, Wolf P. Blackwell, Oxford 2009; *Neurology: a Queen Square Textbook.* Clarke C, Howard R, Rossor M, Shorvon S (eds). Wiley-Blackwell, Oxford 2009; *Handbook of Epilepsy Treatment*, Shorvon S. 3rd ed. Blackwell, Oxford 2010; *Causes of Epilepsy.* Shorvon, Gurerrini, Andermann (eds). Cambridge University Press, Cambridge 2010.

J. Kiffin Penry Excellence in Epilepsy Care Award

Saturday, December 4
Convention Center – Lila Cockrell Theatre
5:30 p.m.
(immediately preceding the AET Symposium)

Andres M. Kanner, M.D.

Dr. Andres M. Kanner is Professor of Neurological Sciences and Psychiatry at Rush Medical College of Rush University in Chicago, IL. He is a senior attending physician in the department of Neurological Sciences at Rush University Medical Center in Chicago, where he has also been director of the Laboratory of Electroencephalography and Video-EEG-Telemetry since 1991, when he joined the staff at the Rush Epilepsy Center. He also holds the positions of Associate Director of the Section of Epilepsy and of the Rush Epilepsy Center. Dr. Kanner is triple boarded in neurology, psychiatry and clinical neurophysiology.

Dr Kanner has had long-standing research interests in the areas of pharmacologic, surgical and psychiatric aspects of treatment-resistant epilepsy. He has authored or coauthored over 65 research publications, over 60 invited review articles and over 60 book chapters and has co-edited six textbooks.

Dr. Kanner serves on the Editorial Board of *Epilepsia*, *Epilepsy & Behavior* and *Epilepsy & Seizure* and is a contributing editor for *Epilepsy Currents.* He is a member of the American Epilepsy Society, where he serves as chair of the Task Force on Psychiatric Aspects of Epilepsy. He is past Chair of the Epilepsy Section of the American Academy of Neurology, and is a member of the American Neurologic Association and American Neuropsychiatric Association. He currently serves as co-Chair of the Neuropsychobiology Commission of the International League Against Epilepsy and is currently on the Professional Advisory Board of the National Epilepsy Foundation.

Extraordinary Contributions to the Field of Epilepsy

Monday, December 6
Convention Center – Lila Cockrell Theatre
9:00 a.m.
(immediately preceding the Merritt-Putnam Symposium)

Susan Axelrod

Susan Axelrod is a parent of a child with epilepsy and Chair and founding member of Citizens United for Research in Epilepsy (CURE). CURE funds cutting-edge research grants exploring new areas.

Susan is active in Vision 2020, the AES initiative to engender better communication and cooperation among the non-profit organizations working in epilepsy. She also participates actively on the AES Advocacy Committee. Susan serves on the NIH's National Advisory Neurological Disorders and Stroke Council and also as a consumer reviewer for the Peer Reviewed Medical Research Program in the Congressionally Directed Medical Research Program within the Department of Defense.

Susan has also brought long overdue media exposure to epilepsy and the devastating effects it can have on individuals and their families, appearing on the *TODAY Show*, MSNBC's Morning Joe, CNN with Campbell Brown and MSNBC with Andrea Mitchell. The February 15, 2009 PARADE magazine cover story, *I Must Save My Child*, shared Axelrod and her family's experience with epilepsy and why CURE was founded, and the April 20, 2009 edition of Newsweek featured a personal essay by Axelrod in their cover package, *The Mystery of Epilepsy: Why We Must Find a Cure.* On October 25, 2009, twelve million viewers tuned into Katie Couric and *60 Minutes* for a special segment on epilepsy and CURE, featuring Susan with her husband, David and daughter, Lauren.

NURSE AWARDEES

Contact Author	Abstract Title	Poster #
Aaron Cohn, M.S.N., ACNP-BC	Initial Post-Marketing Clinical Experience with Lacosamide in Adult Patients with Epilepsy	2.160
Micheale Davies, RN	Screening for Depression in a Tertiary Adult Epilepsy Clinic Using the Neurological Disorders Depression Inventory for Epilepsy	3.260
Wende Fedder, RN	Effective Strategies To Improve Epilepsy Nursing Knowledge Prior To The Development Of An Epilepsy Monitoring Unit At A Community Hospital	3.330
Megan Finnerty, RN	The Efficacy of the Ketogenic Diet in Correlation with Beta-hydroxybuterate Level	2.229
Melanie S. Foster, RN, B.S.N.	Caregiver Anxiety Associated with the Inpatient Pediatric Epilepsy Monitoring Experience	2.012
Diane Friedman, M.S.N., NP	Epilepsy and Epilepsy Surgery Newly Characterized in a 1950 Film	2.366
Patricia Kerr, B.Sc.N., CNN	Managing Aggression in an Epilepsy Monitoring Unit(EMU): A Case of Ictal Rage	2.013
Wendy Miller, M.S.N., RN, CCRN	Epilepsy Self-Management in Older Adults: A Pilot Study	2.011
Diana Moses, RN, M.S., CNRN, CNS	Using Concomitant Remote Cardiac Telemetry to Enhance Patient Safety in the Epilepsy Monitoring Unit (EMU)	2.330
Patricia O. Shafer, M.N., RN	Using an Online Epilepsy Diary to Enhance Self-Management Behaviors of People with Epilepsy	2.025

Acknowledgment: Nurse awards are supported by AES and a grant from UCB, Inc.

New This Year

➤ Poster Walking Tours

This program is designed for residents, fellows, and junior faculty to be able to meet with AES mentors and visit interesting, compelling, or novel posters discussing their perspectives on how the presented data is meaningful. Poster walking tours will be held on the days noted below and cover the topics indicated. Mentors and participants will meet at the Poster Information table near the front of the Poster Session. The tours will depart each day between noon and 1:00 p.m. Approximately 6 – 8 posters will be discussed in each category. These posters have been preselected by the mentors.

Saturday, December 4
- Basic Mechanisms of Epilepsy and AEDs: Robert L. Macdonald, M.D., Ph.D. and David A. Prince, M.D.
- Computer Analysis of EEG: Jean Gotman, Ph.D. and Brian Litt, M.D.
- EEG in Epilepsy: Susan T. Herman, M.D. and Frank W. Drislane, M.D.
- Clinical Studies of AEDs: Mentor TBA and James J. Cereghino, M.D.
- Neuropsychology of Epilepsy: Bruce P. Hermann, Ph.D. and Kimford J. Meador, M.D.

Sunday, December 5
- Clinical Neurophysiology of Epilepsy: Timothy A. Pedley, M.D. and Lawrence J. Hirsch, M.D.
- Imaging of Epilepsy of Epilepsy: Ruben I. Kuzniecky, M.D. and Mentor TBA
- Pharmacology of AEDs: Mentors TBA
- Surgery for Epilepsy: Dennis D. Spencer, M.D. and Steven N. Roper, M.D.
- Epidemiology of Epilepsy: Anne T. Berg, Ph.D. and W. Allen Hauser, M.D.

Monday, December 6
- Animal Models of Seizures and Epilepsy: Scott C. Baraban, Ph.D. and Solomon L. Moshé, M.D.
- Pharmacology of AEDs II: Karen Wilcox, Ph.D. and Mentor TBA
- Functional Imaging and Emerging Techniques: William H. Theodore, M.D. and José E. Cavazos, M.D., Ph.D.
- Genetics of Epilepsy: Peter B. Crino, M.D., Ph.D. and Alica Goldman, M.D., Ph.D.
- Psychiatric Issues in Epilepsy: Mentor TBA and Steven C. Schachter, M.D.

Contact Author	Abstract Title	Poster/ Poster #
Boris Bernhardt, B.Sc.	Mapping Thalamic Pathology in Idiopathic Generalized Epilepsy and Temporal Lobe Epilepsy	2.102
Amy Brewster, Ph.D.	A Candidate Role for Aberrant mTOR Signaling in SE-Associated Alterations in Dendritic Ion Channel Homeostasis	1.007
Julia Brill, Ph.D.	Dynamic Disinhibition of Cortical Circuits	3.339
Tracy Butler, M.D.	Orbitofrontal Thinning in Association with Depressive Symptoms in Patients with Extratemporal Partial Epilepsy	3.248
Edward Chang, M.D.	Single-Trial Cortical Mapping of Sensorimotor Organization in Real-Time	3.229
Michael DiSano, B.S.	Language Lateralization Determined By Tract-Based Spatial Statistics of the Arcuate Fasciculus	2.100
Prabhu Emmady, M.D.	Detection and Clinical Outcome of Status Epilepticus in Patients Undergoing Continuous EEG Monitoring	1.064
Jorge Gonzalez-Martinez, M.D., Ph.D.	Invasive Monitoring Using Depth Electrodes at a North American Center: A Prospective Study Analyzing the Feasibility and Safety of Stereo-Electroencephalography (SEEG) in the Diagnosis and Treatment of Intractable Epilepsy	B.05
Dongjun Guo, M.D., Ph.D.	mTOR Inhibition Has Potential Antiepileptogenic Effects in a Controlled Cortical Impact Model of Traumatic Brain Injury	1.014
Hamada Hamid, D.O., M.P.H.	Long Term Depression Outcomes After Resective Epilepsy Surgery	3.250
Alicia Jensen, Ph.D.	Mechanisms of Axonal Suppression By High Frequency Stimulation	A.01
Susan Lee, D.O.	Utility of Stat EEG in a Tertiary Care Institution	2.036
Jocelyn Lippman Bell, Ph.D.	Early-Life Seizures Lead to Increased AMPA Subunit-Containing Synapses and Higher Ca2+ Responses in Rat Pyramidal CA1 Neurons	1.017
Tobias Loddenkemper, M.D.	Predictors of Death in Pediatric In-Patients with Status Epilepticus	2.336
Sandipan Pati, M.B.B.S., MRCP	Epilepsy-Related Death in Arizona: Mapping Racial and Ethnic Disparities in Mortality at County Level	2.355
Piero Perucca, M.D.	Response to First Antiepileptic Drug Trial Predicts Health Outcome in Epilepsy	3.134
Eduardo Pineda, Ph.D. 1.021	Pharmacological Inhibition of Interleukin-1β and Cycloogenase-2 Decreases Seizure Frequency and Mossy Fiber Sprouting in the Pilocarpine Model of Epilepsy	
Francesca Pittau, M.D.	EEG/fMRI in Focal Epilepsy: What Does the BOLD Response Add to EEG?	3.168
Timothy Simeone, Ph.D.	Carbamazepine Inhibition of Sharp Wave-Ripple Complexes is Associated with Synapse-Specific Effects on Neurotransmission and Short-Term Plasticity	1.239
Aanchel Taneja, M.D.	How Helpful are Repeat Epilepsy Monitoring Unit Admissions After an Initial Nondiagnostic Evaluation?	1.185
Lucy Vivash, M.Sci.	[18F]-Flumazenil-PET for the Localisation of Medically Refractory Focal Epilepsy Using Without Need for Arterial Blood Sampling: A Pilot Study	3.170
Kun Zhang, M.D., Ph.D.	Excitatory Effect of TNF-Alpha on Rat Hippocampal CA1 Pyramidal Neurons After Neonatal Seizure-Inducing Hypoxia	1.023

Ackowledgment: Young Investigator Awards are supported by a grant from Medtronic, Inc. with additional support by a grant from UCB, Inc.

Special Interest Group & Investigators' Workshop Surveys

Help us build better programs!

An online survey is available for those attending Special Interest Groups and/or Investigators' Workshops. Please use the following URL to access this brief survey.

http://www.aesnet.org/sig-noncmesurvey

Visit the Cyber Café

Exhibit Hall

Convention Center – Hall A

Saturday, December 4	11:30 a.m. - 6:00 p.m.	Supported by Supernus Pharmaceuticals, Inc.
Sunday, December 5	11:00 a.m. - 6:00 p.m.	Supported by Lundbeck, Inc.
Monday, December 6	11:00 a.m. - 4:00 p.m.	

CONVENTION CENTER	WIFI*
Lobby Bridge, Street Level	Complimentary
AES Registration – Ballroom A	Complimentary

AES HOTELS	WIFI* IN LOBBY	GUEST ROOM INTERNET
San Antonio Marriott Rivercenter	Complimentary	Wireless $12.95, plus tax, per day
San Antonio Marriott Riverwalk	Complimentary	Wireless $12.95, plus tax, per day
Grand Hyatt San Antonio	No	Wired Internet $9.95 per day Standard; $12.95 per day Business Plan
Hilton Palacio Del Rio	Complimentary in Lobby and Bar	Wired Internet $9.95 per day Standard; $14.95 per day Business Plan
La Quinta Inn Convention Center	Complimentary	Complimentary wired in guestroom

*WIFI = Wireless Zone

8:00 a.m. – 4:30 p.m.

➤ TopScholar Epilepsy Fellows Epilepsy Career Development Seminar

Westin Riverwalk

Chair: Tracy A. Glauser, M.D.

Sponsor: Cincinnati Children's Hospital Medical Center

The 2010 TopScholar program will provide travel grants to 50 epilepsy / clinical neurophysiology fellows (selected by their fellowship directors) to attend the 2010 AES Annual Meeting. The TopScholar program offers unique educational opportunities for trainees, focusing on emerging trends in healthcare policy that may impact epilepsy care delivery as well as career-building issues such as job interviews, employment contracts and career / practice development.

Acknowledgment

This program is supported by an educational grant from UCB, Inc.

8:00 a.m. – 5:00 p.m.

➤ The National EpiFellows Foundation 18th Annual Scientific Forum

(7 CME Credits)

(separate registration required) by invitation only

Marriott Rivercenter – Grand Ballroom, Salon H/K

Note: Workshops in Salon H/K and Salon L

Overview

The National EpiFellows Foundation (NEF) Forum, which convenes epilepsy fellows, is held each year in conjunction with the Annual Meeting of the American Epilepsy Society (AES). This Forum consists of a general session followed by case study workshops, the cases for which are submitted by attendees and selected by the NEF Advisory Board.

Learning Objectives

- Discuss recent guideline updates and seizure classifications
- Describe advances in available epilepsy treatment and management including surgeries and imaging techniques to improve overall patient care
- Summarize clinical presentation of depressive disorder in patients with epilepsy and potential treatment and management strategies for patients suffering from this psychological comorbidity
- Integrate newer medications with improved side effect profiles into their treatment regimens in order to provide patients with the best treatment options available
- Develop and present an interactive case presentation based on clinical experience in epilepsy.

Target Audience

Neurology trainees and residents specializing in epilepsy

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American Epilepsy Society and Collegium LLC. The American Epilepsy Society is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 7.0 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Acknowledgment

This program is supported by an educational grant from Pfizer Inc.

9:00 a.m. – 4:00 p.m.

Advances in the Management of Epilepsy and the Epilepsy Clinic

(separate registration required — see below for instructions)

Marriott Rivercenter – Grand Ballroom, Salon I/J

This intensive one-day conference is designed for those professionals who participate in the care of persons with epilepsy. The overall purpose is to improve services to individuals and families affected by epilepsy. The conference is presented by the Department of Neurology of Wake Forest University School of Medicine, Winston-Salem, NC, through an unrestricted grant committed to the education of health professionals, in an effort to promote the comprehensive care of those with epilepsy and their families.

Noon – 2:30 p.m.

Annual Fundamentals of Epilepsy: Psychogenic Nonepileptic Seizures

(2.5 CME Credits)

Convention Center – Room 103

This session will highlight the following Benchmark goals:

III. Prevent, limit, and reverse the comorbidities associated with epilepsy and its treatment.

E. Develop effective methods for diagnosis, treatment and prevention of non-epileptic seizures (NES).

1. Determine the types and frequency of NES in the general population and in people with epilepsy.

2. Identify common susceptibility factors and etiologies for NES.

3. Validate at least one effective treatment for NES.

Benchmarks Steward: W. Curt LaFrance, Jr., M.D.

For more information, see p 53.

Overview

This symposium is designed to provide an understanding of psychogenic nonepileptic seizures (PNES) in children and adults. Limitations clinicians face and strategies they may utilize to improve care of this common patient population will be identified. Specifically, the symposium will address: 1) steps to accurate diagnosis of PNES, 2) frequent psychiatric comorbidities associated with PNES, and 3) treatment options to consider for PNES. Public health and policy issues will be addressed including screening and coding of PNES. Methods to overcome barriers to multidisciplinary care will be addressed from medical, nursing and social services perspectives.

Learning Objectives

- Recognize terminology, definitions and coding used in psychogenic nonepileptic seizures (PNES) and identify barriers to care
- Develop a strategy to recognize and diagnose psychogenic nonepileptic seizures in adults in a timely manner, reviewing video / EEG LTM and ictal semiology
- Identify the psychiatric comorbidities and risk factors that may result in the occurrence of PNES in adults
- Utilize various components of the clinical history and information obtained with video / EEG monitoring for accurate diagnosis of PNES in children
- Identify the psychiatric comorbidities and risk factors that may result in the occurrence of PNES in children
- Identify treatment model(s) for patients with nonepileptic seizures
- Formulate strategies by which nursing personnel can be actively involved in care of patients with PNES
- Utilize resources provided from multiple healthcare providers to coordinate care of patients with PNES.

Program

Co-Chairs: Brien J. Smith, M.D. and W. Curt LaFrance, Jr., M.D., M.P.H.

Introduction and Overview
Brien J. Smith, M.D.

PNES in Children – Diagnosis
Hema Patel, M.D.

PNES in Children – Psychiatric Considerations
Rochelle Caplan, M.D.

PNES in Adults – Diagnosis
Selim R. Benbadis, M.D.

PNES in Adults – Psychiatric Considerations
John J. Barry, M.D.

Treatment of PNES
W. Curt LaFrance, Jr., M.D., M.P.H.

Coordination / Barriers to Care – Nursing Perspective
Patricia O. Shafer, M.N., RN

Coordination / Barriers to Care – Social Work Perspective
Patricia A. Gibson, M.S.S.W.

Question and Answer Panel

Target Audience

Basic / fundamentals, Intermediate (see page 101 for details)

Pharmacy Credit

ACPE Universal Activity Number (UAN) is 031-999-10-019-L01-P and provides 2.5 contact hours (.25 CEUs)

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nursing contact hours have been applied for through the Texas Nurses Association, an accredited approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. To successfully complete this program and receive 2.5 Nursing Contact Hours, please complete and return the paper evaluation form to the volunteers at the door or the main registration desk at the conclusion of the program. You will receive your CE certificate in exchange for a completed form.

2:45 p.m. – 5:15 p.m.

Spanish Symposium: Status Epilepticus: Novel Concepts in Pathophysiology and Treatment Strategies

(2.5 CME Credits)

Convention Center – Room 007 C/D

Note: Posters from each of the 18 Partnering Epilepsy Centers in the Americas will be displayed at the Spanish Symposium.

Overview

The symposium will present evidence-based information concerning the scientific and clinical fundamentals of status epilepticus (SE) that are relevant for the management of adult and pediatric patients. The pathophysiological consequences of SE, their relationship to SE duration and the need for early intervention will be emphasized. Non-convulsive SE and SE in comatose patients and evidence related to neuronal protection and damage will be emphasized.

Learning Objectives

- When treating convulsive SE, implement appropriate treatment based on physiological consequences of SE
- Recognize non-convulsive SE and address the risks of neuronal damage in managing patient with non-convulsive SE
- Evaluate pediatric patients for age-related etiologies and consequences of SE and develop treatment strategies that address their specific therapeutic challenges.

Target Audience

Basic / fundamentals, Intermediate (see page 101 for details)

Program

Co-Chairs: Vicente J. Iragui, M.D., Ph.D. and Alvaro Izquierdo-Bello, M.D.

Introduction and Overview
Vicente J. Iragui, M.D., Ph.D.

Convulsive Status Epilepticus in Adults
Patricio E. Abad, M.D.

Non-Convulsive Status Epilepticus Including Status in Comatose Patients
Samuel Wiebe, M.D.

Pediatric Status Epilepticus
Luz Stella Caycedo, M.D.

Round Table / Question and Answer Session
Alvaro Izquierdo-Bello, M.D.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE Universal Activity Number (UAN) is 031-999-10-020-L01-P and provides 2.5 contact hours (.25 CEUs)

3:00 p.m. – 4:30 p.m.

Special Interest Group Meetings

Location listed under each session

Please complete program survey – see page 14

Children's Hour – New Developments in Infantile Spasms

Convention Center – Room 007 A/B

Coordinators: Lionel Carmant, M.D., Marcio A. Sotero de Menezes, M.D.
Speakers: Tallie Z. Baram, M.D., Ph.D., Aristea Galanopoulou, M.D., Ph.D., Lionel Carmant, M.D.

The Children's Hour this year will give an overview of the new developments in the understanding of infantile spasms. We will include discussions on basic mechanisms including the role of hypothalamic / pituitary axis / adrenal and its role in stress as well as the new animal models of Infantile Spasms. Last, but not least, Dr. Carmant will lead a discussion on the results of the latest trials aimed at improving cognitive dysfunction due to infantile spasms.

Acknowledgment
This SIG is supported by Questcor.

EEG – What Is a Seizure?

Convention Center – Room 006 A-C

Coordinator: Jean Gotman, Ph.D.
Speakers: Jean Gotman, Ph.D., Francois Dubeau, M.D., Raimondo D'Ambrosio, Ph.D., Frans Leijten, M.D., Ph.D., Tom Tcheng, Ph.D.

Is it possible to have an objective definition of a seizure? Is there such a thing as an electrographic seizure? Do experimental animals have seizures like humans? Are spikes small seizures? Shall we treat the EEG? Which seizures should we "zap?"

Epidemiology – CDC Epidemiologic Research Initiative

Convention Center – Room 203

Coordinators: Dale C. Hesdorffer, Ph.D., David J. Thurman
Speakers: Charles E. Begley, Ph.D., David Labiner, M.D., Barbara Kroner, Ph.D., W. Allen Hauser, M.D., Maria Pisu, Ph.D., Anbesaw Selassie, Ph.D.

The CDC is funding several epidemiological studies of epilepsy to improve surveillance methods, to better define the impact of epilepsy, and to evaluate differences in incidence and prevalence by race / ethnicity and socioeconomic status. This SIG group will be a forum for presentation of the results of several of these projects.

Neuropathology

Convention Center – Room 204

Coordinator: Harvey B. Sarnat, M.D., FRCPC
Speakers: TBD

The 2010 SIG in Neuropathology of Epilepsy will include three didactic themes, each with new advances in the neuropathology of surgical resections and autopsy brain tissue in epilepsy:

1) Columnar cortical architecture as a developmental delay or arrest and also as a newly recognized form of focal cortical dysgenesis that may be epileptogenic; 2) Maturation of the cortical tuber will be traced from fetuses with tuberous sclerosis to infants and children with surgical resection of highly epileptogenic tubers; 3) Satellitosis as a phenomenon of glial cell adhesion to the neuronal soma, will be examined in the context of two opposing theories: neuroprotection and contributing to epileptogenic neurons and later to neuronal death.

Neuropsychology – The Changing Role of Neuropsychology in Epilepsy: Future Directions

Convention Center – Room 202

Coordinator: Marla Hamberger, Ph.D.
Speakers: Bruce P. Hermann, Ph.D., David W. Loring, Ph.D., Mary Lou Smith, Ph.D.

With decades of research behind us and advances in neuroimaging, the role of neuropsychology in epilepsy is changing. The nature of these changes and their implications for both clinical practice and future research will be discussed from adult and pediatric perspectives.

Nursing Research – Osteoporosis

Convention Center – Room 006 D

Coordinators: Rebecca Schultz, RN, CPNP, M.S.N.
Georgette Smith, M.S.N., APRN, CPNP
Speakers: Rebecca Schultz, RN, CPNP, M.S.N., others TBA

The purpose of this SIG is to raise awareness about the nursing research currently being conducted for osteoporosis. Osteoporosis is a concern for people who take antiepileptic medications. A second aim is to generate discussion about gaps in the research examining the link between osteoporosis and antiepileptic medications and research needed to support nursing practice to foster prevention of osteoporosis.

SUDEP – Mechanisms and Models

Convention Center – Room 008

Coordinators: Lawrence J. Hirsch, M.D., Elizabeth J. Donner, M.D., FRCP(C), George B. Richerson, M.D., Ph.D.
Speakers: TBA

Presentation will include an invited data blitz with several brief presentations, partly based on abstracts being presented at this meeting, and a brief synthesis by the Chairs.

5:30 p.m. – 8:00 p.m.

Hot Topics Symposium: From Headlines to Healthcare

(2.5 CME Credits)

Marriott Rivercenter – Grand Ballroom, Salon E/F

Overview

1. Healthcare Reform: Impact on Care for Individuals with Epilepsy

With the recent passage of the Affordable Care Act (ACA), we now need to focus on the law's implementation and how it will affect the delivery of healthcare to individuals with epilepsy. How will the insurance market reforms in the ACA impact individuals with epilepsy? How quickly will uninsured patients have access to new forms of insurance coverage? How will the ACA impact Medicare and Medicaid recipients with epilepsy? How will the quality provisions in the ACA affect the delivery of care to individuals with epilepsy and other chronic illnesses?

2. Blast to the Future: Implications of Combat-Induced TBI on Epilepsy

Military-induced traumatic brain injury (TBI) has become common among the young U.S. population. However, statistics differ between reporting sources. Many veterans who suffer military TBI obtain care in the VA system; many integrate into the civilian practice and receive care from practitioners who may not recognize TBI as the etiology of their epilepsy. The identification / battlefield treatment / surveillance and current armed forces research will be presented and discussed with experts from the armed forces. The clinical correlation and application to epileptologists' current clinical practice will be provided.

Learning Objectives

- Identify changes in access to health care for individuals with chronic illness that will improve access to care
- Address possible impediments to delivery of care for individuals with epilepsy
- Recognize TBI as a cause of epilepsy in military personnel as well as civilians
- Utilize currently accepted preferred practice for treatment of patients with seizures and epilepsy due to TBI.

Target Audience

Basic / fundamentals, Intermediate, Advanced (see page 101 for details)

Acknowledgment

The healthcare reform portion of the symposium is supported in part by an educational grant from UCB, Inc.

Program

Co-Chairs: David M. Labiner, M.D. and Karen L. Parko, M.D., FAAN

1. Healthcare Reform: Impact on Care for Individuals with Epilepsy

Introduction and Overview
David M. Labiner, M.D.

Living with Epilepsy in the Current System
Lisa Moss, parent of child with epilepsy, Epilepsy Foundation Board Member

Healthcare Reform Legislation: Impact on Epilepsy Care
Carly N. Kelly, J.D.

Q & A

2. Blast to the Future: Implications of Combat Induced TBI on Epilepsy

Introduction and Overview
Karen L. Parko, M.D., FAAN

Seizure Care and Prophylaxis on the Battlefield: What is DVBIC
COL Jamie B. Grimes, M.D.

DOD Policy on Treatment of Seizures and Protocols for Prophylaxis of Seizure in TBI
Jack Tsao, M.D., D.Phil.

Physics of Blast Injury and Military Models of Blast Research: What is DARPA?
Geoffrey Ling, M.D., Ph.D.

Care of Veterans in the New Epilepsy Centers of Excellence
Karen L. Parko, M.D, FAAN

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE Universal Activity Number (UAN) is 031-999-10-021-L04-P and provides 2.5 contact hours (.25 CEUs)

New This Year

The American Epilepsy Society is pleased to announce the introduction of

PRODUCT TRAINING PAVILIONS

located inside the Exhibit Hall

These pavilions offer companies an opportunity to provide education and training to meeting attendees in a convenient and more personal environment.

The Product Training Pavilions will be open on the following days:

Saturday, December 4: 11:30 a.m. - 6:00 p.m. — Novartis

Sunday, December 5: 11:00 a.m. - 6:00 p.m. — Lundbeck

Monday, December 6: 11:00 a.m. - 4:00 p.m. — Novartis

EQUIPMENT AUCTION TO BENEFIT THE LENNOX AND LOMBROSO TRUST and THE SUSAN SPENCER FUND

AES is pleased to announce that Nihon Kohden, Grass Technologies, and Optima Neuroscience are participating in the AES Annual Benefit Auction this year! These companies have donated equipment and/or software that has been auctioned off, and winning bids will be announced during the meeting.

These companies are contributing 100% of their proceeds to the Lennox and Lombroso Trust for Research & Training, and the Susan S. Spencer Fund for Education and Research.

Please join us in AES Exhibit Hall at the company's booth to witness the presentation of a check from each company to Dr. Dennis Spencer, Chair of the AES Development Committee.

Saturday, December 4 at Noon • Booth #337

GRASS TECHNOLOGIES (an Astro-Med, Inc. subsidiary)
Auction Item: TREA Ambulatory EEG Recorder
Worth: $15,000. Minimum Bid: $5,000.
Website: http://www.grasstechnologies.com
Auction Contact: Tina Pollard at tpollard@astromed.com

Sunday, December 5 at Noon • Booth #525

NIHON KOHDEN (2nd year)
Auction Item: EEG-1200A Diagnostic and Monitoring Solution
Worth: $38,250. Minimum Bid: $10,000.
Website: www.nkusa.com/neurology_cardiology
Auction Contact: Kathy Hart at Kathy_hart@nkusa.com

Monday, December 6 at Noon • Booth #422

OPTIMA NEUROSCIENCE, INC.
Auction Item: EEG review software IdentEvent
Worth: $8,000. Minimum Bid: $2,000.
Website: www.optimaneuro.com
Auction Contact: Amanda Burks at aburks@optimaneuro.com

We thank these companies for their donations, and you for bidding on these items.

If you know of other companies that would be interested in participating in the AES Annual Benefit Auction, or if you have questions, contact Jeff Melin at jmelin@aesnet.org.

9:15 a.m. – 11:15 a.m.

8th Judith Hoyer Lecture in Epilepsy

Award Presentation: AES Service Award

Convention Center – Lila Cockrell Theatre

Lecturer: Dennis D. Spencer, M.D.

The 8th Judith Hoyer Lecture in Epilepsy, presented by invited Lecturer Dr. Dennis Spencer, is sponsored by the National Institute of Neurological Disorders and Stroke. Dr. Spencer's presentation is the eighth in a series of lectures highlighting the promise of epilepsy research. This series is held in memory of Mrs. Judith Hoyer, an active member of the Board of Directors of the Epilepsy Foundation and the late wife of Representative Steny Hoyer (D-MD). Mrs. Hoyer spent her life both helping families to cope with epilepsy and promoting research into a cure and a better quality of life for those with the disorder. The purpose of the lecture is to raise awareness of epilepsy among researchers and the public and provide intellectual stimulation that will encourage continuing progress toward finding a cure for epilepsy.

9:30 a.m. – 11:00 a.m.

Special Interest Group Meetings

Location listed under each session

Please complete program survey – see page 14

Basic Neuroscience – Depolarizing GABAergic Signaling and Seizures

Convention Center – Room 007 C/D

Coordinators: Brenda E. Porter, M.D., Ph.D., Celine Dube, Ph.D., Michael Wong, M.D., Ph.D.

Speakers: Kevin J. Staley, M.D., Aristea Galanopoulou, M.D., Ph.D., John F. Kerrigan, M.D.

The SIG will discuss the contribution of the depolarizing action of GABA to increased susceptibility to seizures in neonates and to epileptogenesis in adults. Dr. Staley will discuss the role of the bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 in depolarizing GABA actions and its potential therapeutic anticonvulsant effects in neonates. Dr. Galanopoulou will talk about the importance of $GABA_A$-receptor signaling for age and sex-specific effects of seizures. Dr. Kerrigan will discuss the depolarizing GABAergic response in human hypothalamic hamartomas.

MEG / MSI Data Highlights: An International Perspective

Convention Center – Room 007 A/B

Coordinator: Jerry J. Shih, M.D.

Speakers: Hermann Stefan, M.D., Robert Knowlton, M.D., Yung-Yang Lin, M.D., Gregory Barkley, M.D., Timothy Roberts, Ph.D.

Despite the seamless flow of the literature across borders, regional differences exist in the type of research questions addressed. A panel from Europe, Asia and North America will select and present the most important discoveries in the past two years from their own geographical region and assess their impact on clinical practice. The session will conclude with a 10-minute discussion on MEG reimbursement worldwide. Audience participation is strongly encouraged in what should be a lively Q & A session.

Surgery: Work-Up and Surgical Treatment of "Non-Lesional Epilepsy"

Convention Center – Room 006 A-C

Coordinator: Michael M. Haglund, M.D., Ph.D.

Speakers: Saurabh R. Sinha, M.D., Ph.D., Gerald Grant

This year we will discuss the approaches different groups take in the work-up and surgical treatment of "non-lesional epilepsy." Last year we had a great discourse on approaches to specific cases and as usual the audience participation was active and made for great debate. I look forward to moderating another exciting session, especially with the topic of "non-lesional epilepsy." Please e-mail your willingness to present by sending cases to Dr. Haglund at haglu001@mc.duke.edu. The success of this session is dependant upon the great and lively audience participation.

1:45 p.m. – 4:15 p.m.

Presidential Symposium: GABAergic Transmission in Epilepsy

(2.0 CME Credits)

Award Presentation: Research Recognition Awards, William G. Lennox Award, NINDS Update by Story Landis, Ph.D. and ILAE update by Solomon L. Moshé, M.D.

Convention Center – Lila Cockrell Theatre

Overview

This symposium will focus on the role of gamma-aminobutyric acid (GABA) in the pathophysiology of seizures and will include discussion of its role in a variety of clinical settings, including neonatal seizures, status epilepticus and temporal lobe epilepsy. Current understanding of GABA's role in epilepsy, including GABAergic plasticity and GABA receptor mutations, will be presented. Treatment decisions, informed by this understanding, including the use of novel medication for neonatal seizures and the imperative for early treatment of status epilepticus with benzodiazepines, will be discussed.

Learning Objectives

- Establish treatment protocols based on the role of GABA and GABAergic neurons in clinical settings such as status epilepticus and chronic temporal lobe epilepsy
- In treating status epilepticus, use benzodiazepines as first line treatment, initiating benzodiazepines early in treatment
- Use information from translational research on the role of excitatory GABA to manage neonatal seizures
- When evaluating patients with idiopathic (inherited) epilepsies, learner will include recognition of the role of $GABA_A$ receptor mutations in developing a differential diagnosis.

Target Audience

Intermediate, Advanced (see page 101 for details)

Program

Chair: Jaideep Kapur, M.D., Ph.D.

Introduction and Overview
Jaideep Kapur, M.D., Ph.D.

GABA and GABAergic Neurons Orchestrate Synchrony in Developing Hippocampal Networks
Yehezkel Ben Ari, Ph.D.

Novel Therapies for Neonatal Seizures
Kevin J. Staley, M.D.

GABA Receptor Trafficking During Status Epilepticus
Howard Goodkin, M.D., Ph.D.

$GABA_A$ Receptors and GABAergic Interneurons in Chronic Temporal Lobe Epilepsy
Carolyn R. Houser, Ph.D.

$GABA_A$ Receptor Subunit Mutations in Genetic Epilepsies
Robert L. Macdonald, M.D., Ph.D.

Credit Designation
The American Epilepsy Society designates this educational activity for a maximum of 2.0 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 031-999-10-022-L01-P and provides 2 contact hours (.2 CEUs)

5:30 p.m. – 7:15 p.m.

AET Symposium: Channel Surfing: Impact on Treatment Strategies
(1.75 CME Credits)

Award Presentation: J. Kiffin Penry Excellence in Epilepsy Care Award

Convention Center – Lila Cockrell Theatre

Overview
This symposium will address the role of ion channels in the pathophysiology of epilepsy and its treatment. There will be a review of the role of voltage- and receptor-gated ion channels in controlling membrane excitability. The genetic assessment of patients suspected of having channel disorders will be outlined. The importance of ion channels as targets for treatment with antiepileptic medications (AEDs) will be defined. Among topics to be discussed are the impact of developmental differences in chloride transporters on treatment of seizures in children; the contribution of $GABA_A$ receptor availability during periods of intense neuronal excitability to the development of intractable status epilepticus; benign neonatal familial convulsions (BNFC) as an example of a genetic epilepsy due to deficits in Kv7.2 and Kv7.3 channels. Medical management of epilepsy is enhanced by knowledge of the specific mechanisms of action of AEDs on ion channels, leading to more rational therapy and improved clinical outcomes.

Learning Objectives
- Apply an understanding of the role of ion channels in managing patients with epilepsy
- Recognize epilepsy syndromes due to genetic abnormalities in ion channels
- Apply knowledge of ion channel pathophysiology in selecting AEDs and in assessing the role of newly developed drugs.

Target Audience
Intermediate (see page 101 for details)

Program
Co-Chairs: L. James Willmore, M.D. and H. Steve White, Ph.D.

Introduction and Overview
L. James Willmore, M.D.

Central Nervous System Channels: Review of the Basics
Michael A. Rogawski, M.D., Ph.D.

Role of the Sodium Channel in Clinical Disorders: Challenges for Rational Treatment
Samuel F. Berkovic, M.D.

GABA-Induced Depolarization: A Tale of Opposing Forces
Jong M. Rho, M.D.

Potassium Channelopathies: Consequences and Impact on Treatment
Karen S. Wilcox, Ph.D.

Credit Designation
The American Epilepsy Society designates this educational activity for a maximum of 1.75 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 031-999-10-023-L01-P and provides 1.75 contact hours (.175 CEUs)

Acknowledgment
This symposium is supported in part with an educational grant from Sunovion Pharmaceuticals Inc.

6:00 p.m. – 7:30 p.m.

Investigators' Workshop
Convention Center – Room 007 A/B

Peptidopathy, Channelopathy or Bad Network – What Causes Epilepsy in Alzheimer's Disease?
Moderators: Asla Pitkanen, M.D., Ph.D., Helen E. Scharfman, Ph.D.
Speakers: Jeffrey L. Noebels, M.D., Ph.D., Helen E. Scharfman, Ph.D., Jorge Palop, Ph.D.

6:00 p.m. – 8:00 p.m.

Translational Investigators' Workshop
Convention Center – Room 006 A-C

Copy Number Variation in the Epilepsies
Moderator: Sanjay M. Sisodiya, M.D.
Speakers: Ingrid E. Scheffer, Ph.D., FRACP, Sarah von Spiczak, M.D., Sanjay M. Sisodiya, M.D., Heather C. Mefford, M.D., Ph.D.

7:30 p.m. – 9:00 p.m.

Special Interest Group Meetings
Location listed under each session
Please complete program survey – see page 14

Ketogenic Diet – Glucose Restriction Revisited
Marriott Rivercenter – Grand Ballroom, Salon H
Coordinators: Jong M. Rho, M.D., Elizabeth Thiele, M.D., Ph.D.
Speakers: Elizabeth Thiele, M.D., Ph.D., Susan Masino, Ph.D., Beth A. Zupec-Kania, R.D., C.D.

This year's SIG will revisit the topic of reduced glucose as an interventional strategy and potential mechanistic underpinning of ketogenic diet (KD) action. There are emerging data indicating that reduced glucose may have profound effects on neuronal excitability through novel mechanisms, including purinergic modulation. Additionally, low serum glucose levels are not always seen in patients successfully treated with the KD, suggesting more complex metabolic interactions.

Neurostimulation – Breaking News in Neurostimulation for Epilepsy
Marriott Rivercenter – Grand Ballroom, Salon F
Coordinators: James W. Wheless, M.D., Christopher DeGiorgio, M.D.
Speakers: Douglas R. Labar, M.D., Ph.D., Martha J. Morrell, M.D., Erika Fanselow, M.D., Christopher DeGiorgio, M.D.

This SIG will cover three topics. First, Dr. Labar will present an update on safety and efficacy from the pivotal SANTE trial. Second, Dr. Morrell will discuss responsive stimulation for the treatment of medically intractable partial epilepsy using the results of the RNS(r) System trial. Third, Drs. Fanselow and DeGiorgio will discuss trigeminal nerve stimulation, an emerging therapy.

Nonepileptic Seizures
Marriott Rivercenter – Grand Ballroom, Salon G/M
Coordinator: John J. Barry, M.D.
Speakers: Selim R. Benbadis, M.D., W. Curt LaFrance, Jr., M.D., M.P.H., Markus Reuber, M.D., Ph.D.

The first part will feature an enthusiastic debate on terminology between Drs. Benbadis and LaFrance, Jr. The second part will have Dr. Reuber presenting the use of Conversation Analysis in the diagnosis of NES.

Patient Reported Outcomes – Improving Mental Health Outcomes in People with Epilepsy through the CDC Managing Epilepsy Well Network – PEARLS and UPLIFT
Marriott Rivercenter – Grand Ballroom, Salon J
Coordinators: Rosemarie Kobau, M.P.H., Eric K. St. Louis, M.D.
Speakers: Nancy J. Thompson, Ph.D., M.P.H., Paul Ciechanowski, M.D., M.P.H.

Two interventions supported by the CDC Managing Epilepsy Well (MEW) Network are designed to meet the gap in mental health treatment for people with epilepsy. PEARLS (Program to Encourage Active, Rewarding Lives) is a community-integrated, home-based treatment for depression previously shown to be effective at reducing depression symptoms and improving quality of life for individuals with acute and chronic depression (Ciechanowski, et al., 2004). PEARLS consists of problem-solving treatment, behavioral activation, and psychiatric consultation. Adults with epilepsy and comorbid depression receiving PEARLS were more likely to have reductions in depression and improvements in quality of life, as compared to usual care. UPLIFT (Using Practice and Learning to Increase Favorable Thoughts), another home-based treatment for depression in people with epilepsy, was developed to provide group delivery of depression treatment by telephone or Web. UPLIFT materials include eight modules that incorporate mindfulness-based cognitive therapy for depression. With support from the National Center for Minority Health and Health Disparities, UPLIFT has expanded its scope to include prevention of depression in people with epilepsy. UPLIFT participants will be recruited from all MEW sites in Georgia, Michigan, Texas and Washington State. MEW Network members work together to promote epilepsy self-management research and improve the quality of life for people with epilepsy. (http://www.sph.emory.edu/ManagingEpilepsyWell/index.php)

Acknowledgment
This SIG is supported by Sunovion Pharmaceuticals Inc.

Women's Issues – Women with Epilepsy and Special Disabilities
Marriott Rivercenter – Grand Ballroom, Salon A/B
Coordinators: Lisa M. Bateman, M.D., Mary L. Zupanc, M.D.
Speakers: TBA

This group of women poses special challenges to the adult / pediatric epileptologist. The issues include contraception and pregnancy related issues, guardianship, transition to appropriate adult healthcare, and transition from school to adult work / sheltered workshops. There are many other issues as well, similar to all adolescent / adult women with epilepsy, such as bone mineral health, folate supplementation, catamenial epilepsy, etc.

9:00 p.m. – 10:00 p.m.
➤ Social Networking Groups
(registration is not required)

Marriott Rivercenter – Grand Ballroom, Salon C/D
Informal gathering and networking for SIG participants. Space is limited so participants are welcome on a first come, first served basis.

Topic areas to include:
- Indo-American epilepsy education
- Critical care monitoring
- More TBA

Remember to Attend

Sunday, December 5
8:00 a.m. – 8:30 a.m.

AES BUSINESS MEETING

Marriott Rivercenter –
Grand Ballroom, Salon E

coffee available

All AES members are encouraged to attend this yearly meeting.

SCIENTIFIC EXHIBITS

Scientific exhibits will again be on display at this year's annual meeting and will be located in the **Henry B. Gonzalez Convention Center, Rooms 102 and 103.** These exhibits will provide meeting attendees an opportunity to update themselves on the latest research. Authors will be present throughout the exhibit.

Sunday, December 5 • 8:00 a.m. - 11:00 a.m.

Lundbeck *102 A/B*
Novel Anticonvulsants: Vigabatrin, Clobazam, and IV Carbamazepine

UCB, Inc. *103 A*
VIMPAT® (lacosamide) C-V: Optimizing Adjunctive Treatment in Epilepsy

Sunday, December 5 • 8:00 a.m. - 5:00 p.m.

Sunovion Pharmaceuticals Inc. *103 B*
Eslicarbazepine Acetate: Developing a New Treatment for Epilepsy

Sunday, December 5 • 2:00 p.m. - 5:00 p.m.

Questcor Pharmaceuticals, Inc. *103 A*
Acthar in Infantile Spasms: New Insights into a Long-Established Standard of Care

Monday, December 6 • 8:00 a.m. - 11:00 a.m.

NeuroPace *102 B*
The NeuroPace RNS® System: Experience with a Responsive Neurostimulation System for the Treatment of Intractable Partial Epilepsy

Cyberonics, Inc. *103 B*
Cyberonics' Role in the Future of Neurostimulation

Monday, December 6 • 2:00 p.m. - 5:00 p.m.

Eisai, Inc. *102 A/B*
Eisai's Dedication to Patients: Research in Epilepsy

➤ **Authors Present: Noon – 2:00 p.m.**
➤ **Poster Walking Tours (see page 12 for details)**

Translational Research
Basic Mechanisms

1.001 The Relation Between Interictal Spikes And Seizures In Rat Models Of Epilepsy/M. Dichter, H. Juul, J. Keating
1.002 The Role Of Astrocytes In The Epileptogenicity Of Cortical Microgyri/C. Dulla, H. Tani, J. Brill, R. Reimer, J. Huguenard
1.003 GABAergic Excitation Contributes To Seizure Generation In Vitro/K. Lillis, M. Kramer, J. Mertz, J. White, K. Staley
1.004 Chronic Changes Of Reactive Astrocytes In Rat Brain Following Pilocarpine-Induced Seizures/X. Wu, A. Sosunov, G. McKhann II
1.005 HCN Channel Inhibition Enhances Epileptiform Responses In Neocortical Neurons/A. Albertson, S. Williams, J. Hablitz
1.006 Role Of trkB Receptors And Presynaptic Axonal Sprouting In Hyperexcitability After Schaffer Collateral Transection And Its Contribution To Posttraumatic Epilepsy/S. Aungst, P. England, S. Thompson
1.007 A Candidate Role For Aberrant mTOR Signaling In SE-associated Alterations In Dendritic Ion Channel Homeostasis/A. Brewster, J. Lugo, F. Vanegas, Y. Qian, A. Anderson
1.008 Changes In Action Potential Features Correlate With Different Phases Of Focal Seizure Discharges In The Entorhinal Cortex/M. de Curtis, V. Gnatkovsky, F. Trombin
1.009 Prolonged Cannabinoid Exposure Alters $GABA_A$ Receptor Mediated Synaptic Function In Cultured Hippocampal Neurons/L. Deshpande, R. Blair, R. DeLorenzo
1.010 Altered GABA Signaling In The Acute Hippocampal Slice Model Of Brain Trauma/V. Dzhala, M. Mail, K. Staley
1.011 Neurosteroid Withdrawal Increases The GABA-A Receptor Delta-Subunit Expression And Antiseizure Sensitivity Of Neurosteroids/O. Gangisetty, D. Reddy
1.012 WP1066 Slows The Progression Of Pilocarpine-induced Epilepsy By Inhibiting The Phosphorylation Of STAT3/H. Grabenstatter, M. Gonzalez, Y. Raol, Y. Cruz, S. Russek, A. Brooks-Kayal
1.013 Hippocampal Interneurons Increase Firing Rate At The Onset Of Spontaneous Seizures In An Awake, Freely Moving Rat Model Of Temporal Lobe Epilepsy/D. Grasse, K. Moxon
1.014 mTOR Inhibition Has Potential Antiepileptogenic Effects In A Controlled Cortical Impact Model Of Traumatic Brain Injury/D. Guo, L. Zeng, D. Brody, M. Wong
1.015 Transgenic Over-Expression Of Cyclooxygenase-2 (COX-2) In Neurons Suppresses Pentylenetetrazole (PTZ)-induced Acute Seizure Activity And Kindling Acquisition/J. Hewett, K. Andreasson, S. Hewett
1.016 Hypoxia Induced Early Life Seizures Lead To Increased Aberrant CA3 Mossy Fiber Sprouting With No Associated Cell Death/P. Klein, C. Hilario-Gomez, B. Kosaras, S. Rakhade, F. Jensen
1.017 Early-life Seizures Lead To Increased AMPA Subunit-Containing Synapses And Higher Ca2+ Responses In Rat Pyramidal CA1 Neurons/J. Lippman Bell, C. Zhou, P. Klein, F. Jensen
1.018 Kainate-induced Status Epilepticus Alters BDNF Gene Expression In Area CA1 And Memory Formation Using Epigenetic Mechanisms/F. Lubin, R. Parrish
1.019 The Antiepileptic Effect Of A Ketogenic Diet Is Mediated By Adenosine A1 Receptors/S. Masino, T. Li, A. Rahman, B. Fredholm, J. Geiger, D. Boison
1.020 Transient Group I Metabotropic Glutamate Receptor Activation Enhances CA3 Excitatory Synaptic Network Activity/Y. Pan, P. Rutecki
1.021 Pharmacological Inhibition Of Interleukin-1β And Cycloogenase-2 Decreases Seizure Frequency And Mossy Fiber Sprouting In The Pilocarpine Model Of Epilepsy/E. Pineda, D. Shin, R. Sankar, A. Mazarati
1.022 Epileptiform Activity In The Isolated Guinea Pig Brain Triggers Increased Expression Of IL-1beta And Blood-Brain Barrier Damage/A. Vezzani, L. Librizzi, I. Vanzulli, T. Ravizza, M. de Curtis
1.023 Excitatory Effect Of TNF-alpha On Rat Hippocampal CA1 Pyramidal Neurons After Neonatal Seizure-Inducing Hypoxia/K. Zhang, J. Heida, K. Katki, R. Sanchez
1.024 Local Neurometabolic Coupling Surrounding A Seizure Focus In Rat Neocortex/M. Zhao, H. Ma, E. De La Cruz, T. Schwartz
1.025 Early Life Seizures In The Rat Cause Alterations Of NMDA Receptor Function/C. Zhou, J. Lippman Bell, P. Klein, F. Jensen
1.026 Activation Of Innate And Adaptive Immunity After Kainate-Induced Status Epilepticus In Temporal Lobes Sensitized By Early Life Convulsions/J. Abraham, D. Duncan, S. Miller, S. Koh
1.027 Induction And Expression Of miR-146a, An Inflammation Associated MicroRNA, In Experimental And Human Epilepsy And In Cultured Human Astrocytes/E. Aronica, E. Zurolo, K. Fluiter, A. Iyer, J. Vreijling, E. van Vliet, J. Baayen, J. Gorter
1.028 Effects Of Depressed K+ Currents Caused By High [K+]o On The Epileptiform Bursting: A Computational Study/G. Florence, T. Pereira, J. Kurths
1.029 Regional Differences In Arc/Arg 3.1 Protein Expression In The Immature Brain Induced By Seizures/C. Gomez, B. Kosaras, P. Klein, F. Jensen
1.030 Long-term Modulation Of The Synaptic Plasticity In Somatosensory Area Of Neocortex By Recurrent Flurothyl Seizures Induced Early In Life/O. Isaeva, G. Holmes
1.031 Rapid Loss Of Dendritic HCN Channel Expression Following Status Epilepticus/S. Jung, L. Warner, J. Pitsch, A. Becker, N. Poolos
1.032 Reduced Excitability Of GABAergic Interneurons In The Reticular Nucleus Of The Thalamus And Sleep Impairment In A Mouse Model Of Severe Myoclonic Epilepsy Of Infancy/F. Kalume, J. Oakley, R. Westenbroek, T. Scheuer, W. Catterall
1.033 Alterations In Thalamic GABAergic Signaling In A Mouse Model Of Angelman Syndrome/A. Lagrange, L. Herrington, R. Jawa, M. Grier, C. Weitlauf, K. Haas
1.034 Increased Cardiac Arrhythmogenic Potential In A Model Of Temporal Lobe Epilepsy/Y. Lai, S. Wang, F. Vanegas, M. Valderrábano, A. Anderson
1.035 Age- And Time-Dependent Expression Of CD74 After Kainic Acid-Induced Status Epilepticus/K. Li, S. Erisken, H. Chung, S. Koh
1.036 The Inflammatory Chemokine CXCL10 Facilitates Long-Term Potentiation (LTP) In The Hippocampus/G. Moddel, J. Kodangattil Narayanan, M. Müller, A. Gorji
1.037 Predicting Epileptogenesis During The Latent Period After Status Epilepticus On The Basis Of Depression Symptoms Detected Via Behavioral Tests/E. Moroz, A. Bragin, J. Engel Jr
1.038 Recurrent Seizures Suppress Dendritic Growth Of Developing Hippocampal Pyramidal Cells/M. Nishimura, J. Swann
1.039 Focal Status Epilepticus In The Somatosensory Cortex Enhances Intrinsic Excitability And Synaptic Excitation In The Reticular Thalamic Nucleus/J. Paz, W. McDonald, D. Prince, J. Huguenard
1.040 Efficacy Of Flupirtine To Treat Hypoxia-Induced Neonatal Seizures/Y. Raol
1.041 Antiepileptogenic Activity Of Progesterone In Mice Lacking Progesterone Receptors/D. Reddy, S. Briyal, O. Gangisetty
1.042 Pathways Of Interictal Spike Propagation Are Determined By Network Inhibition/W. Swiercz, H. Sabolek, S. Cash, G. Huberfeld, S. Clemenceau, R. Miles, K. Staley
1.043 From Rats To Men: A Virtual Water-Maze Navigation Task To Investigate Cognitive Impairments In Patients With Epilepsy/A. Titiz, R. Scott, G. Holmes, P. Lenck-Santini
1.044 Connexins In The Rat Model Of Temporal Lobe Epilepsy Induced By Pilocarpine: Expression And Gap Junction Blockade/A. Christina Valle, E. Kinjo, E. Morya, A. Kihara, L. Britto

1.045 A Putative Cellular Mechanism For Childhood Absence Epilepsy In Patients With Cav3.2 Gain-Of-Function Mutations/L. Xu, Z. Jin, S. Smith, M. Anderson
1.046 Pentylenetetrazole-induced Seizures Cause Acute, But Not Chronic, mTOR Pathway Activation In Rat/B. Zhang, M. Wong
1.047 An Organotypic Hippocampal Slice Culture Model Of Excitotoxic Injury Induced Spontaneous Recurrent Epileptiform Discharges/J. Ziobro, L. Deshpande, R. DeLorenzo
1.048 Predicting Cortical Neuron Spike Patterns: Point Process Modeling Of An Epilepsy Computational Simulation/W. Anderson, F. Azhar, P. Franaszczuk
1.049 Long-Lasting Changes In mGluR Mediated Long-Term Depression Following A Single Episode Of Early Life Seizures/P. Bernard, A. Castano, T. Benke
1.050 Effects Of Beta Adrenergic Activation On The Interictal And Ictal-Like Activity In Vitro/A. Hazra, T. Wadadekar, N. Nguyen, F. Gu, K. Josic, B. Bodmann, J. Ziburkus
1.051 Deficit Of Small-Conductance, Calcium-Activated SK Potassium Channels In Pilocarpine-Treated Epileptic Rats/L. Pacheco, E. Garrido, B. Ermolinsky, M. Arshadmansab, F. Skinner, I. Garcia, M. Oliveira, C. Mello, H. Knaus
1.052 Functional Effects Of Long-Lasting, Seizure-Induced Alterations In NKCC1 And KCC2 In The Dentate Gyrus Of Kindled Rats/Y. Pan, P. Rutecki, D. Sun, T. Sutula
1.053 ERK and mTOR Pathway Interactions In Epilepsy/V. Patil, S. Agadi, D. Yoshor, D. Curry, A. Brewster, M. Bhattacharjee, J. Swann, A. Anderson
1.054 Mechanisms Of Cortical High-Gamma Activity (60-200 Hz) Investigated With Computational Modeling/P. Suffczynski, N. Crone, P. Franaszczuk
1.055 Rapamycin Suppresses Mossy Fiber And Somatostatin Interneuron Axon Sprouting But Not Epileptogenesis In A Mouse Model Of Temporal Lobe Epilepsy/P. Buckmaster, X. Wen, F. Lew
1.056 Slow Changes In Functional Connectivity During Epileptogenesis In A Spontaneously Seizing Animal Model Of Temporal Lobe Epilepsy/A. Cadotte, S. Myers, M. Parekh, S. Talathi, T. Mareci, P. Carney
1.057 Gene Profiling Of The CA1 After Multiple Early-Life Seizures/ L. Friedman, J. Mancuso, A. Sagyhan, D. Iacobas, S. Iacobas, D. Spray
1.058 A Novel Method For The Separation And Measurement Of Allopregnanolone And Other Pregnanolone Neurosteroids In Cerebrospinal Fluid And Serum/ B. Hallinan, S. Nkinin, T. Glauser, K. Setchell
1.059 TLE Patients Show The Hemispheric Lateralization Of The Autonomic Functions/M. Tripathi, N. Chaudhary, S. Chandra, A. Jaryal, K. Deepak
1.060 Permanently Impaired Mitochondrial Redox Status And Oxidative/Nitrosative Stress During Epileptogenesis/S. Waldbaum, K. Ryan, L. Liang, M. Patel

Clinical Neurophysiology
EEG - Video, ICU or Monitoring, For Epilepsy
1.061 A European Database Of Clinical And EEG Data From Patients With Epilepsy/A. Schulze-Bonhage, M. Ihle, M. LeVanQuyen, F. Sales, A. Dourado
1.062 Correlation Between Interictal High-Frequency Oscillations And Seizure Outcome In Pediatric Resective Epilepsy Surgery/T. Akiyama, C. Go, A. Ochi, I. Elliott, E. Donner, S. Weiss, O. Snead III, J. Rutka, J. Drake, H. Otsubo
1.063 Peri-Ictal Heart Rate Variability In Subjects With Partial Epilepsy/ J. Arias, M. Soto-Salgado, I. Pita
1.064 Detection And Clinical Outcome Of Status Epilepticus In Patients Undergoing Continuous EEG Monitoring/P. Emmady, V. Acharya, J. Acharya
1.065 Is High Frequency Ictal EEG Associated With Favorable Surgical Outcome?/H. Fujiwara, K. Holland-Bouley, J. Seo, D. Rose, F. Mangano, K. Lee
1.066 Into The Spectrum Of Hyperkinetic Seizures: A Clinical-Kinematic And SEEG Study/E. Gardella, L. Castana, G. Io Russo, M. Canevini, S. Francione
1.067 Prevalence Of Non-Convulsive Seizures Due To Cerebral Hemorrhage In The ICU/J. Politsky, I. Ugorec, Z. Rothkopf, M. Heyes
1.068 Cyclic Electrographic Seizures In Children: A Unique EEG Pattern Of Status Epilepticus/J. Riviello, S. Agadi, C. Marx, T. Lotze, C. Akman
1.069 Safety Of Prolonged Video-EEG Monitoring In A Tertiary Pediatric Epilepsy Monitoring Unit/D. Arrington, K. Chapman, J. Kerrigan
1.070 Validation Of An Automated Neonatal Seizure Detector: A Clinician's Perspective/P. Cherian, W. Deburchgraeve, R. Swarte, M. de Vos, P. Govaert, S. Van Huffel, G. Visser
1.071 Computer-Assisted EEG Monitoring In The Adult ICU/ M. Cloostermans, C. de Vos, M. Van Putten
1.072 A Probability Estimate For The Time To First Diagnostic Event During Long-Term Video-EEG Monitoring/O. Lie, W. Kim, J. Miller, J. Oakley
1.073 Prevalence Of Continuous Epileptiform Discharges On EEG In Patients Treated With Cefepime And Meropenem/G. Naeije, S. Lorent, J. Vincent, B. Legros
1.074 Changes In Sympathetic Activity Associated With Epileptic Seizures/M.-Zher Poh, T. Loddenkemper, C. Reinsberger, N. Swenson, S. Goyal, J. Madsen, R. Picard
1.075 Quantitative EEG Trending For Monitoring Non-Convulsive Seizures In ICU Patients/D. Shiau, S. LaRoche, J. Halford, K. Kelly, R. Kern, J. Chien, J. Valeriano, P. Pardalos, J. Sackellares
1.076 Dystonic Posturing And Dystonic Automatisms In Mesial Temporal Lobe Epilepsy: Worse Surgical Outcome?/C. Uchida, O. Barsottini, L. Souza, R. Centeno, H. Carrete Junior, L. Caboclo, E. Yacubian
1.077 New Method For Identification Of Responses To Single Pulse Electrical Stimulation In Epilepsy Patients/ M. van 't Klooster, M. Zijlmans, F. Leijten, C. Ferrier, G. Huiskamp
1.078 Ictal Patterns In Mesial Temporal Lobe Epilepsy Recorded By Foramen Ovale Electrodes/ N. Velez-Ruiz, S. Sheth, M. Morita, D. Costello, E. Eskandar, S. Cash, A. Cole
1.079 Seizures And Rhythmic Activity During Continuous Video-EEG Monitoring In Newborns Receiving Whole Body Hypothermia For Moderate To Severe Encephalopathy/ T. Wechapinan, T. Chang, M. Alduligan, A. Massaro, S. Baumgart, T. Tsuchida
1.080 Short-term Outcome Prediction By Electroencephalographic Features In Children Treated With Therapeutic Hypothermia After Cardiac Arrest/ N. Abend, S. Kessler, A. Topjian, A. Gutierrez-Colina, R. Ichord, M. Donnelly, V. Nadkarni, R. Berg, D. Dlugos, R. Clancy
1.081 Use Of Interictal High Frequency Oscillations As A Predictor In The Identification Of Seizure Onset Zone In Patients With Focal Epilepsy/ A. Bermeo, S. Leurgans, B. Ouyang, A. Kanner
1.082 Time To First Epileptiform Discharge In An Epilepsy Monitoring Unit/M. Fields, L. Marcuse
1.083 EEG Monitoring During Intracranial Surgery For Moyamoya Disease/J. Kaleyias, M. Vendrame, T. Loddenkemper, E. Smith, C. McClain, M. Rockoff, S. Manganaro, B. Mckenzie, L. Gao, M. Scott, B. Bourgeois, S. Kothare
1.084 Significance Of Decrement In Intracranial EEG Interpretation For Localization Of The Epileptogenic Zone In Resective Surgery/H. Kang, S. Wolf, P. McGoldrick, S. Ghatan
1.085 Epileptiform Activities In Continuous EEG Monitoring During Therapeutic Hypothermia/M. Kawai, U. Thapalia, A. Verma
1.086 Spatial And Temporal Relationship Of HFO And Interictal Spikes In Patients With Medically Refractory Non-Lesional Epilepsy/ T. Mihaylova, Y. Tran, D. Barkmeier, D. Fuerst, J. Loeb, S. Mittal, A. Shah
1.087 Clinical Indications And Diagnostic Usefulness Of Prolonged Video Electroencephalogram (VEEG) Monitoring/N. Noor, M. Salam

1.088 Topography Of Sleep Morphology In Patients With Intracranial Electrodes/A. Lecticia Pinto, S. Manganaro, J. Singer, J. Madsen, B. Bourgeois, T. Loddenkemper, S. Kothare
1.089 Asymmetry Of Scalp EMG In The Lateralization Of Focal Epilepsy/H. Saria, G. Kalamangalam
1.090 The Relationship Of Ictal EEG Between Depth And Subdural Electrodes In Mesial Temporal Lobe Epilepsy/Y. Yun, B. Kang, E. Lee, M. Kim, S. Lee, J. Lee, S. Hong, J. Kang
1.091 Day/Night And Sleep/Wake Patterns Of Pediatric Generalized Seizures/M. Zarowski, T. Loddenkemper, M. Vendrame, A. Alexopoulos, E. Wyllie, S. Kothare
1.092 Hand Stereotypies, Partial Motor Seizures Or Giant Evoked Potentials – A Newly Described Phenomena In Rett Syndrome/B. Ben-Zeev, A. Nissenkorn, I. Blatt
1.093 Detection Of Multiple, Single Unit Activity From Continuous, Long-Duration, High-Frequency Recordings In Patients With Epilepsy/M. Bower, M. Stead, F. Meyer, R. Marsh, K. Lee, G. Worrell
1.094 Epileptic Ripple Oscillations In Intraoperative ECoG/S. Rampp, D. Weigel, M. Buchfelder, R. Hopfengärtner, H. Stefan
1.095 Continuous Video-EEG Monitoring For Patients With Acute Encephalopathy In A Pediatric Intensive Care Unit (PICU)/J. Schreiber, J. Carpenter, H. Kaulas, W. Gaillard
1.096 Analysis Of Continuous Electroencephalography In The Intensive Care Unit For Nonconvulsive Seizure Activity – A Comparison Of Four Methods/Y. Taher, E. Fertig, A. Paige, J. Politsky, C. Lambrakis, O. Laban, J. Lee, M. Lancman
1.097 Ambulatory Electroencephalography (EEG) In Adults: Diagnostic Yield And Tolerability/J. Tellez-Zenteno, L. Hernandez-Ronquillo, F. Moien-Afshari
1.098 Convergence Of Ictal Hypoxia And Postictal Hypoventilation As A Potential Mechanism Of SUDEP/I. Yung, S. Rose, S. Hawes-Ebersole, J. Ebersole, J. Tao
1.099 The Role Of The Electrocorticography In The Tailored Temporal Lobe Surgery Due To Mesial Temporal Sclerosis/C. Alfaro, D. Orta, M. Vanegas, M. González-Aragón, A. Mayorga, S. Cash
1.100 Diagnostic Utility Of Continuous EEG Monitoring Among Critically Ill Children/C. Hahn, R. Sharma, A. Ochi, H. Otsubo, J. Hutchison, B. McCoy
1.101 Continuous Video-EEG In The ICU/O. Khan, C. Azevedo, J. Montanye, J. Gonzalez, S. Arshad, M. Natola, S. Surgenor, R. Morse, R. Nordgren, K. Bujarski, G. Holmes, B. Jobst, V. Thadani

Clinical Neurophysiology
Computer Analysis of EEG
1.102 Automatic Detection Of Intracranially Recorded High-Frequency Oscillations Using A Radial Basis Function Neural Network Gives Reliable Information About The Distribution Of HFOs Over Anatomical Regions/M. Duempelmann, K. Kerber, J. Jacobs, A. Schulze-Bonhage
1.103 Discrimination Between Preictal And Interictal Periods In Patients With Temporal Lobe Epilepsy Using Continuous Wavelet Transform In High-Frequency Bands/K. Gadhoumi, F. Mari, J. Gotman, J. Lina
1.104 Abrupt Phase Transition Of Ictal Activity Temporospatially/Y. Hsin, T. Harnod, M. Lo
1.105 Source Localization Of Epileptic Foci From EEG/Z. Nadasdy, B. Kirmani
1.106 Spontaneous And Visually-Driven Physiological High-Frequency Oscillations Measured On Electrocorticography/T. Nagasawa, C. Juhász, R. Rothermel, K. Hoechstetter, S. Sood, E. Asano
1.107 A Comparison Of Automatic Detectors Of High Frequency Oscillations/R. Zelmann, F. Mari, J. Jacobs, M. Zijlmans, R. Chander, J. Gotman
1.108 Electrocorticographic Correlates Of Cognitive Control In A Stroop Task-Intracranial Recording In Epileptic Patients/E. Asano, S. Koga, R. Rothermel, C. Juhasz, T. Nagasawa, S. Sood
1.109 Automatic Seizure Detection In SEEG Using High-Frequency Activities In Wavelet Domain/L. Ayoubian, J. Gotman
1.110 Intracranial Interictal Spike Detection: Use Of A Novel Wavelet-Based Detection Scheme/F. Azhar, M. Vendrame, T. Loddenkemper, B. Dworetzky, C. Reinsberger, K. Parkerson, W. Anderson
1.111 EEG Source Localization In Malignant Rolandic-Sylvian Epilepsy/C. Brown, J. Riviello, Jr, S. Agadi, M. Quach
1.112 Variability Of Naming-Related Function As Observed With Event-Related Electrocorticography/E. Brown, O. Muzik, R. Rothermel, T. Nagasawa, C. Juhasz, A. Shah, D. Fuerst, S. Mittal, S. Sood
1.113 Independent Component Analysis Of EEG Reveals The Cerebral Generators And Propagation Pathway Of Myoclonus/J. Chen, C. Chen
1.114 Phase Coupling And Network Properties Are Abnormal In Idiopathic Generalised Epilepsy Patients And Their Relatives/F. Chowdhury, T. Fitzgerald, L. Nashef, R. Elwes, M. Richardson
1.115 Robustness Of Nonlinear Dynamical Measures Of EEG In The Time-Frequency Domain: Application To Seizure Prediction/A. Faith, S. Sabesan, L. Iasemidis
1.116 Computer-Assisted Identification And Quantification Of Stereo-EEG Frequency During Ictal Events, Clinical And Physiological Correlates Of The Identified Patterns/V. Gnatkovsky, M. de Curtis, S. Francione, C. Pastori
1.117 Interictal EEG Dynamics In Patients With Non-Epileptic Seizures Versus Those With Temporal Lobe Epilepsy/J. Halford, D. Shiau, J. Chien, K. Kelly, R. Kern, P. Pardalos, J. Sackellares
1.118 Spatiotemporal Dynamics Of Stochastic Behavior Of Phase Synchronization: Localizing Epileptic Zones With Interictal EEG/M. Holmes, C. Ramon
1.119 Comparative Study Of Complexity And Entropy During Onset Of Partial Epileptic Seizures/C. Jouny, G. Bergey
1.120 Current Dipole Sources Of Anterior Temporal Spikes: Effects Of Orientation On Clinical Factors/O. Kwon, Y. Kim, S. Jung, S. Kim, H. Kang, K. Park, N. Choi, B. Lim
1.121 Continuous High Frequency Activity In Mesial Temporal Lobe Contacts: Possible Role As A Neurophysiological Marker Of Epileptogenicity/F. Mari, R. Zelmann, L. Valenca, L. Ayoubian, F. Dubeau, J. Gotman
1.122 Comparison Of Electrophysiological And Electro-Cortical Mapping In Implanted Epileptic Patients/M. Mercier, K. Perrine, E. Rubens, J. Foxe, T. Schwartz
1.123 Automatic Detection Of Non-Convulsive Status Epilepticus/G. Minasyan, J. Chatten, R. Harner
1.124 Statistical Mapping Of Ictal High-Frequency Oscillations In Epileptic Spasms/H. Nariai, T. Nagasawa, C. Juhasz, S. Sood, H. Chugani, E. Asano
1.125 A Comparison Of Dipole Source Analysis And Visual Scalp EEG Interpretation/M. Quach, C. Akman, S. Agadi, J. Riviello
1.126 Feasibility Of Focused Neurostimulation Using Injected Currents From Scalp Electrodes/C. Ramon, E. Rezvanian, M. Holmes
1.127 Prediction Of Epileptogenesis After Status Epilepticus In A Lithium Pilocarpine Model/S. Sabesan, S. Marsh, D. Treiman
1.128 Predicting Epileptic Seizures Based On Surface EEG Analysis/A. Zandi, M. Javidan, G. Dumont, R. Tafreshi
1.129 Estimation Of Neurodynamic Modulations In The Pre-Ictal Interval: An Information Theoretic Approach/C. Stamoulis, B. Chang
1.130 Synchrony In Normal And Focal Epileptic Brain: The Seizure Onset Zone Is Functionally Disconnected/C. Warren, S. Hu, M. Stead, B. Brinkmann, M. Bower, G. Worrell
1.131 Accuracy Of Dense-Array EEG Source Estimation Of Interictal Discharge In Patients With Temporal Lobe Epilepsy/M. Yamazaki, A. Fujimoto, T. Yamamoto
1.132 Epileptogenicity Index In Bitemporal Epilepsy/S. Aubert, M. Leveque, J. Regis, J. Peragut, F. Wendling, P. Chauvel, F. Bartolomei
1.133 Identifying Epileptogenic Tubers With BESA And LORETA – A Study Of Non-Invasive Interictal EEG Source Localization/L. Chen, P. Coutin-Churchman, J. Wu

1.134 Dynamics Of Frequency Flow During Temporal Lobe Epileptic Seizure/P. Indic, J. Narayanan
1.135 Changes In Synchrony Within Neuronal Networks Measured During Electrocortigraphy Accompany Character Recognition: A Brain-Computer Interface Paradigm/ S. Johnson, X. Liu, J. Hudson, J. Shih, D. Krusienski, G. Martz, M. Quigg
1.136 Propagation Of Intracranial Electroencephalographic Activity Between Neocortex And Subcortical Structures As An Indicator Of Seizure Onset/A. Korzeniewska, M. Cervenka, C. Jouny, J. Perilla, G. Bergey, N. Crone, P. Franaszczuk
1.137 Observation Of Emerging Ictal Network Dynamics Using Synchrony Index/G. Martz, S. Johnson, J. Hudson, M. Quigg
1.138 Source Localisation Based On Subdural EEG Studies Of Frontal Lobe Epilepsy/G. Ramantani, D. Altenmüller, A. Schulze-Bonhage, M. Dümpelmann
1.139 Effect Of Dura On Scalp EEG Simulations/E. Rezvanian, C. Ramon, M. Holmes
1.140 Comparison Of Dynamic Measurements Between A Cohorts Of Children With Childhood Absence Epilepsy And Children With Partial Seizures/M. Schwabe, K. Hecox
1.141 Effects Of Vagus Nerve Stimulation On Electrocorticography/ K. Usami, K. Kawai, N. Kunii, N. Saito
1.142 Predicting Success Of Vagus Nerve Stimulation (VNS) From Interictal EEG/M. Van Putten, L. Melching, J. van Schoonhoven, J. Ardesch, A. de Weerd, H. van Lambalgen, C. de Vos
1.143 Cortical Gamma-Oscillations Modulated By Picture Naming And Word Reading In Patients With Focal Epilepsy/H. Wu, E. Brown, T. Nagasawa, R. Rothermel, C. Juhasz, S. Sood, E. Asano
1.144 Automatic Seizure Detection Algorithm Based On The Human Visual Interpretation Process Of Scalp EEG/B. Hunyadi, M. De Vos, S. Van Huffel, W. Van Paesschen
1.145 Characterizing Pre-Ictal And Inter-Ictal States With Graph Theoretical Approaches/K. Lehnertz, M. Horstmann, C. Elger
1.146 Characterizing Directed Interactions In Epileptic Brain Networks From Noninvasive EEG Recordings/C. Toepser, M. Martini, M. Staniek, C. Elger, K. Lehnertz

Clinical Epilepsy
Classification and Syndromes
1.147 Classification Of Epileptic Seizures And Epilepsy Syndromes At Pediatric Long-Term Video-EEG Monitoring Unit/S. Alan, D. Yalnizoglu, G. Turanli, K. Karli Oguz, E. Lay Ergun, F. Soylemezoglu, N. Akalan, M. Topcu
1.148 Non-Idiopathic Focal Epilepsy In Children: 'Cryptogenic' Is NOT Identical To 'Probably Symptomatic'/E. Wirrell, K. Nickels
1.149 Neonatal Epileptic Encephalopathies And Their Evolution To Hypsarrhythmia: Etiology And Electroclinical Findings Over Time/ A. Andrade, S. Arnold, R. Said
1.150 Ictal Neocortical Slow Activity And Impaired Consciousness In Temporal Lobe Epilepsy/D. Englot, L. Yang, H. Hamid, N. Danielson, X. Bai, A. Marfeo, L. Yu, A. Gordon, M. Purcaro, J. Motelow, R. Agarwal, D. Ellens, J. Golomb, M. Shamy, H. Zhang, C. Carlson, W. Doyle, O. Devinsky, K. Vives, D. Spencer, S. Spencer, C. Schevon, H. Zaveri, H. Blumenfeld
1.151 Variation Of Seizure Frequency Between Anovulatory And Ovulatory Cycles/A. Herzog, K. Fowler, M. Sperling, J. Liporace, G. Krauss, B. Dworetzky, P. Pennell, C. Harden, K. Gleason, M. Newman, Progesterone Trial Study Group
1.152 Aura Analysis In Patients With Temporal Lobe Epilepsy/J. Hoffmann, C. Elger, A. Kleefuss-Lie
1.153 Which Semiology Explains Axial Muscle Hypotonia?/J. Woo Kang, M. Go
1.154 Clinical Spectrum Of Epileptic Spasms In Children/Y. Jin Lee, A. Berg, D. Nordli
1.155 Asphyxia As A Mechanism Of Sudden Unexpected Death In Epilepsy/J. Tao, S. Qian, M. Baldwin, X. Chen, S. Sandra, S. Ebersole, J. Ebersole
1.156 Clinical Significance Of SCN1A Gene Mutations – Parent, Physician And Genetic Perspectives/ A. Brunklaus, R. Birch, E. Reavey, J. Duncan, G. Forbes, S. Zuberi
1.157 A Novel Genetic Occipital Epilepsy Syndrome In Siblings Showing Clinical And EEG-fMRI Concordance/ P. Carney, A. Harvey, S. Berkovic, G. Jackson, I. Scheffer
1.158 Amytal Versus Brevital: Differences In Wada Test Performance In Temporal Lobe Epilepsy/R. Gillen, A. Ritaccio, T. Lynch, A. Barba
1.159 Secondarily Generalized Clonic-Tonic-Clonic Seizure With Retained Consciousness/C. Griessenauer, S. Goli, J. Dewolfe
1.160 Midbrain-Hindbrain Malformations In Patients With Cortical Malformations/E. Trinka, F. Koppelstätter, I. Unterberger, J. Dobesberger, J. Larch, G. Walser, L. Zamarian, E. Haberlandt, T. Gotwald, M. Ortler, T. Czech, M. Delazer, K. Rostasy, S. Felber, G. Bauer, M. Feucht, G. Kuchukhidze
1.161 Prospective Analysis Of Seizure Frequency In Established Epilepsy/ U. Uysal, L. Miao, N. Fountain
1.162 Clinical Significance Of Photosensitivity In Early Childhood Epilepsy/D. Wijesekara, R. Pressler, S. Boyd, J. Cross
1.163 Idiopathic Hemiconvulsion-Hemiplegia Syndrome (HH): MRI Follow-Up Findings In 6 Patients/G. Barcia, N. Boddaert, I. Desguerre, C. Barnerias, F. Brunelle, O. Dulac, R. Nabbout
1.164 Investigation Of Five Cases With Eating Epilepsy/U. Kokes, B. Baykan, C. Gürses, N. Bebek, A. Gokyigit
1.165 Benign Temporal Lobe Epliepsy: A Case Series/S. Mirsattari, M. Smith, J. Burneo, R. McLachlan
1.166 Reflex Seizures: Clinical And Neurophysiological Features/R. Morse, J. Filiano, S. Gaelic, D. Gardner, G. Holmes, R. Nordgren
1.167 Same Name – Different Story: Heterogeneity Is Typical For Rasmussens Encephalitis – An Evaluation Of 34 Cases/ B. Pohlmann-Eden, M. Beckhaus
1.168 Clinical And Immunological Markers In Steroid Responsive Encephalopathy Associated With Autoimmune Thyroiditis/M. Smith, S. Mirsattari, D. Diosy, J. Burneo, R. McLachlan
1.169 Epilepsy In Dural Arteriovenous Fistulas (dAVF)/I. Takumi, S. Kominami, A. Watanabe, S. Kobayashi, H. Ura, A. Teramoto
1.170 Generalized-Onset Seizures With Alternating Left And Right Focal Evolution/L. Jeradeh Boursoulian, C. Fu, K. Ess, A. Lagrange, B. Abou-Khalil
1.171 Epilepsy In Roberts SC Phocomelia/K. Duffy, P. Maertens
1.172 Calcified Cysticercotic Lesions And Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis: Partners In Crime/M. Oliveira, L. Castro, M. Martin
1.173 Asian Woman Presenting With New Onset Refractory Status Epilepticus : Cyclophosphamide-Responsive Nmda Receptor Encephalitis Without Tumor/ R. Shatzmiller, R. Apelian, J. Cho, D. Ko, D. Millett

Clinical Epilepsy
Clinical Diagnosis
1.174 Seizures And Quasi-Ictal Patterns On Depth And Scalp EEG Monitoring After Subarachnoid Hemorrhage/J. Claassen, J. Schmidt, B. Tu, S. Ko, N. Badjatia, K. Lee, S. Mayer, E. Connolly, L. Hirsch
1.175 Clinical And Genetic Spectrum Of Lafora Disease In 104 Patients/ B. Gonzalez Giraldez, C. Gómez-Abad, R. Guerrero, R. Sanz, C. Almaraz, A. Massot, J. Serratosa
1.176 This poster has been changed to Platform C.09
1.177 Lateralizing And Localizing Value Of Seizure Semiology/P. Kotagal, S. Elwan, A. Alexopoulos, D. Silveira
1.178 Spectroscopic Imaging Of MTLE At 7T/J. Pan, H. Hetherington, D. Spencer
1.179 Localization Of Pediatric Seizure Semiology: A Review Of 1008 Seizures/M. Vendrame, M. Zarowski, A. Alexopoulos, S. Kothare, T. Loddenkemper
1.180 Focal Epilepsy And AntiGAD Antibodies .Clinical And Immunological Profile/M. Falip, L. Sabater, J. Miro, S. Fernandez, M. Juncadella, M. Carreño, A. Saiz, F. Graus

1.181 Characteristics Of HIV-infected Patients With New Onset Seizures/ A. Malone, J. Elliott, M. Para, B. Shneker
1.182 The Accuracy Of Hyperventilation And Parental Report In Assessing The Activity Of Absence Seizures In Children/E. O'Mahony, M. Libenson
1.183 Ictal Lip-Smacking In Temporal Lobe Epilepsy Has A Stereotyped Electrographic Signature/J. Parvizi
1.184 Parietal Lobe Epilepsy: Great Imitator Among Focal Epilepsies/ A. Ristic, C. Wong, A. Alexopoulos, N. So, I. Najm
1.185 How Helpful Are Repeat Epilepsy Monitoring Unit Admissions After An Initial Nondiagnostic Evaluation?/A. Taneja, P. Gupta, P. Van Ness
1.186 Measurement Of QT Intervals During Electroencephalogram (EEG) Testing: Are They Reliable?/ A. Venkatasubramanian, R. Iyer, S. Quigley, C. Fox, U. Susul, D. Dlugos
1.187 Clinical Features Of Status Epilepticus In Children/S. Agadi, C. Akman, C. Marx, T. Lotze, J. Riviello
1.188 Socioeconomic Status And Self-Management In Epilepsy: Comparison Of Diverse Clinical Populations In Houston, Texas/C. Begley, R. Shegog, B. Iyagba, V. Chen, S. Dubinsky, M. Newmark, N. Ojukwu, D. Friedman
1.189 Efficacy And Safety Of Rapid Medication Reduction In The Epilepsy Monitoring Unit/E. Ericson, M. Macken, E. Gerard, J. Toguri, S. Schuele
1.190 The Utility Of Presurgical Evaluation With Foramen Ovale Electrodes/L. Kansal, E. Tecoma, V. Iragui
1.191 Probability Of Developing Epilepsy In Pediatric Arterial Ischemic Stroke/C. Keator, T. Bernard, N. Goldenberg, M. Manco-Johnson, K. Knupp
1.192 Use Of EEG Spectral Analysis In Predicting Development Delay In Infants/K. Kulandaivel, G. Holmes
1.193 Classification Of Generalized Tonic-Clonic Seizures Only: Focal Or Generalized?/M. Lee, Y. Cho, W. Kim, B. Lee, K. Heo
1.194 A Prospective Look At Post Traumatic Seizures In A Pediatric Traumatic Brain Injury Population/ J. Lerner, H. Valino, D. McArthur, S. Yudovin, J. Matsumoto, J. Wu, A. Madikians, M. Van Hirtum-Das, C. Szeliga, A. Duran, C. Giza
1.195 Investigations Ordered In Adults With Epilepsy In Tertiary Care/ M. Lowerison, S. Wiebe, P. Federico, A. Hanson, N. Jette, B. Klassen, W. Murphy, N. Pillay, S. Macrodimitris, S. Save
1.196 Are Children With Temporal Lobe Epilepsy At Increased Risk For Obesity?/V. Micic, P. Kotagal, I. Tuxhorn
1.197 Do Children With Dravet Syndrome Have A Recognizable Face?/K. Nolan, E. Kay, C. Camfield, P. Camfield
1.198 Retrospective Analysis Of Patients With Nocturnal Epilepsy/ C. Ozkara, D. Yavuz Demiray, N. Yeni, N. Karaagaç, M. Uzan
1.199 Heart Rate May Not Differentiate Epileptic From Psychogenic Nonepileptic Seizures/ C. Reinsberger, M. Murphy, B. Dworetzky
1.200 Recent Understanding In The Role Of Genetics In Hot-Water Epilepsy/P. Satishchnadra, R. Ratnapriya, S. Dilipkumar, G. Gadre, A. Anand
1.201 Improvement Of Seizure Classification By Showing A DVD Including Different Types Of Epileptic Seizures And Non-Epileptic Seizure-Like Episodes To Non-Professional Eye-Witnesses – An Update/B. Steinhoff, L. Keller, C. Kurth
1.202 Correlation Of Human Intracranial Microwire Recording With Clinical Factors And Outcomes/ D. Treiman, E. Hickman, P. Steinmetz
1.203 Continuous Video-EEG Monitoring In Pediatric Intensive Care Units/K. Williams, R. Jarrar, J. Buchhalter
1.204 The Frequency Of PLEDS As An Ictal Pattern In Nonconvulsive Status Epilepticus/M. Wong, N. Fountain
1.205 Dreaming Experience As A Useful Diagnostic Clue For Syncopal Episodes/V. Simona Chiesa, P. Terranova, A. Vignoli, F. Lombardi, M. Canevini
1.206 The Prevalence And Localization Of Itcal Laughter Not Caused By Hypothalamic Hamartomas/D. Clarke, M. Perry, K. Richards, M. Mabe, M. Lee
1.207 The Role Of Non-Invasive Diagnostic Modalities In Insular/Periinsular Epilepsy/S. Gibbs, J. Soucy, Y. Boulanger, A. Bouthillier, D. Nguyen
1.208 Clinical Characteristics According To Age Of Onset In Patients With Temporal Lobe Epilepsy: A Single Center Experience/K. Heo, K. Cho, Y. Cho, M. Lee, B. Lee
1.209 Emergency Personnel And Psychogenic Non-Epileptic Seizures/ A. Hussain, J. Cohen, J. Choi, E. Dinetz, N. Ballout, D. Weiner, G. Husk
1.210 Reappraisal Of Epilepsy In Patients With Down Syndrome/ H. Ikeda, T. Hiyoshi, H. Ikeda, Y. Inoue
1.211 Peculiar Seizures In The Infantile Epilepsy With CDKL5 (Cyclin-Dependent Kinase-Like 5) Mutation/Deletion/K. Imai, S. Otani, H. Ikeda, R. Takayama, Y. Horigome, M. Ikegami, H. Takahashi, J. Mine, Y. Mogami, H. Shigematsu, Y. Takahashi, K. Shimojima, T. Yamamoto, Y. Inoue
1.212 Iatrogenic Seizures In Patients With Intracranial EEG Monitoring/ J. Khoury, K. Noe, J. Drazkowski, J. Sirven, M. Hoerth, R. Zimmerman
1.213 "Periictal Bed Leaving" In Temporal Lobe Epilepsy: Incidence And Lateralizing Value/R. Kuba, K. Musilova, M. Brázdil, I. Tyrlíková, I. Rektor
1.214 An Epilepsy Fellow's Perspective On The Discrepancy Between Exposure To A Patient Population And Concomitant Clinical Education/ L. Lehnhoff, S. Chung
1.215 Elevation Of Serum Prolactin Levels In Different Seizure Characters/P. Mekaroonkamol, C. Locharernkul, P. Mekaroonkamol, W. Krongthong, J. Panjarat, N. Wanichakorn
1.216 Prediction Of Generalized Tonic-Clonic Seizures During And Within Three Days After Inpatient Epilepsy Monitoring/S. Miller, E. Faught
1.217 To Laugh Or Not To Laugh: Dichotomy Favoring Right Temporal Lobe Onset Of Seizure/P. Pritchard, P. Lajeunesse, M. Wagner
1.218 Unilateral Abdominal Wall Clonic Onset Seizures (AWCSs)/R. Mark Sadler, S. Rahey, R. Brownstone
1.219 New Evidence Of Heterogeneous Etiology And Outcome Of Pres Among Patients With Solid Organ Transplant/Z. Sha, B. Swenson, T. Henry
1.220 Title-Interictal Spikes And Heart Rate Variability/F. Thomas, E. Martinez, B. Fisch, O. Myers
1.221 Clinical Findings In Hospitalized Pediatric Patients With Status Epilepticus/S. Uysal, V. Gooty, M. Vendrame, A. Rotenberg, S. Kothare, T. Loddenkemper
1.222 Retrospective Study In Characterization Of Non-Epileptic Events In Patient With Some Degree Of Developmental Delay – Intellectual Delay/J. Valero-Fonseca, S. Jain, J. Paolicchi
1.223 EEG Characteristics In Pyridoxal 5'-Phosphate Dependent Epilepsy/ S. Winchester, A. Veerapandiyan, W. Gallentine, E. Smith, K. Hyland, S. Kansagra, M. Mikati
1.224 Catastrophic Epilepsies Seen In The Neonatal Period In Japan/ H. Yamamoto, A. Okumura, M. Fukuda
1.225 Epileptic Loss Of Consciousness Investigated By Prospective Behavioral Tests/L. Yang, L. Hyang, T. Morland, N. Danielson, M. Desalvo, M. Purcaro, J. Anaya, P. Manza, A. Sreenivasan, C. Men, J. Cheng, A. Nunn, T. Mayer, C. Francois, S. Enamandram, M. Albrecht, A. Hutchison, E. Yap, K. Ing, I. Shklyar, S. Balakirsky, K. Detyniecki
1.226 Improving Safety Outcomes In The Epilepsy Monitoring Unit/ M. Atkinson, K. Hari, K. Schaefer, A. Shah
1.227 Head Trauma And Epilepsy In Children/B. Ho Cha, H. Jee, M. Kim, K. Whang
1.228 Focal Reflex Epilepsy Induced By Visual Spatial Imagination/ B. Feddersen, J. Rémi, A. Ebert, A. Danek, S. Noachtar
1.229 Is There A Relationship Between Allergies/Medication Intolerances And Nonepileptic Events?: A Retrospective Analysis/N. Maru, J. Halford

1.230 Prevalence Of Drug Resistant Epilepsy In Children – One Year Prospective Study In Two Polish Epilepsy Centres/ M. Mazurkiewicz-Beldzinska, B. Steinborn, A. Winczewska-Wiktor, A. Matheisel, M. Szmuda
1.231 Pseudo-Gelastic Seizures In A Patient With Hypothalamic Hamartoma And Polymicrogyria/W. Navarre, P. Alore, S. Schuele, E. Gerard, M. Macken
1.232 Periodic Late-Onset Spasms In Focal Symptomatic Epilepsy/L. Souza, A. Hamad, T. Ferrari, A. Zaninoto, L. Caboclo, R. Centeno, H. Carrete Jr, L. Vilanova, E. Yacubian
1.233 Self-Induced Seizures By Peri-Orbital Somatosensory Stimulation: A Report Of Two Cases/R. Takayama, Y. Takahashi, M. Mogami, M. Ikegami, S. Mukaida, H. Ikeda, K. Imai, H. Shigematsu, Y. Suzuki, Y. Inoue
1.234 Wolf-Hirschhorn Syndrome Presenting With Intractable Epilepsy And Distinct Unilateral Cutaneous Finding: A Case Report/K. Velayudam, J. Paolicchi
1.235 Bicycling During Complex Partial Seizures/R. Kotloski, C. O'Donovan
1.236 Electroencephalographic Characteristics Of Sandhoff Disease (Gm2 Gangliosidosis)/E. Pestana Knight, R. Shellhaas, S. Joshi
1.237 Ictal Tremor In A Patient With Temporal Lobe Epilepsy/I. Tyrlikova, R. Kuba, P. Sykora, M. Brazdil, I. Rektor

Antiepileptic Drugs
Mechanisms of Action
1.238 Anticonvulsant Activity Of Pregabalin (Lyrica®) Requires Binding To The a_2o_1 Subunit Of Voltage Sensitive Calcium Channels/J. Offord, S. Lotarski, J. Peterson, S. Galvin, B. Strenkowski, H. Hain, S. Donevan
1.239 Carbamazepine Inhibition Of Sharp Wave-Ripple Complexes Is Associated With Synapse-Specific Effects On Neurotransmission And Short-Term Plasticity/T. Simeone
1.240 Ethosuximide Treatment Inhibits Epileptogenesis And Alleviates Behavioural Co Morbidities In The GAERS Model Of Absence Epilepsy/ G. Dezsi, H. Blumenfeld, M. Salzberg, T. O'Brien, N. Jones
1.241 Modulation Of Sodium Conductance By Phenytoin In Rat Hippocampal CA1 Cells Is Mediated Through Slow Inactivation Processes/ C. French
1.242 CSF And Plasma Pharmacokinetics Of Eslicarbazepine Acetate In Healthy Volunteers/ J. Kharidia, G. Maier, M. Versavel, D. Blum, J. Maia, P. Soares-da-Silva
1.243 Carbamazepine Resistance In Human Temporal Lobe Cortical Neurons/R. McLachlan, C. Gavrilovici, M. Poulter
1.244 Metformin Rescues Aberrant Plasticity In TSC2 Mutant Mice Via AMPK-Dependent Inhibition Of mTOR: Therapeutic Implications/W. Potter, K. O'Riordan, P. Rutecki, C. Burger, A. Roopra
1.245 Lack Of Association Between Multidrug Resistance 1 (MDR1) Gene Polymorphisms In Childhood Drug Resistant Epilepsy/S. Saygi, F. Alehan, B. Ataç, R. Erdem, I. Erol
1.246 Chronic Antagonism Of NMDA Receptors (NMDAR) With The NR2B-Selective Antagonist, Ro25-6981 Suppressed While The High-Affinity Competitive Antagonist, D-APV Exacerbated Seizure Susceptibility In A Concentration-Dependent Manner In Organotypic Hippocampal C/ A. Regnier-Golanov, Y. Dong, S. Bausch
1.247 Investigation Of Lacosamide Binding To Collapsin Response Mediator Protein-2 (CRMP-2)/C. Wolff, B. Carrington, C. Van der Perren, A. Vandendriessche, M. Famelart, M. Varrin-Doyer, M. Gillard, P. Foerch, V. Rogemond, J. Honnorat, A. Lawson, K. Miller
1.248 Development Of Phenytoin Resistance In Post-Traumatic Epileptogenesis/Y. Berdichevsky, V. Dzhala, K. Staley
1.249 Atrial Fibrillation And Ventricular Tachycardia In Patients With Partial Seizures Treated With Lacosamide/T. Desso, A. DeGiorgio, C. DeGiorgio
1.250 Carbamazepine Directly Modulates Mitochondrial Function In Wild-Type And Epileptic Mice/ K. Fenoglio-Simeone
1.251 Chloride Cotransporters NKCC1 And KCC2 Expression In Rat And Human Retina/B. Kosaras, R. Cleary, F. Jensen
1.252 Lacosamide Attenuates Cortical Excitability In The Rat Cortical Stimulation Model/A. Meurs, I. Buffel, R. Raedt, T. Wyckhuys, A. Van Dycke, V. De Herdt, R. El Tahry, I. Dauwe, L. Mollet, K. Vonck, P. Boon

Antiepileptic Drugs
Clinical Trials
1.253 Assessment Of Seizure Classification In Multinational, Multicenter Antiepileptic Drug Trials/ B. Vogelsong, J. French, M. Brodie
1.254 Efficacy Of Ezogabine (Retigabine) As Adjunctive Therapy In Two Randomized Trials In Adults With Drug-Resistant Partial-Onset Seizures: Per-Protocol Population Analysis/D. Burdette, R. Leroy, V. Biton, S. Shaikh, S. Hall
1.255 Adjunctive Therapy With Lacosamide For Extremely Refractory Epilepsy In Children/M. Gustafson, F. Ritter
1.256 The Impact Of Standardization On The Magnitude Of Treatment Effect When Analyzing Log-Transformed Seizure Outcome/M. Johnson, S. Lu, M. Merschhemke
1.257 UCB Antiepileptic Drug Pregnancy Registry – Keppra® Data/ G. Montouris, C. Harden, S. Alekar, I. Leppik
1.258 Retention Rate Of Lacosamide In Comparison To Other Newer Anticonvulsants In Patients With Epilepsy/S. Schusse, K. Kelly, S. Donlon, S. Chung
1.259 Bioequivalence Of Oral And Intravenous Carbamazepine In Adult Patients With Epilepsy/M. Walzer, V. Biton, I. Bekersky, D. Wesche, D. Tolbert, J. Cloyd
1.260 Role Of The mTOR Inhibitor Everolimus In Treating Patients With Neurological Manifestations Of Tuberous Sclerosis Complex (TSC): Rationale And Current Clinical Trials/ A. Wilfong, M. Sahin, J. Bissler, D. Franz, T. Sahmoud, R. Tavorath
1.261 Evaluation Of The Response To Adjunctive Pregabalin Therapy Based On Baseline Seizure Rate In Patients With Refractory Partial-Onset Epilepsy/M. Almas, S. Giordano
1.262 Improved Seizure Severity, Health-Related Quality Of Life And Health Status Reported By Patients During Long-Term Treatment With Lacosamide/S. Borghs, M. De Backer, K. Mueller, P. Doty, J. Cramer
1.263 Long-Term Efficacy Of Lacosamide As Adjunctive Therapy In Patients With Uncontrolled POS: Results From A Phase III Open-Label Extension Trial/E. Faught, S. Chung, A. Husain, J. Isojarvi, C. McShea, P. Doty
1.264 Population Pharmacokinetics And Pharmacodynamics Of Perampanel In Patients With Refractory Partial Seizures/E. Fuseau, D. Templeton, Z. Hussein
1.265 Long-Term Safety Of Lacosamide As Adjunctive Therapy In Patients With Uncontrolled Partial-Onset Seizures: Results From A Phase III Open-Label Extension Trial/A. Husain, E. Faught, S. Chung, J. Isojarvi, C. McShea, P. Doty
1.266 Rufinamide For Refractory Epilepsy In A Pediatric And Young Adult Population/J. Joseph, R. Schultz, A. Wilfong
1.267 Adjunctive Brivaracetam In Adults With Uncontrolled Generalized Seizures: Sub-Population Analysis Of The Results Of A Randomized, Double-Blind, Placebo-Controlled Trial/P. Kwan, M. Johnson, M. Merschhemke, S. Lu
1.268 Intravenous Lacosamide In Refractory Status Epilepticus And Seizure Aggravation/J. Larch, J. Dobesberger, G. Kuchukhidze, G. Walser, I. Unterberger, E. Trinka
1.269 Bioequivalence Of A Captisol-Enabled®Fosphenytoin Sodium Injection Formulation To The Marketed Reference Listed Product Via Iv And Im Administration In Healthy Volunteers/ J. Pipkin, S. Machatha, G. Mosher, Q. He
1.270 First Observations of Rufinamide in Children with Myoclonic-Astatic Epilepsy/C. Von Stuelpnagel, G. Coppola, A. Mueller, G. Kluger
1.271 A Clinical Study Of The Effect Of ICA-105665 On Photic-Induced Paroxysmal EEG Responses/V. Biton, B. Abou-Khalil, D. Kasteleijn-Nolst Trenité, J. French, G. Krauss, G. Rigdon, E. Moore, S. Hetherington

1.272 Pharmacological Effects Of Ezogabine (Retigabine) On Bladder Function: Results From Patients In Phase 2/3 Studies/N. Brickel, J. Hammond, S. DeRossett
1.273 Side Effects And Tolerability Of IV Levetiracetam Vs. IV Phenytoin And Follow-On Oral Regimens In A Neurosurgical Patient Population: A Prospective Randomised Study/W. D'Souza, K. Fuller, M. Murphy, M. Cook
1.274 Perampanel Randomized Controlled Trials In Epilepsy: A Global Phase III Program/J. French, C. Elger, H. Goldberg-Stern, A. Thomson, G. Krauss, D. Squillacote, H. Yang, D. Kumar
1.275 The Relationship Between Mood Symptoms And Baseline Seizure Rate And Response To Pregabalin In Patients With Refractory Partial Seizures: A Post-hoc Analysis/S. Giordano, M. Almas
1.276 Vigabatrin In Epilepsy caused By Tuberous Sclerosis Complex: Comparison Of Infantile Spasms And Partial Epilepsy/T. Ko, M. Yum, E. Lee, M. Jeong
1.277 The Efficacy Of Ezogabine (Retigabine) 600–1200 mg/day Is Not Affected By Number Of Background AEDs At Baseline In Adults With Drug-Resistant Epilepsy/R. Leroy, B. Abou-Khalil, R. Porter, V. Biton, S. Shaikh, S. DeRossett, S. Hall
1.278 Pharmacokinetics, Safety And Tolerability Of Levetiracetam Extended-Release In Children And Adults With Epilepsy/D. Naritoku, V. Biton, P. Klein, C. Otoul, E. Rouits, J. Schiemann-Delgado, A. Stockis
1.279 Results Of A Double Blind, Placebo-Controlled Study Of LEV For The Emergency Treatment Of Seizures In Canine Clinical Patients/E. Patterson, B. Hardy, J. Cloyd, A. Craig, R. Hardy, J. Rarick, I. Leppik
1.280 A Phase II Study Evaluating The Safety, Tolerability And Efficacy Of Perampanel, A Selective AMPA Receptor Antagonist, In Patients With Refractory Partial Seizures/D. Squillacote, G. Krauss, N. Vaiciene-Magistris, D. Kumar
1.281 Clobazam For Treatment Of Medically Refractory Seizures/D. Stock, J. Conry
1.282 Levetiracetam Extended-Release Conversion To Monotherapy For The Treatment Of Patients With Partial-Onset Seizures: A Double-Blind, Randomized, Multicenter, Historical Control Study/S. Chung, H. Ceja Moreno, J. Gawlowicz, G. Avakyan, C. McShea, J. Schiemann-Delgado, S. Lu
1.283 Efficacy And Safety Of Clobazam In The Treatment Of Seizures Associated With Lennox-Gastaut Syndrome: Results Of A Phase III Trial/J. Conry, Y. Ng, R. Drummond, J. Stolle, S. Sagar
1.284 Safety Of Lacosamide Monotherapy In Migraine Prophylaxis, Fibromyalgia, And Osteoarthritis: Placebo-Controlled Evaluations/T. Daniels, S. Lu, P. Verdru, G. Rudd
1.285 Pharmacokinetics And Safety Of Oral And Intravenous Topiramate In Adult Volunteers/R. Kriel, A. Clark, I. Leppik, S. Marino, R. Brundage, J. Cloyd
1.286 First Long-Term Experience With The Orphan Drug Rufinamide In Patients With Dravet Syndrome/A. Mueller, R. Boor, G. Coppola, P. Striano, M. Dahlin, C. Stuelpnagel, H. Holthausen, G. Kluger
1.287 The Incidence Of Cognitive Adverse Events Related To Eslicarbazepine Acetate: An Integrated Analysis Of Three Double-Blind Studies Of Eslicarbazepine Acetate As Adjunctive Treatment For Partial-Onset Seizures/K. Pinette, M. Versavel, D. Blum, W. Spalding, K. Tripp, P. Soares-da-Silva
1.288 An Open-Label Extension Study To Evaluate The Safety, Tolerability, And Efficacy Of Ganaxolone As Add-On Therapy In Adults With Uncontrolled Partial Onset Seizures/J. Tsai, M. Sperling, G. Farfel
1.289 An Exploratory Subgroup Analysis Of The Safety And Efficacy Of Eslicarbazepine Acetate Administered Once Daily As Concomitant Treatment To Levetiracetam: An Integrated Analysis Of Two Phase III Studies/M. Versavel, K. Tripp, D. Blum, T. Nunes, P. Soares-da-Silva
1.290 Efficacy Of Ezogabine (Retigabine) As Adjunctive Therapy In Two Randomized Trials In Adults With Drug-Resistant Partial-Onset Seizures: Completers Population Analysis/B. Abou-Khalil, E. Hirsch, R. Leroy, S. Shaikh, S. Hall
1.291 Seizure-Free Patients And Seizure-Free Days With Ezogabine (Retigabine) 600−200 mg/day Compared With Placebo in Adults with Drug-Resistant Epilepsy/A. Gil-Nagel, D. Burdette, J. Hammond, K. VanLandingham, S. Shaikh
1.292 Successful Enrollment In A Phase III Study Evaluating The Efficacy And Safety Of Perampanel, A Selective AMPA Receptor Antagonist, As Adjunctive Therapy In Patients With Refractory Partial-Onset Seizures/G. Krauss, J. Serratosa, V. Villanueva, M. Endziniene, Z. Hong, J. French, H. Yang, D. Squillacote, J. Zhu
1.293 Tolerability Of Ezogabine (Retigabine) As Adjunctive Therapy In Adults With Drug-Resistant Partial-Onset Seizures During Titration And Maintenance Phases/R. Porter, A. Gil-Nagel, D. Burdette, J. Hammond, S. DeRossett
1.294 Retinal Structure And Function In Adult Patients With Refractory Complex Partial Seizures Treated With Sabril® (Vigabatrin): An Open-Label, Phase IV Study/R. Sergott, E. Faught, S. Torri, D. Wesche

Antiepileptic Drugs
Cohort Studies
1.295 Idiopathic Generalized Epilepsy And Choice Of Antiepileptic Drugs/H.Ali Taha, F. Al Hammadi, O. Al Neaimi, T. Al Saadi
1.296 Risk Of Retinal Toxicity Or Visual Field Impairment For Pediatric Patients Treated With Vigabatrin/E. Lynch, H. Greiner, D. Franz, D. Krueger
1.297 Maladaptive Behavior In Children Born To Women With Epilepsy/G. Baker, R. Bromley, G. Mawer, J. Clayton Smith
1.298 The Time To Stop (TTS) Study: Antiepileptic Drug Withdrawal After Epilepsy Surgery In Children/K. Boshuisen, C. Uiterwaal, O. van Nieuwenhuizen, K. Braun
1.299 A Comprehensive Review Of The Language Abilities Of Children Exposed To Valproate Or Carbamazepine In Utero/R. Bromley, N. Baxter, R. Calderbank, G. Mawer, J. Clayton- Smith, G. Baker
1.300 Vigabatrin For Treatment Of Partial-Onset Childhood Epilepsies/H. Greiner, E. Lynch, D. Franz, D. Krueger
1.301 Differential Dosing Of Antiepileptic Medications: Higher Dosage In The Evening For Nocturnal Seizures/L. Guilhoto, T. Loddenkemper, M. Vendrame, A. Bergin, B. Bourgeois, S. Kothare
1.302 Case Series Of Patients In Refractory Status Epilepticus Treated With Intravenous Lacosamide/N. Minh Le, S. Hantus
1.303 Treatment Of Infantile Spasms With Vigabatrin In An Academic Medical Center/J. Miller-Horn, A. Mittal, M. Andriola
1.304 Safety And efficacy Of Thiopental For Refractory Status Epilepticus In Children/E. Payne, B. McCoy, J. Hutchison, C. Hahn
1.305 Characteristics Of Users Of The Epilepsy Community Of PatientsLikeMe.com And Comparison With A Representative Claims Database/C. de la Loge, D. Keininger, J. Isojärvi, M. Massagli, P. Wicks
1.306 Lacosamide In Canada: A Pre-Marketing, Observational Study/J.C. Martin del Campo, J. Burneo, N. Pillay
1.307 The Safety And Efficacy Of Vigabatrin For Pediatric And Adult Epilepsy In Community-Based Neurological Practice/E. Fertig, S. Thompson, H. Husaini, S. Devi, G. Ghacibeh, M. Zaatreh, R. Kulikova, M. Lancman, D. McBrian
1.308 Conversion From Enzyme-Inducing Antiepileptic Drugs To Topiramate Or Other Non-Inducers: Effects On C-Reactive Protein, Homocysteine, And B-Vitamins/S. Mintzer, C. Skidmore, S. Rankin, I. Chervovena, E. Pequinot, M. Sperling
1.309 Rufinamide Efficacy In The Everyday Clinical Practise/A. Molins, M. Falip, M. Toledo, M. Codina, J. Becerra, G. Pico, J. Burcet, M. Raspall, E. Miravet, A. Cano, P. Fossas, J. Miro, S. Fernandez

1.310 Efficacy And Tolerability Of High Oral Doses Of Levetiracetam In Children With Epilepsy/M. Obeid, A. Pong
1.311 Early Experience With Lacosamide: Real Practice Versus Trial Results. How Do They Compare?/ P. Penovich, J. Hanna, D. Dickens
1.312 A First Look At The Language And Developmental Abilities Of Children Aged Three To Four Years Exposed In Utero To Levetiracetam. On Behalf Of The Liverpool And Manchester Neurodevelopment Group And The UK Epilepsy And Pregnancy Register/ R. Shallcross, R. Bromley, B. Irwin, J. Morrow, G. Baker
1.313 Rufinamide Could A Second Line For The Adjunctive Treatment Of Partial Seizures In Adults?/R. Chifari, M. Lodi, M. Viri, C. Bonaventi, A. Romeo
1.314 Treatment Of Intractable Epilepsy With Rufinamide In An Academic Medical Center/M. Kaku, B. Locicero-Casazza, M. Andriola, J. Miller-Horn
1.315 Preliminary Outcomes With Adjunctive Lacosamide In Patients With Uncontrolled Partial-Onset Seizures/K. Kelly, M. Brodie, L. Stephen, P. Parker
1.316 Efficacy Of Vigabatrin In Controlling Clinical Seizures For Patients With Infantile Spasms: Clinical Experience From The Children's Hospital Of Michigan/K. Khodabakhsh, H. Chugani
1.317 Lacosamide In Refractory Pediatric Epilepsy/R. Rastogi, Y. Ng

AEDs/Other
1.317A Neuroprotective Effect In Rat Hippocampus Of Cyclooxygenase-2 Inhibitor And Diazepam After Pilocarpine-Induced Status Epilepticus/C. Trandafir, W. Pouliot, F. Dudek

Neuropsychology/Language/Behavior Adult
1.318 Individual Verbal Memory Outcome 2 And 10 Years After Tlr: A Longitudinal Controlled Study/ K. Malmgren, L. Andersson-Roswall, E. Engman, H. Samuelsson
1.319 Neuropsychological Testing Of Hispanic Seizure Patients With Comprehensive Testing Developed And Normed On Hispanic Samples/ G. Lancman, L. Myers, G. Vazquez, K. Perrine
1.320 WADA Risk Classification For Memory Loss Reliably Predicts Postoperative Verbal Memory Decline In Left Temporal Lobectomy Patients/ G. Lee, Y. Park, K. Viner, A. Murro, S. Miranda, S. Strickland, J. Smith, C. Giller
1.321 Individual Differences In TPM-induced Cognitive Performance As A Function Of TPM Plasma Levels/ S. Marino, S. Pakhomov, C. Hawkins-Taylor, I. Leppik, A. Birnbaum
1.322 Studying Correlations Between White Matter And Neuropsychological Profile In Temporal Lobe Epilepsy Using Diffusion Tensor Imaging/R. Alexander, M. Liu, L. Concha, T. Snyder, C. Beaulieu, D. Gross
1.323 Learning Words And Remembering Designs: Understanding Left And Right Medial Temporal Lobe Function In Epilepsy/S. Banks, V. Sziklas, J. Bellerose, D. Ladowski, M. Jones-Gotman
1.324 Physiological Response To Emotional Faces In Patients With Temporal Lobe Epilepsy/J. Bellerose, S. Banks, M. Jones-Gotman
1.325 Non-Verbal Communication In Patients With Epilepsy/K. Bujarski, K. Richardson, V. Thadani, K. Gilbert, R. Scott, B. Jobst
1.326 Cortisol Is Not Related To Depressive Symptoms Or Mesial Temporal Integrity In Patients With Medically Intractable Temporal Lobe Epilepsy/R. Busch, T. Frazier, J. Chapin, A. Hamrahian, B. Diehl, A. Alexopoulos, K. Unnwongse, R. Naugle, C. Kubu, G. Tesar, I. Najm
1.327 A Comprehensive fMRI Language Battery Discloses Extensive Inter- And Intra-hemispheric Language Reorganization In Epilepsy With Left Mesial Temporal Sclerosis/L. Castro, J. Almeida, B. Castro, P. Arantes, M. Otaduy, C. Jorge, R. Valerio, E. Amaro, Jr
1.328 Modification And Improvement Of An Existing Group Treatment For Psychological Non-Epileptic Seizures/ M. Fiorito Grafman, L. Myers, C. Zaroff, C. Haward, M. Lancman
1.329 CogScreen In Temporal Lobe Epilepsy Patients Versus Controls/ C. Harden, H. Frost, M. Lowe, E. Serrano, A. Grossman, A. Escandon, K. Perrine
1.330 Psychogenic Nonepileptic Seizure And Psychogenic Movement Disorder Patients: Are They The Same?/J. Hopp, M. Price, K. Anderson, A. Gruber-Baldini, J. Zhu, A. Krumholz, L. Shulman
1.331 Comparison Of The Assessment Of Effort In Patients With Psychological Non Epileptic Seizures And Refractory Partial Epilepsy Using The Test Of Memory Malingering/ J. Kanter, L. Myers, K. Perrine, J. Politsky, M. Lancman
1.332 Interictal Discharges During Encoding And Effects On Recognition/B. Leeman, S. Schachter, E. Macklin, S. Sheth, S. Cash, A. Cole, E. Eskandar, K. Meador
1.333 Neuropsychological Outcome Following Selective Amygdalo-Hippocampectomy/R. Malak, L. Partlo, H. Dhaliwal, T. Fay, E. Sherman, T. Myles, S. Wiebe, N. Pillay, W. Hader
1.334 A New Perspective In The Assessment Of The Psychological Composition Of Patients With Psychological Non-Epileptic Seizure Disorder/L. Myers, M. Lancman, J. Kanter, C. Zaroff
1.335 Anterograde Memory In Humans Is Related To Dentate Gyrus Granule Cells But Not To CA1 Neurons/E. Pauli, H. Stefan, I. Bluemcke
1.336 Impairment Of Prosody During Epileptic Seizures Characterized By Automatisms With Preserved Responsiveness/J. Remi, A. Peters, C. Bilgin, J. Gonzalez-Victores, J. Silva Cunha, S. Noachtar
1.337 Mesial Temporal Activation On Magnetic Source Imaging: Relationship To Cognitive Test Performance/G. Risse, R. Doss, A. Hempel, W. Zhang
1.338 Test Your Memory: A Self Administered Cognitive Test Identifies People With Jme With Wide-Ranging Cognitive Difficulties/R. Thomas, M. Rees, R. Wood, P. Smith
1.339 Postoperative Verbal Memory In Left Anterior Temporal Lobectomy Patients With Bilateral And Right Hemisphere Language Representation On The Intracarotid Amobarbital Procedure/S. Thrasher, F. Winstanley, J. Aurora, R. Constable, D. Spencer
1.340 Juvenile Myoclonic Epilepsy: Two Distinct Phenotypes Considering Neuropsychological Aspects, Personality Traits And Clinical Variables/K. Valente, D. Fuentes, L. Fiore, S. Moschetta
1.341 Decision-Making In Mesial Temporal Lobe Epilepsy Examined With The Iowa Gambling Task/N. Akamatsu, M. Yamano, S. Tsuji, M. Kobayakawa, M. Kawamura
1.342 Are Some Objects In Wada Testing Easier To Remember Than Others?/M. Doherty, A. Grieff, K. Kovach, A. Haltiner
1.343 The Importance Of Studying Social Adjustment In Patients With Temporal Lobe Epilepsy: Subjective Perception May Not Reflect The Real Social Impact Of Epilepsy/J. Gois, K. Valente, S. Vicenttis, S. Moschetta, L. Fiore, D. Fuentes
1.344 Neuroeconomic Decision-Making In Patients With Mesial Temporal Robe Epilepsy Before And After Surgery/ T. Hama, H. Matsui, H. Takahashi, T. Maehara, S. Watanabe, K. Hara, M. Matsuura
1.345 Neuroanatomical Correlates Of Linguistic Processes That Comprise Naming: Implications For Naming Difficulty In Left TLE/M. Hamberger, W. Seidel, C. Morrison, C. Carlson, A. Williams, A. Mehta, G. Klein, M. Miozzo
1.346 Induction Of Psychogenic Non-Epileptic Events: Success Rates Vary With Ictal Semiology And Neuropsychological Profile/S. Izadyar, D. Chen, R. Collins, J. Benge, A. LeMaire, R. Hrachovy
1.347 Correlation Between Psychological Non Epileptic Seizure Severity And Self-Reported State/Trait Anger And Anger Expression/ M. Lancman, O. Laban, E. Fertig, Y. Taher, J. Lee, K. Perrine, L. Myers

1.348 A Comparison Of Self-Reported Quality Of Life In Medically Refractory Partial Epilepsy Patients And Psychological Non Epileptic Patients/ B. Matzner, L. Myers, J. Kanter, O. Laban, M. Lancman
1.349 Psychosocial Functioning In Early- And Late-Onset Intractable Complex Partial Seizures/V. Phatak, V. Rekow, N. Chaytor, J. Miller
1.350 Memory Performances Of Right And Left Temporal Lobe Epilepsy Patients On The WMS-IV, RAVLT, And ROCFT/E. Rinehardt, M. Mattingly, S. Benbadis, A. Bozorg, A. Frontera, N. Rodgers-Neame, F. Vale, M. Schoenberg
1.351 Predictors Of Decline In Verbal Fluency After Frontal Lobe Epilepsy Surgery/R. Arkis, D. Floden, R. Busch, J. Chapin, C. Kalman, L. Jehi, I. Najm
1.352 Nonepileptic Seizures, Epileptic Seizures, And Intrasubtest Scatter/ R. Trobliger, L. Myers, M. Lancman
1.353 Perceived Memory Impairment Before Surgery In Temporal Lobe Epilepsy/S. Hayman-Abello, P. Derry, B. Hayman-Abello, S. Brown, R. McLachlan
1.354 Epilepsy And Creativity, Insights From The Creative Life And Work Of Canadian Playwright Judith Thompson/T. Lena, R. Wennberg
1.355 Inadequate Utility Of A Clinical Method For Predicting The Ultimate Side Of Surgery In Patients With Temporal Lobe Epilepsy Using The Boston Naming Test/M. Lutz, T. Mayer
1.356 Pre-Surgical Wechsler Adult Intelligence Scale – 4th Ed. Functioning Among Selected Right And Left Temporal Lobe Epilepsy Patients/ M. Schoenberg, E. Rinehardt, A. Bozorg, A. Frontera, N. Rodgers-Neame, M. Mattingly, F. Vale, S. Benbadis
1.357 Vagal Nerve Stimulator: Cognitive And Mood Aspects/ A. Piazzini, K. Turner, V. Chiesa, E. Gardella, E. Zambrelli, F. La Briola, A. Vignoli, M. Canevini

Neuropsychology/Language/Behavior Pediatrics
1.358 Age-Related Vulnerability To Risks For Neuropsychological Decline Following Seizure Onset In School-Age Children/P. Fastenau, C. Johnson, A. Byars, S. Perkins, D. Dunn, T. deGrauw, J. Austin
1.359 The Effect Of Developmental And Acquired Brain Lesions On Hemisphere Language Dominance In Children/I. Lax, O. Bar-Yosef, D. Morris, W. Logan, E. Donner
1.360 Motivational Effects On Executive Function In Pediatric Epilepsy: An Fmri And Dti Study/M. Asato, C. Geier, A. Padmanabhan, R. Terwilliger, N. Nawarawong, W. Gaillard, B. Hermann, K. Ellsworth, B. Luna
1.361 Clinical Characteristics Of Psychogenic Non-epileptic Seizures (PNES) In Children/J. Doss, F. Ritter
1.362 Systematic Review And Case Series Of Neuropsychological Outcomes After Epilepsy Surgery In Children With Dysembryoplastic Neuroepithelial Tumours (DNET)/T. Fay, W. Hader, I. Mohamed, E. Sherman
1.363 Subjective Versus Objective Memory In Pediatric Epilepsy: Caregivers' Memory Ratings Reflect Objective Memory Performance Better Than Self-Ratings/L. Ferguson, R. Busch, T. Lineweaver, P. Klaas, J. Haut
1.364 Are Comorbidities In Pediatric Epilepsy Familial?/S. Gurbani, P. Siddarth, J. Levitt, E. Lanphier, R. Caplan
1.365 Peer Acceptance And Friendships In Children With Epilepsy/ L. Hamiwka, L. Bair, K. Vannatta, L. Herren, R. Caplan, K. Yeates
1.366 Gender Differences On Memory Performance In Children With Left TLE/P. Klaas, I. Tuxhorn, R. Busch, J. Haut, S. Bowen
1.367 Retention Score As A Metric Of Mesial Temporal Dysfunction In Pediatric Epilepsy/B. Korman, M. Duchowny, P. Dean, P. Jayakar, T. Resnick, G. Rey
1.368 Is The WISC-Iv Useful For Detecting Cognitive Impairment In Children With Epilepsy?/W. MacAllister, B. Brooks, E. Sherman
1.369 Use Of Special Education Services In Childhood-Onset Epilepsy: A Case-Sibling-Controlled Analysis/ C. Roman, E. Benn, D. Hesdorffer, A. Berg
1.370 Clinical Normative Data For Intelligence Testing In Children And Adolescents With Epilepsy/B. Brooks, W. MacAllister, E. Sherman
1.371 Maternal Anxiety About Epilepsy: Association With Emotional, Behavioral And Social Disturbances/ L. Chapieski, C. Akman, K. Evankovich, R. Schultz, A. Wilfong, A. Malphrus, J. Riviello
1.372 Prolonged Febrile Seizures And Memory Development/M. Martinos, M. Yoong, R. Scott, M. de-Haan
1.373 Neurodevelopmental Outcome Following Epilepsy In Infancy/H. O'Reilly, K. Verhaert, C. Eltze, R. Scott, J. Cross, M. de Haan
1.374 Language Performance And Working Memory In Children With Rolandic Epilepsy/G. Overvliet, S. Klinkenberg, J. van Leeuwen, J. Nicolai, J. Vles, A. Aldenkamp, J. Hendriksen
1.375 Response To High Dose Diazepam Challenge Test In Electrical Status Epilepticus Of Sleep (ESES) In Children/R. Ramachandran Nair, G. Ronen
1.376 The Effects Of Epilepsy Surgery In Children On Everyday Memory Function/M. Lou Smith, C. Oitment
1.377 Anxiety And Depression Symptoms In Childhood Absence Epilepsy/C Vega, J. Guo, B. Killory, M. Vestal, R. Berman, M. Chung, M. Spann, H. Blumenfeld
1.378 Social Behavior In Children With Epilepsy: What Do Their Teachers Think?/L. Bair, L. Hamiwka, K. Vannatta, L. Herren, R. Caplan, K. Yeates
1.379 Psychological Profile Of Epileptic Children And Adolescents/S. EOM, S. Eun, H. Kang, H. Chung, S. Nam, B. Eun, S. Kwon, S. Kim, J. Lee, H. Kim
1.380 Memory Impairment Of Children With Temporal Lobe Epilepsy Is At Least Partially Explained By The Executive Dysfunction/P. Rzezak, C. Guimarães, D. Fuentes, M. Guerreiro, K. Valente

Neuropsychology/Language/Behavior All Ages
1.381 Semantic Knowledge Loss In Patients With Adult Onset Complex Partial Seizures After Left Anterior Temporal Lobe Resection/M. Dulay, A. Verma, R. Grossman
1.382 Seizure Recognition During Inpatient Video/EEG Monitoring/ K. Detyniecki, L. Yang, S. Enamandram, H. Lee, P. Farooque, H. Hamid, C. Vega, R. Duckrow, H. Blumenfeld
1.383 Social And Psychological Outcome Of Epilepsy In Well-Functioning Children And Adolescents 10 Years After Diagnosis/ O. Eeg-Olofsson, P. Jonsson
1.384 Linguistic Performance And Integrity Of The Arcuate Fasciculus In Non-Lesional Epilepsy/ M. Gonzalez-Nosti, Z. Li, E. Castillo, J. Breier, J. Slater, A. Papanicolaou
1.385 Early Life Seizures Lead To Compensatory Increases In Prefrontal Cortex Theta Power To Maintain Cognitive Performance In Adulthood/ J. Kleen, E. Wu, R. Scott, G. Holmes, P. Lenck-Santini
1.386 Right-Sided Receptive Language Dominance In Medically Refractory Resective Epilepsy Surgery Candidates: An Meg Study With Multiple Language Tasks/D. Eliashiv, N. Gage, S. Otis, L. Kurelowech, P. Quint, J. Chung
1.387 Cognitive And Affective Functions In Add-On Therapy With Lacosamide/W. Graf, K. Kurzbuch, F. Kerling, E. Pauli, H. Stefan
1.388 Factors Underlying Discordant Right Hemispheric Language Classification On WADA-Confirmed Left Dominant Patients/A. Hempel, G. Risse
1.389 Reliability Of The Intracarotid Amobarbital Procedure (IAP)/ C. Morrison, L. Whitman, C. Carlson, T. Becske, W. Barr
1.390 Out-Of-Body Experience During Extra-Operative Cortical Stimulation Of Right Precuneus: A Novel Observation/ A. Moosa Naduvil Valappil, J. Bulacio, D. Nair, I. Najm
1.391 Does Consciousness Occur In "Frames"? Evidence From Intracranial EEG Recordings/S. Pockett, B. Brennan, G. Bold, M. Holmes

Why join the American Epilepsy Society?

The **American Epilepsy Society** serves as a resource for its membership and the epilepsy community by providing access to data on the latest breakthroughs, technologies and methodologies in epilepsy research.

The American Epilepsy Society promotes interdisciplinary communication, scientific investigation, and exchange of clinical information about epilepsy. Membership in AES opens doors to educational sessions, networking and knowledge-sharing among its members and Annual Meeting attendees.



AES members have convenient access to opportunities for professional growth through a variety of avenues, including:

- ***Member Benefits & Opportunities***
- ***Continuing Education & Professional Development***
- ***Publications***
- ***Networking***
- ***Research Funding***

Membership Categories	Annual Dues
Active Membership (includes Epilepsia)	$250
Professionals in Epilepsy Care	$125
Corresponding Membership (includes Epilepsia)	$220
Corresponding Membership	$145
Junior Membership (includes Epilepsia) Special Rate (limited time only) – regularly $150	$110
Junior Membership	$35
Special Rate (limited time only) – regularly $75 Associate (includes Epilepsia)	$250

Don't Miss Out! Apply online for membership at **WWW.AESNET.ORG**

or

stop by the AES Membership Booth in the registration area

8:45 a.m. – 5:15 p.m.

Annual Course: Inflammatory Issues and Infectious Causes of Epilepsy

(6.0 CME Credits)

Convention Center – Lila Cockrell Theatre

This session will highlight the following Benchmark goals:

I. Prevent epilepsy and its progression.

A. Identify as yet unrecognized causes of epilepsy (e.g., genetic, autoimmune and infectious).

B. Identify underlying mechanisms of epileptogenesis.

1. Identify at least one susceptibility gene or other risk factor (e.g., viral, trauma, autoimmune) and identify how it predisposes to changes in network excitability.

3. Identify at least one specific role for non-neural mechanisms (e.g., glia, immune cells, angiogenesis) in epileptogenesis.

Benchmarks Steward: William H. Theodore, M.D.

For more information, see p 53.

Overview

The 2010 course is devoted to a comprehensive review of the inflammatory and infectious causes of epilepsy. The course will focus on epilepsy as a manifestation of specific inflammatory or infectious conditions, the pathophysiology of these conditions, the treatment of these conditions, and the treatment of epilepsy. Autoimmune diseases, though uncommon, are being increasingly recognized as a cause of seizures. In contrast, infections are common causes of epilepsy, particularly in lesser developed and tropical countries. The course faculty includes international experts in the field who will review the latest pertinent information. Educational formats include didactic lectures, debate format, panel discussions, and case presentations.

Learning Objectives

- Consider autoimmune causes of epilepsy when evaluating patients
- Undertake appropriate testing to define infectious causes of epilepsy in appropriate patients
- Use knowledge of pathophysiology and prognosis in developing a treatment plan for Rasmussen encephalitis
- Undertake evaluation to diagnose neurocysticercosis in patients with risk factors and, when diagnosed, undertake treatment based on current understanding of the pathophysiology of the disorder
- Identify patients at risk plan for both viral and tropical diseases causing epilepsy
- Use most current understanding regarding prognosis and potential long term consequences of febrile seizures in managing patients with febrile seizures
- Develop a treatment algorithm for status epilepticus.

Target Audience

Intermediate, Advanced (see page 101 for details)

Program

Chair: Michael R. Sperling, M.D.
Vice-Chair: Joseph Sirven, M.D.

8:45 a.m	Introduction Overview Michael R. Sperling, M.D.
8:55 a.m.	Lecture: Epilepsy and Inflammation in the Brain: Overview and Pathophysiology Annamaria Vezzani, Ph.D.
9:20 a.m.	Lecture: Autoimmune Epilepsy Sean Pittock, M.D.
9:50 a.m.	Case Presentation: Patient With Adult-Onset Seizures Enrique Serrano, M.D.
9:55 a.m.	Panel Discussion: Screening and Treating Patients with Autoantibodies Michael Sperling, M.D., Christian Bien, M.D., Sean Pittock, M.D.
10:10 a.m.	Break
10:25 a.m.	Case Presentation: Rasmussen's Encephalitis Sudha Kessler, M.D.
10:30 a.m.	Debate: Rasmussen's Encephalitis and the Timing of Surgery Adam Hartman, M.D., J. Helen Cross, M.D., Ph.D.
11:05 a.m.	Lecture: Epilepsy Associated With Systemic Autoimmune Diseases Orrin Devinsky, M.D.
11:30 a.m.	Case Presentation: Patient with Encephalopathy and Seizures After Vaccination Derek Chong, M.D.
11:35 a.m.	Lecture: Vaccines and Seizures Samuel F. Berkovic, M.D.
Noon – 2:00 p.m.	Lunch Break
2:00 p.m.	Lecture: Febrile Seizures: The Role of Inflammation in Febrile Seizures and Its Relation to Epilepsy Tallie Z. Baram, M.D., Ph.D.
2:25 p.m.	Panel Discussion: Controversies in Febrile Seizures Tallie Z. Baram, M.D., Ph.D, Shlomo Shinnar, M.D., Ph.D., William D. Gaillard, M.D.
2:40 p.m.	Lecture: Neurocysticercosis Jorge G. Burneo, M.D., MSPH
3:05 p.m.	Case Presentation: Patient With Neurocysticercosis Katie Noe, M.D.
3:10 p.m.	Panel Discussion: Controversies in Management of Neurocysticercosis Joseph I. Sirven, M.D., Theodore Nash, M.D., Jorge G. Burneo, M.D., MSPH, Jose Cavazos, M.D., Ph.D.
3:30 p.m.	Break
3:45 p.m.	Lecture: Epilepsy Caused by Tropical Diseases Theodore Nash, M.D.
4:15 p.m.	Lecture: Epilepsy and Viral Infections William H. Theodore, M.D.
4:40 p.m.	Panel Discussion: Management of Status Epilepticus in the Setting of Encephalitis Michael R. Sperling, M.D., Daniel H. Lowenstein, M.D., Elizabeth J. Waterhouse, M.D., Matthew Walker, M.D.
5:05 p.m.	Conclusion Michael Sperling, M.D.
5:15 p.m.	End of Course

Credit Designation

The American Epilepsy Society designates this education activity for a maximum of 6.0 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE Universal Activity Number (UAN) is 031-999-10-024-L01-P and provides 6 contact hours (.6 CEUs)

Acknowledgment

This program is supported in part by an educational grant from UCB, Inc.

8:45 a.m. – 5:45 p.m.

➤ Investigators' Workshops

Marriott Rivercenter – Room names under each session
Please complete program survey – see page 14

Overview

These workshops, conducted informally and designed to encourage interaction, will address several important areas of rapidly emerging knowledge in clinical and basic research in epilepsy. The workshops are intended to identify challenges in current research, propose methods to overcome those challenges, and encourage areas for future investigation.

The four Clinical Investigators' Workshops provide a series of working seminars in matters of active clinical investigation and controversy. In addition, these Workshops cover basic research approaches germane to each clinical topic in addition to relevant and recent human studies. Speakers present results from their ongoing research and place their findings in the context of current understanding. Accordingly, one of these Workshops has been selected in a translational category for a longer presentation of two hours in order to accommodate a particularly broad scope from basic to clinical research.

The 11 Basic Science Workshops will highlight a number of research areas, which have been developing rapidly over the last year. The Basic Science Workshops are scheduled on three days of the Meeting. For the first time this year one of the Workshops has been set aside to highlight a topic from this summer's Gordon Research Conference.

Most of the Workshops will run as concurrent sessions on Sunday, while two concurrent Workshops including the longer translational Workshop are scheduled for Saturday evening and one single Workshop on Monday afternoon. Again this year we will feature the Epilepsy Research Recognition Award recipients in a keynote address session following the Poster Session on Sunday afternoon.

Target Audience

Basic scientists, neurologists, neuroscientists, pharmacologists, neuropsychologists and neurosurgeons who are performing research in epilepsy

Program

Investigators' Workshops Chair: Nicholas P. Poolos, M.D., Ph.D.
Clinical Investigators' Workshop Chair: Matthias J. Koepp, M.D., Ph.D.

Morning Session I – 8:45 a.m. - 10:15 a.m.

1. **Epigenetic Mechanisms of Epileptogenesis**
   Marriott Rivercenter – Grand Ballroom, Salon G/M
   Moderator: Christophe Bernard, Ph.D.
   Speakers: Raymond J. Dingledine, Ph.D., Avtar S. Roopra, Ph.D., Tallie Z. Baram, M.D., Ph.D.

2. **The Endocannabinoid System and Temporal Lobe Epilepsy**
   Marriott Rivercenter – Grand Ballroom, Salon H/K
   Moderator: Astrid Nehlig, Ph.D.
   Speakers: Robert J. DeLorenzo, M.D., Ph.D., M.P.H., Karolien Goffin, M.D., Ph.D., Zsofia Magloczky, Ph.D.

3. **Mapping Brain Networks in Epilepsy: Insights From Novel EEG, fMRI and Morphometric MRI Methods**
   Marriott Rivercenter – Grand Ballroom, Salon I/J
   Moderators: Andrea Bernasconi, M.D., William D. Gaillard, M.D.
   Speakers: Neda Bernasconi, M.D., Ph.D., Maxime Guye, M.D., Ph.D., Madison Berl, Ph.D.

Break: 10:15 a.m. - 10:30 a.m.

Morning Session II – 10:30 a.m. - Noon

4. **The Emerging Role of the Axon Initial Segment in Epileptogenesis**
   Marriott Rivercenter – Grand Ballroom, Salon G/M
   Moderator: Verena C. Wimmer, Ph.D.
   Speakers: Edward C. Cooper, M.D., Ph.D., Matthew N. Rasband, Ph.D., Verena C. Wimmer, Ph.D.

5. **Neurobiological Mechanisms in Genetic Focal Epilepsies: The Case of LGI1**
   Marriott Rivercenter – Grand Ballroom, Salon H/K
   Moderator: Ruth Ottman, Ph.D.
   Speakers: Ruth Ottman, Ph.D., John K. Cowell, Ph.D., D.Sc., Matthew P. Anderson, M.D., Ph.D.

6. **Insights from Neuroimaging on Brain Development in Children with "Epilepsy Only"**
   Marriott Rivercenter – Grand Ballroom, Salon I/J
   Moderators: Rochelle Caplan, M.D., Bruce P. Hermann, Ph.D.
   Speakers: Bruce P. Hermann, Ph.D., Rochelle Caplan, M.D., Hal Blumenfeld, M.D., Ph.D.

Noon - 1:30 p.m. Poster Session (Boxed Lunch)

Marriott Rivercenter – Grand Ballroom, Salon F
Note: Number below refers to poster assignment

1.002 The Role of Astrocytes in the Epileptogenicity of Cortical Microgyri, *C. Dulla, H. Tani, J. Brill, R. Reimer, J. Huguenard*

1.010 Altered GABA Signaling in the Acute Hippocampal Slice Model of Brain Trauma, *V. Dzhala, M. Mail, K. Staley*

1.014 mTOR Inhibition Has Potential Antiepileptogenic Effects in a Controlled Cortical Impact Model of Traumatic Brain Injury, *D. Guo, L. Zeng, D. Brody, Michael Wong*

1.018 Kainate-induced Status Epilepticus Alters BDNF Gene Expression in Area CA1 and Memory Formation Using Epigenetic Mechanisms, *F. Lubin, R. Parrish*

1.029 Regional Differences in Arc/Arg 3.1 Protein Expression in the Immature Brain Induced by Seizures, *C. Gomez, B. Kosaras, P. Klein, F. Jensen*

1.031 Rapid Loss of Dendritic HCN Channel Expression Following Status Epilepticus, *S. Jung, L. Warner, J. Pitsch, A. Becker, N. Poolos*

1.039 Focal Status Epilepticus in the Somatosensory Cortex Enhances Intrinsic Excitability and Synaptic Excitation in the Reticular Thalamic Nucleus, *J. Paz, W. McDonald, D. Prince, J. Huguenard*

1.045 A Putative Cellular Mechanism for Childhood Absence Epilepsy in Patients with Cav3.2 Gain-of-Function Mutations, *L. Xu, Z. Jin, S. Smith, M. Anderson*

1.060 Permanently Impaired Mitochondrial Redox Status and Oxidative/Nitrosative Stress During Epileptogenesis, *S. Waldbaum, K. Ryan, L. Liang, M. Patel*

1.317A Neuroprotective Effect in Rat Hippocampus of Cyclooxygenase-2 Inhibitor and Diazepam after Pilocarpine-induced Status Epilepticus, *C. Trandafir, W. Pouliot, F. Dudek*

1.360 Motivational Effects on Executive Function in Pediatric Epilepsy: An fMRI and DTI Study, *M. Asato, C. Geier, A. Padmanabhan, R. Terwilliger, N. Nawarawong, W. Gaillard, B. Hermann, K. Ellsworth, B. Luna*

3.006 Long-Lasting Alterations in NKCC1 and KCC2 Expression Induced by Evoked and Spontaneous Seizures in Kindled Epileptic Rats, *T. Sutula, K. Gielissen, S. Osting, D. Sun*

3.018 Minocycline Ameliorates Cerebral Lesions but Not Decreases Spontaneous Recurrent Seizures After Pilocarpine-induced Status Epilepticus, *M. Foresti, G. Arisi, L. Shapiro*

3.021 Humanized Mouse Models of Epilepsy, *J. Kearney*

3.164A Increased Crossing of Cortico-striatal Connections Following Resective Epilepsy Surgery in Children: A Probabilistic DTI Tractographic Study, *R. M. Govindan, H. Chugani, S. Sood*

3.164B MU Opioid Receptor mRNA Expression, Binding and Functional Coupling to G-proteins in Human Epileptic Hippocampus, *L. Rocha, M. Cuellar-Herrera, A. Velasco, F. Velasco, L. Chavez, M. Alonso-Vanegas, S. Orozco-Suarez, A. Yalcin, S. Benyhe, A. Borsodi*

3.316 Concordance of Seizure Semiology and Pharmacosensitivity in Sibling Pairs from the Epilepsy Phenome/Genome Project (EPGP), *M. Winawer, R. Fahlstrom, D. Rabinowitz and The EPGP Senior Investigators*

3.341 NRSF/REST Dependent and Independent Gene Pathways in Epileptogenesis, *S. McClelland, C. Flynn, C. Dube, J. Yang, R. Petrosyan, J. Mundy, C. Bernard, T. Baram*

3.362 mTOR Cascade Activation Observed in Human Hippocampal Sclerosis is Not Recapitulated in a Rat Pilocarpine Model of Epilepsy, *A. Sosunov, X. Wu, C. Mikell, R. McGovern, D. Coughlin, R. Goodman, H. Scharfman, G. McKhann*

3.365 Immature Large Newborn Neurons in Human Hippocampal Dentate Gyrus from Patients with Temporal Lobe Epilepsy, *H. Sugano, M. Nakajima, H. Okura, T. Hig, H. Arai*

1:45 p.m. - 2:15 p.m. Keynote Speakers
Marriott Rivercenter – Grand Ballroom, Salon H/K

Research Recognition Award Recipient (Basic Science)
Douglas A. Coulter, Ph.D.

Research Recognition Award Recipient (Clinical Science)
Tracy A. Glauser, M.D.

Afternoon Session I – 2:30 p.m. - 4:00 p.m.

7. **"Interneuronopathies" – Diversity in the Phenotypes of Genetic Mutations that Alter Forebrain GABAergic Interneuron Ontogeny**
   Marriott Rivercenter – Grand Ballroom, Salon G/M
   Moderator: Elizabeth Powell, Ph.D.
   Speakers: Eric Marsh, M.D., Ph.D., Molly Huntsman, Ph.D., Gregory Barnes, M.D., Ph.D.

8. **Adenosine and Epilepsy – Promising Start Into a New Century: The First Decade**
   Marriott Rivercenter – Grand Ballroom, Salon H/K
   Moderator: Detlev Boison, Ph.D.
   Speakers: Thomas H. Swanson, M.D., Philip G. Haydon, Ph.D., Susan Masino, Ph.D.

9. **De-Standardizing Antiepileptic Therapy Development: Translating "Translational" Research Into Clinical Trials**
   Marriott Rivercenter – Grand Ballroom, Salon I/J
   Moderator: Cynthia L. Harden, M.D.
   Speakers: Cynthia L. Harden, M.D., Mark S. Quigg, M.D., Emilio Perucca, M.D., Ph.D.

Break: 4:00 p.m. - 4:15 p.m.

Afternoon Session II – 4:15 p.m. - 5:45 p.m.

10. **Control of Synapse Formation and Epileptogenesis**
    Marriott Rivercenter – Grand Ballroom, Salon G/M
    Moderator: David A. Prince, M.D.
    Speakers: Cagla Eroglu, Ph.D., Beth Stevens, Ph.D., David A. Prince, M.D.

11. **Early Detection of Epileptogenesis and the Search for Preventative Treatments in Experimental Models and the Clinic**
    Marriott Rivercenter – Grand Ballroom, Salon H/K
    Moderator: Anatol Bragin, Ph.D.
    Speakers: Daniel Friedman, M.D., Stanislav L. Karsten, Ph.D., Frances E. Jensen, M.D.

12. **Highlights from the Gordon Research Conference**
    Marriott Rivercenter – Grand Ballroom, Salon I/J
    Moderator: John Huguenard, Ph.D., 2010 GRC Chair
    Speakers: Lori Isom, Ph.D., Elsa Rassignol, M.D., Waldemar Swiercz, Ph.D.

6:00 p.m. – 7:30 p.m.
➤ Investigators' Workshop Poster Session
Marriott Rivercenter – Grand Ballroom, Salon F
Note: Number below refers to poster assignment

1.001 The Relation Between Interictal Spikes and Seizures in Rat Models of Epilepsy, *M. Dichter, H. Juul, J. Keating*

1.006 Role of trkB Receptors, and Presynaptic Axonal Sprouting in Hyperexcitability After Schaffer Collateral Transection and Its Contribution to Posttraumatic Epilepsy, *S. Aungst, P. England, S. Thompson*

1.017 Early-life Seizures Lead to Increased AMPA Subunit-Containing Synapses and Higher Ca2+ Responses in Rat Pyramidal CA1 Neurons, *J. Lippman Bell, C. Zhou, P. Klein, F. Jensen*

1.038 Recurrent Seizures Suppress Dendritic Growth of Developing Hippocampal Pyramidal Cells, *M. Nishimura, J. Swann*

1.042 Pathways of interictal Spike Propagation are Determined by Network Inhibition, *W. Swiercz, H. Sabolek, S. Cash, G. Huberfeld, S. Clemenceau, R. Miles, K. Staley*

1.055 Rapamycin Suppresses Mossy Fiber and Somatostatin Interneuron Axon Sprouting But Not Epileptogenesis in a Mouse Model of Temporal Lobe Epilepsy, *P. Buckmaster, X. Wen, F. Lew*

1.057 Gene Profiling of the CA1 after Multiple Early-Life Seizures, *L. Friedman, J. Mancuso, A. Sagyhan, D. Iacobas, S. Iacobas, D. Spray*

1.136 Propagation of Intracranial Electroencephalographic Activity between Neocortex and Subcortical Structures as an Indicator of Seizure Onset, *A. Korzeniewska, M. Cervenka, C. Jouny, J. Perilla, G. Bergey, N. Crone, P. Franaszczuk*

1.137 Observation of Emerging Ictal Network Dynamics using Synchrony Index, *G. Martz, S. Johnson, J. Hudson, M. Quigg*

1.145 Characterizing Pre-ictal and Inter-ictal States with Graph Theoretical Approaches, *K. Lehnertz, M. Horstmann, C. Elger*

1.346 Induction of Psychogenic Non-Epileptic Events: Success Rates Vary with Ictal Semiology and Neuropsychological Profile, *S. Izadyar, D. Chen, R. Collins, J. Benge, A. LeMaire, R. Hrachovy*

3.015 Epilepsy-induced Pathologic Plasticity and NMDA Alterations in the Malformed Brain of Human FCD Patients and MAM-pilocarpine Rat Model, *F. Colciaghi, A. Finardi, P. Nobili, A. Frasca, L. Castana, G. LoRusso, A. Vezzani, G. Battaglia*

3.036 Differential Neuronal Activation Pattern and Seizure Susceptibility in Newborn Rat Pups Following Maternal Stress and Immune Challenge, *M. Esser, A. Reid, Q. Pittman*

3.045 Low Blood Glucose Increases Absence Seizure Susceptibility, *C. Reid, T. Kim, S. Berkovic, S. Petrou*

3.053 Fast Ripples in an Experimental Non-lesional Temporal Lobe Epilepsy, *J. Jefferys, P. Jiruska, G. Finnerty, A. Powell, N. Lofti, R. Cmejla*

3.062 A Closed-Loop Implantable Device For Epileptic Seizure Detection and Neurostimulation, *M. Salam, F. Mounaim, M. Sawan, D. Nguyen*

3.212 Cluster Analysis Applied to fMRI Data in Typical Childhood Absence Seizures, *X. Bai, B. Killory, J. Guo, M. Vestal, R. Berman, M. Negishi, E. Novotny, R. Constable, H. Blumenfeld*

3.339 Dynamic Disinhibition of Cortical Circuits, *J. Brill, J. Mattis, K. Deisseroth, J. Huguenard*

3.340 Aberrant Integration of Postnatally Generated Neurons is Sufficient to Cause Epilepsy, *S. Danzer, D. Richards, K. Holland, J. Uhl, C. Faulkner, H. Yin, B. Murphy, S. Bronson, R. Pun*

3.357 Temporal Lobe Epilepsy Induced Increases in Persistent (INaP) and Resurgent (INaR) Na Currents, *M. Patel, N. Hargus, E. Bertram*

6:00 p.m. – 7:30 p.m.

Special Interest Group Meetings

Convention Center – Location listed under each session
Please complete program survey – see page 14

Engineering and Epilepsy – Modeling Epileptic Networks

Convention Center – Room 008

Coordinators: Piotr J. Franaszczuk, Ph.D., Gregory K. Bergey, M.D.
Speakers: Stiliyan Kalitzin, Ph.D., Ivan Osorio, M.D., Alexander Rothkegel, Dipl.Phys., Dipl.Math, Piotr Suffczynski, Ph.D., Michal Zochowski, Ph.D.

The recent advances in recording from intact biological systems (e.g. increased sampling, special recording wires for recording high frequency activity) have further increased the value of neural network modeling of seizure dynamics. Improved computational power and the use of parallel processors (clusters) have facilitated computationally intensive modeling studies. The advantage of neural network modeling is the ability to "record" and modify variables simultaneously on different levels of the modeled system. This may include investigating and/or modifying synaptic weights, concentrations of ions, neurotransmitters, changes in neural membrane potentials, as well as simulations of local field potentials, and the effects of external stimulation. These studies can be done for single neurons, small networks of neurons as well as the larger networks and whole brain structures. This allows for systematic testing of influences on seizure dynamics that then can be compared with biological systems. This SIG will have presentations by experts in neural modeling who will address the various considerations important in implementing these models and considerations of the different approaches currently available.

➤ How to Obtain NIH Funding - Changes in Peer Review and Grant Applications

Convention Center – Room 006 D

Coordinator: Randall Stewart, Ph.D. and Bill Benzing
Speakers: Alan Willard, Ph.D.

Allan Willard, Chief of the NINDS Scientific Review Branch and Acting Deputy Director of the NINDS Division of Extramural Research, will provide helpful hints to deal with the changes to NIH peer review.

Neuroendocrinology – Hormonal Issues in Men with Epilepsy: The Impact of Seizures, AEDs and Aging

Convention Center – Room 201

Coordinators: Jana Veliskova, M.D., Ph.D., Doodipala Samba Reddy, Ph.D., R.Ph.
Speakers: Expert panel and open discussion

This SIG will discuss hormonal issues in men with epilepsy during their lifespan. Discussion will focus on the effects of epilepsy on hormones, which AEDs do and do not affect the hormonal levels, on the impact of these changes on sexual function and fertility, on the aging component, and the importance of counseling available for the male patients.

Neuroimaging – Imaging in Focal Cortical Dysplasia (FCD): What's New in the Diagnosis and Classification?

Convention Center – Room 007 A/B

Coordinator: Fernando Cendes, M.D., Ph.D.
Speakers: Ingmar Blumcke, M.D., Imad M. Najm, M.D., André Palmini, M.D., Ph.D.

In this SIG we will discuss the imaging and histopathological spectrum of FCDs in the light of recent clinical and experimental evidence. FCDs are highly epileptogenic lesions which present a wide spectrum of imaging abnormalities: They can be either small or invisible to standard imaging techniques in one end of this spectrum, or they can be easily detected by MRI and sometimes affect multiple lobes in the other end of the spectrum. FCDs may occur also in combination with other types of lesion such as low grade tumors and hippocampal sclerosis.

Quality & Value Indicators – Practice, Research and Education of Epilepsy Using the 8 Epilepsy Quality Metrics

Convention Center – Room 202

Coordinator: Joseph I. Sirven, M.D.
Speakers: Richard Zimmerman, M.D., Nathan B. Fountain, M.D., Sandra L. Helmers, M.D.

There are 8 Epilepsy Quality Metrics which will need to be addressed in each and every visit with patients with epilepsy in order to assure quality care. Moreover, all recent board certified neurologists must have some quality metrics demonstrated in order to maintain board certification. The logical question that follows is how do we best use these metrics to inform and guide research, education and practice. The 2010 SIG will address the following topics in order to answer that question: 1. How do we best alter or transform the health care delivery system at your institution to best deliver quality care for patients with epilepsy?; 2. What are potential research questions and examples of current research projects that can be done using the 8 quality metrics?; 3. An Introduction to the American Academy of Neurology Epilepsy Performance in Practice Module for Maintenance of Certification

Acknowledgment
This SIG is supported by Sunovion Pharmaceuticals Inc.

Tuberous Sclerosis – How Does Genotype Matter?

Convention Center – Room 007 C/D

Coordinators: Elizabeth Thiele, M.D., Ph.D., E. Martina Bebin, M.D., M.P.A.
Speakers: Hope Northrup, M.D., Peter Crino M.D., Ph.D.

A disease-causing mutation in the TSC1 or TSC2 gene is found in 85% of individuals with TSC. Speakers will discuss the current understanding of the genetics of TSC, including the value of testing, and interpretation of the results. Possible genotype / phenotype correlations with regard to epilepsy and other neurologic symptoms will also be addressed, as well as possible mechanisms explaining those with "no mutation identified."

6:00 p.m. – 8:30 p.m.

Professionals in Epilepsy Care Symposium: How Practitioners Can Use Neuropsychological Testing to Improve Patient Care and Outcomes

(2.5 CME Credits)

Convention Center – Room 006 A-C

Overview

Neuropsychological assessment has played a prominent role in epilepsy care for many decades. Neuropsychological functioning has been related to many outcomes in children and adults with epilepsy, including academic and vocational success, social functioning, and mental health. Furthermore, cognitive functioning can affect the degree to which individuals with epilepsy can participate in their clinical education and self-care. Existing and emerging research findings have important implications for how professionals in epilepsy care should use neuropsychological test results to change patient outcomes in a variety of spheres. This symposium will help clinicians from wide-ranging backgrounds and specialties translate neuropsychological test findings into relevant interventions and multidisciplinary collaborations for improving outcomes in patients across the lifespan.

Learning Objectives

- Apply a theoretical model to conceptualize the role of neuropsychological functioning in various psychosocial outcomes among children and adults with epilepsy and refer for neuropsychological evaluation and intervention in timely fashion
- Collaborate more closely with school staff and educational specialists to ensure that cognitive and behavioral strengths are incorporated into an individualized treatment plan to improve academic performance in children and adolescents with epilepsy
- Collaborate more closely with vocational rehabilitation specialists to use documented cognitive and behavioral strengths to optimize vocational success in adults with epilepsy
- Utilize neuropsychological data in coordinating psychiatric treatment plans to enhance psychosocial adaptation and quality of life
- Tailor patient education and care to the individual's cognitive limitations, coordinate consultations and interventions by multiple disciplines, and monitor the individual's academic, vocational, and mental health progress.

Target Audience

Basic / fundamentals, Intermediate (see page 101 for details)

Program

Co-Chairs: Philip S. Fastenau, Ph.D. and Linda Allen, B.S.N., RN

Overview of Neuropsychological Functioning in Epilepsy Across the Lifespan and Implications for Use of Testing to Modify Patient Outcomes
Philip S. Fastenau, Ph.D.

How to Use Neuropsychological Test Results to Improve Academic and Behavioral Outcomes in Schools
Mary Lou Smith, Ph.D.

Role of Neuropsychological Functioning in Vocational Rehabilitation
Robert T. Fraser, Ph.D., M.P.A., C.R.C., C.L.C.P.

Role of Neuropsychological Functioning in Psychiatric Assessment and Treatment
Rochelle Caplan, M.D.

Role of Neuropsychological Functioning in Patient Education and Coordination of Care
Madona D. Plueger, B.S.N., RN, CNRN

Case Presentation and Discussion
Linda Allen, B.S.N., RN

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nursing contact hours have been applied for through the Texas Nurses Association, an accredited approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

To successfully complete either program and receive 2.5 Nursing Contact Hours, please complete and return the paper evaluation form to the volunteers at the door or the main registration desk at the conclusion of the program. You will receive your CE certificate in exchange for a completed form.

Pharmacy Credit

ACPE Universal Activity Number (UAN) is 031-999-10-025-L01-P and provides 2.5 contact hours (.25 CEUs)

Acknowledgment

This program is supported by an educational grant from Pfizer Inc.

Notes

Educational Reflections

Want CME/CE credit?

Go to www.AESNET.org

See page 101 for further details

➤ **Authors Present: Noon – 2:00 p.m.**
➤ **Poster Walking Tours (see page 12 for details)**

Translational Research
Human Tissue & Pathology
2.001 High Resolution Copy Number Variation Of Ion Channel Genes In Epilepsy/A. Goldman, T. Klassen, W. Gu, F. Zhang, V. Bomben, T. Chen, J. Lupski, J. Noebels
2.002 Epileptogenic Regions Of Human Cortical Dysplasia Display A Persistently Immature GABAergic Pharmacologic Profile/L. Jansen, W. Roden, L. Peugh, H. Alexander, J. Ojemann
2.003 Differential Metabotropic Glutamate Receptor Type 5 (Mglur5) Expression In The Hippocampus Of Patients With Mesial Temporal Lobe Epilepsy/L. Kandratavicius, P. Rosa-Neto, M. Monteiro, M. Guiot, C. Carlotti, Jr, J. Assirati, J. Leite, E. Kobayashi
2.004 Differences In Persistent Calcium And Sodium Inward Currents Between Focal And Parafocal Regions In Pediatric Neocortical Epilepsy/C. Marcuccilli, M. Király, A. Tryba, S. Lew, F. Elsen
2.005 In-Situ Single-Unit Microelectrode Recordings From Hypothalamic Hamartomas Demonstrate Bimodal Neuron Firing Rates/P. Steinmetz, S. Wait, G. Lekovic, H. Rekate, J. Kerrigan
2.006 Increased Expression Of Growth Associated Protein 43 (Gap-43) In Human Epileptic Dysplastic Cortex/Z. Ying, R. O'Dwyer, J. Gonzalez-Martinez, W. Bingaman, I. Najm
2.007 Neuronal Binucleation And Cyclin Expression In Human Temporal Lobe Epilepsy/A. Guekht, N. Gulyaeva, A. Stepanenko, M. Onufriev, M. Popova, M. Stepanichev, A. Lebedeva, I. Aryasova, E. Gusev
2.008 High GM-CSF Concentrations In Post Ictal Plasma: A Possible Temporal Lobe Seizure Biomarker/J. Pollard, E. Brand, H. Pollard, C. Anderson, M. Baybis, O. Eidelman, S. Ivaturi, M. Lerario, E. Burakgazi, P. Crino
2.009 Effect Of Everolimus On Normal-Appearing White Matter In Patients With Tuberous Sclerosis (TS)/J. Tillema, D. Franz, D. Krueger, J. Leach
2.010 Human Herpesvirus-6 (HHV6) And Children With Medically Refractory Epilepsy/P. Kankirawatana, F. Lakeman, H. Kim, J. Blount, C. Rozzelle, D. Kimberlin

Professionals in Epilepsy Care
Nursing
2.011 Epilepsy Self-Management In Older Adults: A Pilot Study/W. Miller, J. Buelow
2.012 Caregiver Anxiety Associated With The Inpatient Pediatric Epilepsy Monitoring Experience/M. Foster, T. Gregory, J. Paolicchi
2.013 Managing Aggression In An Epilepsy Monitoring Unit (EMU): A Case Of Ictal Rage/P. Kerr, S. Koutsogiannopoulos, F. Dubeau
2.014 The Rocky Road To Epilepsy Surgery: A Case Study/L. Ortiz, C. Bordson

Professionals in Epilepsy Care
Psychosocial
2.015 Making Meaning Of Life With Epilepsy: The Use Of Metaphor In Understanding Individual Experiences/D. Andersen, U. Teucher
2.016 Recession Escalates Need For Patient Supports/A. Bezuyen
2.017 Managing Epilepsy: Perspectives Of Professionals With And Without Epilepsy/N. Clark, R. Derry, E. Youatt, M. Sweetman, S. Stoll
2.018 Foundations For Developing A Support Group For Parents Of Children With Intractable Epilepsy: A Qualitative Exploration Of Parents' Support Needs/S. Macrodimitris, E. Sherman, T. Fay, M. Blackman, D. Rutherford, K. Fiest
2.019 Opinion Survey Of Health Care Providers Towards Psychogenic Non-Epileptic Seizures/K. Sahaya, S. Dholakia, D. Lardizabal, P. Sahota
2.020 Therapeutics Approaches To The Treatment Of Epilepsy In Slovakia/V. Donath, M. Ciernik

Professionals in Epilepsy Care
Education
2.021 Teachers' Epilepsy Knowledge And Confidence In Instructing Students With Epilepsy: Preliminary Findings/D. Wodrich, R. Jarrar, J. Buchhalter, C. Gay, R. Levy
2.022 Experience In Electroencephalography During Neurology Residency/C. Chansakul, S. Chung, R. Maganti
2.023 IBE Promising Strategies Program 2008: "Epilepsy At School: Teaching The Teachers". Educational Plan Of "Associação Brasileira De Epilepsia" With Teachers Of Elementary School/H. Martins, L. Guilhoto, M. Vidal-Dourado, E. Almeida, S. Mesquita, C. Tavares, K. Lin, V. Alexandre, Jr, A. Castro, A. Masuko, A. Mendonça, M. Martins, M. Galvez, M. Camarinho, N. Mateus, R. Jurjuck, E. Yacubian
2.024 Establishing A Comprehensive Epilepsy Surgery Center In South America, The Dartmouth – Uruguayan Experience/M. Natola, B. Jobst, A. Scaramelli, A. Bogacz, P. Braga, W. Spire, P. Pereda, D. Roberts
2.025 Using An Online Epilepsy Diary To Enhance Self-Management Behaviors Of People With Epilepsy/P. Shafer, R. Fisher, E. Bartfeld
2.026 Medical Identification Use Patterns In Patients With Epilepsy & Methods To Increase Their Use/P. McGoldrick, S. Wolf
2.027 Early Education Teachers' Knowledge About Epilepsy – How Well Are They Prepared In Their Undergraduate Years?/J. Mifsud, J. Dempsey
2.028 Resident Physician Activity Recommendations For Patients With Seizures/H. Skinner, W. Morgan, B. Riggeal, J. Cibula, S. Eisenschenk, J. Sackellares
2.029 Predictors Of Falls Among Patients Admitted In Epilepsy Monitoring Unit: A Retrospective Case-Control Study/M. Plueger, S. Pati, A. Deep, G. Kiyota, S. Chung, D. Treiman

Clinical Neurophysiology
Clinical EEG
2.030 Correlation Between EEG Findings And Language Lateralization For Intracarotid Amobarbital Procedure In Children/C. Akman, C. Cassidy, A. Wilfong, V. Micic, R. Schultz, A. Welsh, M. Quach, A. Malphrus, A. Anderson, J. Owens, S. Agadi, J. Riviello, M. Chapieski
2.031 Periodic Lateralized Epileptiform Discharges (PLEDs): Clinical Significance, Neuroimaging Findings, Etiology, And Outcome In 51 Infants And Children/A. Gupta, A. Moosa
2.032 Interictal Fast Oscillations Can Be Recorded From Scalp EEG/L. Andrade-Valença, F. Dubeau, F. Mari, R. Zelmann, J. Gotman
2.033 High-Frequency Oscillations (HFOs) In Patients With Refractory Epilepsy And Normal MRIs/F. Dubeau, L. Andrade-Valença, F. Mari, R. Zelmann, J. Jacobs, J. Gotman
2.034 Pseudo-Temporal Ictal Patterns Compared To True Temporal Ictal Patterns/S. Elwan, N. So, R. Enatsu, W. Bingaman, I. Najm
2.035 Occurrence Of High-Frequency Oscillations Depends On Pathology In Patients With Focal Cortical Dysplasia/J. Jacobs, K. Kerber, P. Levan, M. Dümpelmann, R. Korinthenberg, A. Schulze-Bonhage
2.036 Utility Of Stat EEG In A Tertiary Care Institution/S. Lee, M. Teleb, A. Crepeau, J. Chang, T. Wu, S. Chung, R. Maganti
2.037 Enhanced Intracortical Inhibition: A Cortico-Cortical Evoked Potential Study/C. Malpe, D. Nair
2.038 Extent Of The Intracranial Ictal Onset Zone In Seizures With And Without Ictal Scalp EEG Pattern: A Case-Control Study/K. Unnwongse, T. Wehner, A. Alexopoulos
2.039 The Added Value Of Intracerebral Seeg Recordings In The Pre-Surgical Evaluation Of Refractory Focal Epilepsy Cases/F. Babtain, A. Olivier, J. Hall, F. Andermann, J. Gotman, F. Dubeau
2.040 Generalized Paroxysmal Fast Activity And Tonic Seizures In Older Adults/A. Bhatt, R. Brenner, A. Van Cott
2.041 Diagnostic Yield Of Emergent EEG/N. Gaspard, M. Van Nuffelen, C. Melot, B. Legros

2.042 The Value Of Scalp Spike Frequency As An EEG Marker Of Epileptogenesis In Temporal Neocortex In Patients With MTLE/Y. Geng, I. Yung, S. Hawes-Ebersole, J. Ebersole, J. Tao
2.043 The Stability Of Spike Counts In Children With Interictal Epileptiform Activity/A. Haldar, M. Libenson
2.044 Lateralization Of Generalized Spikes After Corpus Callosotomy/ M. Iwasaki, N. Nakasato, S. Osawa, M. Uematsu, K. Haginoya, T. Tominaga
2.045 Consciousness And Seizure Characteristics In Adults With Recurrent Absence Status And Generalized Epilepsy/P. Mireles, C. O'Donovan
2.046 Neonatal Seizures: Ictal EEG Characteristics/L. Nagarajan, L. Palumbo, S. Ghosh
2.047 The Epilepsy Phenome/Genome Project (EPGP): Informatics Tools And Workflow For Processing Electroencephalogram (EEG) Data/ G. Nesbitt, A. Carpenter, D. Dlugos, J. Sullivan, R. Shellhaas, A. Boro, R. Fahlstrom, K. Miller, V. Mays, The EPGP Senior Investigators
2.048 Assessment Of Trainee Expertise In Interpretation Of Neonatal EEG With The Use Of Inter-Reader Reliability Methods/M. Quigg, R. Bailey, U. Uysal, H. Goodkin
2.049 Scalp Temporal Positive Sharp Waves May Originate From The Mesial Temporal Cortex/R. Serafini, G. Barkley, K. Elisevich, K. Mason
2.050 Inter-Rater Variability In Quantification Of Epileptic Spikes; A Spike-By-Spike Analysis/M. Takeoka, D. Sarco, K. Boyer, A. Haldar
2.051 Longer Intermittent Photic Stimulation Increases Photoparoxysmal Response Yield/D. Tarquinio, A. Nwaubani, R. Jonas, W. DeBassio, L. Douglass
2.052 Interictal Spike And HFO Occurrence Frequency In Tumor-Related Refractory Epilepsy/Y. Tran, T. Mihaylova, D. Barkmeier, D. Feurst, J. Loeb, S. Mittal, A. Shah
2.053 The Diagnostic Utility Of Routine (20-40 Minutes) Electroencephalogram In Elucidating The Etiology Of Altered Mental Status Not Otherwise Specified/M. Chen, C. Sinsioco, N. Sethi, G. Solomon
2.054 P300 In Temporal Lobe Epilepsy Patients/K. Hara, H. Iino, M. Miyajima, K. Ohta, T. Maehara, A. Matsuda, M. Baba, E. Matsushima, M. Watanabe, S. Watanabe, M. Hara, M. Matsuura
2.055 Chronic Use Of Felbamate Increased Ripples In EEG/H. Hasegawa
2.056 Head-surface EEG Geometry Of Focal Interictal Epileptiform Transients (FIET)/F. Matsuo
2.057 Suppression Of Interictal Epileptiform Discharges By Levetiracetam During Video-EEG Monitoring/J. Moeller, C. Bazil, R. Emerson
2.058 Early EEG In Patients With New-Onset Seizures: Correlation With Neuroimaging Findings And Seizure Recurrence/R. Rathakrishnan, K. Ali, I. Ibrahim, T. Sim, E. Wilder-Smith
2.059 The Diagnostic Yield Of An Extended Sleep EEG In Angelman Syndrome/A. Robinson, K. Haas, B. Malow, J. Paolicchi
2.060 Clinical Significance Of Very High Frequency Oscillations (Over 1000 Hz) In Epilepsy/N. Usui, K. Terada, K. Baba, K. Matsuda, F. Nakamura, K. Usui, M. Yamaguchi, T. Tottori, S. Umeoka, S. Fujitani, A. Kondo, T. Mihara, Y. Inoue
2.061 Changing Semiology And Its Relation To Functional Brain Networks In Children With Refractory Partial Epilepsy/E. van Diessen, C. Stam, M. van Breemen, K. Braun, O. van Nieuwenhuizen, F. Jansen
2.062 CIRDA – Central Intermittent Rhythmic Delta Activity – A Localizing Interictal Abnormality In Surgical Partial Epilepsy/L. Williams, J. Britton
2.063 Can We Evoke Epileptic High-Frequency Oscillations By Single Pulse Stimulation? Yes, We Can!/M. Zijlmans, M. van 't Klooster, G. Huiskamp, C. Ferrier, F. Leijten
2.064 Anticonvulsant Termination Of Seizures In Neonates Undergoing Whole Body Hypothermia For Moderate To Severe Encephalopathy/M. Alduligan, T. Wechapinan, T. Chang, T. Tsuchida, A. Massaro, S. Baumgart
2.065 Clinical Outcome Of EEG Findings At 3-12 Months Of Age/ S. Almubarak, P. Wong
2.066 The Signal Detecting Ability Of The Scalp Dense Array Electroencephalogram – Spike Comparison With The Simultaneous Subdural Electrodes/A. Fujimoto, T. Yamazoe, M. Yamazaki, H. Enoki, T. Okanishi, T. Yokota, T. Yamamoto
2.067 The Effect Of Ylang-Ylang Aroma On Auditory P300 Event-Related Potentials In Temporal Lobe Epilepsy/ S. Watanabe, H. Iino, M. Miyajima, K. Hara, K. Ohta, A. Matsuda, T. Maehara, M. Hara, M. Matsuura, E. Matsushima
2.068 Nonpharmacological Management Of Epilepsy Comorbidities/M. Legarda, S. Ford, A. Kondratyev, K. Gale
2.069 EEG Presentation In Rapidly Evolving Sporadic Creutzfeldt-Jakob Disease (sCJD)/S. Sehgal, A. Bollineni, I. Ali, H. Li
2.070 Methods Of Sleep Deprivation In Children Undergoing Sleep-Deprived EEG/S. Sharma, R. Ramachandran Nair
2.071 Scotosensitive Myoclonic Epilepsy/T. Buchanan, F. Matsuo, P. Afra

Clinical Neurophysiology
MEG
2.072 Prospective Multicenter Study Assessing The Clinical Added Value Of MEG In The Presurgical Evaluation Of Refractory Partial Epilepsy/X. De Tiege, E. Carrette, B. Legros, K. Vonck, M. Op de beeck, M. Bourguignon, N. Massager, D. Van Roost, A. Meurs, K. Deblaere, S. Goldman, P. Boon, P. Van Bogaert
2.073 Which Spikes Are Visible On MEG? – Three Case Reports Of Simultaneous Recordings Of Interictal Epileptiform Discharges By MEG And Invasive Stereo-EEG/K. Jin, A. Alexopoulos, J. Gonzalez-Martinez, J. Bulacio, R. Burgess, J. Mosher, I. Najm
2.074 Magnetoencephalography Using Total Intravenous Anesthesia In Pediatric Patients With Intractable Epilepsy: Comparison Of Spike Sources With And Without Propofol/ H. Okamoto, A. Fujimoto, A. Ochi, S. Chuang, O. Snead III, H. Otsubo
2.075 Is A Cortical Focus Driving A Cortico-Thalamic Circuit In Human Absence Epilepsy?/P. Ossenblok, B. Kornips, P. Van Houdt, D. Gupta, P. Boon, G. Van Luijtelaar
2.076 Postoperative Seizure Outcomes When Interictal MEG Concordant With Ictal Depth EEG/ K. Upchurch, J. Stern, N. Salamon, S. Dewar, D. Eliashiv
2.077 MEG Source Localization Of Epileptogenic Zone In Children With Porencephalic Cyst/O. Bennett-Back, A. Ochi, E. Widjaja, S. Chuang, J. Rutka, J. Drake, S. Nanbu, C. Go, O. Snead, H. Otsubo
2.078 Stat Magnetoencephalography — An Emergency Tool Whose Time Has Come/R. Burgess, S. Hantus, D. Cleary, D. Engle, J. Mosher, A. Alexopoulos
2.079 Sensitivity Of MEG To Interictal Events Arising From The Irritative And Ictal Onset Zones: Findings From Simultaneous MEG-iEEG Recordings/ E. Castillo, Z. Li, G. Von Allmen, J. Baumgartner, J. Slater, C. Bodden, A. Papanicolaou
2.080 Bilateral Asymmetries In The Maximal Activation Of Same Subject SSEP's/N. Phillips, D. Clarke, F. Perkins, R. Ogg, M. McManis
2.081 Yield Of Magnetoencephalography In Mesial Temporal Lobe Epilepsy/S. Singh, A. Antony, N. Thakur
2.082 Characterization Of Magnetoencephalographic Interictal Epileptiform Discharges With Time-Resolved Cortical Current Maps Using The Helmholtz-Hodge Decomposition/ J. Slater, E. Castillo, Z. Li, A. Papanicolaou
2.083 Synthetic Aperture Magnetometry-Kurtosis (SAM(g2)) For Single/Multiple Epileptic Foci In Children With Neocortical Epilepsy/I. Sugiyama, K. Imai, A. Ochi, T. Akiyama, C. Go, E. Widjaja, D. Cheyne, S. Chuang, O. Snead III, H. Otsubo

2.084 Magnetoencephalography Of Spike And Wave Discharges In Drug Naive Childhood Absence Epilepsy/ J. Tenney, H. Fujiwara, D. Rose, N. Hemasilpin
2.085 MEG Functional Connectivity And Complex Networks Relate To Clinical Characteristics Of Lesional Epilepsy Patients/E. van Dellen, L. Douw, A. Hillebrand, J. Heimans, I. Ris-Hilgersom, M. Schoonheim, J. Baayen, P. De Witt Hamer, C. Stam, J. Reijneveld
2.086 MEG Aids Interpretation Of Epileptic Activity Propagation Where Invasive Electrode Sampling Is Inadequate/Z. Wang, J. Mosher, R. Burgess, K. Jin, Y. Kakisaka, I. Najm, A. Alexopoulos
2.087 Generalized 3 Hz Spike-And-Wave Complexes Emanating From Focal Epileptic Activity In Pediatric Cases/ Y. Kakisaka, J. Mosher, A. Alexopoulos, I. Wang, M. Iwasaki, R. Burgess

Clinical Neurophysiology
Brain Stimulation
2.088 A Case Report Using High Precision, Navigated Transcranial Magnetic Stimulation/T. Hallböök, M. Thordstein, S. Kohler, J. Lundgren, S. Bergstrand, G. Pegenius, M. Elam
2.089 Identifying Pathological And Functional Networks With Single Pulse Electrical Stimulation In Patients With Intractable Epilepsy/C. Keller, L. Entz, S. Bickel, M. Argyelan, S. Hwang, S. Jain, A. Mehta
2.090 Altered Cortical Excitability In Drug-Naïve Generalized Or Focal Epilepsy Patients/E. Yeon Joo, J. Lee, S. Lee, S. Hong
2.091 Connectivity Between The Posterior Cingulate And Mesial Temporal Structures/M. Koubeissi, R. Maciunas, J. Miller, K. Smith, S. Nehamkin, H. Luders
2.092 Human Hippocampal-Cingulate Gyral Connectivity-Cortico-Cortical Evoked Potentials(CCEP) Study/ Y. Kubota, D. Nair, R. Enatsu, J. Bulacio, J. Gonzalez, I. Najm
2.093 Intracranial Electrophysiological Study Of The Human Posterior Cingulate Gyrus During Rest, Self-Referential Memory Processing, And Arithmetic Tasks/M. Dastjerdi, B. Foster, J. Parvizi
2.094 Monopolar Versus Bipolar Electrical Stimulation For Extraoperative Cortical Mapping In Patients With Focal Epilepsy/B. Diehl, S. Kovac, C. Scott, S. Smith, V. Maglajlija, M. Walker, N. Toms, P. Allen, A. McEvoy
2.095 Perceptual And Behavioral Phenomena During Electrical Stimulation Of The Human Brain/ A. Selimbeyoglu, J. Parvizi
2.096 Stimulation-Based Paradigm For Assessment Of Epileptogenic Potential/ S. Kalitzin, D. Velis, S. Claus, F. Lopes da Silva

Neuro-Imaging
Structural Imaging
2.097 Intelligence Relates To Structural Integrity Of Normal Appearing White Matter In Tuberous Sclerosis Complex/ S. Koudijs, J. van Campen, O. Braams, A. Leemans, O. van Nieuwenhuizen, K. Braun, F. Jansen
2.098 Structural Connectivity In Pediatric Epilepsy Measured With W-Matrix Diffusion Tensor Tractography/I. Amarreh, D. Hsu, B. Hermann, K. Dabbs, M. Hsu, M. Meyerand
2.099 Hippocampal Atrophy In Patients With Medial Temporal Lobe Epilepsy: Differences Between The 'Generator' And The 'Receiver'/ L. Bonilha, J. Halford, J. Edwards
2.100 Language Lateralization Determined By Tract-Based Spatial Statistics Of The Arcuate Fasciculus/M. DiSano, T. Ellmore, T. Pieters, O. Hope, G. Kalamangalam, J. Slater, J. Breier, N. Tandon
2.101 Reorganization Of The Right Arcuate Fasciculus Following Left Arcuate Fasciculus Resection In Children With Intractable Epilepsy/ D. Goradia, H. Chugani, R. Govindan, C. Juhasz, S. Sood
2.102 Mapping Thalamic Pathology In Idiopathic Generalized Epilepsy And Temporal Lobe Epilepsy/H. Kim, B. Bernhardt, J. Natsume, A. Bernasconi
2.103 Three-Dimensional Caudate Atrophy Pattern In Recent-Onset Juvenile Myoclonic Epilepsy/J. Lin, J. Riley, K. Dabbs, M. Seidenberg, B. Hermann
2.104 Stereotactic Amygdalohippocampectomy For The Treatment Of Mesial Temporal Lobe Epilepsy: Good Clinical Seizure Outcome Despite Of Only Partial Volume Reduction Of The Target Structures/H. Malikova, R. Liscak, Z. Vojtech, T. Prochazka, J. Vymazal
2.105 Impaired Fronto-Striatal Connections Are Associated With Executive Dysfunction In Temporal Lobe Epilepsy/J. Riley, J. Lin
2.106 Application Of Tractography To Delineate The Relationship Of The Optic Radiation To Epileptogenic Lesions Prior To Neurosurgery/G. Winston, M. Yogarajah, S. Bonelli, M. Symms, C. Micallef, J. Duncan
2.107 Focal Brain Abnormalities In Patients With Epilepsy With Absence Seizures: Evidence From High-Resolution T1-Weighted And Diffusion Tensor MR Images/S. Alves-Leon, T. Doring, M. Cardoso, I. D'Andrea Meira, V. Pereira, C. Rego, M. Zimmermann, J. Vilela, N. Ventura, B. Bizzo, E. Gasparetto
2.108 Hippocampal Volume As A Predictor Of Verbal Memory Decline After Left Anterior Temporal Lobectomy/P. Bauer, J. Binder, S. Swanson, D. Sabsevitz, B. Stengel, T. Hammeke, M. Raghavan, W. Mueller
2.109 MRI-Based Cortical Thickness Analysis In Temporal Lobe Epilepsy: Reproducibility And Relation To Surgical Outcome/B. Bernhardt, N. Bernasconi
2.110 Tract-Based Spatial Statistics In Idiopathic Generalized Epilepsies/ L. Betting, C. Yasuda, L. Min, C. Guerreiro, F. Cendes
2.111 Structural Changes In A Family With Autosomal Dominant Partial Epilepsy With Auditory Features And LGI1 Mutation/A. Coan, C. Yasuda, L. Betting, F. Torres, F. Pereira, I. Lopes-Cendes, F. Cendes
2.112 Inverse Relationship Between Structural Volume And Hemispheric Connectivity Strength In Temporal Lobe Epilepsy Patients With Hippocampal Sclerosis/T. Ellmore, N. Tandon
2.113 Three-Dimensional Atrophy Patterns Of The Thalamus In Recent-Onset Juvenile Myoclonic Epilepsy/ B. Hermann, J. Lin, J. Riley, K. Dabbs, D. Hsu, R. Sheth, C. Stafstrom, M. Seidenberg
2.114 Voxel-Based Morphometry And Cognitive Abnormality In Benign Childhood Epilepsy With Centrotemporal Spikes/J. Hwa Lee, S. Kim, H. Lee
2.115 Effect Of Focal Versus Generalized Epilepsy On The DTI Of Corpus Callosum For Patients With Normal MRI/Z. Li, E. Castillo, M. González Nosti, J. Slater, G. Von Allmen, O. Hope, A. Papanicolaou
2.116 Postoperative Changes In Fiber Tract Integrity And Visual Fields After Anterior Temporal Lobectomy/ C. McDonald, D. Hagler, Jr, H. Girard, C. Pung, M. Ahmadi, D. Holland, R. Patel, D. Barba, E. Tecoma, V. Iragui, E. Halgren, A. Dale
2.117 Diffusion Tensor Imaging (DTI) Shows Motor Fibers May Be Intimately Related To Cortical Dysplasia/ J. Ojemann, A. Poliakov, D. Shaw, R. Saneto, J. Kuratani, E. Novotny
2.118 Benign Mesial Temporal Lobe Epilepsy Associated With Isolated Amygdala Or Amygdala And Hippocampal Enlargement/N. Pillay, S. Myles, J. Scott, J. Singh, S. Wiebe
2.119 Comparative Ability Of Volumetry, T2-Relaxometry, And Magnetization Transfer Ratio To Preoperative Lateralization Of Hippocampal Sclerosis/A. Santos, P. Diniz, C. Salmon, S. Escorsi-Rosset, T. Velasco, J. Leite, A. Sakamoto
2.120 Fractional Anisotropy And Mean Diffusivity In Temporal Lobe Epilepsy With And Without Mesial Temporal Sclerosis Using TBSS Analysis/ C. Scanlon, S. Mueller, D. Tosun, I. Cheong, M. Weiner, K. Laxer
2.121 Whole-Brain Cortical Thickness Analysis In Focal Cortical Dysplasia Reveals Accelerated Age-Related Thinning/D. Schrader, B. Bernhardt, A. Bernasconi

2.122 DTI Of The Fornix And Frontal White Matter In Children With Epilepsy: Association With Memory And Executive Function/E. Sherman, H. Carlson, C. Beaulieu, G. Gong, X. Wei, A. Keller, W. Hader, L. Bello-Espinosa, A. Kirton, K. Barlow, B. Brooks, W. Abou Reslan, S. Wiebe, I. Mohamed
2.123 Automatic Detection Of "MRI-Negative" Epileptogenic Cortical Malformations With Surface-Based MRI Morphometry/T. Thesen, J. DuBois, B. Quinn, C. Carlson, E. Halgren, H. Wang, V. Neilman, J. French, O. Devinsky, R. Kuzniecky
2.124 Longitudinal MRI Volume In Temporal Lobe Epilepsy/V. Tuchscherer, M. Seidenberg, K. Dabbs, R. Sheth, P. Rutecki, J. Jones, B. Hermann
2.125 Increased Cortical Folding Complexity In Temporal Lobe Epilepsy/ N. Voets, B. Bernhardt, H. Kim, N. Bernasconi
2.126 VBM And Cortical Analysis In Focal Cortical Dysplasia Reveal Areas With Widespread GM Abnormalities In Cortex And Cerebellum/C. Yasuda, F. Cappabianco, F. Pereira, A. Costa, A. Saúde, F. Bergo, A. Coan, L. Betting, F. Cendes
2.127 Nociferous Cortex In Refractory Temporal Lobe Epilepsy: Measuring Prefrontal Atrophy/R. Gale-Ross, D. Fuerst, A. Baird, C. Watson
2.128 Assessment Of MRI Issues For The VNS Therapy System At 3-Tesla/ P. Kim, C. Heck, M. Law, R. Torres, S. Valencerina, M. Shiroishi, M. Mogensen, A. Lerner, F. Shellock
2.129 Abnormalities In Diffusion Tensor Imaging Of The Superior Longitudinal Fasciculus And Cingulum In Pediatric Partial Epilepsy/R. Kozitza, J. Provenzale, W. Moon, M. De Bellis, W. Gallentine, M. Mikati
2.130 Cortical Thickness And White Matter/Gray Matter Boundary Delineation Reveal Dysplastic Seizure Inducing Cortex/P. LaViolette, S. Rand, M. Raghavan, K. Schmainda, W. Mueller
2.131 Now displayed as 3.164A
2.132 Diffusion Tensor Imaging In Cryptogenic West Syndrome: TBSS Analysis/J. Natsume, T. Fukasawa, T. Nakata, S. Yokoi, N. Ishihara, N. Ando, T. Nagoro, K. Watanabe
2.133 Clinical And Radiological Profile Of Epilepsy Patients With Signal Changes In The Corpus Callosum/ S. Prabhu, A. Haldar, T. Loddenkemper, S. Kothare
2.134 Cortical Thickness Extratemporal In Temporal Lobe Epilepsy/S. Rosset, P. Diniz, C. Salmon, T. Velasco, J. Leite, A. Sakamoto, A. Santos
2.135 Fronto-Temporal Phenotypes In Pediatric Epilepsy/P. Siddarth, B. Hermann, J. Levitt, S. Gurbani, R. Caplan
2.136 Extrahippocampal Cortical Thickness Changes In Temporal Lobe Epilepsy/T. Stoub
2.137 Mesial Temporal Sclerosis (MTS) In Childhood: Is A Mutation In The SCN1A Gene The Most Common Cause?/K. Van Poppel, Z. Patay, A. McGregor, D. Clarin, F. Perkins, D. Clarke, J. Wheless
2.138 Widespread Cortical Thinning In Children With Frontal Lobe Epilepsy/ E. Widjaja, S. Zarei Mahmoodabadi, O. Snead, A. Almehdar, M. Smith
2.139 Fractional Anisitropy Analysis On Major White Matter Fibers In Children With Medically Intractible Focal Epilepsy: A Diffusion Tensor Imaging Study/H. Kim, A. Harrison, P. Kankirawatana, C. Rozzelle, J. Blount
2.140 Correlation Between Water Diffusion Abnormalities And Regional Volume Reduction In TLE Patients With Unilateral Hippocampal Sclerosis/ S. Lim, Y. Shon, Y. Kim
2.141 Longitudinal MRI Of The Limbic System In Medically Intractable Temporal Lobe Epilepsy/M. Liu, L. Concha, C. Beaulieu, D. Gross
2.142 Widespread Alterations Of White Matter In Temporal Lobe Epilepsy: A Study Using Diffusion Tensor Imaging And Magnetization Transfer Ratio/A. Sakamoto, P. Rejane Diniz, C. Salmon, T. Velasco, J. Leite, A. Santos
2.143 The Importance Of Diffusion Weighted Magnetic Resonance Imaging And Hippocampal Apparent Diffusion Coefficient Values In The Pre-Surgical Evaluation Of Patients With Temporal Lobe Epilepsy/T. Tombul, A. Dogan, O. Unal
2.144 Now displayed as 3.164B
2.145 3T Brian MRI And Ictal Findings Of Patients With Non-Lesional Partial Epilepsy Refractory To Medical Treatment/E. Andrade, Z. Liu, S. Eisenschenk, J. Cibula, I. Goldsmith, M. Parekh, W. Triplett, A. Cadotte, T. Mareci, P. Carney
2.146 Subtle Cortical Gyral Abnormalities Predict Focal Cortical Dysplasia: A Review Of 3 Cases/ J. Oster, E. Igbokwe, G. Cosgrove, A. Cole

Antiepileptic Drugs
Drug Interaction
2.147 Pharmacokinetic Evaluation On The Influence Of Enzyme Inducing Antiepileptic Drugs On The Disposition Of Levetiracetam In Patients With Epilepsy/V. Alexandre, P. Freitas-Lima, L. Pereira, F. Feletti, E. Perucca, A. Sakamoto
2.148 Influence Of Win 55,212-2 Mesylate, A Potent Non-Selective Cannabinoid Receptor Agonist, On The Anticonvulsant Activity Of Four Classical Antiepileptic Drugs Against Pentylenetetrazole-Induced Seizures In Mice/S. Czuczwar, J. Luszczki
2.149 Voltage-Dependent Calcium Channel And Nmda Receptor Antagonists Augment Anticonvulsant Effects Of Lithium Chloride On The Pentylenetetrazole-Induced Clonic Seizure In Mice/M. Ghasemi, H. Shafaroodi, A. Ghasemi, A. Dehpour
2.150 Cross-Section Study Of 389 Veterans Analyzing The Effect Of AEDs On Cholesterol Levels And Simvastatin Dose Utilization In Clinical Practice/ G. Jetter, L. Moreno, S. Rogers, S. Carlson, W. Gentry, S. Lee, J. Cavazos
2.151 Differences In Tolerability And Discontinuation Rate Of Lacosamide Among Patients With Or Without Concurrent Sodium Channel Blocking AEDs/K. Kelly, S. Donlon, C. Schusse, S. Chung
2.152 Pharmacokinetics And Clinical Experience Of Rufinamide In Treating Children With Severe Epilepsy/ M. Dahlin, I. Ohman
2.153 An Evaluation Of The Effect Of Eslicarbazepine Acetate On Weight, Glucose, And Lipids: An Integrated Analysis Of Three Double-Blind Phase III Clinical Studies/J. Zummo, D. Blum, M. Versavel, K. Tripp, P. Soares-da-Silva

Antiepileptic Drugs
Other
2.154 Response To AED Treatment In A Tertiary Epilepsy Center In 2003-09/J. Janousek, P. Klein, A. Barber
2.155 Use Of Retrospective Data And A Structured Decision Approach To Characterize Drug-Level And Patient-Level Antiepileptic Drug Response For The Epilepsy Phenome/G. Project/ R. Fahlstrom, The EPGP Senior Investigators
2.156 Phenobarbital-Induced Apoptosis In The Neonatal Rat Brain Occurs In A Limited Compartment Of Neurons/A. Kondratyev, K. Gale, S. Tsukerman
2.157 Final Results From An International Observational Study Of Pregnancy Outcomes Following Exposure To Lamotrigine/ J. Messenheimer, M. Cunnington
2.158 Acute Therapeutic Effects Of Carisbamate In A Rat Model Of Infantile Spasms/T. Ono, A. Galanopoulou
2.159 Role Of Lacosamide As Adjunctive Treatment Of Adults With Primary Generalized Epilepsy/P. Afra, L. Strom, J. Bainbridge, T. Buchanan, A. Berry, M. Spitz
2.160 Initial Post-Marketing Clinical Experience With Lacosamide In Adult Patients With Epilepsy/A. Cohn, C. Harden, M. Lowe, E. Serrano
2.161 Efficacy Of Lacosamide As An Adjunctive Therapy In Patients With Partial Epilepsy, The First Year Experience/S. Donlon, C. Schusse, K. Kelly, S. Chung
2.162 Severity And Temporal Pattern Of Levetiracetam And Lamotrigine Withdrawal Seizures During Epilepsy Monitoring/H. Kettani, Y. Song, N. Azar
2.163 Use Of Intravenous Levetiracetam In Acute Seizure Management In Neonates/O. Khan, E. Chang, C. Cipriani, C. Wright, P. Ritch, E. Crisp, B. Kirmani

2.164 Pharmacological Characterization of a Systemically Bioavailable Galanin Receptor (GalR) Subtype-2 Preferring Analog In Rodent Models Of Pain And Epilepsy/B. Klein, E. Scholl, M. Smith, C. Metcalf, T. Pruess, C. Robertson, G. Bulaj, H. White

2.165 Stated Preferences For Attributes Of Anti-Epileptic Drugs (AEDs) In Patients With Uncontrolled Epilepsy/R. Manjunath, F. Johnson, J. Yang, A. Ettinger

2.166 Croatian Pregnant Women With Epilepsy And Effects Of Antiepileptic Drugs Exposure In Their Offspring – Seven Years Of Prospective Surveillance/S. Miskov, R. Gjergja Juraski, A. Fucic, T. Ivicevic Bakulic, I. Mikula, L. Cvitanovic Sojat, J. Bosnjak, V. Demarin

2.167 Sabril® Registry Initiated To Characterize Vision Loss Associated With Vigabatrin Therapy/J. Pellock, E. Faught, R. Sergott, M. Smith, D. Shields, G. Burkhart, D. Wesche, E. Lainey

2.168 Caregiver Measures For Seizure Control And Efficacy Of Antiepileptic Drugs For Childhood Epilepsy: Results Of A Preference Survey/M. Scott Perry, C. Swint, J. Hawley, K. Rask, S. Blake, S. Kohler, N. Krawiecki

2.169 Stiripentol: Our Experience/ S. Philip, S. Agrawal, E. Wassmer, R. Gupta, M. Smith, A. Sudarsanam

2.170 Analysis Of Pregabalin Use And Effectiveness In A Clinic Setting: A Pilot Of The Web-Based Post-Marketing Antiepileptic Drug Registry/J. Rasmussen, G. Morris, J. Kroll, S. Trayanov, D. Steber

2.171 Inverse Agonism Of Cannabimimetic (R+)WIN55, 212 On Behavior And Seizure Threshold During The Juvenile Period/V. Rudenko, A. Rafiuddin, L. Friedman

2.172 The Effect Of Food On The Bioavailability Of USL255, A Novel Extended-Release Formulation Of Topiramate/W. Todd, L. Lambrecht, M. Boulware, M. Halvorsen

2.173 Now displayed as 1.317A

2.174 Aggravation Of Absence Seizure Related To Levetiracetam/S. Auvin, S. Chunn, P. Berquin, E. Bourel, C. Delanoe, C. Chiron

2.175 Lowered Platelet Counts In Levetiracetam Treated Epilepsy Patients/T. Bachmann, K. Bertheussen, S. Svalheim, M. Rauchenzauner, G. Luef, E. Taubøll

2.176 Pharmacokinetic Equivalence Between Immediate-Release Topiramate And USL255, A Novel Extended-Release Formulation Of Topiramate/M. Halvorsen, L. Lambrecht, M. Boulware, W. Todd

2.177 ARK™ Immunoassays For Antiepileptic Drugs: Gabapentin, Lamotrigine, Levetiracetam, Topiramate, Zonisamide/K. Kasper, K. Chung, B. Moon, J. Nguyen, A. Orozco, J. Valencia, J. Valdez

2.178 Development Of A Web-Based, Post-Marketing Surveillance Registry For Antiepileptic Medications/J. Kroll, G. Morris, S. Trayanov, D. Steber, J. Rasmussen

2.179 Development And Optimization Of Extended-Release Formulations Of Topiramate/L. Lambrecht, M. Halvorsen, M. Boulware, W. Todd, J. Carrithers

2.180 Safety Of Lacosamide For Hospitalized Patients With Seizures/ M. Luk, W. Freeman, A. Patel, W. Tatum, K. Nau

2.181 Inter-Pregnancy Variability In Lamotrigine Pharmacokinetics In A Single Patient/R. Marawar, M. Kaur, A. Ritaccio

2.182 Valencian Community Lacosamide Experiences Collection Group (RELACOVA)/J. Palau, E. Lopez-Gomariz, J. Lopez-Trigo, M. García, V. Villanueva

2.183 Evidence For The Nootropic Effects Of Acthar Gel (ACTH) In Epileptic Kcna1-null Mice/H. Parker, D. Kim, J. Wilke, Y. Ahn, J. Rho

2.184 Efficacy And Tolerability Of Classic Versus New Generation Antiepileptic Treatment Of Patients With Low Grade Brain Tumors And Epilepsy/A. Ricciardi Ciocchini, J. Becerra, C. Balanya, S. Fumanal, M. Codina

2.185 Oculogyric Crises Secondary To Lamotrigine Overdosage/ A. Veerapandiyan, W. Gallentine, S. Winchester, S. Kansagra, J. Baker, M. Mikati

2.186 Antiepileptic Drugs And Side Effects In Adults With Epilepsy In Tertiary Care/S. Wiebe, P. Federico, A. Hanson, N. Jette, B. Klassen, W. Murphy, N. Pillay, S. Save, M. Lowerison, S. Macrodimitris

2.187 Lack Of Association Of Polymorphisms In The Cytochrome P450 (CYP) 2D6 Genes In Intractable Childhood Epilepsy/F. Alehan, S. Saygi, B. Atac, I. Erol, R. Erdem

2.188 Reversible Visual Changes And Electroretinogram (ERG) Changes In A Child On Vigabatrin For Infantile Spasms/S. Benes, K. Zamel

2.189 The Effects Of Antiepileptic Drugs On Rat Uterine Implantation/ A. Cansu, S. Gurgen, M. Yildirim, S. Canpolat, M. Serin, I. Abidin

2.190 Disposition And Adverse Effects Of Intravenous Topiramate In Adult Patients With Epilepsy Or Migraine Headaches/J. Cloyd, A. Clark, I. Leppik, J. White, T. Henry, R. Brundage, R. Kriel

2.191 Lacosamide Does Not Alter Bone Densitometry Parameters In Juvenile Dogs/M. Cornet, D. Tytgat, M. Léonard

2.192 Bioequivalence Of Rufinamide Oral Suspension Formulation And The Marketed Tablet/D. Critchley, J. Aluri, P. Boyd, M. Whayman, M. Narurkar, H. Delargy, F. Bibbiani

2.193 The Role Of Phenytoin In The Era Of Newer Anti Epileptic Medications: An Internet Based International Survey Of Neurologists And Epileptologists/R. Das, D. Griesemer, S. Kothare

2.194 Use Of Lacosamide In Nonconvulsive Seizures In Critically Ill Patients/M. Doreswamy, T. Lassiter, A. Husain

2.195 Treatment Of Malignant Migrating Partial Seizures Of Infancy With Rufinamide: Report Of 5 Cases/ S. Kothare, T. Loddenkemper, G. Kluger, G. Coppola, M. Vendrame

2.196 Long-Term Use Of Vigabatrin In Adults With Epilepsy/K. Pargeon, S. Resor, Jr, P. Gouras, A. Manzee, S. Tsang, L. Hirsch

2.197 Efficacy Of Lacosamide As Adjunctive Therapy In Adolescents With Intractable Epilepsy: A Case Series/C. Patterson, S. Williams, P. Crumrine, S. Gedela, R. Varma, D. Holder

2.198 Enteric-Coated, Delayed-Release Divalproex With 1st-Order Absorption Characteristics Vs. Extended-Release Divalproex With Zero-Order Absorption: Graphical Comparison And Visual Analysis Of Plasma Concentration-Time Profiles/ R. Reed, S. Dutta, W. Liu, D. Kasteleijn Nolst-Trenite, R. Ramsay

2.199 Rufinamide: Efficacy And Safety In Intractable Epilepsy (Lennox Gastaut Syndrome And Non Lennox Gastaut Syndromes) – Our Experience/ A. Sudarsanam, E. Wassmer, R. Gupta, M. Smith, S. Agrawal, S. Philip

2.200 Levetiracetam And Neonatal Seizures/J. Verma, A. Wilfong

2.201 Safety And Efficacy Of Lacosamide In Critically Ill Patients/ S. Cherry, L. Judd, H. Elzawahry, S. LaRoche

2.202 Efficacy Of A New Antiepileptic Medication Vimpat/A. Kogan, N. Dzhafarova, M. Andriola, R. Spiegel

2.203 Bone Density In Ambulatory Epilepsy Patients In South Florida/ E. Serrano, C. Harden, M. Lowe, R. Martinez, A. Escandon-Sandino, A. Cohn, J. Gonzalez, Y. Grillo

2.204 Rufinamide In Pediatric Patients With Lennox-Gastaut Syndrome And Neuronal Migration Disorders/ A. Spalice, F. Del Balzo, L. Papetti, F. Ursitti, C. Cerminara, F. Nicita

2.205 Rufinamide In Frontal Lobe Epilepsy/S. Adhami, C. Harini

2.206 Adjunctive Treatment With Lacosamide: An Option For Generalized Epilepsy?/S. Arnold, A. Beige

2.207 Use Of Pregabalin In Nonconvulsive Seizures In Critically Ill Patients/T. Lassiter, M. Doreswamy, A. Husain

2.208 The Effect Of Valproic Acid On Serum Total Cholesterol Level In Children With Epilepsy/S.-Ook Nam, Y. Kim

2.209 Lacosamide In Brain Tumor Patients With Seizure Disorder/ L. Robles Irizarry, G. Stevens, K. Lupica, H. Newton, J. Connelly, J. Lima, H. Cunningham, D. Pearl, M. Malkin

Non-AED/Non-Surgical Treatments (Hormonal, Ketogenic, Alternative, Etc.)
Adult
2.210 A Ketogenic Diet Reduces Hippocampal Long-Term Potentiation In Freely Behaving Adult Rats/J. Blaise, J. Koranda, D. Ruskin, U. Chow, S. Masino
2.211 Characteristics And Clinical And Economic Outcomes In Medicaid Patients Receiving Vagus Nerve Stimulation (VNS) Therapy For The Treatment Of Refractory Epilepsy/ S. Helmers, M. Duh, A. Guerin, S. Sarda, T. Samuelson, E. Faught
2.212 Vagus Nerve Stimulation Allows Reduction Of Polypharmacy In Medically Refractory Epilepsy: 10-Year Outcome/J. Dean, C. Allen
2.213 Does Modafinil Exacerbate Seizures In Epilepsy?/E. Artsy, D. McCarthy, S. Hurwitz, B. Dworetzky, J. Lee
2.214 Seven-Year Follow-Up In Patients With Refractory Epilepsy Treated With Medial Temporal Lobe Deep Brain Stimulation/E. Carrette, K. Vonck, A. Van Dycke, V. De Herdt, R. Raedt, T. Wyckhuys, D. Van Roost, K. Deblaere, A. Meurs, P. Boon
2.215 Brain Oxygenation Responses In Control And Tetanus Toxin Treated Rats/N. Nathwani, N. Hasulak, D. Erdheim, F. Sun, T. Tcheng, J. Goodman
2.216 Adult-Onset Rasmussen Encephalitis Treated Using Transcranial Electrical Stimulation/D. Orta, J. Calcaneo, M. González-Aragón, L. Maldonado, A. Avellán, E. Argumosa, F. Fregni
2.217 Evaluation Of Induced Current Near The Lead Electrodes Of Vagus Nerve Stimulators Due To Time-Varying Gradient Magnetic Fields During MRI/M. Wang, M. Kayali, E. Eubank, J. Begnaud, J. Chen

Non-AED/Non-Surgical Treatments (Hormonal, Ketogenic, Alternative, Etc.)
All Ages
2.218 The Functional Neuroprotective Effects Of The Ketogenic Diet Versus Standard Antiepileptic Drugs In Epileptic Kcna-Null Mice/D. Kim, H. Milligan, J. Rho
2.219 Ketogenic Diet For The Treatment Of Seizures Associated With Hypothalamic Hamartomas/ K. Chapman, D. Kim, J. Rho, Y. Ng, J. Kerrigan
2.220 Reduction Of Neocortical Neuronal Firing By Therapeutic Trigeminal Nerve Stimulation/ E. Fanselow, D. Noel
2.221 Effect Of Everolimus On Seizure Activity In Patients With Tuberous Sclerosis (TS)/D. Krueger, M. Care, K. Holland-Bouley, K. Agricola, C. Tudor, P. Mangeshkar, A. Weber-Byars, T. Sahmoud, D. Franz
2.222 The Ketogenic Diet Inhibits The Mammalian Target Of Rapamycin (Mtor) Pathway/S. McDaniel, N. Rensing, L. Thio, K. Yamada, M. Wong
2.223 Children On The Ketogenic Diet Combined With Zonisamide Or Topiramate, Are They At Higher Risk For Acidosis?/I. Muzyka, H. Kayyali, A. Hafez Abdelmoity, V. Driscoll, A. Sherman, A. Abdelmoity
2.224 The Risk Of Seizure Recurrence In Children With Refractory Epilepsy Seizure Free On The Ketogenic Diet/ K. Taub, S. Kessler, C. Bergqvist
2.225 Long-Term Efficacy Of Vagal Nerve Stimulation Therapy In Young Children With Intractable Epilepsy/ L. Romantseva, P. Ogden, A. Hussein
2.226 Ketogenic Diet Efficacy In The Treatment Of Intractable Infantile Spasms/A. Abdelmoity, H. Kayyali
2.227 Urgent Ketogenic Diet Initiation Helps Accomplish Discharge In Unremitting Seizures/K. Costas, S. Tarrant, B. Bourgeois, M. Takeoka, A. Poduri, A. Bergin
2.228 Cathodal Transcranial Direct Current Stimulation Suppresses PTZ-Induced Seizures In Rats/D. Ekstein, S. Dhamne, P. Muller, T. Loddenkemper, A. Pascual-Leone, F. Jensen, A. Rotenberg
2.229 The Efficacy Of The Ketogenic Diet In Correlation With Beta-Hydroxybuterate Level/H. Kayyali, A. Hafez Abdelmoity, I. Muzyka, V. Driscoll, A. Sherman, A. Abdelmoity
2.230 Will Seizures Improve By Switching From The Modified Atkins Diet To The Traditional Ketogenic Diet?/E. Kossoff, H. Kang, M. Miranda, A. Wiemer-Kruel
2.231 Ketogenic Diet: Clinical Predictors For Significant Seizure Control/N. Agarwal, M. Ramanathan, M. Hartley-McAndrew, C. Gillogly, A. Weinstock
2.232 Deep Brain Stimulation For Dravet Syndrome: A 10-Year Follow-Up Study/D. Andrade, R. Wennberg, A. Lozano, C. Hamani
2.233 Concurrent Betahydroxybutyrate And Glucose Levels In Children Receiving Ketogenic Diet Therapy/ B. Kania, A. Edlbeck, S. O'Connor
2.234 Effect Of ACTH And Corticosteroids In Patients With Down Syndrome And Epileptic Spasms: A Case Series/B. Mudigoudar, S. Gandhi, K. Arya, G. Chari
2.235 Vagus Nerve Stimulation (VNS) Therapy In Children And Adolescent With Refractory Epilepsy/A. Soto, G. Contreras, V. Sainz, H. Scholtz, F. Duran
2.236 Ketogenic Diet Exhibits Anti-Inflammatory Properties: Involvement Of Ppar Pathways?/N. Curatolo, C. Lecointe, J. Benoist, P. Gressens, S. Auvin
2.237 Adding A Ketogenic Diet To Vagus Nerve Stimulation Or Implanting Vagus Nerve Stimulator In Patients Receiving A Ketogenic Diet, Does It Make A Difference In Seizure Control And Quality Of Life?/V. Driscoll, M. Finnerty, A. Hafez Abdelmoity, A. Abdelmoity
2.238 Nicotine Patch For The Treatment Of Intractable ADNFLE In A Non-Smoking Pediatric Patient/ J. Schoenfeld, M. Sotero de Menezes
2.239 Successful Maintenance Of Ketosis Using Parenteral Nutrition Therapy/S. Tarrant, K. Costas, A. Bergin, S. Huh
2.240 Life-Long Refractory Epilepsy Controlled By A Novel Acidosis-Sparing, Euketonemic Ketogenic Diet: A Case History/A. Yuen, I. Walcutt

Surgery
Adult
2.241 Epilepsy Surgery For Temporal Lobe Epilepsy With Mesial Temporal Sclerosis: The Impact Of Measuring Health-Related Quality Of Life And Psychosocial Outcome/N. Alonso, A. Azevedo, R. Centeno, H. Martins, L. Caboclo, G. Filho, E. Yacubian
2.242 Recent Advances In Stereoelectroencephalography (SEEG)/J. Hall
2.243 Amygdalar Epilepsy, Comparative Study/J. Miró, M. Falip, M. Aiguabella, M. Juncadella, R. Fortuny, G. Plans, J. Acebes, S. Fernandez, S. Castañer, J. Mora, N. Cardoner
2.244 Epileptogenic Zones Are Often Far Removed From Brain Tumors: An Intracranial EEG Analysis/A. Shah, D. Barkmeier, Y. Tran, D. Fuerst, J. Loeb, D. Pai, J. Hua, S. Mittal
2.245 Surgical Treatment Of Nonlesional Supplementary Sensorimotor Area Epilepsy/D. Steven, E. Goellner, J. Burneo, A. Parrent, J. Girvin
2.246 Cortical Dysplasia In Patients With Temporal Lobe Epilepsy; Morphological Study Of 60 Cases/ J. Villeda, M. Alonso, L. Rocha, S. Orozco
2.247 Stimulation Of The Anterior Nucleus (AN) Of The Thalamus For Epilepsy Does Not Appear To Promote Adverse Ventilatory Changes During Sleep/C. Anderson, R. Mani, M. Rizk, M. Callanan, J. Pollard, R. Fisher
2.248 A New Percutaneous Surgically Implanted System For Trigeminal (V3) Nerve Stimulation In Human Epilepsy/ A. Blum, M. Cheng
2.249 Resective Epilepsy Surgery In Patients With Perirolandic Epilepsy/ M. Brazdil, R. Kuba, J. Chrastina, Z. Novak, J. Hemza, M. Hermanova, I. Tyrlikova, M. Ryzi, H. Oslejskova, J. Kocvarova, M. Pazourkova, I. Rektor
2.250 Review Of Predictive Factors For Successful Epilepsy Surgery Based On MRI, Routine Electroencephalogram And Clinical Factors/M. Bunch, N. Jette, C. Carlson, J. French

2.251 Drug Withdrawal Protocol After Temporal Lobe Epilepsy Surgery/ R. Centeno, M. Guimarães, L. Caboclo, H. Carrete, E. Yacubian
2.252 Drug-Resistant Epilepsy, Neurocysticercosis And Mesial Temporal Sclerosis: Variations On The Theme Of Dual Pathology/L. Chen, S. Shaw, P. Kim, C. Heck, L. Kalayjian, D. Ko, C. Liu, D. Millett
2.253 Reoperation For Failed Epilepsy Surgery: Outcome In Patients With Refractory Temporal Lobe Epilepsy/ A. Deep, S. Pati, G. Kiyota, Y. Ng, R. Maganti, S. Chung
2.254 Utilizing A Decision Tree Model To Predict Outcome For Patients Assessed For Epilepsy Surgery With EEG, MRI And IQ As Factors/P. Dugan, C. Carlson, J. Menendez, P. Flom, R. Knowlton, J. French
2.255 Frontal Lobe Epilepsy Surgery: Factors Influencing Outcome/ K. Fountas, J. Smith, Y. Park, A. Murro, P. Jenkins
2.256 Epilepsy Surgery In Adults With Medically Intractable Temporal Lobe Epilepsy In Croatia/H. Hecimovic, T. Sajko, V. Demarin, K. Rotim
2.257 Surgical Outcomes For Post-Traumatic Extra-Temporal Epilepsy Surgery/A. Kershenovich, S. Hakimian, J. Ojemann, M. Holmes, A. Hebb, J. Miller, R. D'Ambrosio
2.258 Clinical Features And Pathological Characteristics Of Amygdala Enlargement In Mesial Temporal Lobe Epilepsy/D. Kim, S. Lee
2.259 No Infection In 100 Consecutive Cases Of Vagus Nerve Stimulation For Treatment Of Refractory Epilepsy/ H. Senties-Madrid, M. Alonso-Vanegas, C. Castillo-Montoya, S. Pérez, F. Rubio-Donnadieu
2.260 Outcome Of Temporal Lobectomy For Hippocampal Sclerosis In Older Patients/T. Srikijvilaikul, S. Tepmongkol, S. Lerdlum, S. Shuangshoti, C. Locharernkul
2.261 Management Of Extra-Axial Fluid Collections After Sub-Dural Electrode Placement/N. Tandon, S. Villarreal
2.262 Seizure Outcome After Temporal Lobe Epilepsy Surgery. Comparison Between The Engel And The Proposed International League Against Epilepsy Classifications/ A. Tanner, M. Al-Kaylani, R. Lüders, J. Lüders, H. Lüders
2.263 Refractory Epilepsy Due To Meningioangiomatosis And Focal Cortical Dysplasia Treated By A Staged Surgical Approach/S. Hwang, J. Hira, A. Zubera, M. Nasim, S. Bickel, S. Stevens, A. Mehta
2.264 Gamma Knife Surgery For Refractory Insular Cortex Epilepsy/ M. Irislimane, D. Mathieu, C. Deacon, D. Nguyen
2.265 Hippocampal Transection For Temporal Lobe Epilepsy Patients With Organic Lesions And MRI-Normal Hippocampus/T. Maehara, T. Nariai, Y. Tanaka, K. Hara, M. Matsuura, K. Ohno
2.266 Correlation Of Scalp EEG And MRI Findings With Outcome Of Extraoperative Electrocorticography In Temporal Lobe Epilepsy/V. Wasade, K. Elisevich, B. Smith, M. Spanaki, J. Constantinou
2.267 Seizure And Neuropsychological Outcome Following Mesial Temporal Lobe Epilepsy Surgery: Selective Amygdalohippocampectomy Vs. Anterior Temporal Lobectomy/A. Weil, A. Bouthillier, I. Rouleau, E. Dagenais, W. Surbeck, R. Rahme, P. Cossette, N. Giard, G. Bouvier, J. St-Hilaire, D. Nguyen
2.268 Statistical Modeling Of ICEEG Features That Determine Resection Planning/W. Mathews, L. Ver Hoef, A. Paige, J. DeWolfe, R. Elgavish, K. Riley, R. Knowlton
2.269 Long Term Efficacy Of The SANTE Trial (Stimulation Of The Anterior Nucleus Of Thalamus For Epilepsy)/V. Salanova, R. Fisher, The SANTE Study

Surgery
Pediatrics
2.270 Temporal Lobe Epilepsy Surgery In Children: Considerations For Prognostic Predictors/Y. Park, B. Choi, S. Stickland, G. Lee, A. Murro, P. Culberson-Brown, M. Cohen, S. Miranda, J. Smith, M. Lee
2.271 Does Multimodality Imaging Contribute To Management Of Pharmaco-Resistant Epilepsy In Children With Tuberous Sclerosis Complex?/J. Seo, K. Holland-Bouley, D. Rose, L. Rozhkov, H. Fujiwara, D. Franz, J. Leach, M. Gelfand, L. Miles, F. Mangano, P. Horn, K. Lee
2.272 Vagus Nerve Stimulation (VNS) In Children With Refractory Secondary Generalized Or Multifocal Epilepsy Who Were Not Candidates For Cortical Resection/M. Argentoni-Baldochi, C. Forster, C. Baise, C. Cukiert, V. Mello, A. Cukiert, J. Burattini, P. Mariani
2.273 Invasive Intracranial Monitoring In Pediatric Epilepsy Surgery: When Useful And When Not/P. Brna, P. Jayakar, C. Dunoyer, M. Duchowny, T. Resnick
2.274 Surgical Efficacy And Safety In Multilobar Pediatric Epilepsy/S. Ghatan, P. McGoldrick, S. Wolf
2.275 Functional Consequences And Morbidity Of Hemispherotomy/ A. Hamad, R. Centeno, L. Costa, L. Caboclo, H. Carrete Junior, L. Vilanova, A. Sakamoto, E. Yacubian
2.276 Proposed Multi-Axial Classification For Outcome Of Epilepsy Surgery In Children/K. Holland, A. Byars, T. Glauser, J. Seo, T. Arthur, F. Mangano, K. Lee
2.277 Localization Of Interictal Neuromagnetic Spike-Locked High Frequency Oscillations (40-120 Hz) In Pediatric Intractable Extratemporal Epilepsy/I. Mohamed, H. Otsubo, P. Ferrari, A. Ochi, E. Widjaja, S. Chuang, O. Snead, D. Cheyne
2.278 Prevalence And Predictors Of Delayed Intractability In Children Undergoing Resective Epilepsy Surgery/P. Monrad, K. Nickels, M. Hnojcikova, N. Wetjen, E. Wirrell
2.279 Subtotal Hemispherectomy Sparing The Primary Sensorimotor Region (pSMR) – An Alternative To Hemispherotomy In Children With Hemispheric Epilepsy Without Hemiparesis?/B. Pascher, T. Pieper, S. Kessler, H. Eitel, I. Bluemcke, M. Kudernatsch, P. Winkler, H. Holthausen
2.280 Longitudinal Analyses Of The Surgical Outcomes Of Pediatric Epilepsy Patients With Focal Cortical Dysplasia/J. Phi, B. Cho, Y. Hwang, K. Kim, J. Chae, K. Wang, J. Han, S. Kim
2.281 Effect Of Hemispherectomy On Contralateral Spikes/G. Popli, A. Pinto, M. Takeoka
2.282 Early Surgical Treatment Of Early Infantile Epileptic Encephalopathy/ Ohtahara Syndrome/F. Ritter, M. Dunn, H. Chugani, I. Pavkovic, J. Doescher, M. Frost
2.283 Vagus Nerve Stimulation For Medically Refractory Epilepsy In The Pediatric Population/T. Yamamoto, W. Doyle, A. Sylverberg, O. Devinsky
2.284 Repeat Surgery For Medically Refractory Epilepsy In Children: Features And Seizure Outcome/ D. Depositario-Cabacar, J. Walker, H. Kaulas, A. Yaun, J. Conry, P. Pearl, T. Tsuchida, C. Heath, T. Zelleke, L. Vezina, W. Gaillard
2.285 Transsylvian Selective Amygdalohippocampectomy In Children: Seizure And Cognitive Outcome/ A. Durnford, P. Heffer-Rahn, A. Beaton, J. Limond, F. Kirkham, A. Whitney, W. Gray
2.286 Epilepsy Surgery In Children With Intracranial Shunts/M. Goyal, S. Robinson
2.287 Successful Surgical Treatment Of Intractable Epilepsy For Children With Tuberous Sclerosis Complex/ M. Guerra, E. Castillo, J. Baumgartner, G. Von Allmen
2.288 The Use Of An Automatic SPECT Injector Improves The Quality Of Ictal Studies In Pediatric Epilepsy Surgery Patients/D. Holder
2.289 The Effect Of VNS Therapy On Body Mass Index In Children/ S. Kansagra, N. Ataya, D. Lewis, W. Gallentine, G. Grant, M. Mikati
2.290 Outcome And Complication In Hemispherectomies Of Infants Less Than A Year Old/S. Koh, L. Zawadzki, P. Laoprasert, K. Knupp, K. Park, M. Handler
2.291 Clinical Outcomes In Reoperation After Comphrehensive Epilepsy Surgery/E. Kwon, H. Kang, H. Kim, J. Lee
2.292 Bilateral Multistage Approach In Epilepsy Surgery/K. Lee, J. Seo, K. Holland-Bouley, F. Mangano

2.293 Hyponatremia In Pediatric Patients Undergoing Intracranial Monitoring And Epilepsy Surgery For Intractable Partial Seizures/ A. McGregor, S. Fulton, D. Clarke, F. Perkins, F. Boop, S. Einhaus, J. Wheless
2.294 Repeat Surgery Of Hypothalamic Hamartoma For Refractory Epilepsy/Y. Ng, S. Pati, K. Kelly, S. Donlon, R. Rastogi
2.295 Early Surgery For Infantile Intractable Epilepsy Associated With Hemimegalencephaly/A. Takahashi, T. Otsuki, T. Kaido, Y. Kaneko, E. Nakagawa, K. Sugai, M. Sasaki
2.296 Quality Of Life Changes Following Pediatric Epilepsy Surgery/ J. Titus, M. Smyth, D. Limbrick, L. Thio, J. Rogier, K. Steger-May
2.297 Presurgical Invasive Explorations In Childhood Epilepsy: Our Experience With Subdural Electrodes And Stereo-Electroencephalography/ G. Dorfmuller, D. Taussig, S. Ferrand Sorbets, C. Bulteau, C. Jalin, M. Fohlen, O. Delalande
2.298 Complete Section Of The Corpus Callosum Associated With Vagal Nerve Stimulation For Atonic Seizures In Pediatrics/ R. Villalobos-Nieto, F. Guzman, J. Torres-Corzo, R. Rodriguez
2.299 Reactivation Of Herpes Simplex Virus Encephalitis Following Epilepsy Surgery/S. Arnold, A. Price
2.300 Comparison Of Outcome After Callosotomy And Vagus Nerve Stimulation Therapy In Children With Drop Attacks/M. Chiara Colonnelli, S. Varadkar, S. Hannan, W. Harkness, J. Cross
2.301 Value Of Computed Tomography (CT) Scan In Children With Medically Refractory Epilepsy Caused By Focal Cortical Dysplasia/P. Laoprasert, D. Arndt, S. Koh, B. Kleinschmidt-Demasters, M. Handler
2.302 Drug Withdrawal In The Epilepsy Monitoring Unit: Outcomes In A Newly Established Service/H. Singh, D. Clark, S. Gurr, J. Richmond, S. Malone

Surgery
All Ages
2.303 Hippocampal Deep Brain Stimulation (Hip-DBS) In Patients With Bilateral Temporal Lobe Epilepsy (TLE) And Normal MRI Findings Or Bilateral Mesial Temporal Sclerosis (MTS)/ A. Cukiert, J. Burattini, P. Mariani, C. Cukiert, C. Baise, M. Argentoni-Baldochi, C. Forster, V. Mello
2.304 Centro-Median Deep Brain Stimulation (CM-DBS) In Patients With Refractory Secondary Generalized Epilepsy Previously Submitted To Callosal Section/C. Cukiert, A. Cukiert, M. Argentoni-Baldochi, C. Baise, C. Forster, V. Mello, J. Burattini, P. Mariani
2.305 Differences In Seizure Frequency During Scalp Versus Intracranial Video/EEG Monitoring/ C. Kahlenberg, V. Thadani, K. Bujarski, K. Gilbert, K. Kulandaivel, D. Roberts, B. Jobst
2.306 Can Acute Electrocorticography Obviate The Need For Chronic Implantation Of Electrodes And Predict Outcome In A Subgroup Of Patients With Temporal Lobe Epilepsy And A Normal MRI?/T. Schwartz, N. Luther, A. Tsiouris, D. Labar, N. Sethi, E. Rubens
2.307 Depth Electrode Recording In Epilepsy Surgery. A Five Year Review/ M. Wheatley, D. Gross, D. Sinclair, N. Ahmed
2.308 Change In Seizure Severity After Anterior Temporal Lobectomy/ S. Alur, L. Stott, M. Nei, A. Sharan, M. Sperling
2.309 Anterior Nucleus Of The Thalamus Deep Brain Stimulation (AN-DBS) In Patients Who Failed Extra-Temporal Or Temporal Lobe Resection/ C. Baise, C. Cukiert, M. Argentoni-Baldochi, C. Forster, V. Mello, A. Cukiert, J. Burattini, P. Mariani
2.310 Long-Term Epilepsy Surgery Outcome In Argentina/M. Donadío, M. Moussalli, L. Barrios, C. Vazquez, G. Ugarnes, M. Segalovich, J. Pociecha, C. Petre, H. Pomata, C. D'Giano
2.311 Application Of Focal Cerebral Cooling For The Treatment Of Intractable Epilepsy: An Overview Of Past Studies/M. Fujii, H. Imoto, H. Fujioka, Y. Maruta, H. Koizumi, S. Nomura, K. Kajiwara, T. Saito, T. Yamakawa, T. Yamakawa, M. Suzuki
2.312 Long-Term Follow-Up After Frontal Lobe Epilepsy Surgery/ S. Lazow, D. Roberts, V. Thadani, K. Gilbert, R. Morse, K. Bujarski, K. Kulandaivel, B. Jobst
2.313 The Use Of Vagus Nerve Stimulation (VNS) In Refractory Epilepsy Patients/S. Miranda, A. Murro, K. Drake, Y. Park, S. Strickland, J. Smith, C. Giller, G. Lee
2.314 Intracranial Survey Studies: Usefulness And Prognostic Implications/M. Zaatreh, M. Lancman, O. Laban, G. Ghacibeh, E. Fertig, M. EL Khashab, A. Fried
2.315 Seizure Outcomes And Quality Of Life Following Corpus Callosotomy For Drop Seizures/R. Bower, J. Van Gompel, G. Worrell, R. Marsh, E. Wirrell, F. Meyer
2.316 Clinical Use Of Functional Magnetic Resonance Imaging For Clearing Brain Areas For Resective Surgery/L. Entz, S. Bickel, M. Argyelan, G. Klein, S. Hwang, S. Jain, S. Schaffer, P. Kingsley, A. Mehta
2.317 Is Additional Amygdalo-Hippocampectomy Necessary For Intractable Lesional Temporal Lobe Epilepsy?/H. Kishima, S. Oshino, K. Hoshimi, M. Hirata, A. Kato, T. Yoshimine
2.318 Planning Intracranial Electrode Studies For Seizure Localization In Cases Of Nonlesional Neocortical Epilepsy/A. Papanastassiou, K. Vives, D. Spencer
2.319 A Minimal Invasive Surgical Approach: Thermoablation For An Isolated Periventricular Nodular Heterotopia/F. Schmitt, A. Ebner, H. Pannek, J. Buentjen, H. Heinze, J. Voges
2.320 Mortality After Epilepsy Surgery/M. Sperling, S. Durbhakula, L. Stott, M. Nei, A. Zangaladze, S. Mintzer, C. Skidmore, J. Evans, A. Sharan
2.321 New Micro Cryogenic Probe As New Facilities For Brain Surgery/ L. Zimin, T. Yamakawa
2.322 Temporomandibular Disorders Following Craniotomy For Refractory Epilepsy: A Prospective Evaluation/ A. Costa, C. Yasuda, H. Tedeschi, E. Oliveira, F. Cendes
2.323 Evaluation Of The Frequency And Clinical Importance Of Electrically-Induced Seizures By Using Intracerebral And Subdural Electrodes/ T. Hoshida, T. Murakami, K. Kawata, K. Tamura, H. Nakase
2.324 Corpus Callosotomy For Medically Refractory Epilepsy Secondary To Congenital Bilateral Perisylvian Syndrome/T. Yamazoe, A. Fujimoto, M. Yamazaki, T. Yamamoto

Practice Resources
2.325 Early Postoperative Antiepileptic Drug Withdrawal In Seizure-Free Mesial Temporal Lobe Epilepsy Patients With Concordant Epileptogenic Zone/ D. Adstamongkonkul, K. Sripankaew, W. Krongthong, A. Arnamwong, C. Lim-arune, S. Suwaroporn, C. Locharernkul
2.326 Developing A Systematic Team Approach To Monitor, Measure, Modify And Implement Safety In The EMU/ M. Spanaki-Varelas, V. Remedio, D. Budzyn, C. McCloskey, M. Holland, B. Smith
2.327 National Institute Of Neurological Disorders And Stroke National Institute Of Neurological Disorders And Stroke (NINDS), National Institutes Of Health (NIH), Common Data Element (CDE) Project: Version 1.0 Of Epilepsy CDEs Available For Use/A. Stout, S. Grinnon, L. Hunegs, J. Odenkirchen, B. Fureman
2.328 The Feasibility Of Providing Tele-Epilepsy Services On The Indian Reservation/K. Drake, J. Chong, D. Labiner
2.329 Developing A Functional Status Diary (FSD) For Epilepsy/S. Fehnel, R. Manjunath, C. Ervin, J. French, K. VanLandingham, C. Sweeney, A. Ettinger, E. Faught, A. Kanner
2.330 Using Concomitant Remote Cardiac Telemetry To Enhance Patient Safety In The Epilepsy Monitoring Unit (EMU)/D. Moses, P. Gerber-Gore

2.331 Epilepsy On YouTube: A Review Of 100 Videos/K. Noe, D. Shulman, L. Tapsell
2.332 Indeterminate EMU Admissions: Does Repeating The Admission Help?/S. Zarkou, M. Grade, M. Hoerth, K. Noe, J. Sirven, J. Drazkowski
2.333 Assessing YouTube Videos As A Teaching Tool For Infantile Spasms/ M. Fat, E. Sell

Epidemiology
2.334 Epilepsy And Activity – A Population-Based Study/K. Gordon, J. Dooley, P. Brna
2.335 Population-Based Prevalence And Incidence Of Epilepsy In Washington, D.C./A. Kenyon, B. Kroner, M. Fahimi, W. Gaillard, W. Hauser, D. Thurman
2.336 Predictors Of Death In Pediatric In-Patients With Status Epilepticus/ T. Loddenkemper, T. Syed, V. Gooty, S. Kothare, A. Alshekhlee, M. Koubeissi
2.337 Diagnosis And Hospital Stay For Status Epilepticus: Gender Differences Over A Decade/A. Arain, P. Singh, Y. Song, V. Cain, B. Husaini
2.338 Prevalence Of Sleep Disorders Symptoms In Children With Epilepsy And Type 1 Diabetes/J. Baron, R. Levy, B. Ostrander, C. Ray
2.339 Patients With A Lifetime Of Epilepsy: Characteristics And Co-Morbidities/B. Botti, E. Geller, P. Widdess-Walsh
2.340 A Prospective Study Of A Cohort Of Patients With Newly-Diagnosed Epilepsy: Their Response To Medication, And The Role Of EEG And MRI/J. Burneo, E. Sandison
2.341 Patterns Of Hospital Utilization Among Patients With Seizures And Epilepsy/J. Chong, E. Ouellette, K. Drake, D. Labiner
2.342 The Diagnosis Of Nonepileptic Seizures On EEG Telemetry Reduces Acute Health Care Utilization/J. Jirsch, S. Ahmed, D. Gross
2.343 Lack Of Reliability Of ICD9 Codes For Generalized Convulsive Status Epilepticus Detection/J. Langer, N. Fountain
2.344 Racial/Ethnic Differences In Incident Epilepsy/Seizure Disorder Following Admission To US Nursing Homes, 2003-2007/I. Leppik, S. Harms, K. Svendsen, S. Li, L. Eberly
2.345 Etiology Of Epilepsy In Southeastern Brazil: A Population-Based MRI Study/L. Li, P. Fernandes, S. Stefanello, L. Marín-Léon, N. Botega
2.346 Epilepsy-Related Mortality Is Low In Children: A 25-Year Population-Based Study In Rochester, MN/ K. Nickels, E. Wirrell
2.347 Wait Time For First Medical Assessment After A Single Unprovoked Seizure, Does It Matter?/J. Anang, J. Tellez-Zenteno
2.348 Attitudes Relating To Driving And Risk Taking In Adolescents And Young Adults With Epilepsy/A. Dantzig, E. Macdonald
2.349 Prevalence Of Epilepsy In Korea: Nationwide Study From The National Health Insurance Statistics/S. Lee, K. Jung, D. Kim
2.350 Seizure Remission And Relapse In Adults With Intractable Epilepsy: An Extended Follow-Up Study/H. Munger Clary, G. Heiman, M. Etienne, W. Hauser, H. Choi
2.351 Mortality Following Childhood Status Epilepticus: A Population-Based Study/S. Pujar, R. Scott, R. Chin
2.352 Socio-Occupational And Employment Profile Of Patients With Epilepsy/J. Serratosa, E. Elices, A. Gil-Nagel, J. Salas-Puig, J. Sánchez, M. Carreño, V. Villanueva, J. Rosendo, J. Porcel, A. Marinas
2.353 How Often Is Childhood Epilepsy "Preventable"?/L. Wong-Kisiel, K. Nickels, E. Wirrell
2.354 Development And Validation Of A Case Definition For Epilepsy For Use With Administrative Data/A. Reid, M. Liu, S. Sadiq, H. Quan, S. Wiebe, P. Faris, S. Dean, N. Jetté

Public Health
2.355 Epilepsy-Related Death In Arizona: Mapping Racial And Ethnic Disparities In Mortality At County Level/S. Pati, A. Sharma, K. Chapple, C. Mrela, R. Porter, A. Deep, R. Dhall, S. Chung, J. Sirven
2.356 Electrocardiographic And Oximetric Changes In Patients During Partial Complex And Generalized Seizures/B. Moseley, E. Wirrell, K. Nickels, J. Johnson, M. Ackerman, J. Britton
2.357 Epilepsy Partnerships That Work: The South Texas Border — Rio Grande Valley Region/S. Rosales, J. Cavazos, C. Szabo, L. Morgan
2.358 Results Of A Randomized Controlled Trial Evaluating WebEase, An Online Self-Management Program/C. Dilorio, Y. Bamps, E. Walker
2.359 Trends In Healthcare Cost Utilization, Length Of Stay, In-Hospital Mortality And Discharge Disposition In Patients Hospitalized For Epilepsy And Convulsions, 1993-2008/M. Rao, A. Bhatt, A. Majid, M. Kassab
2.360 Decreasing The Epilepsy Treatment Gap In The Ecuador Amazon Region/P. Espinosa, N. Falcone, B. Vasquez, B. Dworetzky, E. Ortiz, A. Salom, Y. Garzon, O. Pacheco, A. Berkowitz, D. Fee, K. Swartz, S. Cash, R. Baumann
2.361 Knowledge, Beliefs, And Healthcare Perceptions Of Epilepsy In Minnesota's Native American Nations/M. Fiol, K. Allison, S. Rosenstone, G. Vazquez
2.362 Translating Research To Practice: CDC Managing Epilepsy Well Network/R. Kobau, C. Dilorio, Y. Bamps, N. Thompson, N. Clark, C. Begley, R. Shegog, R. Fraser, P. Ciechanowski
2.363 Survey Of Non-Neurologists Knowledge Of Department Of Motor Vehicles Rules And Regulations For Loss Of Consciousness In A Mandatory Reporting State/E. Neiman, R. Bitra, S. Sane, A. Farheen, K. Narayana, J. Drazkowski
2.364 Disobedience And Driving In Patients With Epilepsy/W. Tatum, M. Selenica
2.365 Revising Project UPLIFT From A Treatment Intervention To A Prevention Intervention/N. Thompson, A. Edwards, A. Garcia-Williams, R. Fraser, C. Begley, L. Selwa

History of Epilepsy
2.366 Epilepsy And Epilepsy Surgery Newly Characterized In A 1950 Film/ D. Friedman

Late-Breaking Abstracts
2.367 Predictors Of Five-Year Remission In Focal Epilepsy Of Unknown Cause/E. Beghi, U. Aguglia, A. Labate, S. Gasparini, L. Mumoli, C. G. Leonardi, V. Cianci, M. A. Latella, A. Gambardella
2.368 SCN1A-Targeted siRNA In Rats Causes Behavioral Impairment: Implications For Dravet Syndrome/ A. C. Bender, G. L. Holmes, P. P. Lenck-Santini
2.369 Association Between Infantile Spasms And The "Shaken-Baby Syndrome"/A. Birca, L. Carmant
2.370 Epilepsy Co-Morbidity In Complex Childhood Developmental Disorders: Seizure Susceptibility In A Genetic Mouse Model Of RTT Syndrome Demonstrates Age And Genotype Interactions/G. Carlson, T. N. Ferraro, G. G. Smith, R. J. Buono
2.371 Potential Novel Molecular Players In Homeostatic Plasticity Of Hippocampal Neurons Identified By Gene Expression Profiling/H. Chung, S. Royston, M. Vest, D. Ley, K. Lee
2.372 Fluoxetine Reverses Both An Allocentric Spatial Learning Deficit And Reduced Neurogenesis In A Rodent Kainate Model Of Mesial Temporal Lobe Epilepsy/W. P. Gray, L. Barkas, M. Taylor, A. Shtaya, D. Hamilton, E. Redhead
2.373 The Effect Of Early Life Seizures On Synaptic Plasticity In The Prefrontal Cortex Later In Life/ A. Hernan, G. Holmes, E. Isaeva
2.374 Hippocampal Theta Rhythm Amplitude Is Reduced After Intraseptal Injection Of GAT1-SAP/S. Jaime, M. G. Perez-Cordova, L. V. Colom
2.375 Splenectomy Modulates Experimental Seizures Induced By Cholinergic Or Glutamatergic Activation/D. Janigro
2.376 Quantitative Video-EEG In A Mouse Model Of Neonatal Ischemic-Seizures: Age-Dependent Efficacy Of Phenobarbital/S. D. Kadam, G. J. Markowitz, S. K. Kang, A. M. Comi, F. E. Dudek, M. V. Johnston

2.377 Activation Of Suicidal Ideation With Adjunctive Rufinamide In Bipolar Disorder/K. R. Kaufman, P. J. Struck
2.378 Levetiracetam Monotherapy In Children With Epilepsy In Chungbuk, Korea/W. S. Kim, G. Sim
2.379 Inter-Rater Reliability Of Engel And ILAE Seizure Outcome Classifications/F. J. Kirkham, A. Durnford, W. Rodgers, K. Forrest, M. A. Mullee, A. Whitney, L. Kinton, M. Prevett, M. J. Harris, W. P. Gray
2.380 Efficacy And Safety Of Perampanel, An AMPA Receptor Antagonist, As An Adjunctive Therapy In A Phase III Study Of Patients With Refractory Partial-Onset Seizures/ G. L. Krauss, J. M. Serratosa, V. E. Villanueva, M. Endziniene, Z. Hong, J. French, H. Yang, D. Squillacote, J. Zhu, A. Laurenza
2.381 The Soluble Epoxide Hydrolase Regulates Hippocampal Neuroinflammation In Adult Mice After Pilocarpine-Induced Status Epilepticus/ Y. Lin, M. Lai, Y. Hung, T. Lee
2.382 Comparison Of P3 Responses Before And After Surgery In TLE Patients Using CD Analysis/ A. Matsuda, K. Hara, M. Miayajima, K. Ohta, T. Maehara, E. Matsushima, M. Watanabe, M. Hara, M. Matsuura
2.383 Perforant Pathway Stimulation In Freely-Moving Rats: Threshold For Hippocampal Neurodegeneration/ B. Norwood, F. Rosenow
2.384 Structural Alteration In BBB And Mdr-1 Protein Expression In Tissue Of Pediatric Patients With Partialis Continua Epilepsia/ S. Orozco-Suárez, I. Feria-Romero, D. Rayo, R. Garcia, J. Diegopèrez, M. I. Fraire, G. Ramìrez, R. Cabrera, J. Proaño, L. Arriaga, I. Grijalva
2.385 Noninvasive Ultrasonic Neuromodulation For Status Epilepticus: Preliminary Observations/ S. Pati, A. Yoshihiro, Y. Tufail, W. J. Tyler
2.386 Multiple Mechanisms Rapidly Regulate Tonic GABA Currents In Cultured Rat Hippocampal Neurons/ C. Ransom, Y. M. Wu, G. B. Richerson
2.387 Resistance To Classical Antiepileptic Drugs In The MTLE Mouse: A Model Of Mesial Temporal Lobe Epilepsy To Explore New Mechanisms Of Actions?/C. Roucard, K. Bressand, A. Depaulis
2.388 Epilepsy After Febrile Seizures: Twins Suggest Genetic Influence/ S. Seinfeld, J. M. Pellock, M. J. Kjeldsen, K. O. Nakken, H. Jensen, L. A. Corey
2.389 Normal Vigilance Cycling Compromises The Ability Of EEG To Predict Seizures/S. Sunderam, N. Chernyy, J. P. Mason, S. L. Weinstein, S. J. Schiff, B. J. Gluckman
2.390 Use Of Rufinamide In Adults With Epilepsy/L. M. Tiedemann, A. Svoronos, R. Buchsbaum, P. G. Amar, M. E. Wingo, S. R. Resor, L. J. Hirsch
2.391 Definition Of The Neurological Phenotype Associated With Dup (X)(p11.22-p11.23) Syndrome/ P. Tinuper, M. Broli, F. Bisulli, M. Mastrangelo, E. Fontana, I. Fiocchi, C. Zucca, M. C. Bonaglia, S. Reitano, R. Corrado, R. Agati, B. Bernardi, D. Cevolani, R. Gallassi, P. Magini, F. Oppi, R. Poda, R. Giorda, O. Zuffardi, B. Dalla Bernardina, M. Seri
2.392 Presurgical Planning Of Intracranial Grid Placement For Improvement Of Seizure Control/ R. D. Triolo, S. Vogrin, M. Wagner, K. Morris, M. Cook, M. Murphy
2.393 Emergent EEG In The Emergency Department In Patients With Altered Mental States/W. Ziai, D. Schlattman, R. Llinas, M. Truesdale, S. Venkatesha, A. Shevchenko, P. Kaplan
2.394 Fetal GABAergic Progenitor Grafts In The Dentate Gyrus Of Adult Mice Suppress Spontaneous Recurrent Seizures In The Pilocarpine Model Of Temporal Lobe Epilepsy/ S.E. Royston, X. Maisano, N.I. Woods, C. Lassiter, S.M. Tagliatela, G.B. Aaron, J.R. Naegele



Here are a few of the highlights:

Membership – Join online and you may also visit the AES membership area at the registration desk at the Annual Meeting

Professional Development – Epilepsy education programs and archived AES symposia

Annual Meeting Information

Abstracts – Searchable database

Research – Information regarding awards and grants

Publications – Featuring *Epilepsy Currents*, *Epilepsia*, AES *News* and AES Annual Reports

Press Room – Press release archives, fact sheets and position statements

www.AESNET.org

Log on to the AES Website

ONLINE EDUCATIONAL OPPORTUNITIES

63RD ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY

NOW AVAILABLE!

The **American Epilepsy Society** is proud to offer a wide variety of sessions repurposed from the **2009 Annual Meeting – Boston, MA.**

These online sessions integrate knowledge and dynamic interaction to enhance the online learning experience for epilepsy-related professionals. Each session delivers interactive knowledge as presented at the Annual Meeting and provides quality continuing medical education for physicians, researchers and other professionals whose goal is to improve the quality of life for those with epilepsy and other seizure-related disorders.

- Annual Fundamentals of Epilepsy: *Neurophysiology 101*
- Hot Topics Symposium: *Biomarkers in Epilepsy*
- Spanish Symposium: *Pitfalls in Diagnosis and Treatment of Epilepsy*
- 7th Judith Hoyer Lecture in Epilepsy: *Battling Epilepsy with Models and Molecules*
- Professionals in Epilepsy Care Symposium: *Predictors and Methodologies of Epilepsy Self-Management*
- Merritt-Putnam Symposium: *Beyond Seizures: Mechanisms Underlying Epilepsy Spectrum Disorder*
- Antiepileptic Therapy Symposium: *Treatment Strategies for the Patient with Epilepsy*
- Annual Course: *Selecting Patients for Epilepsy Surgery*
- Presidential Symposium: *It Takes a Village: Solving the Treatment Gap*
- Pediatric State of the Art Symposium: *Treatable Metabolic Epilepsies*
- Plenary II: *The Postictal and Interictal Periods: What Are We Missing?*
- International League Against Epilepsy Symposium: *Redefining Treatment-Resistant Epilepsy*
- Plenary III: *ICU Monitoring*

9:00 a.m. – 10:30 a.m.

➤ Special Interest Group Meetings

Convention Center – Location listed under each session
Please complete program survey – see page 14

Botanicals & Alternative Therapies for Epilepsy – Botanicals and Natural Products: Open Mic Night

Convention Center – Room 008
Coordinator: Steven C. Schachter, M.D.
Speakers: Platform presentations

Are you working with botanicals or natural products? Do you want to share your findings with the epilepsy botanical community and meet potential collaborators? Then come join us for an "open microphone" at this year's Botanical SIG for 5-minute presentations followed by 5-minute discussions. Space is limited, so presenters will be scheduled on a first come, first served basis.

➤ Junior Investigator Workshop – Mentoring as an Essential Part of Career Advancement

Convention Center – Room 006 D
Coordinators: Audrey S. Yee, M.D., Brandy E. Fureman, Ph.D.
Speakers: Helen E. Scharfman, Ph.D., Scott C. Baraban, Ph.D., Robert L. Macdonald, M.D., Ph.D., Amy Brooks-Kayal, M.D.

Join us for an exciting Junior Investigator workshop on Mentoring with pioneers in epilepsy research: Scott Baraban, Amy Brooks-Kayal, Robert MacDonald and Helen Scharfman. This will be an interactive session where our panelists will share their pearls of wisdom and then we will open the floor for discussion. Join us for this lively interchange!

Pregnancy Registry Outcomes – Update in Pregnancy Registries of AEDs

Convention Center – Room 007 C/D
Coordinators: Cynthia L. Harden, M.D., Georgia D. Montouris, M.D.
Speakers: TBA

This SIG was started in 2004 by Drs. Pennell and Meador to provide an annual update on the recent findings of international pregnancy registries in which outcomes of the offspring born to women with epilepsy were collected. This SIG has continued to provide this update every year, but has also evolved and expanded to include the South India Pregnancy Registry and late-breaking information from the European Pregnancy Registry. In addition to structural teratogenesis, cognitive teratogenesis from the NEADs study is presented. Registry information is becoming more and more detailed and refined, and now specific dose effects of AEDs, longer term effects on cognition and fertility are being put forth. This SIG continues to represent the best efforts of the American Epilepsy Society, which are to provide timely and scientifically valid epilepsy education. This year we will strive to have presentations from all global registries including Australian, European, South Indian, United Kingdom, North American, and the NEADs group. The focus will be on teratogenic outcomes from exposure to newer AEDs and to present teratogenic dose effects of AEDs.

Psychiatry in Epilepsy – Anxiety Disorders in Epilepsy: The Forgotten Psychiatric Comorbidity

Convention Center – Room 007 A/B
Coordinator: Andres M. Kanner, M.D.
Speakers: Michael Trimble, M.D., Dale C. Hesdorffer, Ph.D.

This SIG will be devoted to a discussion on the screening, diagnosis and treatment of anxiety disorders in patients with epilepsy. The last decade has been pivotal in the recognition of the importance of early identification and treatment of psychiatric comorbidities. While most of the interest has been focused on mood disorders, little attention has been paid to anxiety disorders. And yet, the prevalence of symptoms of anxiety and anxiety disorders in patients with epilepsy is comparable to that of mood disorders. Furthermore, mood and anxiety disorders tend to occur together in a very high percentage of patients. Also, the presence of anxiety disorders is associated with a worse quality of life, more frequent complaints of adverse events to antiepileptic drugs and increases the suicidal risk in depressed patients. Finally, in patients with mood disorders, untreated comorbid symptoms (and / or episodes) of anxiety increase the recurrence risk of major depressive episodes. Despite all of the above, anxiety disorders remain undetected and untreated in a very large percentage of patients with epilepsy.

9:00 a.m. – Noon

Merritt-Putnam Symposium: Consequences of Epilepsy Through the Ages: When Is the Die Cast?

(2.75 CME Credits)
Award Presentation: Extraordinary Contributions to the Field of Epilepsy Award
Convention Center – Lila Cockrell Theatre

Overview

Epilepsy occurs throughout the lifetime with the behavioral and electroencephalographic features of the disorder heavily influenced by age. Likewise, the consequences of epilepsy are age-dependent. In this symposium we will review how maturational and aging changes in brain circuitry account for age-specific sequelae of epilepsy.

The symposium will begin with a review of developmental and aging changes in the brain that provide a biological framework for considerations of the consequences of seizures across the lifetime. The consequences of seizures through the lifespan, using both animal and human data, will follow. While many childhood epilepsies remit with age, many of the sequelae of childhood epilepsy continue into adults raising important issue about management. The outcome of the childhood epilepsies will be discussed and the topic of whether comorbidities associated with epilepsy are due to the underlying cause of the epilepsy or due to the seizures themselves will be reviewed. Just as developmental factors can influence outcome, the multidimensional process of physical and psychological change during aging which have a profound role in outcome of epilepsy will be discussed. Given this information about age-related morbidity with epilepsy, the symposium will conclude with a discussion of how intervention across the lifespan can improve outcome in patients.

Learning Objectives

- Understand how developmental changes in brain circuitry are related to age-related consequences of epilepsy
- Learn how the consequences of epilepsy vary as a function of age
- Understand the relationships between age, etiology and outcome in individuals with epilepsy
- Learn how age-specific interventions can improve outcome in individuals with epilepsy.

Target Audience

Basic / fundamentals, Intermediate (see page 101 for details)

Program

Chair: Gregory L. Holmes, M.D.

Introduction and Overview
Gregory L. Holmes, M.D.

Brain and Seizures Throughout Life: Understanding a Moving Target
Tallie Z. Baram, M.D., Ph.D.

Transition from Pediatric to Adult Epilepsy Care: A Difficult Process Marked by Medical and Social Crisis
Peter R. Camfield, M.D., FRCP(C)

Neuropsychological Deficits in Childhood Epilepsy: Timing and Risk Factors
Philip S. Fastenau, Ph.D.

The Aged Brain: Causes and Consequences of Late-Onset Epilepsy
Kevin M. Kelly, M.D., Ph.D.

AED Treatment Through Different Ages: As Our Brains Change, Should Our Drug Choices Also?
Jacqueline A. French, M.D.

Closing Remarks
Gregory L. Holmes, M.D.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.75 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE Universal Activity Number (UAN) is 031-999-10-026-L04-P and provides 2.75 contact hours (.275 CEUs)

Acknowledgment

This program is supported in part by an educational grant from UCB, Inc. with additional support from Eisai, Inc.

2:15 p.m. – 3:00 p.m.

Lennox & Lombroso Lecture: Looking Forward — Opportunities and Challenges for NINDS

Convention Center – Lila Cockrell Theatre

Lecturer: Story C. Landis, Ph.D.

3:15 p.m. – 4:45 p.m.

➢ Mentoring Session for Junior Investigators

Pre-application is required

Convention Center – Room 006 D

This program is targeted to fellows, postdoctoral researchers, instructors, and assistant professor level junior faculty. Epilepsy professionals at the Associate Professor or Professor level will volunteer to serve as mentors. Accepted applicants will meet with their assigned mentors during this time.

3:15 p.m. – 4:45 p.m.

Patient Education for Clinicians

Marriott Rivercenter – Grand Ballroom, Salon A/B
(registration is not required)

Moderator: Debbie Carr

The Epilepsy Foundation and the Epilepsy Therapy Project offer numerous provider and patient resources both online and in hard copy that can help patients, their caregivers, and their physicians improve treatment and self-management of this condition. This session will discuss the tools and programs to assist with self-management, patient and physician web events and other programs and resources that are available at no cost through these organizations.

3:15 p.m. – 4:45 p.m.

Investigators' Workshop

Convention Center – Room 006 A-C

Endogenous Regulation of Group 1 mGluR-Mediated Epileptogenesis

Moderator: Lisa R. Merlin, M.D.
Speakers: Henri Tiedge, Ph.D., Eric Klann, Ph.D., Randi Hagerman, M.D.

3:15 p.m. – 4:45 p.m.

Special Interest Group Meetings

Convention Center – Location listed under each session
Please complete program survey – see page 14

Controversies in Epilepsy

Convention Center – Room 007 A/B
Coordinator: Hans O. Luders, M.D., Ph.D.
Speakers: Hans O. Luders, M.D., Ph.D., Philippe Kahane, M.D., Felix Rosenow, M.D., Ingrid Tuxhorn, M.D.

Classical epileptology describes seizures with typical semiology for epilepsies localized to specific brain regions. Infrequently, however, seizure semiology may be misleading suggesting a wrong seizure onset zone. In this session the moderator is going to show videos of seizures and ask the audience to discuss the semiology and define the epileptogenic zone based on semiological features. The moderator will also provide additional evidence that helps to define the location of the epileptogenic zone. Attempts will be made to have a highly interactive session.

Genetics – Genetic Modifiers in Epilepsy: Of Mice and Men

Convention Center – Room 008 A
Coordinators: Jennifer Kearney, Ph.D., Andrew P. Escayg, Ph.D.
Speakers: P. Elyse Schauwecker, Ph.D., Melodie Winawer, M.D., Jennifer Kearney, Ph.D.

This year's topic for the genetics SIG is Genetic Modifiers. The role of genetic modifiers in influencing clinical severity is becoming increasingly important for understanding the pathophysiology of disease. We will discuss recent progress identifying genetic modifiers that influence epilepsy susceptibility and disease progression in animal models and patient populations. We will also consider how these discoveries might be translated into improved treatment for patients.

Military Epileptologists: Epilepsy Care Within the VA System

Convention Center – Room 008 B

Coordinator: Jonathan Halford, M.D.
Speakers: Sunita Dergalust, Pharm.D., Mary Jo Pugh, Ph.D., Jonathan Halford, M.D., Aatif Husain, M.D., Paul Rutecki, M.D.

In this SIG, we will discuss the role of pharmacists in epilepsy clinic at the VA, the development of a protocol to examine how the organization of care is associated with outcomes for epilepsy using the epilepsy quality indicators developed for use in the VA/ DoD and the barriers to setting up remote access to neurophysiology data at the VA due to IT regulations. Several of the directors of the regional Epilepsy Centers of Excellence, including Aatif Husain, M.D. and Paul Rutecki, M.D., will briefly discuss progress in setting up the Epilepsy Centers of Excellence in their regions.

Neuropharmacology – Experimental Methods to Guide the Use of Combination AED Therapy

Convention Center – Room 201

Coordinators: Gail D. Anderson, Ph.D., R. Eugene Ramsay, M.D., Jacqueline Bainbridge, Pharm.D.
Speakers: Jong M. Rho, M.D., Michael A. Rogawski, M.D., Ph.D., Nicholas P. Poolos, M.D., Ph.D.

This SIG will present "Experimental Methods to Guide the use of Combination Antiepileptic Drug Therapy." This session will discuss the rationale and controversies of using pre-clinical and clinical data to guide practitioners in the use of combination antiepileptic drug therapy. Dr. Rho will discuss antiepileptic drug Polypharmacy, the rationale, definitions and controversies. Dr. Rogawski will review experimental studies of AED combinations and whether they provide useful guidance for the clinician. Lastly, Dr. Poolos will discuss the comparative efficacy of combination AED therapy in refractory epilepsy.

Temporal Lobe Club – WADA Test: If, When and How?

Convention Center – Room 007 C/D

Coordinator: Kimford J. Meador, M.D.
Speakers: Marilyn Jones-Gotman, Ph.D., William Gaillard, M.D., David Loring, Ph.D.

The pre-operative localization of cerebral dysfunction allows reduction or avoidance of impaired cognitive function from epilepsy surgery. Further, it is complimentary to the localization of seizure onset by providing additional confidence in delineation of the epileptogenic region. The WADA test was first introduced over 60 years ago as a method of cerebral inactivation to determine language lateralization and shortly thereafter modified to assess hemispheric contribution to memory function. The WADA test has been a mainstay in the preoperative evaluation for epilepsy surgery, but not without problems, controversies and new challenges. The intracarotid amobarbital procedure is not a single test, and methodological differences in the Wada test can lead to quite variable results. Recent shortages in amobarbital have led to the need to employ alternative medications for the amobarbital, but there is some uncertainty as to the methodology and comparability of these alternatives. Emerging techniques (e.g., fMRI) provide potentially new alternatives for pre-operative functional assessment, but the data on post-operative outcomes is less than the WADA test.

4:00 p.m. – 5:30 p.m.

Pediatric Epilepsy Highlights Session

Convention Center – Lila Cockrell Theatre

Note: number refers to poster assignment

This session will showcase selected scientific abstracts focused on topics in clinical care and research in pediatric epilepsy. Authors will present a six-minute overview of their work.

1.019 The Antiepileptic Effect of a Ketogenic Diet is Mediated by Adenosine A1 Receptors, *Susan Masino, T. Li, A. Rahman, B. Fredholm, J. Geiger, D. Boison*

1.179 Localization of Pediatric Seizure Semiology: A Review of 1008 Seizures, *Martina Vendrame, M. Zarowski, A. Alexopoulos, S. Kothare, T. Loddenkemper*

1.255 Adjunctive Therapy With Lacosamide For Extremely Refractory Epilepsy in Children, *Mary Gustafson, F. Ritter*

2.001 High Resolution Copy Number Variation of Ion Channel Genes in Epilepsy, *Alicia Goldman, T. Klassen, W. Gu, F. Zhang, V. Bomben, T. Chen, J. Lupski, J. Noebels*

2.031 Periodic Lateralized Epileptiform Discharges (PLEDs): Clinical Significance, Neuroimaging Findings, Etiology, and Outcome in 51 Infants and Children, *Ajay Gupta, A. Moosa*

2.097 Intelligence Relates to Structural Integrity of Normal Appearing White Matter in Tuberous Sclerosis Complex, *Suzanne Koudijs, J. van Campen, O. Braams, A. Leemans, O. van Nieuwenhuizen, K. Braun, F. Jansen*

2.221 Effect of Everolimus on Seizure Activity in Patients with Tuberous Sclerosis (TS), *Darcy Krueger, M. Care, K. Holland-Bouley, K. Agricola, C. Tudor, P. Mangeshkar, A. Weber-Byars, T. Sahmoud, D. Franz*

2.270 Temporal Lobe Epilepsy Surgery in Children: Considerations for Prognostic Predictors, *Yong Duck Park, B. Choi, S. Stickland, G. Lee, A. Murro, P. Culberson-Brown, M. Cohen, S. Miranda, J. Smith, M. Lee*

2.304 Centro-Median Deep Brain Stimulation (CM-DBS) in Patients with Refractory Secondary Generalized Epilepsy Previously Submitted to Callosal Section, *C. Cukiert, A. Cukiert, M. Argentoni-Baldochi, C. Baise, C. Forster, V. Mello, J. Burattini, P. Mariani*

2.338 Prevalence of Sleep Disorders Symptoms in Children With Epilepsy and Type 1 Diabetes, *Joshua Baron, R. Levy, B. Ostrander, C. Ray*

3.007 Blocking Early GABA Depolarization with Bumetanide Results in Permanent Alterations in Cortical Circuits and Sensorimotor Gating Deficits, *Doris Wang, A. Kriegstein*

3.261 Are AEDs Associated with Suicidal Ideation?, *David Dunn, C. Johnson, P. Fastenau, A. Byars, T. deGrauw, S. Perkins, J. Austin*

3.296 A Distinctive Seizure Type in Patients with CDKL5 Mutations: Hypermotor-Tonic-Spasms Sequence, *Karl Klein, S. Yendle, A. Harvey, G. Wallace, T. Bienvenu, I. Scheffer*

3.337 Adolescents in Transition: Developmental and Psychosocial Concerns for Youth with Intractable Epilepsy, *Sarah Ahlm, H. Kaplan, A. Berg, M. Forcier, D. Nordli*

4:00 p.m. – 6:15 p.m.

➤ Platform Sessions: 3 Concurrent Sessions

Convention Center – See page 54

There will be three concurrent sessions consisting of selected key scientific abstracts. Authors will present a ten-minute overview of their work followed by a five-minute Q & A.

6:30 p.m. – 8:30 p.m.

Pediatric State of the Art Symposium: Identifying and Managing the Comorbidities of Pediatric Epilepsy

(2.0 CME Credits)

Marriott Rivercenter – Grand Ballroom, Salon E/F

This session will highlight the following Benchmark goals:

III. Prevent, limit, and reverse the co-morbidities associated with epilepsy and its treatment.

A. Identify and characterize the full range and age specificity of comorbidities in people with epilepsy.
B. Identify predictors and underlying mechanisms that contribute to comorbidities.
C. Determine the optimal treatments for the neuropsychiatric and cognitive comorbidities in people with epilepsy.

Benchmarks Stewards: Anne Berg, Ph.D. and Amy Brooks-Kayal, M.D.
For more information, see p 53.

Overview

Children with epilepsy have an increased risk of neuropsychological and neuropsychiatric impairments that may predate seizure onset and can persist — even after seizures are medically controlled — into adulthood, and thus are arguably more impairing than seizures themselves. The comorbidities of pediatric epilepsy have historically been understudied, resulting in limited understanding of the scope and specifics of the impairments. Moreover, insufficient availability of mental health providers makes referrals difficult to find or delayed in taking place, obliging the epilepsy clinician to manage the comorbidities in the meantime. This symposium will characterize the cognitive phenotypes of pediatric epilepsy (beyond IQ), delineate the range and prevalence of psychiatric disorders, and provide practical recommendations for the clinician based on recent neuroimaging and outcome studies.

Learning Objectives

- Identify the range of psychiatric comorbidities evident in pediatric epilepsy and apply knowledge of psychiatric phenotypes to pediatric patients to know what questions to ask to screen for disorders
- Utilize a screening plan to provide initial care, including decisions regarding pharmacological treatment and when to refer to a mental health specialist
- Identify specific cognitive vulnerabilities in children with epilepsy and recognize associated neuroimaging evidence
- Apply knowledge of cognitive phenotypes to provide immediate, home-based recommendations (e.g., use of technology, internet).

Target Audience

Basic / fundamentals, Intermediate (see page 101 for details)

Program

Co-Chairs: Madison Berl, Ph.D. and Joseph Sullivan, M.D.

Opening Remarks
Joseph Sullivan, M.D.

Identifying Psychiatric Comorbidities of Pediatric Epilepsy
Elaine C. Wirrell, M.D.

Practical Suggestions for Treating and Monitoring Psychiatric Comorbidities and Pharmacological Interventions
Jay A. Salpekar, M.D.

Cognitive Phenotypes of Pediatric Epilepsy
Bruce P. Hermann, Ph.D.

Practical Suggestions for Cognitive Comorbidities
Madison Berl, Ph.D.

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 2.0 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit

ACPE Universal Activity Number (UAN) is 031-999-10-027-L01-P and provides 2 contact hours (.2 CEUs)

Notes

Educational Reflections

Want CME/CE credit?

Go to www.AESNET.org

See page 101 for further details

THE EPILEPSY RESEARCH BENCHMARKS

The Epilepsy Research Benchmarks were established by and for the epilepsy community to guide research toward cures, defined as no seizures and no side effects for people with epilepsy and the prevention of epilepsy in those at risk. First developed in 2000 and updated in 2007, the Benchmarks and their implementation are the shared responsibility of the entire epilepsy community, including NIH, extramural research scientists, epilepsy professional and patient organizations, and people with or affected by epilepsy. Beginning this year, the National Institute of Neurological Disorders and Stroke (NINDS), AES, and researchers who volunteer as Epilepsy Benchmarks Stewards are working together to highlight Benchmarks goals during the AES Annual meeting. In addition to the sessions specifically emphasized throughout this year's meeting program, we are impressed and encouraged by the number of other events and presentations that also fall within the scope of the Benchmarks. We look forward to hearing about progress made in all areas of the Benchmarks and to continuing our work together toward these goals in years to come.

Story C. Landis, Ph.D.
Director, National Institute of Neurological Disorders and Stroke

Jaideep Kapur, M.D., Ph.D.
President, AES
University of Virginia Health Sciences

Daniel H. Lowenstein, M.D.
Chair, Epilepsy Research Benchmarks
University of California, San Francisco

Benchmarks Area I: Prevent epilepsy and its progression.

A. Identify as yet unrecognized causes of epilepsy (e.g., genetic, autoimmune and infectious).
B. Identify underlying mechanisms of epileptogenesis.
C. Identify biomarkers for epileptogenesis.
D. Identify approaches to prevent epilepsy or its progression.
E. Develop new animal models to study epileptogenesis.
F. Test the efficacy of prevention strategies.

Benchmarks Area II: Develop new therapeutic strategies and optimize current approaches to cure epilepsy.

A. Identify basic mechanisms of ictogenesis (seizure generation) that will lead to the development of cures.
B. Develop tools that facilitate the identification and validation of a cure.
C. Optimize existing therapies and develop new therapies and technologies for curing epilepsy.

Benchmarks Area III: Prevent, limit, and reverse the comorbidities associated with epilepsy and its treatment.

A. Identify and characterize the full range and age specificity of comorbidities in people with epilepsy.
B. Identify predictors and underlying mechanisms that contribute to comorbidities.
C. Determine the optimal treatments for the neuropsychiatric and cognitive comorbidities in people with epilepsy.
D. Prevent or limit other adverse consequences occurring in people with epilepsy (including SUDEP, sleep disturbances, and endocrine, reproductive, bone-related or other systemic effects).
E. Develop effective methods for diagnosis, treatment and prevention of nonepileptic seizures (NES).

Area I Benchmarks Stewards

Ray Dingledine, Ph.D., Emory University School of Medicine
Jerome Engel, Jr., M.D., Ph.D., University of California at Los Angeles
Matthew Anderson, M.D., Ph.D., Harvard Medical School
Jocelyn F. Bautista, M.D., Cleveland Clinic
Solomon Moshé, M.D., Albert Einstein College of Medicine
Carl Stafstrom, M.D., Ph.D., University of Wisconsin

Area II Benchmarks Stewards

Edward Bertram, M.D., Ph.D., University of Virginia
Jacqueline A. French, M.D., New York University
Tracy A. Glauser, M.D., University of Cincinnati
Brian Litt, M.D., University of Pennsylvania
William H. Theodore, M.D., National Institute of Neurological Disorders and Stroke
H. Steve White, Ph.D., University of Utah
Karen Wilcox, Ph.D., University of Utah

Area III Benchmarks Stewards

Anne Berg, Ph.D., Northern Illinois University
Amy Brooks-Kayal, M.D., University of Colorado School of Medicine
John J. Barry, M.D., Stanford University
Bruce P. Hermann, Ph.D., University of Wisconsin
Ruben Kuzniecky, M.D., New York University
W. Curt LaFrance, Jr., M.D., Brown Medical School
John W. Swann, Ph.D., Baylor College of Medicine

Additional contributors to recent Benchmarks activities:

Area I: Aristea S. Galanopoulou, M.D., Ph.D., Albert Einstein College of Medicine; Annapurna Poduri, M.D., M.PH., Harvard Medical School; Michael Wong, M.D., Ph.D., Washington University
Area II: Chad Carlson, M.D., New York University; Greg Worrell, M.D., Mayo Clinic
Area III: Miya Asato, M.D., Children's Hospital of Pittsburgh; Timothy A. Benke, M.D., Ph.D., University of Colorado, Denver; Robert C. Doss, Psy.D., LP, ABPP-CN, Minnesota Epilepsy Group; Daniel L. Drane, Ph.D., ABPP-CN, Emory University School of Medicine; Alica Goldman, M.D., Ph.D., Baylor College of Medicine; Molly Huntsman, Ph.D., Children's National Medical Center; Jack J. Lin, M.D., University of California, Irvine; Alison Pack, M.D., Columbia University Medical Center; Page Pennell, M.D., Brigham and Women's Hospital; Elson So, M.D., Mayo Clinic; Mark Stewart, M.D., Ph.D., SUNY Downstate Medical Center; Tanvir Syed, M.D., M.PH., Case Western Reserve University; David Thurman, M.D., M.PH., Centers for Disease Control and Prevention

*For a detailed list of the 2007 Epilepsy Research Benchmarks and a review of recent advances, see the NINDS website: http://www.ninds.nih.gov/research/epilepsyweb/2007_benchmarks.htm.

Monday December 6, 2010 Platform Sessions

4:00 p.m. - 6:15 p.m.

	A. Translational Research *Convention Center – Room 202* Moderators: Karen S. Wilcox, Ph.D., Robert Brenner, Ph.D.	B. Surgery / Neuro-Imaging *Convention Center – Room 203* Moderators: Cynthia L. Harden, M.D., Lawrence J. Hirsch, M.D.	C. Clinical *Convention Center – Room 204* Moderators: Barbara E. Swartz, M.D., Ph.D., José E. Cavazos, M.D., Ph.D.
4:00 p.m.	**A.01** Mechanisms Of Axonal Suppression By High Frequency Stimulation/D. M. Durand, A. L. Jensen	**B.01** Pilot Study Of Parahippocampectomy: A New Surgical Approach, As Efective As Selective Temporal Lobe Resections, In Mesial Temporal Lobe Epilepsy/M. A. Alonso-Vanegas, C. Castillo Montoya, S. Perez Cardenas , J. Gordillo Espinoza, D. San Juan	**C.01** Over 10-30 Years Of Follow-Up, How Often Do People With Childhood-Onset Intractable Focal Epilepsy Have A Substantial But Temporary Remission?/C. S. Camfield, P. R. Camfield
4:15 p.m.	**A.02** Baboons And Humans: Comparison Of EEG Traits For Translational Research Purposes/ D. G. Kasteleijn-Nolst Trenite, C. A. Szabó, J. T. Williams	**B.02** Bilateral Posterior Periventricular Nodular Heterotopia: An Infrasylvian Syndrome/ S. A. Mandelstam, R. J. Leventer, A. Fischer, G. McGillivray, S. Robertson, S. F. Berkovic, G. D. Jackson, I. E. Scheffer	**C.02** Long-Term Follow-Up Of The RNS(TM) System In Adults With Medically Intractable Partial Onset Seizures/C. N. Heck, The RNS System Investigators
4:30 p.m.	**A.03** Silk-Based Adenosine Delivery: Therapeutic Tool To Prevent Seizures And Disease Progression/ T. Li, E. M. Pritchard, D. L. Kaplan, D. Boison	**B.03** Different Anatomical Correlates For Verbal Memory Impairment In Temporal Lobe Epilepsy/ S. G. Mueller, K. D. Laxer, C. Scanlon, P. Garcia, W. J. McMullan, D. Loring, K. J. Meador, M. W. Weiner	**C.03** Combined Analysis Of Risk Factors For SUDEP/D. C. Hesdorffer, T. Tomson, E. Benn, J. S. Sander, L. Nilsson, Y. Langan, T. S. Walczak, E. Beghi, M. Brodie, W. A. Hauser
4:45 p.m.	**A.04** Hippocampal Microseizures In Epileptogenesis/A. E. Musto, T. M. Quebedeaux, N. G. Bazan	**B.04** Subtle Imaging Findings Of The Hippocampus In Temporal Lobe Epilepsy/L. W. Ver Hoef, F. B. Williams, R. E. Kennedy	**C.04** Uncontrolled Epilepsy In A Medicaid Population/P. Paradis, R. Manjunath, M. Duh, M. H. Lafeuille, N. Mishagina, H. Parisé, L. Rovba, P. Lefebvre, E. Faught
5:00 p.m.	**A.05** Blood-Brain Barrier Disruption On T1-Weighted MRI Is A Biomarker For Seizure Susceptibility After Experimental Traumatic Brain Injury In The Rat/L. Frey, A. Lepkin, K. Hasebroock, N. Serkova	**B.05** Invasive Monitoring Using Depth Electrodes At A North American Center: A Prospective Study Analyzing The Feasibility And Safety Of Stereo-Electroencephalography (SEEG) In The Diagnosis And Treatment Of Intractable Epilepsy/ J. A. Gonzalez-Martinez, G. Hughes, T. Chen, J. Bulacio, N. So, W. Bingaman, L. Jeha, S. Hantus, I. Najm	**C.05** Continuous EEG Monitoring In Pediatric Moderate-Severe Traumatic Brain Injury/D. Arndt, M. Tripputi, A. Brooks-Kayal
5:15 p.m.	**A.06** Antiepileptic Actions Of A Novel AMPA GluR1 Splice Modulating Oligomer In A Model Of Neonatal Seizures/N. M. Lykens, D. J. Coughlin, J. M. Reddi, G. J. Lutz, M. K. Tallent	**B.06** Paucity Of Hippocampal Digitations Detected By 7 Tesla MRI In TLE With Hippocampal Sclerosis/T. R. Henry, M. Chupin, S. Lehericy, J. P. Strupp, M. A. Sikora, Z. Y. Sha, K. Ugurbil, P. F. Van de Moortele	**C.06** Mortality In Epilepsy – Results From A Large Danish Cohort/J. Christensen, C. B. Petersen, P. C. Sidenius, J. Olsen, M. Vestergaard
5:30 p.m.	**A.07** EEG Phenotypes In An Extended Baboon Pedigree/C. A. Szabo, K. Knape, F. S. Salinas, M. M. Leland, J. T. Williams	**B.07** Surgical Outcome In Subdural Grid-Based Neocortical Epilepsy Resections/R. C. Knowlton, W. H. Matthews, S. R. Miller, L. W. Ver Hoef, A. L. Paige, J. DeWolfe, R. A. Elgavish, J. Blount, K. O. Riley	**C.07** Cognitive Functions At Age 4.5 Years In Children Exposed In Utero To Antiepileptic Drug/ K. J. Meador, G. A. Baker, N. Browning, J. Clayton-Smith, M. Cohen, T. Crawford, L. Kalayjian, A. Kanner, J. Liporace, P. Pennell, M. Privitera, D. Loring, A. NEAD Study Group
5:45 p.m.	**A.08** Rapamycin Attenuates The Increases In Seizure Susceptibility And Neuronal Excitability Following Neonatal Seizures In Rat/D. Talos, H. Sun, M. C. Jackson, A. Joseph, E. C. Fitzgerald, F. E. Jensen	**B.08** Phosphorus Magnetic Resonance Spectroscopy At High Field In Patients With Malformations Of Cortical Development/ C. S. Andrade, M. C. Otaduy, D. F. Maia, K. Valente, C. C. Leite	**C.08** Hippocampal Growth In Children Is Not Affected By Prolonged Seizures/M. Yoong, M. Martinos, C. Clark, R. Chin, R. Scott
6:00 p.m.	**A.09** Multiplexed, High-Density Active Electrodes Using Flexible Silicon Electronics/J. Viventi, D. Kim, L. Vigeland, D. Contreras, J. Rogers, B. Litt	**B.09** Orbitofrontal Thinning In Association With Depressive Symptoms In Patients With Extratemporal Partial Epilepsy/T. Butler, K. Blackmon, C. McDonald, W. Barr, O. Devinsky, R. Kuzniecky, B. Quinn, J. DuBois, C. Carlson, J. French, D. Hagler, E. Halgren, T. These	**C.09** Lateralization Of Temporal Lobe Epilepsy With Long-Term Ambulatory Intracranial Monitoring Using The RNS™ System: Experience At 4 Centers/ D. King-Stephens, E. Mirro, P. Van Ness, V. Salanova, D. Spencer

➤ **Authors Present: Noon – 2:00 p.m.**
➤ **Poster Walking Tours (see page 12 for details)**

Translational Research
Animal Models

3.001 Adenosine Kinase Is A Target For Therapeutic Antisense Strategies In Epilepsy/P. Theofilas, S. Brar, K. Stewart, U. Sandau, D. Poulsen, D. Boison

3.002 Single-Cell Knockout Of Tsc1 In Utero Generates Cortical Tuber-Like Lesions And Heterotopic Nodules With Cytomegalic Neurons/D. Feliciano, T. Su, A. Bordey

3.003 ADK Antisense Virus Reduces Seizure Susceptibility Following Severe Traumatic Brain Injury/T. Lusardi, N. Lytle, D. Boison

3.004 Loss Of GABAergic Tonic Inhibition In A Mouse Model Of Absence Epilepsy Correlates With Decreased Thalamocortical Bursting In Vitro/K. Mangan, S. Petrou, S. Johnson, K. Hengen, M. Jones

3.005 Which Type Of Adenosine Receptors May Suppress Cortical Epileptic After Discharges?/P. Mares

3.006 Long-Lasting Alterations In NKCC1 And KCC2 Expression Induced By Evoked And Spontaneous Seizures In Kindled Epileptic Rats/T. Sutula, K. Gielissen, S. Osting, D. Sun

3.007 Blocking Early GABA Depolarization With Bumetanide Results In Permanent Alterations In Cortical Circuits And Sensorimotor Gating Deficits/D. Wang, A. Kriegstein

3.008 Alterations Of Intrinsic Membrane Properties And Excitatory-Inhibitory Tone In CA3 Pyramidal Neurons In Young Adult And Aged Fischer 344 Rats Following Sensorimotor Cortical Photothrombosis/H. Xu, D. Shiau, Z. Mtchedlishvili, K. Kelly

3.009 Altered Synaptic Input Produces Quiescent Interneurons In Experimental Cortical Dysplasia/ F. Zhou, S. Roper

3.010 Effect Of Central 5-HT Neuron Deletion On Post-Ictal Respiration, Seizure-Susceptibility And Seizure-Related Mortality/G. Buchanan, G. Richerson

3.011 Increased Interconnectivity Between Hippocampal Lamellae Might Contribute To Circuitry Hyperexcitability In Experimental Temporal Lobe Epilepsy/J. Cavazos, G. Tolstykh

3.012 New Insights Into Mechanisms Of Cryptogenic Infantile Spasms From An Animal Model/T. Chachua, M. Yum, J. Veliskova, L. Velisek

3.013 Adult Human Neuronal Progenitors Generate Functional Neurons In Rat Neocortex/H. Chen, F. Siebzehnrubl, F. Zhou, D. Steindler, S. Roper

3.014 Detectable Blood And Brain Concentrations Of The NKCC1 Inhibitor Bumetanide Following Anticonvulsant Doses/R. Cleary, Y. Li, M. Jackson, B. Kosaras, J. Soul, G. Berry, F. Jensen

3.015 Epilepsy-Induced Pathologic Plasticity And NMDA Alterations In The Malformed Brain Of Human FCD Patients And MAM-Pilocarpine Rat Model/F. Colciaghi, A. Finardi, P. Nobili, A. Frasca, L. Castana, G. LoRusso, A. Vezzani, G. Battaglia

3.016 Lipopolysaccharide Potentiates Hyperthermia Induced Seizures: Development Of A New Model Of Prolonged Febrile Convulsions/B. Eun, M. Kim, S. Koh

3.017 Plasticity In The Pathway From Amygdala To Periaqueductal Gray (PAG) Is An Important Mechanism Of Epileptogenesis In Audiogenic Kindling (AK)/C. Faingold, S. Tupal

3.018 Minocycline Ameliorates Cerebral Lesions But Not Decreases Spontaneous Recurrent Seizures After Pilocarpine-Induced Status Epilepticus/ M. Foresti, G. Arisi, L. Shapiro

3.019 Ictal Death In Dravet Syndrome Model Mice/Y. Horigome, H. Ohtani, Y. Inoue, S. Sakai, I. Ogiwara, K. Yamakawa, Y. Takahashi

3.020 Occurrence Of Spontaneous Seizure Activity In A Bilateral Prenatal Freeze-Lesion Rat Model/T. Kamada, W. Sun, K. Takase, H. Shigeto, J. Kira

3.021 Humanized Mouse Models Of Epilepsy/J. Kearney

3.022 Thalamic Kindling In Rats With Genetic Absence Epilepsy/M. Kendirli, F. Onat, E. Bertram

3.023 Deficits In Memory And Social Behavior Following Seizures Early In Life/J. Lugo, K. Winoske, J. Swann, A. Anderson

3.024 Minocycline Reverses Anhedonia In An Animal Model Of Comorbidity Between Epilepsy And Depression/ A. Mazarati, E. Pineda, R. Sankar, D. Shin

3.025 Electrophysiological Investigation Of Hippocampal Neurogenesis Induced By Epilepsy/ M. Nakajima, H. Sugano, T. Higo, H. Ohkura, Y. Ilmura, K. Nishimura, H. Arai

3.026 Mechanism-Based Combination Drug Therapy In A Mouse Model Of Severe Myoclonic Epilepsy In Infancy/ J. Oakley, F. Kalume, R. Westenbroek, T. Scheuer, W. Catterall

3.027 Treatment With Lacosamide Impedes Generalized Seizures In Rodent Model Of Cortical Dysplasia/ R. O'Dwyer, A. Nemes, I. Najm, A. Alexopoulos

3.028 Functional Studies Of Interleukin 1-Beta In The Pilocarpine Rat Model Of Epilepsy Using Rna Interference/V. Pascoal, R. Marchesini, A. Matos, T. Pereira, R. Gilioli, J. Malheiros, R. Polli, A. Tannús, L. Covolan, E. Cavalheiro, F. Cendes, I. Lopes-Cendes

3.029 Pentylenetetrazole-Induced Neonatal Seizures In Transgenic Knock-In Mice Lacking GluR1 Phosphorylation Reveal Critical Role Of AMPA Phosphorylation In Epileptogenesis/ S. Rakhade, C. Zhou, M. Jackson, E. Fitzgerald, P. Klein, R. Huganir, F. Jensen

3.030 The Interactions Of Interleukin-18 And Interferon-γ On The Neuroprotection In The Rat Hippocampus Following Status Epilepticus/H. Song, D. Shin, H. Ryu, S. Suh, T. Kang, H. Choi

3.031 Circadian Rhythm Of Core Body Temperature In An Animal Model Of Chronic Epilepsy/S. Talathi, J. Zhao, A. Cadotte, P. Carney

3.032 CCL2 Is Rapidly Increased In Piriform Cortex, Hippocampus, And Neocortex But Not In Cerebellum After Pilocarpine-Induced Seizures/G. Arisi, M. Foresti, K. Katki, L. Shapiro

3.033 Comparison Of Two Seizure Threshold Rat Models For Evaluation Of Proconvulsant Drug Properties/ M. Bankstahl, J. Bankstahl, W. Löscher

3.034 Spontaneous Infantile Spasm-Like Events Provoked By Chonic Early Life Stress: A New Model Of Idiopathic Infantile Spasms That Explains The Efficacy Of ACTH?/C. Dube, A. Ivy, E. Kleeman, Y. Alaghband, M. Pakhdikian, M. Look, T. Baram

3.035 A Blind Randomized Study Of Anti-Epileptic And Anti-Epileptogenic Effects Of Carisbamate On Posttraumatic Epilepsy In The Rat/ C. Eastman, J. Fender, D. Verley, T. Stewart, G. Curia, E. Nov, R. D'Ambrosio

3.036 Differential Neuronal Activation Pattern And Seizure Susceptibility In Newborn Rat Pups Following Maternal Stress And Immune Challenge/ M. Esser, A. Reid, Q. Pittman

3.037 Confirmation Of Multiple Seizure Susceptibility QTLs On Chromosome 15 In C57BL/6J And DBA/2J Inbred Mice/T. Ferraro, G. Smith, C. Schwebel, G. Doyle, S. Ruiz, J. Oleynick, F. Lohoff, W. Berrettini, R. Buono

3.038 Antiepileptic Drugs (AEDs) In Neonatal Rats Disrupt Striatal Synaptic Maturation/P. Forcelli, M. Janssen, S. Vicini, K. Gale

3.039 Early Life Status Epilepticus Compromises Nonassociative Learning And Increases Anxiety In Juvenile Rats/H. Kubova, P. Mares

3.040 Stroke-Related Hyper Excitability In A Novel Acute In Vitro Model Of Focal Ischemia/L. Librizzi, G. Breschi, M. de Curtis

3.041 Animals With Malformations Of Cortical Development Have Relatively Normal Eeg And Place Cell Characteristics/M. Lucas, P. Lenck-Santini, G. Richard, G. Holmes, R. Scott

3.042 High Dose Phenobarbital Decreased Seizure Suppression And Lost Neuroprotection, Compared To Low Dose, In Immature Mouse Model Of Stroke/G. Markowitz, S. Kadam, D. Smith, M. Johnston, A. Comi
3.043 Spontaneous Convulsive Seizures And Spike-Wave Discharges In Aged Alzheimer's Disease Mice/ H. Nygaard, S. Strittmatter
3.044 Modification Of Status Epilepticus Models To Simulate Temporal Lobe Epilepsy Without Extensive Brain Damage/ A. Poveda-Ramos, J. D'Amour, D. Friedman, J. LaFrancois, N. MacLusky, H. Scharfman
3.045 Low Blood Glucose Increases Absence Seizure Susceptibility/C. Reid, T. Kim, S. Berkovic, S. Petrou
3.046 Acute Aβ Neurotoxicity Induces Hippocampal Sclerosis With Seizures Independent Of Alzheimer's Pathology/U. Sandau, A. Rahman, D. Blum, D. Boison
3.047 Estimating State-Of-Vigilance Dynamics To Improve Prediction Of Epileptic Seizures/M. Sedigh-Sarvestani, B. Gluckman, S. Schiff
3.048 Brd2 Haploinsufficiency Predisposes For GABA Downregulation, Increased Seizure Susceptibility, And Spontanteous Seizures/L. Velisek, E. Shang, J. Veliskova, T. Chachua, G. Maglakelidze, S. Macchiarulo, D. Wolgemuth, D. Greenberg
3.049 A Potential Treatment For Infantile Spasms: An Evidence From The Animal Model Of Cryptogenic Infantile Spasms/M. Yum, T. Chachua, J. Veliskova, L. Velisek
3.050 EEG Correlates Of Catamenial Epilepsy In Intact Female Rats/ J. D'Amour, D. Friedman, A. Poveda, T. Radman, J. LaFrancois, C. Schevon, R. Emerson, C. Schroeder, N. MacLusky, H. Scharfman
3.051 Intrapulmonary Midazolam Protects Against Chemoconvulsant Seizures In Mice/A. Dhir, D. Zolkowska, M. Rogawski
3.052 Genetic And Behavioural Characterization Of A Rodent Model Of Depression And Epilepsy CoMorbidity/ S. Alisha Epps, K. Tabb, S. Lin, K. Boss-Williams, J. Weiss, D. Weinshenker
3.053 Fast Ripples In An Experimental Non-Lesional Temporal Lobe Epilepsy/ J. Jefferys, P. Jiruska, G. Finnerty, A. Powell, N. Lofti, R. Cmejla
3.054 Long-Duration Epileptiform Activity In Mouse Neocortical Slices Associated With Zero Mg^{2+} /High K^{+} Conditions: An *In Vitro* Seizure Model/M. Király, F. Ben Mabrouk, A. Tryba, C. Marcuccilli
3.055 Electrochemical Analysis Of An Acute Swine Model Of Cortical Epileptiform Activity: Adenosine's Rise And Fall/J. Van Gompel, M. Bower, M. Stead, B. Brinkmann, S. Chang, I. Kim, S. Goerss, W. Marsh, F. Meyer, C. Kimble, B. Winter, K. Bennet, G. Worrell, K. Lee
3.056 Alteration Of Wnt Signaling Following Status Epilepticus/A. Yee, J. Wojcik, K. Saul, K. Paulson, M. Gonzalez, A. Yee
3.057 Comparison Of Acute Electrographic Abnormalities In A Rat Model Of Hypoxia/Hypoxia-Ischemia/ A. Zayachkivsky, M. Lehmkuhle, J. Ekstrand, F. Dudek
3.058 Investigating The Risk Of Seizure At High Frequency Repetitive Transcranial Magnetic Stimulation Using Epileptic And Control Non-Human Primates/S. Narayana, F. Salinas, W. Zhang, M. Leland, C. Szabo
3.059 Enhanced Excitability And Epileptogensis On Hippocampal CA3 In EL Mice/K. Oguro, H. Yokota, K. Shimazaki, Y. Murashima, E. Watanabe
3.060 Frontal Cortex Requires Optimal Parvalbumin Interneurons For Seizure Prevention And Cognition/ J. Xu, G. Bissonette, E. Powell

Translational Research
Devices, New Technology
3.061 Physiologic Sensor Array To Identify Generalized Seizures In Children In A Residential Setting/ B. Kroner, A. Pitruzzello, J. Shorey, W. Gaillard, D. Strubé
3.062 A Closed-Loop Implantable Device For Epileptic Seizure Detection And Neurostimulation/M. Salam, F. Mounaim, M. Sawan, D. Nguyen
3.063 Mouse Embryonic Stem Cell-Derived Pyramidal Neurons Are Able To Survive In A Kainic Acid Cortical Lesion And In A Sclerotic Hippocampus/P. Boon, I. Dauwe, K. Michelsen, S. Acosta, T. Wyckhuys, A. Van Dycke, K. Vonck, W. Wadman, P. Vanderhaeghen, R. Raedt
3.064 On-Demand Pulsatile Intracerebral Delivery Of Carisbamate Concurrent With Closed-Loop Direct Neurostimulation Therapy In A Self-Sustained Limbic Status Epilepticus (SSLSE) Rat Model/E. Mangubat, M. Rossi
3.065 This poster has been changed to Platform A.09
3.066 Poisson Distributed High Frequency Hippocampal Stimulation Suppresses Epileptic Seizures In The Kainate Rat Model/T. Wyckhuys, P. Boon, R. Raedt, B. Van Nieuwenhuyse, K. Vonck, W. Wadman
3.067 Effect Of Transcutaneous Electrical Stimulation On Pentylenetetrazole-Induced Seizure Activity Synchrony In Beta And Gamma Bands In Rats/W. Besio, X. Liu, L. Wang, A. Medvedev, K. Koka
3.068 Muscimol-Delivering Subdural Pharmacotherapy Device For The Treatment Of Intractable Neocortical Epilepsy: Preliminary Safety And Efficacy Studies In Freely-Behaving Bonnet Macaques/N. Ludvig, H. Tang, S. Baptiste, G. Medveczky, J. Kral, C. Novotney, J. Charchaflieh, J. French, O. Devinsky, C. Carlson, R. Kuzniecky
3.069 Convection-Enhanced Delivery Of Levetiracetum For Treatment Of Epilepsy/S. Osawa, M. Iwasaki, N. Nakasato, T. Tominaga
3.070 Vagus Nerve Stimulation-Induced Increase In Hippocampal Noradrenaline Levels Is Responsible For The Control Of Limbic Seizures/ R. Raedt, R. Clinckers, L. Mollet, K. Vonck, R. El Tahry, T. Wyckhuys, V. De Herdt, E. Carrette, W. Wadman, I. Smolders, Y. Michotte, P. Boon, A. Meurs
3.071 Control Of A Visual Keyboard Using An Electrocorticographic Brain-Computer Interface/J. Shih, D. Krusienski
3.072 Rapid Termination Of In Vivo Neocortical Seizures By Photorelease Of GABA With A Blue Light Emitting Diode/X. Yang, D. Rode, D. Peterka, R. Yuste, S. Rothman
3.073 Evaluation Of StatNet Device For Rapid EEG Recordings/T. Pang, M. Selvitelli, F. Drislane, S. Herman, K. Krishnamurthy, S. Schachter, L. Walker, D. Schomer

Clinical Epilepsy
Clinical Treatments
3.074 Changes In Efficacy Of Vagus Nerve Stimulation (VNS) Over Time: Review Of 65 Consecutive Patients With Treatment-Resistant Epilepsy Treated With VNS ≥ 10 Years/ R. Elliott, A. Morsi, A. Silverberg, C. Carlson, E. Geller, O. Devinsky, W. Doyle
3.075 Surgical Treatment Of The Patients With Rasmussen's Encephalitis (20 Cases)/G. Luan, Y. Guan
3.076 Status Epilepticus In A Veteran Population: Causes, Treatment Approaches And Outcomes In 72 Patients/V. Nguyen, L. Pham, S. Dergalust
3.077 Refractory Status Epilepticus In Children: Clinical And Continuous Electroencephalogram Monitoring Characteristics And Response To Treatment/K. Acevedo, I. Cardoso, T. Mesa, S. Uribe, P. Moya, J. Godoy, J. Santin
3.078 Effects Of Vagal Nerve Stimulation On Patients With Epilepsy And Mental Retardation/K. Bohlmann, A. Friedo, H. Straub
3.079 Lacosamide As Add-On Therapy In Pediatric Epilepsy: Retrospective Clinical Experience/M. Chez
3.080 Pilot Feasibility Trial Of The Acute And Long-Term Safety Of External Trigeminal Nerve Stimulation For Epilepsy/C. DeGiorgio, J. Pop

3.081 Medical Simulation Of Sentinel Events: Validation And Implementation Of A Team Training Curriculum For Patient Safety In The Epilepsy Monitoring Unit (EMU)/B. Dworetzky, S. Peyre, E. Bubrick, T. Milligan, H. Doucette, M. Gulley, C. Pozner
3.082 Selective Serotonin Reuptake Inhibitors: A Safe Treatment For Depression In Children With Refractory Epilepsy/N. Fonseca, E. Oliveira, S. Thome-Souza, E. Kuczynski, K. Valente
3.083 Continuous Midazolam Infusion Use In The Cessation Of Neonatal Status Epilepticus While On Continuous Video EEG Monitoring/E. Freilich, T. Tsuchida, J. Scafidi, T. Chang
3.084 Predictors For Seizure Outcome In A Prospective AVM Database Using Multimodal Treatment Strategies/V. Geib, B. Pohlmann-Eden, M. Wallace, D. Cook
3.085 The Effects Of Intracranially-Placed Electrodes For Epilepsy Surgery In Seizure Frequency/M. Hamilton, D. Steven, J. Burneo
3.086 Propofol Infusion Syndrome In Patients With Intractable Status Epilepticus/D. Koo, W. Hwang, E. Joo, D. Seo, K. Ji
3.087 Selenium Status Of Children Treated With The Classic And Medium-Chain Triglyceride (MCT) Ketogenic Diets/Y. Liu, H. Lowe, M. Zak, V. Chan, J. Kobayashi, E. Donner
3.088 Use Of Nutritional Supplements And Recreational Substances In Adults With Epilepsy In Tertiary Care/C. Ma, S. Macrodimitris, P. Federico, N. Jette, M. Lowerison, W. Murphy, N. Pillay, A. Hanson, S. Wiebe
3.089 Intraoperative Electrocorticography In Temporal Lobe Epilepsy Surgery/K. Medani, E. Bubrick, T. Loddenkemper, J. Madsen, B. Dworetzky
3.090 Effect Of Seizures On Cognition, Behavior, And Quality Of Life During Carbamazepine Or Lamotrigine Monotherapy In Patients With Newly Diagnosed Partial Epilepsy/K. Ju, S. Lee, H. Lee, K. Heo, D. Shin, H. Song, O. Kim, S. Lee, S. Kim, B. Lee
3.091 Factors Contributing To Driving In Patients With Epilepsy In Korea/ Y. No, S. Lee, H. Park, S. Lee
3.092 Lacosamide In The Treatment Of Acute Recurrent Seizures And Periodic Epileptiform Activity In Critically Ill Patients/K. Parkerson, C. Reinsberger, S. Chou, B. Dworetzky, J. Lee
3.093 Callosotomies In Sweden 1990-2004: Data From The The Swedish National Epilepsy Surgery Register/B. Rydenhag, I. Olsson, H. Silander, R. Flink
3.094 Similar Response To Antiepileptic Medications Among Epileptic Siblings/H. Sonmezturk, B. Abou-Khalil
3.095 Outcome Of Patients Undergoing Hemispherectomy For Rasmussen Encephalitis Receiving An Intensive Post Surgical Rehabilitation Programme/S. Aylett, P. Kashyape, V. Burch, E. Tingley, J. Norrington, J. Chitty, S. Harrison, P. Rankin, W. Harkness, J. Cross
3.096 Intravenous Lacosamide In The Treatment Of Status Epilepticus/ B. Berger, A. Crepeau, S. Chung, R. Maganti
3.097 To Evaluate The Tolerability Of Lacosamide As Add-On Therapy To Either Non-Sodium Channel Blocking Or Traditional Sodium Channel Blocking Anticonvulsant Agents/M. Frey, M. Denny, D. Zielinski, J. Gattone, L. Bogojevich, A. Kanner, G. Stebbins
3.098 Post Hypothermic Status Epilepticus – Is It Treatable?/J. Gill, J. Narayanan
3.099 Treatment Of Electrical Status Epilepticus In Slow-Wave Sleep With High-Dose Oral Diazepam/S. Hussain, J. Matsumoto, J. Lerner, C. Szeliga, J. Wu, P. Sharifi-Hannauer, W. Shields, R. Sankar
3.100 Surgical Prognostic Factor For MRI-Negative Temporal Lobe Epilepsy/ Y. Iimura, H. Sugano, M. Nakajima, T. Higo, H. Arai
3.101 Long Term Prognostic Factors After Hemispherotomy In Catastrophic Epilepsy/J. Lee, S. Kim, H. Kang, D. Kim, H. Kim
3.102 Obstructive Sleep Apnea In An Epilepsy Population/P. Li, S. Ghadersohi, B. Jafari, M. Sazgar
3.103 Allergic Rash With Generic Substitution: When To Leave Well Enough Alone/M. Lowe, E. Serrano, C. Harden
3.104 Characteristics Of Intractibility In A Community-Based Epilepsy Surgery Program/P. Lyons, C. Bradley, L. Phillips, L. Selznick
3.105 Evaluating The Concerns Of Pregnant Women With Epilepsy: A Focus Group Approach/J. McAuley, C. Patankar, C. Lang, M. Prasad, P. Samuels
3.106 Recurrence Of Seizures In Sreat After Discontinuation Of Immunomodulation/D. McDermott, R. Kemp, L. Strom
3.107 A Pilot Study Of Nonepileptic Seizures (NES): Support And Education At The Time Of Diagnostic Disclosure/W. Nowack, N. Thompson, J. Peltzer, L. Connelly, I. Osorio, M. Kavalir, E. Hamera, B. Gajewski, N. Hammond, E. Hunter
3.108 Lacosamide In Progressive Myoclonic Epilepsy Type 1: A Case Report/K. Polovitz, M. Spitz
3.109 The Curious Case Of Seizure Remission In A Patient With Refractory Bitemporal Epilepsy: Role Of Neutropenia?/E. Tecoma, R. Compton, V. Iragui-Madoz
3.110 Efficacy And Safety Of Adjuvant Intravenous Lacosamide In Children With Intractable Epilepsy/G. Yadava, G. Phillipps, A. Hussein
3.111 Efficacy And Tolerability Of Lacosamide In Refractory Epilepsy/Maria Aguilar Amat Prior, V. Ivañez Mora
3.112 Topiramate Is Effective For Status Epilepticus And Seizure Control In Neuraminidase Deficiency/ J. Bragatti, C. Torres, C. Netto, L. Vedolin, E. Garzon, C. Rieder, I. Schwartz, M. Bianchin
3.113 Epilepsy In Children Hashimoto Encephalopathy/D. Dees, P. Maertens, C. Bullock, R. Vidal
3.114 New Onset Refractory Status Epilepticus/S. Gonzalez Reiley, G. Chari, N. Peguero, M. Ramirez
3.115 Intractable Epilepsy And SCN1A Mutations: Clinical Characterization, Treatment Options And Outcome/ A. Hall, M. Guerra, G. VonAllmen, J. Baumgartner
3.116 Improving The Patient Experience For Families With Children Undergoing Vagus Nerve Stimulation Therapy: A Qualitative Study/ S. Hannan, J. Cross, M. Colonnelli, W. Harkness, S. Varadkar
3.117 Electrical Status Epilepticus During Slow Sleep: A Review Of 7 Pediatric Cases/G. Hmaimess, I. Dabaj, H. Mansour
3.118 Lamotrigine Is Favorable For Startle-Induced Seizures/H. Ikeda, K. Imai, H. Ikeda, T. Shishido, R. Takayama, Y. Takahashi, Y. Inoue
3.119 Add-On Lacosamide In Refractory Focal Epilepsy. Which Other AED?/V. Ivanez Mora, M. Aguilar-Amat
3.120 Long-Term Outcome Of Ethosuximide, Valproic Acid, And Lamotrigine, In Childhood Absence Epilepsy : A Single Center Observational Outcome Study/H. Kim, S. Kim, S. Kim, S. Kim, J. Lee, B. Lim, H. Hwang, J. Choi, J. Chae, K. Kim, Y. Hwang
3.121 Electroretinogram Changes In A Paediatric Population With Epilepsy – Is Vigabatrin Acting Alone?/B. McCoy, T. Wright, C. Westall, S. Weiss, C. Go
3.122 Efficacy And Tolerability Of Vimpat In Patients With Intractable Epilepsy/D. Mungall, R. Castillo, B. Kirmani
3.123 Neurodevelopmental Outcome In Children Exposed To Antiepileptic Drugs In Utero/G. Pushchinska, N. Dzhafarova, T. Bindra, M. Andriola, R. Spiegel
3.124 Adults With Epilepsy In Tertiary Care: Risk Factors, Seizure Triggers And Psychiatric Comorbidity/S. Save, S. Macrodimitris, P. Federico, A. Hanson, N. Jette, B. Klassen, W. Murphy, N. Pillay, M. Lowerison, S. Wiebe
3.125 Ablative Temporal Lobe Epilepsy Surgery Should Be Considered In Patients With A Pre-Existing Liver Transplantation/M. Spitz, S. Moreland, L. Frey, C. O'Brien, A. Shrestha, L. Strom
3.126 Pharmacotherapy Of Non-Idiopathic Partial Epilepsies Based On Precise Seizure Symptoms: A Prospective Study/K. Sugai, E. Nakagawa, H. Komaki, Y. Saito, H. Sakuma, M. Sasaki

3.127 Topiramate In Refractory Status Epilepticus: Experience From A Tertiary Care Center/A. Synowiec, K. Yandora, K. Kelly, J. Valeriano
3.128 Analysis Of Prognostic Factors Of Vagus Nerve Stimulation For Refractory Epilepsy – Review Of 40 Cases/M. Bao, G. Luan
3.129 The History Of The FDA 80-125 Rule For Bioequivalence Of Generic Drugs Including AEDs/M. Berg, M. Privitera, B. Gidal, J. Cloyd, T. Welty, R. Sawchuk
3.130 Basal Ganglia Injury Due To Prior Temporal Lobe Surgery: Variable Expression Of Movement Disorder After Subsequent Epilepsy Surgery In Children/S. Wolf, P. McGoldrick, A. Hussein, N. Lubarr, S. Ghatan

Clinical Epilepsy
Prognosis
3.131 Seizure Control Is One Of Many Factors Determining The Quality Of Life In Epilepsy Patients/L. Jehi, G. Tesar, I. Katzan, J. Bautista, A. Alexopoulos, N. Foldvary-Schaefer, S. Hantus, D. Nair, S. Neme-Mercante, D. Silveira, N. So, A. Stojic, I. Najm
3.132 Following A First Unprovoked Seizure When Is The Risk Of A Reccuence Low Enough To Restart Driving? Further Analysis Of The MESS Study/T. Marson, L. Bonnett, C. Tudur Smith, P. Williamson
3.133 Utility Of Imaging In Status Epilepticus/L. Morton, L. Kopec, V. Ramakrishnan, A. Towne, E. Waterhouse, L. Kernitsky, R. DeLorenzo
3.134 Response To First Antiepileptic Drug Trial Predicts Health Outcome In Epilepsy/P. Perucca, F. Gilliam
3.135 The Effect Of Seizures On Outcome In Neonatal Ischemic Stroke/J. Pablo Appendino, M. Cortez, G. deVeber, H. Otsubo, M. Moharir
3.136 Increased Incidence Of Sudden Unexpected Death In Epilepsy (SUDEP) With Lamotrigine In Rogaland County, Norway/D. Aurlien, J. Larsen, E. Taubøll, L. Gjerstad
3.137 Perinatal Stroke And The Risk Of Developing Epilepsy/M. Balestri, F. Del Balzo, D. Longo, M. Soldati, F. Greco, A. Spalice, M. Cilio
3.138 Rhythmical And Periodic Patterns In Adults With Aneurysmal Subarachnoid Hemorrhage And Altered Mental Status/A. Crepeau, K. Chapman, A. Little, G. Parikh, P. Gerber, H. Jahnke, P. Nakaji, J. Kerrigan
3.139 Seizure Outcome In Patients With Intellectual Disability/P. Modur, W. Milteer, R. Bhupalam, S. Zhang
3.140 The Effect Of Lead Time To Treatment And Of Age Of Onset On Developmental Outcome In Infantile Spasms: Evidence From The United Kingdom Infantile Spasms Study (UKISS)/F. O'Callaghan, A. Lux, K. Darke, S. Edwards, E. Hancock, A. Johnson, C. Kennedy, R. Newton, C. Verity, J. Osborne
3.141 The Duration Of The Negative Myoclonias Is A Main Reason For The Progression In Locomotory Disability In Patients Suffering From Unverricht-Lundborg Disease/H. Vogt, T. Baisch, I. Mothersill
3.142 How Do Neurologists Use EEGs When Withdrawing AEDs In Seizure-Free Patients? Results Of An International Internet-Based Questionnaire/P. Bergin, W. D'Souza, E. Beghi, M. Richardson, J. Burneo, Z. Mogal, B. LeGros, A. Raymond
3.143 Use Of A New Disability Scale-SERDAS In Epilepsy Patients/ E. Burakgazi-Dalkilic, J. Pollard, A. Thaler, J. French
3.144 Abnormal MRI Is A Predictor Of Poor Outcome In Focal Epilepsy/ D. Consalvo, M. Kauffman, S. Oddo, B. Giagante, S. Kochen
3.145 Neuropathological Study Of Medically Intractable Mesial Temporal Lobe Epilepsy (MTLE): Histological & MRI Classification Of Hippocampal Sclerosis And Its Clinical Relevance/ T. Hori, H. Miyata, S. Kondo
3.146 Seizures After Hematopoietic Stem Cell Transplantation In Children/ I. Lee, S. Kim, H. Hwang, J. Bin, Y. Kim, S. Chung
3.147 New Onset Critical Seizures In The Elderly: Experience From A Tertiary Care Centre From South India/ S. Sinha, P. Satishchandra, K. Thennarasu, K. Balaji
3.148 Postoperative Interictal Epileptiform Discharge Within One Month Is Associated With Seizure Recurrence After Anterior Temporal Lobectomy/H. Yu, D. Yen, C. Yiu, Y. Lin, S. Kwan, C. Chen, S. Hsu, Y. Shih
3.149 Progressive Deterioration Of Heart Rate Variability Prior To SUDEP/ A. DeGiorgio, G. Rausch, P. Miller, C. DeGiorgio
3.150 Does Seizure-Related Head Injury Influence Health Related Quality Of Life In People With Epilepsy?/ D. Friedman, X. Li, H. Levin
3.151 A Case Of Non-Herpetic Acute Limbic Encephalitis With Severe Psychiatric Symptoms/M. Fukuda, Y. Takahashi, H. Yamamoto
3.152 Favorable Outcome In Near SUDEP Followed By Refractory Status Epilepticus/G. Ghearing, A. Bhatt, A. Delios
3.153 Central Ictal Apnea As A Risk Factor For Subsequent SUDEP/ S. Schuele, Z. Afshari, E. Gerard, M. Macken
3.154 Clinical Characteristics And Outcomes Of Neonatal Seizures In A Single Center/J. Yu, K. Hong, J. Park, Y. Chang
3.155 Outcome Of Patients With PLEDs During Continuous EEG Monitoring/C. Lamar, J. Boggs, M. Sam, W. Bell, C. O'Donovan

Neuro-Imaging
Animal Studies
3.156 Optical Imaging Of Primate Neocortex Using Oxygen-Sensing Nanoparticles/D. Hochman, M. Haglund, G. Palmer, G. Zhang, C. Fraser
3.157 Noninvasive Imaging Of Epilepsy Using Fast Diffuse Optical Tomography/ R. Jiang, Z. Yuan, Q. Zhang, L. Ji, J. Zhou, P. Carney, H. Jiang
3.158 Morphological And Quantitative Brain Alterations Induced By Status Epilepticus: A Longitudinal MR Study On Rat Brain At 7 Tesla/J. Bankstahl, M. Meier, M. Bankstahl, H. Lanfermann, W. Löscher, X. Ding
3.159 MicroPET Study Of Very Early Regional Glucose Uptake Changes In Lithium-Pilocarpine Model Of Epileptogenesis/E. Raffo, F. Maskali, S. Ben Mahmoud, S. Poussier, P. Monin, G. Karcher, P. Marie, A. Nehlig
3.160 Rate Dependent Regional Brain Activations During Intermittent Light Stimulation In Photosensitive And Control Non-Human Primates/ F. Salinas, S. Narayana, K. Knape, M. Leland, C. Szabo
3.161 Effect Of P-Glycoprotein Function On Cerebral Uptake Of The $GABA_A$-Receptor Ligand [^{11}C]flumazenil In Rats And Mice/F. Froklage, S. Syvänen, N. Hendrikse, C. Molthoff, A. Windhorst, M. Huisman, A. Lammertsma, E. de Lange, R. Voskuyl
3.162 Diffusion Tensor MRI In Absence Epilepsy/A. Mishra, D. Coman, N. Danielson, C. Bhasyal, M. Coquillette, M. Negishi, M. Vestal, B. Killory, T. van Rijn, P. Edelbroek, R. Constable, F. Hyder, G. van Luijtelaar, H. Blumenfeld
3.163 Functional Activity Of Generalized Spike-And-Wave Discharges In The GBL Rat Model: An EEG-fMRI Study/R. Hutchison, L. Leung, J. Gati, S. Mirsattari
3.164 Subdermal EEG Electrode Placement In The Dog Using Neuronavigation/R. Poma, S. Frey, L. Barnard, A. Zaborowsky, J. Ives

Neuro-Imaging Structural Imaging
3.164A Increased Crossing Of Cortico-striatal Connections Following Resective Epilepsy Surgery In Children: A Probabilistic DTI Tractographic Study/R. Govindan, H. Chugani, S. Sood
3.164B Mu Opioid Receptor mRNA Expression, Binding And Functional Coupling To G-Proteins In Human Epileptic Hippocampus/L. Rocha, M. Cuellar-Herrera, A. Velasco, F. Velasco, L. Chavez, M. Alonso-Vanegas, S. Orozco-Suarez, A. Yalcin, S. Benyhe, A. Borsodi

Neuro-Imaging
Functional Imaging

3.165 Seizure Frequency Is Related To Brain Perfusion Status In Children With Sturge-Weber Syndrome/ C. Juhasz, J. Hu, Y. Miao, Y. Xuan, H. Chugani

3.166 Glutamatergic Dysfunction Underlying Hypometabolism In Temporal Lobe Epilepsy (TLE): A Positron Emission Tomography (PET) Multiparametric Study/E. Kobayashi, J. Rowley, J. Soucy, P. Rosa-Neto

3.167 Interhemispheric Connectivity In Temporal Lobe Epilepsy/L. Maccotta, R. Hogan

3.168 EEG/fMRI In Focal Epilepsy: What Does The BOLD Response Add To EEG?/F. Pittau, F. Dubeau, J. Gotman

3.169 Simultaneous EEG-fNIRS Recording Of Dorsolateral Frontal Lobe Seizures/P. Pouliot, J. Tremblay, O. Florea, P. Vannasing, F. Lesage, F. Lepore, M. Lassonde, D. Nguyen

3.170 [18F]-Flumazenil-PET For The Localisation Of Medically Refractory Focal Epilepsy Using Without Need For Arterial Blood Sampling: A Pilot Study/L. Vivash, M. Gregoire, E. Lau, R. Ware, P. Roselt, D. Binns, V. Bouilleret, A. Katsifis, D. Myers, R. Hicks, T. O'Brien

3.171 Imaging Ictal Rhythmic Activity Using High-Density EEG/L. Yang, C. Wilke, B. Brinkmann, G. Worrell, B. He

3.172 High Temporal Resolution Photoacoustic Imaging For Seizure Localization And Network Mapping/ Q. Zhang, B. Hu, Z. Yuan, J. Zhou, P. Carney, H. Jiang

3.173 Metabolic And Molecular Imaging Characteristics Of Epileptogenic Dysembryoplastic Neuroepithelial Tumors (DNETs)/ B. Alkonyi, O. Muzik, D. Chugani, I. Zitron, H. Chugani, S. Sood, S. Mittal, P. Chakraborty, C. Juhász

3.174 Simultaneous EEG And fMRI Of Sleep Spindles And K-Complexes/ M. Caporro, Z. Haneef, H. Yeh, C. Buttinelli, A. Lenartowicz, J. Stern

3.175 Memory Dysfunction In Frontal Lobe Epilepsy. The Role Of Frontal Lobes In Long-Term Memory Process/M. Centeno, C. Vollmar, J. O'Muircheartaigh, M. Symms, G. Barker, V. Kumari, P. Thompson, J. Duncan, M. Richardson, M. Koepp

3.176 Ictal BOLD Changes And Behavioral Performance Variability In Childhood Absence Epilepsy/ N. Danielson, J. Guo, B. Killory, X. Bai, M. Negishi, M. Vestal, R. Berman, C. Vega, M. Spann, E. Novotny, R. Constable, H. Blumenfeld

3.177 Interaction Of The Networks Sustaining Epileptic Discharge And Memory Function In Temporal Lobe Epilepsy/V. Dinkelacker, L. Thivard, C. Poupon, S. Samson, M. Baulac, S. Lehéricy, S. Dupont

3.178 Language Lateralization In Patients With Tuberous Sclerosis Complex (TSC) Using MEG And fMRI/ A. Gallagher, N. Tanaka, N. Suzuki, H. Liu, S. Camposano, E. Thiele, S. Stufflebeam

3.179 Hippocampal Networks In Temporal Lobe Epilepsy: A 'Seed-Based' fMRI Study/Z. Haneef, H. Yeh, A. Lenartowicz, J. Mumford, J. Stern

3.180 Diminished Recruitment Of Hippocampus Into Default Mode Network In Temporal Lobe Epilepsy/ G. James, J. Ojemann, D. Drane

3.181 Oxygen-Enhanced MRI: A Novel Imaging Modality For The Diagnosis And Lateralization Of Temporal Lobe Epilepsy/G. Kalamangalam, J. Nelson

3.182 Functional Integrity Of Malformations Of Cortical Development In A Language Network: An fMRI Study/G. Kuchukhidze, F. Koppelstaetter, I. Unterberger, J. Dobesberger, G. Walser, J. Larch, M. Delazer, T. Gotwald, S. Felber, E. Trinka

3.183 High-Density EEG Source Imaging And Connectivity Analysis In Partial Epilepsy Patients/Y. Lu, L. Yang, G. Worrell, B. He

3.184 Decreased Amplitude Of Low Frequency BOLD Fluctuations In Thalamic Subregions Of Patients With Idiopathic Generalized Epilepsy/ M. McGill, X. Wang, O. Devinsky, E. Halgren, C. Carlson, R. Kuzniecky, J. French, T. Thesen

3.185 The Use Of SPECT In The Evaluation Of Epilepsy Surgery In Infants/I. Miller, P. Kršek, M. Duchowny, P. Jayakar, N. Altman

3.186 ISAS Inter-Rater Agreement Is Superior To SISCOM And Raw SPECT On Measures Of Localization And Diagnostic Conclusiveness/A. Paige, J. Miller, K. Lee, B. Ojha, J. Kar, R. Knowlton

3.187 MRI Diffusion Tensor Imaging (DTI) And MR Spectroscopy (MRS) In Structural Negative Temporal Lobe Epilepsy/M. Xu, E. Ergene, M. Zagardo, W. Liu, M. Nancy

3.188 "Ictal" Or "Peri-Ictal" PET Findings In Patients With Refractory Epilepsy And Focal Cortical Dysplasia/ M. Campos, D. Ladrón de Guevara, G. Kuester, L. Ríos, M. Galvez, G. Rojas, F. Otayza, C. Pardo

3.189 Simultaneous Intracranial EEG And fMRI Of Interictal Epileptic Discharges In Patients With Epilepsy/D. Carmichael, S. Vulliemoz, R. Rodionov, K. Rosenkranz, B. Diehl, M. Walker, A. McEvoy, L. Lemieux

3.190 Seizure Foci Identification: Comparing fMRI-Based Intrinsic Connectivity Mapping And Spike Correlated fMRI/T. Constable, F. Tokoglu, M. Negishi, D. Spencer

3.191 Two Methods Of Functional Connectivity In Language Comprehension/E. Duke, M. Berl, B. Yerys, L. Rosenberger, J. Mayo, J. VanMeter, C. Vaidya, W. Gaillard

3.192 The Effect Of Frontal And Temporal Seizure Foci On Regional Language Networks/W. Gaillard, E. Duke, M. Tesfaye, M. Berl, J. Walker, E. Ritzl, R. Fasano, S. Sato, W. Theodore

3.193 Magnetoencephalography For Language Mapping: A New Approach To Localize Both Language Receptive And Expressive Areas/M. Huang, L. Cui, T. Song, M. Diwakar, R. Lee

3.194 EEG-fMRI Without EEG: Can BOLD Changes Caused By Epileptic Discharges Be Detected Without Recording The EEG?/Y. Khatamian, J. Gotman

3.195 Absence Seizures Impair Attention And Network Connectivity In Children/B. Killory, X. Bai, M. Negishi, C. Vega, M. Spann, M. Vestal, R. Berman, N. Danielson, J. Guo, S. Foote, E. Novotny, R. Constable, H. Blumenfeld

3.196 Factors Influencing Ictal SPECT Findings In Children With Focal Cortical Dysplasia/P. Krsek, A. Jahodova, S. Malone, B. Maton, Z. Hrncir, M. Kudr, V. Komarek, P. Jayakar, C. Dunoyer, I. Miller, T. Resnick, M. Duchowny

3.197 Dynamic Imaging Of Coherent Sources In Absences And Generalized Photoparoxysmal Responses – A Comparison With EEG-fMRI Studies/ F. Moeller, M. Muthuraman, U. Stephani, S. Groppa, G. Deuschl, J. Raethjen, M. Siniatchkin

3.198 Cross Hippocampal Influence In TLE Measured By fMRI With Granger Causality/V. Morgan, B. Rogers, H. Sonmezturk, B. Abou-Khalil

3.199 Laterality Of The EEG-fMRI Seeded Functional Connectivity As A Predictor Of The Surgical Outcome Of Epilepsy/M. Negishi, R. Martuzzi, E. Novotny, D. Spencer, R. Constable

3.200 Functional Connectivity Analysis Of Memory Networks In Epilepsy/ E. Novotny, A. Poliakov, H. Shurtleff, M. Warner, J. Kuratani, R. Saneto, D. Shaw, J. Ojemann

3.201 Basal Ganglia And Default Mode Networks In Epilepsy/I. Rektor, J. Tomcik, M. Mikl, R. Marecek, M. Brazdil, I. Rektorova

3.202 Cannabinoid Type 1 (CB_1) Receptor Binding Imaged In Vivo Using The PET Ligand [^{11}C]MePPEP/ D. Riano Barros, C. McGinnity, A. Egerton, L. Rosso, S. Battacharyya, R. Heckemann, F. Turkheimer, D. Brooks, O. Howes, M. Koepp, A. Hammers

3.203 Meta-Analytic Connectivity Modeling Of Mesial Temporal Lobe Epilepsy/J. Robinson, B. Kirmani, D. Barron, R. Savjani, R. Malla, P. Fox

3.204 Imaging Cortical Networks Involved In Preictal And Ictal Childhood Absence Epilepsy With Magnetoencephalography/ J. Stapleton-Kotloski, T. Huitt, B. Boles, C. O'Donovan, D. Godwin

3.205 Coregistration Of Magnetoencephalography(MEG) And Subtraction Ictal SPECT Coregistered To MRI (SISCOM) In Planning For Epilepsy Surgery/M. Stein, T. Stoub, J. Lewine, M. Rossi
3.206 Thalamic Nuclei Involvement In Secondary Generalized Seizures: A SISCOM Study/S. Strickland, Y. Park, B. Choi, P. Brown, A. Murro, S. Miranda, K. Drake
3.207 Preprocessing Of Magnetoencephalographic Data In Evaluation Of Language Lateralization/N. Suzuki, N. Tanaka, M. Hämäläinen, S. Stufflebeam
3.208 Metabotropic Glutamate Receptor Type 5 (mGLUR5) And Verbal Memory Performance In Mesial Temporal Lobe Epilepsy/V. Sziklas, P. Rosa-Neto, N. Sanford, J. Rowley, M. Jones-Gotman, E. Kobayashi
3.209 Language Lateralization Represented By Spatiotemporal Mapping Of Magnetoencephalography/ N. Tanaka, N. Suzuki, H. Liu, M. Hämäläinen, J. Madsen, B. Bourgeois, B. Dworetzky, S. Stufflebeam
3.210 Effect Of Brain-To-Skull Conductivity Ratio On EEG Source Localization From Epileptiform Activity/G. Wang, G. Worrell, B. He
3.211 Social Network Theory Applied To Resting-State fMRI Connectivity Data In The Analysis Of Epilepsy Networks/X. Zhang, M. Negishi, D. Spencer, T. Constable
3.212 Cluster Analysis Applied To fMRI Data In Typical Childhood Absence Seizures/X. Bai, B. Killory, J. Guo, M. Vestal, R. Berman, M. Negishi, E. Novotny, R. Constable, H. Blumenfeld
3.213 Localization Of Epileptic And Functional Networks At Rest Using Independent Component And Functional Connectivity Analysis Of The BOLD Signal/S. Bickel, L. Entz, C. Keller, C. Kelly, P. Kingsley, S. Jain, S. Hwang, A. Mehta
3.214 EEG-fMRI BOLD Response Associated With Diffuse Bilateral EEG Events In Focal Epilepsy Patients/ T. Gholipour, F. Pittau, J. Gotman, F. Dubeau
3.215 Localizing Seizure Onset Zone Using Ictal SPECT At Varying Thresholds/C. Newey, C. Wong, Z. Wang, G. Wu, A. Alexopoulos
3.216 3.0T-Functional MRI Can Detect Dominant Hemisphere Contributing Memory Function In The Patient With Mesial Temporal Lobe Epilepsy/ H. Okura, T. Takahashi, H. Sugano, M. Nakano, K. Fusegi, K. Asano, H. Arai
3.217 Correlation Of Pre-Surgical PET, MRI And Intracranial EEG With Pathologic Findings In Pediatric Epilepsy Surgery/J. Piantino, A. Hussein
3.218 Usefulness Of SPM Analysis Of FDG PET In Detecting Epileptogenic Tuber And Cortex In Tuberous Sclerosis Complex/L. Rozhkov, J. Seo, K. Holland-Bouley, M. Gelfand, F. Mangano, D. Franz, P. Horn, K. Lee
3.219 Effect Of Temporal Lobe Epilepsy On The Default Mode Network/J. Stern, H. Yeh, Z. Haneef, A. Lenartowicz, J. Mumford
3.220 FDG-PET And SPECT Co-Registration For Detection Of Epileptogenic Zone In Patients With Non-Lesional Neocortical Epilepsy/ C. Wong, A. Ristic, A. Alexopoulos, D. Lachhwani, N. So, G. Wu, I. Najm
3.221 Identification Of Epileptiform Activity Using eConnectome/H. Zhang, L. Yang, G. Wang, Y. Lu, G. Worrell, B. He
3.222 Non-Invasively Reconstructing Epileptogenic Zones Using Scalp MEG Data For Pre-Surgical Evaluation/ M. Zhu, L. Ding, W. Zhang, D. Dickens, J. King
3.223 The Clinical Value Of Magnetoencephalography In Epileptic Children With Frontal Lobe Tumors: Two Cases/L. Cui, T. Song, M. Diwakar, M. Huang, R. Lee
3.224 fMRI Language Dominance And FDG-PET Hypometabolism/W. Theodore, M. Berl, E. Duke, S. Miranda, C. Liew, A. Finegersh, A. Martinez, I. Dustin, S. Sato, W. Gaillard
3.225 Interictal MRI Perfusion Abnormalities Observed By Arterial Spin Labelled Sequences In Focal Epilepsies/M. Toledo, N. Lacuey, S. Sarria, M. Quintana, X. Salas Puig, E. Santamarina, A. Rovira
3.226 Ictal-MRI Focal Hyperperfusion Localizes The Epileptogenic Zone Using Arterial Spin Labeled Sequences/ M. Salvadó, N. Lacuey, L. Guzmán, M. Toledo, E. Santamarina, X. Salas-Puig, M. Sueiras, R. Rovira, G. Cuberas, C. Lorenzo, J. Munuera, S. Sarria, A. Rovira
3.227 The Usefulness Of Double Density Optical Topography/H. Yokota, K. Oguro, A. Izawa, E. Watanabe
3.228 Thalamic Hyperperfusion Using Pulse Arterial Spin Labeling In Generalized Epilepsy/A. Evans, D. Godwin, C. O'Donovan

Neuro-Imaging
Other Emerging Techniques
3.229 Single-Trial Cortical Mapping Of Sensorimotor Organization In Real-Time/E. Chang, C. Cheung, P. Garcia, N. Barbaro, R. Knight
3.230 Increased In Vivo Expression Of An Inflammatory Marker In Temporal Lobe Epilepsy/J. Hirvonen, W. Kreisl, M. Fujita, I. Dustin, S. Miranda, Y. Zhang, C. Morse, V. Pike, R. Innis, W. Theodore
3.231 Hemodynamic Changes During Temporal Lobe Seizures: A Simultaneous EEG-fNIRS Study/ J. Tremblay, P. Pouliot, O. Florea, P. Vannasing, F. Lepore, F. Lesage, M. Lassonde, D. Nguyen
3.232 Relationship Between Interictal MEG Background Source Spectral Anomalies And Epileptogenic Zones/ M. Raghavan, P. LaViolette, W. Mueller, S. Baillet
3.233 Application Of Diffusion Tensor Imaging In Temporal Lobe Epilepsy With Mesial Temporal Sclerosis Drug-Resistant: Correlation With FDG-PET Hypometabolic Area/J. Calvo, A. Pedraza, A. Boixet, C. Falcón, S. Sureda, X. Perego, M. Martínez
3.234 Corpus Callosum Involvement In Patients With Epilepsy Associated With Hippocampal Sclerosis/K. Lyra, E. Park, C. Rimkus, C. Leite, L. Castro, M. Otaduy
3.235 Combining Granger Causality And Diffuse Optical Tomography To Investigate The Effective Connectivity In Temporal Lobe Epilepsy (TLE)/Z. Yuan, R. Jiang, L. Ji, J. Zhou, P. Carney, H. Jiang
3.236 Magnetic Resonance Spectroscopy Detects Neuronal Dysfunctions In Extra-Hippocampal Region In Patients With Medial Temporal Epilepsy/T. Velasco, P. Diniz, C. Salmon, A. Sakamoto, J. Leite, A. Santos

Comorbidity (Somatic and Psychiatric)
Medical Conditions
3.237 Bone Mineral Density In Ambulatory Pediatric Patients With Epilepsy/C. Arsnow, R. Wehbeh, J. Buchlis, B. Weinstock-Guttman, A. Weinstock
3.238 Comorbid Obstructive Sleep Apnea In Epilepsy: Clinical Characteristics And Seizure Reduction Following Nasal Cpap Therapy/W. Berth, Erik St. Louis, M. Granner, M. Zimmerman, M. Dyken
3.239 Prevalence And Predictors Of Obstructive Sleep Apnea In Epilepsy: Do Traditional Risk Factors Matter?/ D. Pornsriniyom, N. Andrews, N. Foldvary-Schaefer
3.240 Significant Reductions In Heart Rate Variability During Ictal And Postictal Episodes In Pharmacoresistant Epilepsy/R. Staba, L. August-Schmidt, J. Pop, P. Miller, C. DeGiorgio
3.241 Are Children With Epilepsy At Higher Risk For Injury? – A Prospective Study Of Injury Rates In Children With Epilepsy Compared To Their Nearest-Aged Sibling/M. Blackman, N. Thornton, E. Wirrell
3.242 Children With Epilepsy Have Increased Arousal Indices On Polysomnography Compared To Age Matched Controls/S. Jain, L. Thampratankul, N. Simakajornboon
3.243 Status Epilepticus Reduces Cardiac Ventricular Function/J. Little, S. Bealer
3.244 Tension Type Headache, Migraine And Other Types Of Headache In Epilepsy: A Multivariated Analysis/ R. Londero, J. Bragatti, C. Torres, A. Dal Pizzol, K. Martin, A. Souza, L. Bastianelli, M. Oliveira, P. Cherubini, M. Bianchin

3.245 Risk Factors For Migraine In Epilepsy: A Logistic Regression Analysis/M. Bianchin, R. Londero, J. Bragatti, C. Torres, A. Dal Pizzol, K. Martin, A. Souza, M. Oliveira, P. Cherubini
3.246 A New Epilepsy Specific Risk Adjustment Comorbidity Index/ C. St. Germaine, M. Liu, H. Quan, S. Wiebe, N. Jette
3.247 KCNQ Channels In The Nucleus Tractus Solitarius Of The Brainstem Might Be Involved In SUDEP/ G. Tolstykh, J. Cavazos

Comorbidity (Somatic and Psychiatric)
Psychiatric Conditions
3.248 This poser has been changed to Platform B.09
3.249 Testing Epilepsy Candidate Genes In Autism/M. Cuccaro, R. Tuchman, D. Ma, R. Abramson, H. Wright, J. Gilbert, M. Pericak-Vance
3.250 Long-Term Depression Outcomes After Resective Epilepsy Surgery/H. Hamid, L. Haibei, X. Cong, J. Dziura, O. Gilani, O. Devinsky, W. Barr, B. Vickrey, A. Berg, C. Bazil, S. Pacia, J. Langfitt, T. Walczak, M. Sperling, S. Shinnar, S. Spencer
3.251 Increased iPLA2 Activity Is A Marker In The Hyppocampus Of Patients With Temporal Lobe Epilepsy And Psychosis/L. Talib, K. Valente, N. Raposo, S. Vincentiis, W. Gattaz
3.252 Prevalence And Predictors Of Depression In 2,128 Epilepsy Patients/G. Tesar, L. Jehi, I. Najm
3.253 Psychiatric Comorbidity In Childhood-Onset Epilepsy: Neurodevelopment May Be The Key/ A. Berg, R. Caplan, M. Hannah
3.254 The Impact Of Psychiatric Comorbidity On Quality Of Life In Children With Epilepsy/C. Bower Baca, B. Vickrey, R. Caplan, S. Vassar, A. Berg
3.255 PAI Vs. MMPI-2 In Differentiating NES From Epilepsy Patients/R. Doss, S. Mason
3.256 Psychiatric Disease In Adults With Occipital Epilepsy: Role Of Complex Partial Semiology/A. Fessler, J. Henry, L. Liu, J. Langfitt
3.257 Screening For Depression And Suicidality In An Epilepsy Clinic/ S. Mason, R. Doss, P. Penovich
3.258 Epilepsy And Family History Of Psychiatric Disorders In The National Comorbidity Survey Replication (NCS-R)/J. Pillai, S. Calhoun, J. Mossey
3.259 Depression In Epilepsy Is Associated With Lack Of Seizure Control/M. Seyal, R. Dias, L. Bateman, S. Farias, C. Li, T. Lin, J. Jorgensen
3.260 Screening For Depression In A Tertiary Adult Epilepsy Clinic Using The Neurological Disorders Depression Inventory For Epilepsy/M. Davies, J. Sandhu, M. Starky, S. Ahmed, J. Jirsch, T. Synder, D. Gross
3.261 Are AEDs Associated With Suicidal Ideation?/D. Dunn, C. Johnson, P. Fastenau, A. Byars, T. deGrauw, S. Perkins, J. Austin
3.262 Psychosis In Temporal Lobe Epilepsy: Right-Sided Mesial Temporal Sclerosis And Longer Duration Of Epilepsy Are Risk Factors/K. Goldberg, R. Alessi, S. Vincentiis, K. Valente
3.263 Role Of Anxiety And Sleep Disorders For Overall Quality Of Life In People With Epilepsy And Controls/ A. Jacoby, D. Snape, S. Lane, G. Baker
3.264 A 2-Year Prospective Study Of Psychiatric Comorbidity In Children With Recent Onset Epilepsy/J. Jones, M. Seidenberg, B. Hermann
3.265 Postictal Exacerbation In Severity Of Interictal Psychiatric Symptoms Worsens Significantly The Quality Of Life Of Patients With Epilepsy/A. Kanner, H. Kanner, M. Rovner
3.266 Seemingly Similar But Essentially Distinct: Comparison Of Clinical And Paraclinical Characteristics In Patients With Epileptic Seizures And Psychogenic Nonepileptic Seizures/ I. Karakis, A. Cole, G. Montouris, M. San Luciano, A. Tsiakiri, C. Piperidou
3.267 Outcomes Of Trauma-Induced Psychogenic Nonepileptic Attacks Treated With Eye Movement Densensitization And Reprocessing/ S. Kelley, A. Bozorg
3.268 Depression In Elderly Patients With Epilepsy/O. Laban-Grant, E. Fertig, J. Kanter, H. Husaini, L. Myers, M. Lancman
3.269 Comparing Standard Medical Care For NES In Latin America To North America/W. Curt LaFrance, A. de Marinis, J. Machan, M. Rusch, A. Kanner
3.270 Tonic Gabaergic Inhibition In The Basolateral Amygdala Is Heavily Mediated By α5 Subunit-Containing Receptors, And Is Reduced In A Mouse Model Of Fragile-X Syndrome/ B. Martin, M. Huntsman
3.271 The Relationship Between Mood And Antiepileptic Drug Side Effects In Patients With Epilepsy/K. Perrine, H. Husaini, E. Fertig
3.272 Paroxysmal Nonepileptic Events In The Elderly: A Video-EEG Review/ D. Silveira, L. Jehi, E. Novak, B. Wolgamuth
3.273 Validity Of A Depression Screening Instrument For Youth With Epilepsy (YWE)/G. Smith, P. Ferguson, J. Wagner, V. Hall, B. Wannamaker
3.274 Prevalence Of Anxiety And Sleep Disorder In People With Epilepsy And Controls And Contributing Factors/D. Snape, A. Jacoby, S. Lane, G. Baker
3.275 Communicating The Diagnosis Of Psychogenic Nonepileptic Spells Is A Tricky Business/M. Tammaa, F. Chaudhary, S. Gill, Y. Song, N. Bangalore-Vittal, N. Azar, P. Singh, A. Arain
3.276 Independent Predictors Of Anxiety Disorders In Temporal Lobe Epilepsy: A Cross-Sectional Study/ C. Torres, J. Bragatti, A. Dal Pizzol, K. Martin, A. Souza, L. Bastianelli, P. Cherubini, M. Oliveira, G. Manfro, M. Bianchin
3.277 Behavioral Attention And Prefrontal Dopamine Receptor Density In The Rat Perinatal Hypoxia Model Of Epilepsy/A. Willner, S. Briffa-Mirabella, D. McCloskey
3.278 Comorbidity In Patients With Psychogenic Nonepileptic Attacks/ E. Acton, E. Vo, W. Tatum
3.279 Psychogenic Nonepileptic Seizures In Children: Age-Related Risk Factors And Clinical Findings/R. Alessi, S. Vincentiis, K. Valente
3.280 The Teddy Bear Sign Does Not Indicate The Presence Of Psychogenic Non-Epileptic Seizures/M. Cervenka, T. Tran, D. Muthugovindan, R. Lesser
3.281 Life-Threatening Nonepileptic Seizures: Report Of Two Cases/ L. de Paola, F. B. Germiniani, C. Silvado, A. Crippa, C. Domingos, C. Del Claro Hopker, M. M. Joaquim, A. Gaspari
3.282 Agitation In Epilepsy Patients Monitored With Intracranial EEG/ A. Dole, G. Tesar
3.283 Psychopathology And Family Dynamics In Patients With Psychogenic Nonepileptic Spells (PNES)/S. Gill, Y. Song, A. Arain
3.284 Body Outline Task In Epilepsy And Its Mimickers/A. Pak, A. Bae, S. Zhang, D. Anschel
3.285 Can Multiple Drug Allergies Predict The Final Diagnosis In Patients Undergoing Video-EEG Monitoring?/ D. Robertson, A. Bozorg
3.286 Psychogenic Nonepileptic Seizures (PNES): Psychiatric Treatment Of 12 Patients/A. Velez, L. Morgan, K. Karkar, C. Szabo
3.287 Which Screening Tools For Depression In Epilepsy?: A Comparison Of Conventional And Visual-Analogue Methods/T. von Oertzen, J. Rampling, A. Mitchell, H. Cock, N. Agrawal
3.288 Anxiety And Quality Of Life In Patients With Epilepsy And Psychogenic Nonepileptic Seizures/ H. Williams, M. Bagary
3.289 Surrealism And Epilepsy: Max Ernst's Une Semaine De Bonté: A Graphic Representation Of Non-Epileptic Seizures?/F. Germiniani, L. de Paola, H. Teive, C. Silvado, A. Crippa, M. Madder Joaquim, C. Del Claro Hopker, C. Domingos, D. Zorzetto, A. Gaspari

Human Genetics
3.290 Whole-Genome Sequencing In Multiplex Epilepsy Families: An Approach To Identify Rare Susceptibility Variants/E. Ruzzo, E. Heinzen, A. Poduri, R. Wedel, R. Ottman, D. Goldstein
3.291 Clinical Phenotypes, Epilepsy And Genetics Of Various Subtypes Of Polymicrogyria And Evidence For A Novel Locus For Bilateral Perisylvian Polymicrogyria Narrowed To 2p16.1-p16.3/D. Amrom, A. Poduri, B. Dan, N. Deconinck, C. Christophe, B. Pichon, F. Dubeau, D. Tampieri, F. Andermann, W. Dobyns, C. Walsh, E. Andermann

3.292 Action Myoclonus-Renal Failure Syndrome (AMRF) In French Canadian Families Is Due To A Founder Effect/ E. Andermann, D. Amrom, M. Bayly, J. Mulley, M. Talani, M. Pierre, M. Jomphe, S. Berkovic, F. Andermann, L. Dibbens
3.293 Putative Susceptibility Alleles Identified From A Genome Wide Association Study In Epilepsy/R. Buono, H. Zhang, K. Wang, M. Sperling, D. Dlugos, W. Lo, P. Cossette, C. Hou, J. Glessner, J. Bradfield, P. Sleiman, Y. Guo, C. Kim, R. Chiavacci, F. Mentch, H. Qui, B. Keating, S. Grant, M. Privitera, J. French, S. Schachter, F. Lohoff, W. Berret
3.294 Malignant Migrating Partial Seizures Of Infancy May Be Caused By Sodium Channel Mutations/ D. Carranza, L. Hamiwka, J. McMahon, L. Dibbens, T. Arsov, A. Suls, M. Bayly, C. Burke, T. Stödberg, T. Bienvenu, P. De Jonghe, D. Thorburn, S. Berkovic, J. Mulley, I. Scheffer
3.295 The Contribution Of PCDH19 Gene Mutations In Epilepsy And Mental Retardation In Females (EFMR)/ L. Dibbens, M. Bayly, T. Arsov, T. Desai, S. Sisodiya, J. Gecz, F. McKenzie, S. Berkovic, J. Mulley, S. von Spiczak, A. Ronan, I. Scheffer
3.296 A Distinctive Seizure Type In Patients With Cdkl5 Mutations: Hypermotor-Tonic-Spasms Sequence/ K. Klein, S. Yendle, A. Harvey, G. Wallace, T. Bienvenu, I. Scheffer
3.297 Screening For GLUT1 Deficiency Is A Diagnostic Test In Early-Onset Absence Epilepsy: A Replication Study/S. Mullen, T. Arsov, K. Lawrence, J. Damiano, S. Berkovic, I. Scheffer
3.298 SCN1A Channelopathy In Malignant Migrating Partial Seizures In Infancy/P. Pearl, E. Freilich, W. Gaillard, J. Conry, T. Tsuchida, J. Jones, C. Reyes, S. Dibb-Hajj, S. Waxman, M. Meisler
3.299 Myoclonic Epilepsy As A Major Symptom Of A Novel Mutation In The Mitochondrial tRNAlleu Gene/Y. Weber, G. Zsurka, H. Gdynia, W. Kunz, H. Lerche
3.300 Varying Febrile Seizure Susceptibility Among Scn1a GEFS+ Mutants/S. Dutton, A. Escayg
3.301 Next-Generation Sequencing Of Refractory Juvenile Myclonic Epilepsy Patients/E. Heinzen, G. Cavalleri, M. McCormack, S. Alhusaini, G. O'Connor, R. Radtke, C. Depondt, S. Sisodiya, N. Delanty, D. Goldstein
3.302 Domain-Dependent Clustering And Phenotype Association Of LGI1 Gene Mutations In Autosomal Dominant Partial Epilepsy With Auditory Features (ADPEAF)/Y. Ho, I. Ionita-Laza, R. Ottman
3.303 Outcomes From The Discovery Of A Novel $GABA_A$ Receptor Mutation In An Epilepsy Family/J. Johnston, J. Davies, K. Baer, C. Hammond, R. Thomas, T. Cushion, S. Chung, J. Mullins, C. White, P. Smith, M. Rees
3.304 Estimates Of Familial Risk For Genetic Counseling In The Epilepsies/ A. Peljto, C. Barker-Cummings, C. Leibson, V. Vasoli, W. Hauser, J. Buchhalter, R. Ottman
3.305 Methylenetetrahydrofolate Reductase (MTHFR) Deficiency And Infantile Epilepsy/A. Prasad, C. Rupar, C. Prasad
3.306 Association Study Shows Relationship Between Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis And *IL1B* And *PTPRM* Genes/R. Santos, M. Silva, R. Secolin, C. Yasuda, T. Velasco, A. Sakamoto, F. Cendes, I. Lopes-Cendes, C. Maurer-Morelli
3.307 Response To Antiepileptic Drugs In Mesial Temporal Lobe Epilepsy Is A Polygenic Trait/M. Saragiotto da Silva, R. Secolin, E. Bilevicius, R. Santos, C. Maurer-Morelli, F. Cendes, I. Lopes-Cendes
3.308 Genes Acting In Growth, Differentiation, And Neuronal Migration Potentially Involved In Temporal Lobe Epilepsy/S. Vincentiis, E. Ojopi, J. Flores, W. Tzu, W. Gattaz, K. Valente
3.309 Mutation Screening Of *GRIN2A* As A Candidate Gene For Idiopathic Focal Epilepsies/S. von Spiczak, K. Finsterwalder, C. Reutlinger, H. Muhle, A. Caliebe, T. Obermeyer, M. Schilhabel, A. Franke, I. Helbig, U. Stephani
3.310 Evaluating The Clinical Use Of Genetic Testing In Patients With Dravet And Doose Syndromes/ M. Gonsales, P. Preto, M. Montenegro, M. Guerreiro, I. Lopes-Cendes
3.311 Phenotype Definition In LGI1-Related Epilepsy/K. Kamberakis, R. Wedel, H. Choi, T. Pedley, W. Hauser, R. Ottman
3.312 Profound Ictal Apnea In PCDH19 Related Epilepsy: 2 Cases With Novel Phenotypic And Genetic Findings/K. Nash, I. Ahronowitz, J. Sullivan
3.313 Association Of Intronic Variants Of The KCNAB1 Gene With Lateral Temporal Epilepsy/C. Nobile, G. Busolin, S. Malacrida, F. Bisulli, P. Striano, C. Di Bonaventura, G. Egeo, E. Pasini, V. Cianci, E. Ferlazzo, A. Bianchi, G. Coppola, M. Elia, O. Mecarelli, U. Aguglia, S. Striano, P. Tinuper, A. Giallonardo, R. Michelucci
3.314 Genome-Wide Linkage Analysis In ADPEAF Families Without Mutations In LGI1/R. Ottman, G. Crockford, Y. Wang, M. Winawer, H. Choi, W. Hauser
3.315 Common Genetic Variation In Drug Metabolising Enzymes As A Determinant Of Carbamazepine Dose Requirement In Newly Diagnosed Epilepsy/K. Shazadi, G. Sills, A. Jorgensen, A. Alfirevic, M. Pirmohamed, A. Marson
3.316 Concordance Of Seizure Semiology And Pharmacosensitivity In Sibling Pairs From The Epilepsy Phenome/Genome Project (EPGP)/ M. Winawer, R. Fahlstrom, D. Rabinowitz, The EPGP Senior Investigators
3.317 Identification And Characterisation Of Endophenotypes For Epilepsy Through MRI/S. Alhusaini, J. Meaney, G. Boyle, A. Fagan, P. Iyer, C. Scanlon, L. Ronan, G. Borgulya, S. Maguire, P. Brennan, C. Doherty, N. Delanty, M. Fitzsimons, G. Cavalleri
3.318 Familial Lateral Temporal Lobe Epilepsies: The Clinical And Genetic Spectrum In Italy/R. Michelucci, E. Pasini, G. Busolin, C. Di Bonaventura, O. Mecarelli, A. Gambardella, M. Elia, F. Bisulli, S. Binelli, P. Striano, S. Striano, G. Coppola, P. Tinuper, A. Giallonardo, G. Egeo, V. Sofia, M. Marchini, A. La Neve, F. De Falco, P. Pulita
3.319 Recruitment Of Subjects For Genetic Studies Of Temporal Lobe Epilepsy/S. Misiewicz, M. Winawer
3.320 Molecular Classification Of Neonatal And Infantile Epilepsies/ J. Mulley, S. Heron, L. Dibbens
3.321 CYP2C9 *2 And *3 Genotype Predicting Non-Response To Valproate In Patients With Epilepsy/E. Ojopi, S. Thomé-Souza, W. Gattaz, K. Valente
3.322 A Novel Gene Locus Of Photogenic Childhood Absence Evolving To JME/M. Tanaka, P. Cossette, J. Bailey, R. Duron, A. Delgado-Escueta

Health Services
Delivery of Care
3.323 The Effect Of Seizures In Health-Resources Utilization In Patients With Ischemic Strokes: A Canadian Multi-Center Prospective Study/A. Alabousi, G. Saposnik, J. Fang, J. Burneo
3.324 Racial Disparities Of Seizure Care In The Emergency Department/ K. Gleason, S. Hurwitz, K. O'Laughlin, B. Dworetzky
3.325 Measuring Parents' Perceptions Of Patient-Centered Care In Childhood Epilepsy: Reliability And Validity Of The Patient Perceptions Of Patient-Centeredness (PPPC) Questionnaire/ S. Craigie, M. Stewart, G. Zou, K. Speechley
3.326 Epileptologist Adherence To Depression Treatment Guidelines/ E. Franco, G. Tesar, I. Najm
3.327 Knowledge Of Women's Issues Related To Pregnancy In Epilepsy: A Survey Of Healthcare Professionals/ N. Jette, F. Abdulla, J. Roberts, S. Wiebe, A. Hanson, P. Federico, A. Metcalfe
3.328 Healthcare Costs For Children With Seizures Presenting To Le Bonheur Children's Hospital Emergency Department/N. Shah, R. Kink, K. Cox, J. MacDonald, J. Wheless

3.329 Patient Perceptions Of Information Needs For TLE Surgery Decisions/H. Choi, K. Pargeon, J. Wong, A. Mendiratta, S. Bakken
3.330 Effective Strategies To Improve Epilepsy Nursing Knowledge Prior To The Development Of An Epilepsy Monitoring Unit At A Community Hospital/W. Fedder, C. Musson, M. Smith
3.331 Quality Improvement In The Epilepsy Clinic/M. Hoerth, J. Drazkowski, K. Noe, J. Sirven
3.332 Using A Standardized Assessment Tool To Measure Patient Experience On A Seizure Monitoring Unit Compared To A General Neurology Unit/J. Roberts, K. Sauro, K. Osiowy, J. Knox, N. Jette, S. Macrodimitris
3.333 Staff Experience And Satisfaction With Working On A Seizure Monitoring Unit/K. Sauro, C. Krassman, J. Knox, E. Mercer, M. Rigby, M. Suddes, N. Jette, S. Macrodimitris

Health Services
Access to Care
3.334 Factors Affecting Hospital Length Of Stay For Patients With Epilepsy: Results From A National Inpatient Survey/T. Smith, L. Shi, M. Khan, C. Bazil

Health Services
Healthcare Models
3.335 A Consumer Generated Self-Management Intervention Model/ R. Fraser, E. Johnson, J. Miller, N. Temkin, P. Ciechanowski, N. Chaytor, L. Caylor, J. Barber

Health Services
Special Populations
3.336 Depression In Mothers In The 24 Months Following A Diagnosis Of Epilepsy In Their Children: Survival Analysis And Risk Factors/M. Ferro, W. Avison, M. Campbell, K. Speechley
3.337 Adolescents In Transition: Developmental And Psychosocial Concerns For Youth With Intractable Epilepsy/S. Ahlm, H. Kaplan, A. Berg, M. Forcier, D. Nordli
3.338 Development Of A Conceptual Model For The Study Of Breakthrough Seizures In Hospitalized Children With Epilepsy And Associated Risk Factors/C. Jones, F. Yu, J. Kaffka, K. Saag, M. Safford

Neuropathology of Epilepsy
3.339 Dynamic Disinhibition Of Cortical Circuits/J. Brill, J. Mattis, K. Deisseroth, J. Huguenard
3.340 Aberrant Integration Of Postnatally Generated Neurons Is Sufficient To Cause Epilepsy/S. Danzer, D. Richards, K. Holland, J. Uhl, C. Faulkner, H. Yin, B. Murphy, S. Bronson, R. Pun
3.341 NRSF/REST Dependent And Independent Gene Pathways In Epileptogenesis/S. McClelland, C. Flynn, C. Dube, J. Yang, R. Petrosyan, J. Mundy, C. Bernard, T. Baram
3.342 Aberrant Mossy Fiber Sprouting Preferentially Innervates Immature Cells In A Rodent Model Of Temporal Lobe Epilepsy/A. Althaus, M. Kron, H. Zhang, N. Kransz, J. Parent
3.343 Mechanisms For Prenatal Radiation-Induced Rat Cortical Malformations That Simulate Cortical Disorganizations Found In Human Neurologic Disorders/T. Babb, J. Chorostecki
3.344 Neuronal Degeneration In Hypothalamus Induced By Status Epilepticus In Immature Rats/R. Druga, P. Mares, H. Kubova
3.345 Hilar GABAergic Interneurons Receive Increased Excitatory Inputs From Granule Cells And Pyramidal Neurons After Traumatic Brain Injury/R. Hunt, S. Scheff, B. Smith
3.346 Parallel Computing Enables Full-Scale Modeling Of The Control And Epileptic Rat Dentate Gyrus/ C. Schneider, M. Case, I. Soltesz
3.347 Single-Cell Microinjection Of Small Hypothalamic Hamartoma Neurons/A. Strobel, Y. Jin, G. Li, J. Wu, J. Kerrigan
3.348 Cell Specific Ablation Of PTEN Signaling Alters GABAergic Circuitry/ G. Barnes, Y. Li, S. Siegel
3.349 In Vivo Neuroprotective Role Of M-Type K+ Channels During A Transient Ischemic Attack/S. Bierbower, L. Watts, M. Shapiro
3.350 An Investigation Of Spontaneous Cortical Slow Oscillations Using 256-channel EEG In Normal And Epileptic Patients/T. Gilbert, P. Luu, M. Holmes, D. Tucker
3.351 In Vivo Model Of Group I mGluR-Mediated Epileptogenesis/J. Goodman, D. Erdheim, S. Chuang, R. Wong
3.352 Early-Onset Seizures In Adult Mice Following Hypoxic-Ischemic Brain Injury/S. Huang, N. Patel, C. Du, Y. El-Hayek, C. Wu, L. Zhang
3.353 High-Frequency (80-500 Hz) Oscillations In A Rat Model Of Temporal Lobe Epilepsy/M. Lévesque, A. Bortel, J. Gotman, M. Avoli
3.354 Cortical And Subcortical Network Dysfunction In Limbic Seizures: High Field BOLD fMRI In A Rodent Complex Partial Seizure Model/J. Motelow, A. Mishra, D. Englot, B. Sanganahalli, K. Furman, F. Hyder, H. Blumenfeld
3.355 Effect Of Beta-Estradiol On Synaptic Plasticity In Dentate Gyrus Depends On Stimulation Paradigm/ N. Nebieridze, L. Velisek, J. Veliskova
3.356 Early Enhancement Of Phasic GABAergic Inhibition In The Pilocarpine-Treated Rat Subiculum/G. Panuccio, M. Avoli
3.357 Temporal Lobe Epilepsy Induced Increases In Persistent (INaP) And Resurgent (INaR) Na Currents/ M. Patel, N. Hargus, E. Bertram
3.358 MRI Hippocampal Volume Is Associated With CA1 Neuron Density And Chondroitin Sulfate Expression In Temporal Lobe Epilepsy/ J. Peixoto-Santos, O. Galvis-Alonso, D. Araujo, A. Santos, J. Assirati, C. Carlotti Jr, R. Scandiuzzi, J. Leite
3.359 Is BGT1 mRNA Expression Following Status Epilepticus Influenced By Inflammation And/Or Dehydration In C57/B6 Mice?/N. Rowley, M. Smith, J. Lamb, A. Schousboe, H. White
3.360 Galanin Receptor Type 1 Deletion Exacerbates Hippocampal Neuronal Loss After Systemic Kainate Administration In Mice/ P. E. Schauwecker
3.361 Temporal Cytokine Expression Patterns In The Rat Hippocampus Following A Traumatic Brain Injury/ L. Shapiro, M. Foresti, G. Arisi, A. Ruch, K. Katki
3.362 mTOR Cascade Activation Observed In Human Hippocampal Sclerosis Is Not Recapitulated In A Rat Pilocarpine Model Of Epilepsy/ A. Sosunov, X. Wu, C. Mikell, R. McGovern, D. Coughlin, R. Goodman, H. Scharfman, G. McKhann
3.363 Mechanisms Generating Spike-Wave Discharges In A Detailed Thalamocortical Simulation/E. Thomas, J. Chambers, S. Petrou, D. Abramson, S. Berkovic
3.364 Increased Endoplasmic Reticulum Stress In The Amygdaloid Kindling Model Of Rats/Y. Ueda, Y. Chihara, T. Doi, J. Willmore
3.365 Immature Large Newborn Neurons In Human Hippocampal Dentate Gyrus From Patients With Temporal Lobe Epilepsy/H. Sugano, M. Nakajima, H. Okura, T. Higo, H. Arai
3.366 Neuropathology Of Epilepsy/ M. Tristán Agundis, C. Castañeda-Gonzáles, J.V. Hernandez, D. Rembao Bojórquez, S.P. Escalona, M. Manzanarez Colin, L. Rocha

CAMELICE Posters*
3.367 G_i Protein Activation And D2-Like Dopaminergic Receptor Binding In A Temporal Lobe Epilepsy Model/ D. Alcantara-Gonzalez, B. Florán, L. Rocha
3.368 Evaluation Of 5-HT1A Receptor In The Hippocampus Of Patients With Refractory Epilepsy To Antiepileptic Drugs/ M. Cuellar Herrera, L.L. Rocha, S. Orozco, L. Chávez, J.M. Núñez, F. Velasco, A.L. Velasco
3.369 Metabolic Activity Test Using Functional Magnetic Resonance With Temporal Lobe Epilepsy Patients During The Stroop Test/J. Alvarez-Alamilla, M. Corsi-Cabrera, D. Trejo Martínez, I.Y. del Río, A.L. Velasco

*Abstracts from the Junior Epileptologist Program from the Mexican Chapter of ILAE (CAMELICE)

3.370 Factors Related To Refractory Epilepsy In Children: "Federico Gomez" Children's Hospital Experience In Mexico City/E. I. Arellano Montellano, E. Barragan Perez,
3.371 Characteristics Of Patients With First Seizure/ M. J. Berenguer-Sánchez, F. A. Gutiérrez-Manjarrez, H. Sentíes-Madrid, G. García-Ramos, B. Estañol-Vidal
3.372 Evaluation Of Patients With Probable First Epileptic Seizure/ F.A. Gutiérrez-Manjarrez, M.J. Berenguer-Sánchez, H. Sentíes-Madrid, G. García-Ramos, B. Estañol
3.373 Thyroid Abnormalities With The Use Of Valproate, Carbamazepine And Phenytoin In Mono And Polytherapy And Their Correlation With Blood Levels: Prospective Study At The National Institute Of Neurology And Neurosurgery "MVS" Mexico/ M.A. Díaz-Torres, S. Morán-Molina, M.A. Fernández-Aguilar, I.E. Martínez-Juárez
3.374 Callosotomy As An Adjuvant Treatment In A Patient With Cryptogenic Catastrophic Epileptic Encephalapothy: Case Report/ R. Domínguez Herz, C. García, F. Soto, R. Ortiz, B. Garcia, N. Teyes, C. Paz
3.375 Epilepsy and Migraine/ N. Plascencia-Alvarez, R.I. González-Gómez, E. Juárez-Martínez, G. Maldonado-Torres, E. Arrazola-Cortez, L. Núñez-Orozco
3.376 Clinical Utility Of Short-Term Videoelectroencephalogram Monitoring In Epilepsy/I. M. González Orizaga, M. Berenguer Sánchez, F. Gutiérrez Manjarrez, E. Soto Cabrera, F. Zavala Ferrer, O. Campos Villarreal, M. Alonso Vanegas, H. Sentíes Madrid, B. Estañol, G. García Ramos
3.377 Comparative Study Of The Efficiency And Security Between The Molecule Of Original And Generic Oxcarbazepine Control In Children With Partial Epilepsy Diagnosis Of Recent/C.S. Marquez Chuquimia, E.J. Barragan Perez, M. Hernandez Hernandez
3.378 Clinical Characteristics Of Seizures In Patients With Sturge-Weber Syndrome. Implications On Evolution/C.A. Montes Lahuerta, E. Barragan-Perez
3.379 Assessment Of Olfactory Capability Of Mesial Temporal Lobe Epilepsy (MTLE) Patients/ P. Severiano-Pérez, U.R. Moreno-Araujo, M.A. Cejudo-Tejeda, N. González-Fernández, C. Mendez-Quintal, J.M. Nuñez-de la Vega, A.L. Velasco, R. Guevara-Guzmán
3.380 Voltage-Dependant Verbal Memory – Effects On The Cognitive Function Through Changing Voltage Parameters In Deep Brain Stimulation/ A. Nuche-Bricaire, M. Montes De Oca, J. Marcos Ortega, D. Trejo, J.M. Núñez, D. Vazquez, A.L. Velasco-Monroy
3.381 Brain Hypoperfusion During Todd's Paralysis: Differential Diagnosis With Acute Stroke/ Y.O. Piquet-Uscanga, E.O. Jiménez-Domínguez, D.A. Espinoza-López, I.E. Martínez-Juárez, A. Moreno-Avellán
3.382 Mental Development Of Infants At Corrected Age Of 24 Months At High Risk Of Impaired Development And Epilepsy Attributed To Peri-Natal Insults Discharged From Neonatal Intensive Care Unit/E. Porras-Kattz, J.E. Barrera-Reséndiz, T. Harmony, G.N. Avecilla-Ramírez, J. Ricardo-Garcell, A. Fernández-Bouzas, D. Martínez de la Escalera, E. Valencia-Solís
3.383 Hot Water Epilepsy: A Case Report/ R. Sandoval-Pacheco, R. Avalos-Plata, P. Herrera-Mora, M. Ruiz-García, A. García-Briseño
3.384 Language Laterality In Patients With Epilepsy And Healthy Subjects By A Dichotic Listening Task/ D. Trejo-Martínez, A.L. Velasco, F. Velasco, J.M. Nuñez, R. Conde, E. Colin-Ramírez, A. Nuche
3.385 Surgical Treatment Of Drug Resistant Mesial Temporal Lobe Epilepsy With Bilateral Foci/D. Vázquez, A.L. Velasco, F. Velasco, J.M. Núñez
3.386 Cortical Dysplasia In Patients With Temporal Lobe Epilepsy; Morphological Study Of 60 Cases/ J. Villeda Hernandez, M. Alonso, L. Rocha, S. Orozco

9:00 a.m. – 10:30 a.m.

Special Interest Group Meetings

Convention Center – Location listed under each session
Please complete program survey – see page 14

Basic Mechanisms of Epilepsy

Convention Center – Room 006 A-C
Coordinators: Claude G. Wasterlain, M.D., Raman Sankar, M.D., Ph.D.
Speakers: TBA

Description not available at time of printing.

Clinical Nursing – Paving the Way to Epilepsy Specialty in Nursing Certification

Convention Center – Room 008
Coordinators: Madona D. Plueger, B.S.N., RN, CNRN, Sarah Kiel, M.S.N.
Speakers: Janice M. Buelow, RN, Ph.D., others TBD

Objectives of this SIG are: 1. Discuss the American Board of Nursing Specialties requirements for application of Speciality Certification; 2. Define the process that is needed to create a formal method of creating an Epilepsy Nurse Specialty Certification; 3. Demonstrate the skills, knowledge and experience desired for nurses seeking Epilepsy Nurse Specialty Certification; 4. Demonstrate ways that could improve patient outcomes in facilities in which there would be certified Epilepsy Nurses.

Clinical Roundtable – Neonatal Seizures — Little Patients, Big Issues

Convention Center – Room 007 C/D
Coordinator: Kevin E. Chapman, M.D.
Speakers: Frances E. Jensen, M.D., Eli M. Mizrahi, M.D., Ronit Pressler, M.D., Ph.D.

Neonatal seizures are a common and ominous sign of neurologic injury that can arise from a variety of etiologies. The immature brain presents particular challenges regarding semiology, mechanisms and response to treatment compared to adults. This discussion will bring together experts in the field of neonatal seizures to discuss their approach to patients in terms of practical issues and future directions. Audience participation is encouraged.

Practice Management Course

Convention Center – Room 006 D
Coordinator: Gregory L. Barkley, M.D.
Speakers: TBA

Description not available at time of printing.

Translational Research – Epilepsy Models, Clinical Syndromes, and "Personalized" Medicine: Are Pre-clinical and Pipeline Pathways Aligned for Successful Translational and Commercial Development?

Convention Center – Room 007 A/B
Coordinators: Thomas P. Sutula, M.D., Ph.D., Warren Lammert
Speakers: Daniel H. Lowenstein, M.D., Jacqueline A. French, M.D., John A. Messenheimer, M.D., Rusty Katz

This SIG will discuss gaps between what basic epilepsy researchers and clinical epileptologists think are suitable target areas for translational research in epilepsy, and how these questions align with industry and regulatory perspectives. Questions to be addressed include: 1) "Do current experimental models of epilepsy adequately recapitulate clinically relevant epileptic syndromes?", 2) "Are neocortical and non-hippocampal syndromes underemphasized causes of intractable localization-related epilepsy?", 3) "What syndromes, targets, and markets are attractive for big pharma development? Is the epilepsy research community providing targets that are attractive for commercial development?" and 4) "Can small market therapies be developed? – principles and pitfalls of the orphan drug pathway."

9:00 a.m. – 10:30 a.m.

Plenary II: Neurostimulation in the Treatment of Epilepsy: The Road Traveled and the Road Ahead

(1.5 CME Credits)

Convention Center – Lila Cockrell Theatre

This session will highlight the following Benchmark goals:

II. Develop new therapeutic strategies and optimize current approaches to cure epilepsy
  C. Optimize existing therapies and develop new therapies and technologies for curing epilepsy.
    2. Develop new approaches (e.g., gene therapy, brain stimulation, cellular therapy, pharmacotherapy) for targeted therapies.

Benchmarks Stewards: Jacqueline A. French, M.D. and Greg Worrell, M.D.
For more information, see p 53.

Overview

Despite the introduction of a large number of new AEDs in recent years, the number of patients with seizures who are refractory to medical therapy has not been significantly reduced. This has prompted renewed interest in studies of therapy with neurostimulation. Neurostimulation for the treatment of epilepsy has the benefits of no drug-related side effects and mechanisms of action presumed to be distinct from antiepileptic drugs, although the actual mechanisms of action are not established. Following the approval in 1997 of vagus nerve stimulation for adjunctive treatment of partial seizures, more recent trials have targeted intracranial sites. Just recently, separate pivotal trials for both programmed anterior thalamic stimulation and responsive neurostimulation have been completed in patients with intractable partial seizures. This symposium will focus on the principles of neurostimulation, the different types of therapy, the results of the clinical trials, and the questions that remain for the optimal application of these novel therapies.

Learning Objectives

- Apply the principles and targets of the various types of neurostimulation (chronic programmed and responsive) in determining which of these potential therapies might be appropriately used for the treatment of epilepsy
- Utilize the results of clinical trials for the three neurostimulation treatment modalities that have either been approved or have completed pivotal trials incorporating these treatment modalities into the treatment of selected patients with pharmacoresistent epilepsy
- Address unresolved questions regarding the application of neurostimulation as therapy for epilepsy and learn about additional investigations when developing care plans for patients with intractable epilepsy.

Target Audience

Intermediate, Advanced (see page 101 for details)

Credit Designation

The American Epilepsy Society designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Program
Chair: Gregory K. Bergey, M.D.

Neurostimulation: What Do We Need to Know?
Gregory K. Bergey, M.D.

Vagus Nerve Stimulation: Dawn of a New Era
Elinor Ben-Menachem, M.D., Ph.D.

Cerebral Programmed Stimulation
Richard Wennberg, M.D., FRCPC

Responsive Stimulation
Lawrence J. Hirsch, M.D.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 031-999-10-028-L01-P and provides 1.5 contact hours (.15 CEUs)

Acknowledgment:
This program is supported in part by an educational grant from Cyberonics, Inc.

10:45 a.m. – 12:15 p.m.
ILAE Symposium: Epilepsy Treatment in North America and Around The World: Can We Learn From Each Other?
(1.5 CME Credits)
Convention Center – Lila Cockrell Theatre

Overview
Despite globalization of the science that underlies medical care, common issues in epilepsy are being addressed in ways that continue to reflect specific geographic and cultural approaches to provision of healthcare. This symposium will explore areas which reflect these differences: new drug development and clinical trials; epilepsy surgery; and the impact of limited resources on availability of care. New perspectives on these topics can inform both health policy and clinical decisions related to care of people with epilepsy in North America.

Learning Objectives
- Broaden treatment options by applying geographic and cultural differences that inform approaches to temporal lobe resections in North America and around the world
- Use complementary information from clinical trial designs from different regions in managing patients with epilepsy
- Address limited resources for epilepsy care based on the experience of health policy and treatment decisions in areas outside North America.

Target Audience
Intermediate (see page 101 for details)

Program
Co-Chairs: Jacqueline A. French, M.D., Sheryl Haut, M.D.

Introduction and Overview
Jacqueline A. French, M.D., Sheryl Haut, M.D.

Are Placebo Controlled or Pragmatic Trials More Informative?
Anthony Marson, Ph.D. and Russell Katz, M.D.

How Are Epilepsy Resources Allocated Around the World? Lessons From Epilepsy Surgery
Frans Leijten, M.D., Ph.D. and Samuel Wiebe, M.D.

Credit Designation
The American Epilepsy Society designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacy Credit
ACPE Universal Activity Number (UAN) is 031-999-10-029-L04-P and provides 1.5 contact hours (.15 CEUs)

Acknowledgment:
This program is supported in part by an educational grant from Pfizer Inc.

10:45 a.m. – 12:15 p.m.
Special Interest Group Meetings
Convention Center – Location listed under each session
Please complete program survey – see page 14

Frontal Lobe Epilepsy – The Added Yield of ESI, MEG, fMRI/DTI and PET/SPECT
Convention Center – Room 007 C/D
Coordinator: Matthias J. Koepp, M.D., Ph.D.
Speakers: Matthias J. Koepp, M.D., Ph.D., Czaba Juhasz, M.D., Ph.D., Gregory D. Cascino, M.D., Margitta Seeck, M.D., Richard C. Burgess, M.D., Ph.D.

This SIG will address the added yield of new neurophysiological (ESI, MEG / MSI) and imaging (fMRI / DTI, PET / SPECT) techniques in the assessment and evaluation of patients with frontal lobe epilepsy. Speakers will present the methodological advances and limitations, challenges and opportunities for each of these techniques, and then discuss illustrative cases, which include head-to-head comparisons, illustrating which patients stand to benefit the most from which technique.

Pediatric Epilepsy Case-Based Discussion – Advances in Diagnosis and Medical and Surgical Treatment of Children with Epilepsy
Convention Center – Room 006 A-C
Coordinator: Elaine Wyllie, M.D.
Speakers: TBA

Six dynamic faculty will each present an exciting case from his or her clinical experience that teaches an important clinical point and advances our field of pediatric epilepsy. Topics will be diverse and touch on aspects of EEG, seizure semiology, genetics, neuroimaging, antiepileptic drug therapy, epilepsy surgery, and psychosocial comorbidity. We encourage audience interaction!

Sleep and Epilepsy – Memory and Cognitive Dysfunction Related to Subclinical / Interictal Epileptiform Activity During Sleep
Convention Center – Room 007 A/B
Coordinators: Carl Bazil, M.D., Ph.D., Mark S. Quigg, M.D.
Speakers: Carlo Tassinari, M.D., Mark S. Quigg, M.D.

This year's SIG will continue last year's discussion of memory relating to sleep with presentations regarding electrical status epilepticus of sleep and potential impact on cognitive development. This will lead into discussion regarding the broader question of the potential impact of interictal epileptiform discharges on memory. We will also discuss data regarding EEG changes during apnea in children and impact on cognition.

Status Epilepticus – NEW
Convention Center – Room 008
Coordinator: Tobias Loddenkemper, M.D., Susan T. Herman, M.D.
Speakers: Edward H. Bertram, M.D., James J. Riviello, M.D., Thomas P. Bleck, M.D.

This year'' inaugural SIG will provide an overview and outline new frontiers in the diagnosis and treatment of status epilepicus: Dr. Bertram will review the basic pathogenesis of pediatric status epilepticus and how rodent models may explain some of the difficulties encountered in the clinical treatment of patients. Dr. Riviello will subsequently discuss approaches and algorithms for clinical workup, identification and monitoring of status epilepticus, and Dr. Bleck will present current and novel treatment options of status epilepticus, particularly of those patients with refractory status epilepticus.

NOTES

Educational Reflections

Want CME/CE credit?

Go to www.AESNET.org

See page 101 for further details

EXHIBITOR FLOOR PLAN



Poster Walking Tours begin at the **Poster Information** table

Poster Session Entrance is outside **AES Registration**, when Exhibits are closed

Henry B. Gonzalez Convention Center, Hall A, Street Level

Exhibit Hall Hours:

Saturday, December 4 ..... 11:30 a.m. - 6:00 p.m.
Sunday , December 5 ..... 11:00 a.m. - 6:00 p.m.
Monday , December 6 ..... 11:00 a.m. - 4:00 p.m.

EXHIBITOR LOCATIONS

*Denotes Passport to Prizes Participants as of 10/22/10

Ad-Tech Medical Instrument Corp. ..... Booth #530
AED Pregnancy Registry ..... Booth #330
The American Board of Clinical Neurophysiology (ABCN) ..... Table #2
The American Board of Registration of EEG and EP Technologies (ABRET) ..... Table #1
AnalyzeDirect, Inc. ..... Booth #131
The Anita Kaufmann Foundation ..... Table #9
Athena Diagnostics ..... Booth #216
Blackrock Microsystems ..... Booth #427
Brain Vision LLC ..... Booth #615
Cadwell Laboratories, Inc. ..... Booth #431
CareFusion / Cardinal Health ..... Booth #513
Child Neurology Foundation (CNF) ..... Booth #327
Citizens United for Research in Epilepsy ..... Table #4
Clever Sys Inc. ..... Booth #238
CNS Vital Signs ..... Booth #116
Cochrane Epilepsy Group ..... Table #11
Compumedics USA ..... Booth #331
Cyberonics, Inc. ..... Booth #413
Data Sciences International ..... Booth #139
Demos Medical Publishing ..... Booth #611
DigiTrace EEG Services ..... Booth #233
Dixi Medical ..... Booth #136
Eisai, Inc. ..... Booth #501
Electrical Geodesics, Inc. ..... Booth #618
ELEKTA, Inc. ..... Booth #531
Elsevier, Inc. ..... Booth #220
Emfit Corp. ..... Booth #526
Epilepsy Foundation ..... Booth #223
Epilepsy Phenome/Genome Project ..... Booth #609
Epilepsy Therapy Project ..... Table #3
www.EpilepsyCongress.org ..... Table #13
GeneDx ..... Booth #332
GlaxoSmithKline ..... Booth #101
Global Neuro-Diagnostics, LP ..... Booth #426
Grass Technologies, An Astro-Med, Inc. Subsidiary ..... Booth #337
Integra NeuroSciences ..... Booth #324
International Dravet Syndrome Epilepsy Action (IDEA) League ..... Table #8
Intractable Childhood Epilepsy Alliance (ICE) ..... Table #14
John Libbey EUROTEXT ..... Booth #224
LGS (Lennox-Gastaut Syndrome) Foundation ..... Table #5
Lippincott Williams & Wilkins ..... Booth #226
Lundbeck Inc.* ..... Booth #313, 322
Meda Pharmaceuticals Inc. ..... Booth #617
National Association of Epilepsy Centers ..... Booth #231
Natus Medical Incorporated ..... Booth #421
Neuralynx ..... Booth #127
neuroConn GmbH ..... Booth #134
NeuroNexus Technologies ..... Booth #227
NeuroTrax ..... Booth #326
Neurovirtual USA, Inc. ..... Booth #236
The New York Times (exhibitor OTA) ..... Booth #125
Nihon Kohden America, Inc. ..... Booth #525
NINDS – National Institute of Neurological Disorders and Stroke ..... Booth #607
Northeast Regional Epilepsy Group ..... Booth #144
Novartis* ..... Booth #107, 613
Nutricia North America ..... Booth #137
Optima Neuroscience, Inc. ..... Booth #422
Oxford University Press ..... Booth #128
Pfizer Inc. ..... Booth #201
Pinnacle Technology, Inc. ..... Booth #140
PMT Corporation* ..... Booth #519
Questcor Pharmaceuticals, Inc.* ..... Booth #213, 323
Rhythmlink International, LLC ..... Booth #619
Ripple ..... Booth #118
Rochester Electro-Medical, Inc. ..... Booth #117
Seizure Tracker ..... Table #7
Smart Monitor Corp. ..... Booth #528
South Texas Comprehensive Epilepsy Center ..... Booth #424
Sunovion Pharmaceuticals Inc. ..... Booth #207
Supernus Pharmaceuticals, Inc. ..... Booth #120
SynapCell ..... Booth #122
Transgenomic, Inc. ..... Booth #229
Triangle BioSystems, Inc. ..... Booth #110
Tuberous Sclerosis Alliance ..... Table #6
Tucker-Davis Technologies ..... Booth #328
UCB, Inc.* ..... Booth #301
Wiley-Blackwell ..... Booth #218

Participate in the AES PASSPORT TO PRIZES PROGRAM!



In your AES Annual Meeting tote, you will find a Passport brochure. To be included in the drawing to win a variety of great prizes, visit all of the participating exhibitors to get your Passport validated.

When all boxes have been validated, complete your contact information and drop the Passport in the raffle drum located in the Epilepsy Resource Center (Booth #537). All entries must be received by 11:00 a.m. on Monday, December 6. The drawing will be held during lunch in the exhibit hall on that day.

Participants must be present to win. See your Passport brochure for a list of participating exhibitors.

Ad-Tech Medical Instrument Corp.
Booth #530
1901 William St
Racine, WI 53404
Phone: 262-634-1555
Toll-Free Phone: 800-776-1555
Fax: 262-634-5668
Email: ltheama@adtechmedical.com
URL: www.adtechmedical.com
Contact: Ms. Lisa Theama
For over 25 years, Epilepsy Centers have made Ad-Tech their choice for invasive electrodes for brain mapping and epilepsy monitoring. We offer a large variety of electrodes and accessories to meet you and your patients needs. Visit our Booth #530 to discover why Ad-Tech is your best choice.

AED Pregnancy Registry
Booth #330
121 Innerbelt Rd - Rm 220
Massachusetts General Hospital
Somerville, MA 02143
Phone: 617-726-7739
Toll-Free Phone: 888-233-2334
Fax: 617-724-8307
Email: csreilly@partners.org
URL: www.aedpregnancyregistry.org
Contact: Ms. Caitlin Smith
The North American AED Pregnancy Registry is dedicated to determine the safety of anticonvulsant medications taken by women during pregnancy. Stop by our booth to find out more about how your patients can participate in the Registry, and to learn more about our research findings.

The American Board of Clinical Neurophysiology (ABCN)
Table #2
2509 W Iles Ave - Ste 102
Springfield, IL 62704
Phone: 217-726-7980
Fax: 217-726-7989
Email: abcn@att.net
URL: www.abcn.org
Contact: Ms. Janice Walbert
The ABCN has a 65 year history of promoting excellence in Clinical Neurophysiology and offers an advanced examination with added competency in Epilepsy Monitoring or Intraoperative Monitoring. Oral exams were discontinued as of 2010. International testing available.

The American Board of Registration of EEG and EP Technologies (ABRET)
Table #1
2509 W Iles Ave - Ste 102
Springfield, IL 62704
Phone: 217-726-7980
Fax: 217-726-7989
Email: abreteo@att.net
URL: www.abret.org
Contact: Ms. Janice Walbert
The American Board of Registration of Electroencephalographic and Evoked Potential Technologists (ABRET) is the credentialing board for EEG, Evoked Potential, Long Term Monitoring, and Neurophysiologic Intraoperative Monitoring Technologists, and offers laboratory accreditation programs, LAB-EEG, LAB-NIOM, and LAB-LTM. Stop by the booth for the AES Job Posting special!

AnalyzeDirect, Inc.
Booth #131
7380 W 161st St
Overland Park, KS 66085
Phone: 913-338-2527
Fax: 913-338-2554
Email: info@analyzedirect.com
URL: www.analyzedirect.com
Contact: Mr. Stuart Jackson
SISCOM (Subtraction Ictal SPECT Co-registered to MRI) is an epilepsy-oriented application that enables ictal/interictal SPECT scans to be fused with an MRI of the same patient, allowing a precise anatomic localization of epileptic activation sites. SISCOM is part of the Analyze visualization and analysis software suite for research.

The Anita Kaufmann Foundation
Table #9
PO Box 11
New Milford, NJ 07646
Phone: 201-655-0420
Email: debra@akfus.org
URL: www.akfus.org
Contact: Ms. Debra Josephs
Our sole mission is to educate the public about epilepsy and to counteract stigma. We provide FREE: a groundbreaking fifth grade educational program about epilepsy, educational materials, seizure first aid training to retail establishments. We sponsor Purple Day, the largest grassroots epilepsy initiative in the world. www.purpleday.org.

Athena Diagnostics
Booth #216
377 Plantation St
Worcester, MA 01605
Toll-Free Phone: 800-394-4493
Fax: 508-752-7421
Email: aaron.keyes@athenadiagnostics.com
URL: www.athenadiagnostics.com
Contact: Mr. Aaron Keyes
Athena Diagnostics is the leader in Epilepsy genetic testing. Our comprehensive offering includes testing for Dravet syndrome, EFMR, GEFS+, Myoclonus Epilepsy, and other forms of epilepsy.

Blackrock Microsystems
Booth #427
391 Chipeta Way - Ste G
Salt Lake City, UT 84108
Phone: 801-582-5533
Fax: 801-582-1509
Email: agotshalk@i2smicro.com
URL: www.blackrockmicro.com
Contact: Mr. Andy Gotshalk
Blackrock Microsystems is recognized as a leading worldwide provider of advanced hardware and software tools that help neuroscientists, engineers, and clinicians perform cutting-edge research in areas such as fundamental neuroscience, brain-machine interfaces, and neuro-prosthetics.

Brain Vision LLC
Booth #615
2530 Meridian Pkwy - Ste 300
Durham, NC 27713
Phone: 919-806-4307
Toll-Free Phone: 877-334-4674
Fax: 214-224-0829
Email: sales@brainvision.com
URL: www.brainvision.com
Contact: Mr. Patrick Britz
Brain Vision LLC is offering you full-service solutions for neurophysiological research purposes including EEG/ERP soft- & hardware, fMRI compatible equipment, stimulation devices and accessories.

Cadwell Laboratories, Inc.
Booth #431
909 N Kellogg St
Kennewick, WA 99336
Phone: 509-735-6481
Toll-Free Phone: 800-245-3001
Fax: 509-783-6503
Email: lorik@cadwell.com
URL: www.cadwell.com
Contact: Ms. Lori Kaufman
Cadwell designs and markets neurophysiogic monitoring instruments worldwide. The Easy® III is a highly adaptable 32-150 channel system for long term epilepsy monitoring, routine clinical EEG, and continuous EEG monitoring in the ICU. Easy Ambulatory provides EEG monitoring. An all new wireless EEG recorder will be on display as well.

CareFusion / Cardinal Health
Booth #513
1850 Deming Way
Esser Place
Madison, WI 53562
Phone: 608-829-8574
Toll-Free Phone: 800-356-0007
Fax: 608-869-8737
Email: julie.phillips@carefusion.com
URL: www.carefusion.com
Contact: Ms. Julie Phillips

Child Neurology Foundation (CNF)
Booth #327
2000 W 98th St
Bloomington, MN 55431
Phone: 952-641-4466
Fax: 952-881-6276
Email: jennifer.wright704@gmail.com
URL: www.childneurologyfoundation.org
Contact: Ms. Jennifer Wright
The mission of the Child Neurology Foundation is to: advocate for 18 million children with neurologic disorders, fund research, promote child neurology as a career, foster continuing education and inform the general public as to the status and value of child neurology services. This is carried out thanks to the generosity of our doctors, donors and volunteers.

Citizens United for Research in Epilepsy
Table #4
223 W Erie St - Ste 2SW
Chicago, IL 60654
Phone: 312-255-1801
Fax: 312-255-1809
Email: danielle.davis@cureepilepsy.org
URL: www.cureepilepsy.org
Contact: Ms. Danielle Davis
Citizens United for Research in Epilepsy (CURE) is a nonprofit organization dedicated to finding a cure for epilepsy by raising funds for research and by increasing awareness of the prevalence and devastation of this disease.

Clever Sys Inc.
Booth #238
11425 Isaac Newton Square - Ste 202
Reston, VA 20190
Phone: 703-787-6946
Fax: 703-757-7467
Email: nzhang@cleversysinc.com
URL: www.cleversysinc.com
Contact: Ms. Naili Zhang
Clever Sys Inc develops products for lab animal behavior analysis with "Behavior Recognition" technology, utilizing information of animal full body as well as body parts to automatically analyze behaviors, to provide support for novel behavioral paradigms, measurements of new parameters, which are more revealing of the intrinsic of animal behaviors.

CNS Vital Signs
Booth #116
598 Airport Blvd - Ste 1400
Morrisville, NC 27560
Toll-Free Phone: 888-750-6941
Fax: 888-650-6795
Email: support@cnsvs.com
URL: www.cnsvs.com
Contact: Ms. Nancy Jo Chatham
CNS Vital Signs is a world leader in the design and development of neurocognitive assessment tools. CNS Vital Signs gives practicing clinicians and researchers assessment platforms that provide the ability to detect subtle cognitive deficits while creating a baseline of cognitive function (MEASURE) and track subtle cognitive changes (MONITOR).

Cochrane Epilepsy Group
Table #11
Department of Neurological Science
University of Liverpool
Clinical Sciences Building - Lower Lane
Liverpool L9 7LJ United Kingdom
Phone: 44-151-529-5462
Fax: 44-151-529-5465
Email: a.g.marson@liv.ac.uk
URL: www.epilepsy.cochrane.org
Contact: Professor Tony Marson
The Cochrane Epilepsy Group comprises an international network of health care professionals, researchers and consumers preparing, maintaining, and disseminating systematic reviews of randomised controlled trials in the treatment of epilepsy.

Compumedics USA
Booth #331
6605 W WT Harris Blvd - Ste F
Charlotte, NC 28269
Phone: 704-749-3200
Fax: 704-749-3299
Email: tom.lorick@compumedicsusa.com
URL: www.compumedics.com
Contact: Mr. Tom Lorick

Cyberonics, Inc.
Booth #413
100 Cyberonics Blvd
Houston, TX 77058
Phone: 281-228-7200
Toll-Free Phone: 800-332-1375
Fax: 281-218-9332
Email: kari.sokolow@cyberonics.com
URL: www.cyberonics.com
Contact: Ms. Kari Sokolow
Cyberonics, Inc. is a leader in the neurostimulation market and continues to demonstrate this commitment to physicians and their patients by providing innovative and effective medical device solutions for epilepsy. VNS Therapy® is the only FDA-approved device for the treatment of refractory epilepsy, with more than 55,000 patients implanted worldwide.

Data Sciences International
Booth #139
119 14th St NW - Ste 100
St. Paul, MN 55112
Phone: 651-481-7400
Fax: 651-481-7404
Email: shachtman@datasci.com
URL: www.datasci.com
Contact: Mr. Steve Hachtman
DSI provides advanced physiological monitoring solutions for pulmonary, cardiovascular, and CNS applications involving acute or chronic studies. Products include advanced data acquisition and analysis systems synchronizing implantable and externally worn telemetry with hardwired amplifiers. Infusion solutions include catheters and iPRECIO infusion pumps.

Demos Medical Publishing
Booth #611
11 W 42nd St - 15th Fl
New York, NY 10036
Phone: 212-683-0072
Toll-Free Phone: 800-532-8663
Fax: 212-941-7842
Email: thastings@demosmedpub.com
URL: www.demosmedpub.com
Contact: Mr. Thomas Hastings
Visit Demos Medical Publishing in Booth #611 to see our complete list of titles in epilepsy and related disciplines. Demos is offering a 15% discount on all orders placed at the meeting with free domestic shipping on orders over $29.

DigiTrace EEG Services
Booth #233
200 Corporate Pl - Ste 5
Peabody, MA 01960
Phone: 978-536-7400
Toll-Free Phone: 800-334-5085
Fax: 978-535-9778
Email: stuthill@sleepmed.md
URL: www.sleepmed.md
Contact: Mr. Stuart Tuthill
DigiTrace EEG Services is a division of SleepMed, Inc. We are the largest provider of sleep and EEG home monitoring services in the U.S. DigiTrace EEG products and services are used by dozens of U.S. comprehensive epilepsy centers as well as over 30 SleepMed service locations around the country. We conduct 25,000 EEG and video EEG test days annually.

Dixi Medical
Booth #136
4 Chemin De Palente - BP 889
Besancon 25025 France
Phone: 03-81-88-98-90
Fax: 03-81-88-98-99
Email: secretariat@diximicrotechniques.com
URL: www.diximedical.com
Contact: Mr. Jose Moya
Medical devices used in functional and stereotactic neurosurgery for the treatment of epilepsy and Parkinson (depth electrodes, cortical electrodes, foramen oval electrodes, epidural electrodes, surgical implements, products developed according to your specific requirements) Main customers: neurosurgical departments of the main centers in Europe, Canada, South America.

Eisai, Inc.
Booth #501
100 Tice Blvd
Woodcliff Lake, NJ 07677
Phone: 201-692-1100
Fax: 201-746-3196
Email: dawn_couch@eisai.com
URL: www.eisai.com
Contact: Ms. Dawn Williams
Eisai Inc. is the U.S. pharmaceutical operation of Eisai Co. Ltd., a research-based human healthcare (hhc) company that discovers, develops and markets products throughout the world. Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care.

Electrical Geodesics, Inc.
Booth #618
1600 Millrace Dr - Ste 307
Eugene, OR 97403
Phone: 541-687-7962
Fax: 541-687-7963
Email: info@egi.com
URL: www.egi.com
Contact: Ms. DeeDee Nunes
Electrical Geodesics, Inc. (EGI) offers complete EEG systems from 32-channel routine and ambulatory EEG systems to 256-channel epilepsy monitoring dEEG systems. Designed to maximize patient comfort, clinical performance and workflow. Also, EGI offers MRI compatible EEG systems, the first practical whole-head EEG products that work within the MR environment.

ELEKTA, Inc.
Booth #531
4775 Peachtree Industrial Blvd - Bldg 300 - Ste 300
Norcross, GA 30092
Phone: 770-670-2409
Fax: 770-448-6338
Email: doris.aubuchon@elekta.com
URL: www.elekta.com
Contact: Ms. Doris Aubuchon
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. Elekta Neuromag, the world's most advanced and most used MEG system, provides real-time mapping of brain activity by non-invasively measuring the magnetic fields produced by the brain, better and more accurately than before.

Elsevier, Inc.
Booth #220
25607 Singing Rain
San Antonio, TX 78260
Phone: 210-497-3198
Fax: 210-497-3198
Email: g.dixon@elsevier.com
URL: www.gdixon.com
Contact: Mr. Greg Dixon
SAUNDERS, MOSBY, CHURCHILL LIVINGSTONE, BUTTERWORTH HEINEMANN and HANLEY BELFUS, now under the umbrella of ELSEVIER, INC., proudly present our latest titles. Visit us at booth 220 and browse through our complete selection of publications including books, periodicals and software. ELSEVIER, INC., building insights, breaking boundaries.

Emfit Corp.
Booth #526
2009 Ranch Rd 620 N - Ste 820
Austin, TX 78734
Phone: 512-266-6950
Toll-Free Phone: 877-323-6348
Fax: 512-266-7203
Email: sales.us@emfit.com
URL: www.emfit.com
Contact: Ms. Christine Ocean-Rintala
Emfit is a world-leading manufacturer of ferroelectret sensors and related embedded electronics. For over a decade we have manufactured fall & wandering alarms, and non-body-contact seizure detection systems for both hospital and home care. We are featuring the Movement Monitor, a unique system designed for nighttime monitoring of abnormal movements.

www.EpilepsyCongress.org
Table #13
7 Priory Hall
Stillorgan
Dublin, Ireland 18
Phone: 353-1-205-6720
Fax: 353-1-205-6156
Email: info@epilepsycongress.org
URL: www.epilepsycongress.org
Contact: Mr. Gus Egan
The ILAE / IBE Congress Secretariat is the point of contact for the International Epilepsy Congress and all regional epilepsy congresses of the International League Against Epilepsy and the International Bureau for Epilepsy. For details on all upcoming congresses, please visit http://www.epilepsycongress.org.

Epilepsy Foundation
Booth #223
8301 Professional Pl E
Landover, MD 20785
Phone: 301-459-3700
Fax: 301-918-2103
Email: gjones@efa.org
URL: www.epilepsyfoundation.org
Contact: Ms. Gigi Jones
The Epilepsy Foundation is the national voluntary agency dedicated solely to the welfare of the nearly 3 million people with epilepsy in the U.S. and their families. The organization works to ensure that people with seizures are able to participate in all life experiences; and to promote research for a cure.

Epilepsy Phenome/Genome Project
Booth #609
UCSF, Dept of Neurology
521 Parnassus Ave, Box 0138
San Francisco, CA 94143
Phone: 415-519-8962
Toll-Free Phone: 888-279-EPGP
Email: info@epgp.org
URL: www.epgp.org
Contact: Ms. Kristen Schardein
The Epilepsy Phenome/Genome Project is an NINDS-sponsored collaboration to identify genes that influence the development of epilepsy and pharmacoresponsiveness. The study is enrolling 1) pairs of first-degree relatives with nonsymptomatic epilepsy, and 2) participants with infantile spasms, Lennox-Gastaut Syndrome, polymicrogyria, or periventricular heterotopias.

Epilepsy Therapy Project
Table #3
PO Box 742
Middleburg, VA 20118
Phone: 540-687-8077
Fax: 540-687-8066
Email: dianna@epilepsytherapyproject.org
URL: www.epilepsy.com
Contact: Mrs. Dianna Pinkerton
Epilepsy Therapy Project, sponsor of epilepsy.com, is a 501 (c) (3) not-for-profit organization founded by parents and doctors caring for children with uncontrolled seizures by supporting the development of new therapies that offer freedom from seizures and side effects. Our mission is to accelerate ideas into therapies for people living with epilepsy and seizures.

GeneDx
Booth #332
207 Perry Pkwy
Gaithersburg, MD 20877
Phone: 301-519-2100
Toll-Free Phone: 800-229-5227
Fax: 201-791-1941
Email: genedx@genedx.com
URL: www.genedx.com
Contact: Ms. Marianne Sansing
GeneDx offers tests for more than 300 rare Mendelian disorders, using DNA sequencing and deletion/duplication analysis of the associated gene(s) and also offers oligonucleotide microarray-based testing. Services include mutation analysis, carrier testing, prenatal diagnosis, and mutation confirmations.

GlaxoSmithKline
Booth #101
5 Moore Dr
Research Triangle Park, NC 30310
Phone: 404-921-5179
Toll-Free Phone: 800-421-9202
Fax: 404-921-5195
Email: csoltes@czarnowski.com
URL: www.gsk.com
Contact: Ms. Christy Soltes
GlaxoSmithKline is a leading research-based pharmaceutical company with a powerful combination of skills to discover and deliver innovative medicines. We offer a number of program resources to support effective health management strategies and improve patient care. Please visit our exhibit to learn more about our products and resources.

Global Neuro-Diagnostics, LP
Booth #426
1278 Justin Rd - Ste 109
Lewisville, TX 75077
Toll-Free Phone: 866-848-2522
Fax: 877-290-1544
Email: janice.shock@globalneuro.com
URL: www.globalneuro.net
Contact: Ms. Janice Shock
Global Neuro-Diagnostics is the gold standard for Ambulatory Video EEG monitoring. Long-term monitoring brought directly to the patient in the comfort of their own home.

Grass Technologies, An Astro-Med, Inc. Subsidiary
Booth #337
600 E Greenwich Ave
West Warwick, RI 02893
Phone: 401-828-4000
Toll-Free Phone: 877-472-7779
Fax: 401-822-2430
Email: tpollard@astromed.com
URL: www.grasstechnologies.com
Contact: Ms. Tina Pollard
Grass offers instrumentation for PSG, EEG, LTM, Neuromonitoring — from lab-based to ambulatory to WIRELESS recorders — at affordable prices. We also offer the new S12X Cortical Stimulator and a full line of electrodes, transducers, etc. — visit our Online Store.

Integra NeuroSciences
Booth #324
22 Terry Ave
Burlington, MA 01803
Phone: 781-272-1233
Toll-Free Phone: 800-466-6814
Fax: 781-272-2428
Email: steve.scavone@integralife.com
URL: www.integralife.com
Contact: Mr. Jason Ellnor
Integra NeuroSciences offers a wide array of EEG electrodes and tools for Brain Mapping. Auragen™ cortical and depth electrodes are designed to maximize strength, sensitivity, and pliability to facilitate safe and accurate EEG monitoring. A wide range of features simplify the placement, performance, and identification of the electrodes.

International Dravet Syndrome Epilepsy Action (IDEA) League
Table #8
PO Box 797
Deale, MD 20751
Phone: 443-607-8267
Email: baker@idea-league.org
URL: www.idea-league.org
Contact: Ms. Marilyn Baker
The IDEA League is a powerful global partnership of parents and medical experts united in the goal of improving treatment for Dravet syndrome and related forms of epilepsy while providing information and support to patients and families.

Intractable Childhood Epilepsy Alliance (ICE)
Table #14
464 Heritage Dr
Lewisville, NC 27023
Phone: 336-918-9440
Fax: 336-946-1571
Email: michellewelborn@gmail.com
Contact: Dr. Michelle Welborn

John Libbey EUROTEXT
Booth #224
127 Avenue de la Republique
Montrouge 92120 France
Phone: 33-1-4673-0679
Fax: 33-1-4084-0999
Email: gilles.cahn@jle.com
URL: www.jle.com
Contact: Mr. Gilles Cahn
John Libbey Eurotext is the publisher of the greatest world-renowned specialists in epilepsy, through the journals *Epileptic Disorders* and *Épilepsies* (official organ of the French League Against Epilepsy), and moreover through book series like *Current problems in Epilepsy, Progress in Epileptic Disorders, Topics in Epilepsy, Mariani Foundation Paediatric Neurology,* etc.

LGS (Lennox-Gastaut Syndrome) Foundation
Table #5
PO Box 6948
New York, NY 10150
Phone: 718-374-3800
Email: christina@lgsfoundation.org
URL: www.lgsfoundation.org
Contact: Ms. Christina San Inocencio
The LGS Foundation is a non-profit organization dedicated to providing information about Lennox-Gastaut syndrome, a rare and severe form of epilepsy, while raising funds to pursue additional research, services and programs for LGS families.

Lippincott Williams & Wilkins
Booth #226
1114 Jack Pine
San Antonio, TX 78232
Phone: 210-643-1745
Toll-Free Phone: 888-637-7741
Fax: 210-499-0783
Email: geremey.deborde@wolterskluwer.com
URL: www.lww.com
Contact: Mr. Geremey DeBorde

Lundbeck Inc.*
Booth #313, 322
4 Parkway North - Ste 200
Deerfield, IL 60015
Phone: 847-282-1000
Fax: 847-282-1001
Email: contact@lundbeck.com
URL: www.lundbeckinc.com
Contact: Ms. Margaret Trempe
Headquartered in Deerfield, Illinois, with a portfolio of 17 specialty therapies and a pipeline of promising central nervous system (CNS) drugs, Lundbeck Inc. is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders and rare diseases for which few, if any, effective treatments are available.

Meda Pharmaceuticals Inc.
Booth #617
265 Davidson Ave
Somerset, NJ 08873
Phone: 732-564-2326
Fax: 732-564-2300
Email: jrisimini@medapharma.us
URL: www.medpointepharma.com
Contact: Ms. Jean Risimini
Meda Pharmaceuticals is a global specialty pharmaceutical company that markets and promotes branded prescription products in the respiratory, pain therapeutics, and cancer palliative care areas.

National Association of Epilepsy Centers
Booth #231
5775 Wayzata Blvd - Ste 200
Minneapolis, MN 55416
Phone: 952-525-4511
Fax: 952-525-1560
Email: info@naec-epilepsy.org
URL: www.naec-epilepsy.org
Contact: Ms. Barbara Anstett

Natus Medical Incorporated
Booth #421
1501 Industrial Rd
San Carlos, CA 94070
Phone: 650-802-0400
Toll-Free Phone: 800-303-0306
Fax: 650-802-0401
Email: marcom@natus.com
URL: www.natus.com
Contact: Ms. Carol Stone
Natus Medical Incorporated, under the Xltek, Dantec & Bio-logic brands, designs, manufactures and distributes a wide range of neurology & sleep diagnostic systems and supplies. Natus Neurology product lines are designed to deliver the latest innovations in EEG, Epilepsy, ICU, Ambulatory, PSG, EMG and IOM needs.

Neuralynx
Booth #127
105 Commercial Dr
Bozeman, MT 59715
Phone: 406-585-4542
Fax: 406-585-9034
Email: shawn@neuralynx.com
URL: www.neuralynx.com
Contact: Mr. Shawn Olson
Neuralynx has been providing Electrophysiology and Neuroscience researchers with the highest quality single-unit, multichannel Electrophysiology recording equipment since 1993. Our products represent the "state of the art" in high density Data Acquisition and Experiment Control solutions.

neuroConn GmbH
Booth #134
Grenzhammer 10
Ilmenau 98693 Germany
Phone: 49-3677-68-9790
Fax: 49-3677-68-979
Email: klaus.schellhorn@neuroconn.de
URL: www.neuroconn.de
Contact: Mr. Klaus Schellhorn
Rogue Resolutions offers suites of products for research in neuromodulation (tDCS, rTMS, neurofeedback) and noninvasive neuroimaging (fMRI-EEG, TMS-EEG, TMS-NIRS & BRAINSIGHT TMS navigation) from Rogue Research, neuroConn & Jalimedical.

NeuroNexus Technologies
Booth #227
655 Fairfield Ct
Ann Arbor, MI 48108
Phone: 734-913-8858
Fax: 734-786-0069
Email: kckong@neuronexus.com
URL: www.neuronexus.com
Contact: K. C. Kong
NeuroNexus Technologies, Inc. is a global leader for innovative neural interface products and technologies to meet both current and upcoming needs in neuroscience research, neurosurgery, and neurostimulation. Visit our Booth for a sample of intracortical and microECoG array.

NeuroTrax
Booth #326
5909 West Loop South - Ste 555
Bellaire, TX 77401
Phone: 888-418-0380
Fax: 713-660-6777
Email: jay@neurotrax.com
URL: www.neurotrax.com
Contact: Ms. Shiri Oberlender
NeuroTrax Corporation's MindStreams® is a Computer Administered neurocognitive testing system that is supervised by a Medical Support staff. Mindstreams evaluates seven cognitive domains that may be impacted by disease conditions such as epilepsy, MS, PD and more. Performance scores are compared by a normative Database of matched age and education demographics.

Neurovirtual USA, Inc.
Booth #236
2315 NW 107th Ave - Ste 1M27 - Box 27
Doral FL 33172
Phone: 786-693-8200
Toll-Free Phone: 888-675-3378
Fax: 305-393-8429
Email: tpierson@neurovirtual.com
URL: www.neurovirtial.com
Contact: Mr. Tad Pierson
Neurovirtual is the manufacturer of the BWII EEG, a fully portable turnkey EEG system. The BWII EEG has synchronized video, FFT digital analysis, free unlimited reading stations, lifetime free software upgrades and lifetime free technical support.

The New York Times (exhibitor OTA)
Booth #125
613 South Ave
Weston, MA 02493
Phone: 781-890-2661
Fax: 781-890-2799
Email: paula@ontheavenuemarketing.com
URL: www.ontheavenuemarketing.com
Contact: Ms. Paula Sumberg
The New York Times is distributed internationally and is the largest metropolitan newspaper in the United States. Founded in 1851, the newspaper has won 94 Pulitzer prizes, winning its first in 1918 for its World War I reporting. Subscribe today!

Nihon Kohden America, Inc.
Booth #525
90 Icon St
Foothill Ranch, CA 92610
Phone: 949-580-1555
Toll-Free Phone: 800-325-0283
Fax: 949-580-1550
Email: info@nkusa.com
URL: www.nkusa.com
Contact: Ms. Deidra Miltimore
Nihon Kohden's Neurology product portfolio includes instrumentation for Epilepsy Monitoring, Electroencephalography, EEG & PSG Ambulatory Recording, Polysomnography, Wireless EEG & PSG, Home Sleep Testing/PSG, Electromyography, Evoked Potentials, Intra-operative and cEEG ICU monitoring.

NINDS – National Institute of Neurological Disorders and Stroke
Booth #607
31 Center Dr - Bldg 31 - Rm 8A07
Bethesda, MD 20892
Phone: 301-496-5751
Fax: 301-402-2186
Email: braininfo@ninds.nih.gov
URL: www.ninds.nih.gov
Contact: Ms. Ann Brown
The National Institute of Neurological Disorders and Stroke (NINDS) supports basic, translational, and patient-oriented research on epilepsy prevention, diagnosis and treatment, including mechanisms underlying seizures and epileptogenesis, gene discovery and targeted therapeutics, epidemiology, psychosocial and behavioral consequences, and development of new therapies.

Northeast Regional Epilepsy Group
Booth #144
20 Prospect Ave - Ste 800
Hackensack, NJ 07601
Phone: 201-343-6676
Fax: 201-343-6689
Email: hasanhusaini@gmail.com
URL: www.epilepsygroup.com
Contact: Mr. Hasan Husaini

Novartis*
Booth #107, 613
180 Park Ave
Florham Park, NJ 07932
Phone: 862-778-6577
Fax: 973-781-6774
Email: robert.fairbairn@novartis.com
URL: www.novartisoncology.com
Contact: Mrs. Judith Picciuti
Novartis discovers and develops innovative therapies that aim to help change the way patients live with neurological disorders. With a strong marketed portfolio and one of the broadest and most comprehensive pipelines in the industry, Novartis is a global market leader with medicines that address unmet patient needs.

Nutricia North America
Booth #137
9900 Belward Campus Dr - Ste 100
Rockville, MD 20850
Phone: 301-795-2300
Toll-Free Phone: 800-365-7354
Fax: 301-795-2301
Email: ronda.keys@shsna.com
URL: www.shsna.com
Contact: Ms. Ronda Keys

Optima Neuroscience, Inc.
Booth #422
13420 Progress Blvd - Ste 200
Alachua, FL 32615
Phone: 352-371-8281
Toll-Free Phone: 877-900-5334
Fax: 386-462-0606
Email: aburks@optimaneuro.com
URL: www.optimaneuro.com
Contact: Ms. Amanda Burks
Founded by epileptologist J. Chris Sackellares, M.D., Optima Neuroscience develops novel software, systems, and devices for the diagnosis and treatment of neurological disorders. The company's initial product IdentEvent® EEG Review Software with Seizure Detection, allows clinicians to quickly identify seizure activity with accuracy and confidence.

Oxford University Press
Booth #128
198 Madison Ave
New York, NY 10016
Phone: 212-726-6000
Fax: 212-726-6494
Email: colleen.mccue@oup.com
URL: www.oup.com/us
Contact: Ms. Colleen McCue

Pfizer Inc.
Booth #201
235 E 42nd St
New York, NY 10017
Phone: 212-733-2323
Fax: 212-973-7465
Email: krista.j.busch@pfizer.com
URL: www.pfizer.com
Contact: Ms. Krista Busch
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Please visit the Pfizer, Inc. exhibit featuring: LYRICA® (pregabalin)

Pinnacle Technology, Inc.
Booth #140
2721 Oregon St
Lawrence, KS 66046
Phone: 785-832-8866
Fax: 785-749-9214
Email: donnaj@pinnaclet.com
URL: www.pinnaclet.com
Contact: Ms. Linda Lane
Pinnacle Technology provides new tools for rodent research that simplify measurement, reduce cost and enable new discoveries. Current products include: wireless systems for the real-time measurement of neurotransmitters including glutamate and glucose, EEG/EMG systems for seizure and sleep monitoring, sleep deprivation chambers and integrated video recording.

PMT Corporation*
Booth #519
1500 Park Rd
PO Box 610
Chanhassen, MN 55317
Phone: 952-470-0866
Toll-Free Phone: 800-626-5463
Fax: 952-470-0865
Email: ecaille@pmtcorp.com
URL: www.pmtcorp.com
Contact: Mr. Eric Caille
PMT offers the latest innovation in Electrodes and Microwires electrodes for epilepsy & research. With our direct sales force nationwide we can be on-site with you working on refining our products to your requirements. For more information, a free consultation or to schedule a few trial, contact us today at 1-800-MANKIND or (952)470-0866.

Questcor Pharmaceuticals, Inc.*
Booth #213, 323
3260 Whipple Rd
Union City, CA 94587
Phone: 510-400-0700
Toll-Free Phone: 800-301-7426
Fax: 510-400-0799
Email: agasperino@questcor.com
URL: www.questcor.com
Contact: Ms. Andrea Gasperino
Questcor Pharmaceuticals is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Questcor's lead product is HP Acthar® Gel (repository corticotropin injection), a naturally-derived formulation of adrenocorticotropic hormone (ACTH) used in a variety of disorders, including the treatment of exacerbations associated with MS.

Rhythmlink International, LLC
Booth #619
1140 First St South
Columbia, SC 29209
Phone: 803-252-1222
Toll-Free Phone: 866-633-3754
Fax: 803-252-1111
Email: sales@rhythmlink.com
URL: www.rhythmlink.com
Contact: Ms. Lori Melton
Rhythmlink International, LLC designs, manufactures and distributes a suite of neurodiagnostic accessories including Disposable EEG Cup Electrodes, Spider™ EEG Electrodes, Sticky Pad™ Surface Electrodes and Subdermal Needle Electrodes. For more information about Rhythmlink or to request FREE samples, visit Rhythmlink.com.

Ripple
Booth #118
2015 South 1100 East
Salt Lake City, UT 84106
Phone: 801-413-0139
Fax: 801-413-2874
Email: sales@rppl.com
URL: www.rppl.com
Contact: Dr. Daniel McDonnall
Ripple provides neurophysiology data acquisition systems for research. Our systems are compact, portable, and heavily optimized for real-time, closed-loop control applications with hundreds of channels of EMG, EEG and microelectrode data. Many of our software components are available as Open Source with support for Windows, Mac OS X, and Linux.

Rochester Electro-Medical, Inc.
Booth #117
4212 Cypress Culch Dr
Lutz, FL 33559
Phone: 813-963-2933
Fax: 813-960-4563
Email: aberkins@rochesterelectromed.com
URL: www.rochesterelectromed.com/2010
Contact: Ms. Alayne Berkins

Seizure Tracker
Table #7
7964-R Conell Ct
Alexandria, VA 22079
Phone: 703-399-8448
Email: rob@seizuretracker.com
URL: www.seizuretracker.com
Contact: Mr. Robert Moss
SeizureTracker.com is dedicated to providing people living with epilepsy and their care givers with free comprehensive tools to help understand relationships between seizure activity and anti-epileptic treatments.

Smart Monitor Corp.
Booth #528
5655 Silver Creek Valley Rd
San Jose, CA 95138
Phone: 408-754-1690
Fax: 408-351-0154
Email: anoo@smart-monitor.com
URL: www.smart-monitor.com
Contact: Ms. Anoo Nathan

South Texas Comprehensive Epilepsy Center
Booth #424
7703 Floyd Curl Dr - MSC 7883
San Antonio, TX 78229
Phone: 210-617-5161
Fax: 210-567-4659
Email: cavazosj@uthscsa.edu
Contact: Dr. Jose E. Cavazos
The South Texas Comprehensive Epilepsy Center is the only level IV center in South Texas. It offers the most advanced medical, dietary and surgical therapies to people whose seizures are not well controlled, and inpatient and outpatient diagnostic evaluations to determine the best treatment for adults and children with epilepsy.

Sunovion Pharmaceuticals Inc.
Booth #207
84 Waterford Dr
Marlborough, MA 01752
Phone: 508-481-6700
Fax: 508-357-7490
Email: info@sunovion.com
URL: www.sunovion.com
Contact: Ms. Allison Bumsted
Sunovion Pharmaceuticals Inc., is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving large and growing markets and unmet medical needs. Learn more about our research in epilepsy at our Booth.

Supernus Pharmaceuticals, Inc.
Booth #120
1550 East Gude Dr
Rockville, MD 20850
Phone: 301-838-2500
Fax: 301-424-1364
Email: inquiries@supernus.com
URL: www.supernus.com
Contact: Ms. Christine Ray
Supernus is a specialty pharma company dedicated to improving the lives of patients. We use our innovative technologies to develop products that are designed to: - improve patient compliance - reduce side effects - improve tolerability, and - address unmet medical needs. For further information please contact Todd Horich at 301-838-2500 or inquiries@supernus.com.

SynapCell
Booth #122
Pépinière Biopolis
5 avenue du grand sablon
La Tronche 38700 France
Phone: 334-76-63-75-90
Email: contact@synapcell.com
URL: www.synapcell.com
Contact: Dr. Corinne Roucard
SynapCell is a preclinical CRO providing highly predictive solutions to evaluate the therapeutic potential of CNS drug candidates in epilepsy and neuroprotection. We develop innovative and customized solutions based on well validated animal models of absence epilepsy (GAERS rat) or mesial-temporal lobe epilepsy (MTLE mouse), as well as solutions in neuroprotection.

Transgenomic, Inc.
Booth #229
12325 Emmet St
Omaha, NE 68164
Phone: 610-293-8089
Fax: 610-293-8099
Email: bkreifels@transgenomic.com
URL: www.transgenomic.com
Contact: Ms. Becky Kreifels
Transgenomic provides clinical reference laboratory services specializing in molecular diagnostics and pharmacogenomic services specializing in mutation detection, assay design and validation, and pre-clinical to clinical trial support. Transgenomic also manufactures automated systems for high-sensitivity genetic variation analysis, mutation detection and cytogenetics.

Triangle BioSystems, Inc.
Booth #110
2228 Page Rd - Ste 108
Durham, NC 27703
Phone: 919-361-2663
Fax: 919-544-3061
Email: mcalarco@trianglebiosystems.com
URL: www.trianglebiosystems.com
Contact: Mr. Michael Calarco
Triangle BioSystems Inc. of Durham, North Carolina is an international biomedical device company focused on miniature hardware telemetry solutions. Our products aid research in areas such as Electrophysiology, Psychology, Neurology and Pharmacology. We also partner with universities and institutions to develop custom products and solutions.

Tuberous Sclerosis Alliance
Table #6
801 Roeder Rd - Ste 750
Silver Spring, MD 20910
Phone: 301-562-9890
Toll-Free Phone: 800-225-6872
Fax: 301-562-9870
Email: info@tsalliance.org
URL: www.tsalliance.org
Contact: Ms. Katie Smith
Founded in 1974, the TS Alliance is the only national voluntary health agency dedicated to finding a cure for TSC while improving the lives of those affected. TSC is a genetic disorder characterized by seizures and tumor growth in vital organs such as the brain, heart, kidneys, lungs and skin.

Tucker-Davis Technologies
Booth #328
11930 Research Circle
Alachua, FL 32615
Phone: 386-462-9622
Fax: 386-462-5365
Email: calldredge@tdt.com
URL: www.tdt.com
Contact: Ms. Cheryl Alldredge
Tucker-Davis Technologies is a leading manufacturer of DSP-based data acquisition and stimulus systems, offering products ranging from electrodes to complete neurophysiology and evoked potentials workstations. New this year: high channel count data streamer, volt/current stimulator, and software updates to our ABR and spike sorting software.

UCB, Inc.*
Booth #301
1950 Lake Park Dr
Smyrna, GA 30080
Phone: 770-970-7500
Toll-Free Phone: 800-477-7877
Fax: 770-970-8917
Email: betsy.andrews@ucb.com
URL: www.ucb.com
Contact: Ms. Betsy Andrews
UCB is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta, Ga. Visit www.ucb.com for more information about UCB.

Wiley-Blackwell
Booth #218
111 River St
Hoboken, NJ 07030
Phone: 201-748-6000
URL: http://onlinelibrary.wiley.com/subject/neuro
Contact: Ms. Ashley Melando
Wiley-Blackwell is the international scientific, technical, medical and scholarly publishing business of John Wiley & Sons, with strengths in neurology and neuroscience and the official publishing partner of AES and ILAE. For more information on *Epilepsy Currents* and *Epilepsia*, please visit http://onlinelibrary.wiley.com/subject/neuro.

A

Abdelmoity, A. 2.223, 2.226, 2.229, 2.237
Abdulla, F. 3.327
Abend, N.S. 1.080
Abidin, I. 2.189
Abou Reslan, W. 2.122
Abou-Khalil, B. 1.170, 1.271, 1.277, 1.290, 3.094, 3.198
Abraham, J. 1.026
Abramson, D. 3.363
Abramson, R.K. 3.249
Acebes, J. 2.243
Acevedo, K.G. 3.077
Acharya, J. 1.064
Acharya, V. 1.064
Ackerman, M. 2.356
Acosta, S. 3.063
Acton, E.K. 3.278
Adhami, S. 2.205
Adstamongkonkul, D. 2.325
Afra, P. 2.071, 2.159
Afshari, Z. 3.153
Agadi, S. 1.053, 1.068, 1.111, 1.125, 1.187, 2.030
Agarwal, N. 2.231
Agarwal, R. 1.150
Agrawal, N. 3.287
Agrawal, S. 2.169, 2.199
Agricola, K. 2.221
Aguglia, U. 3.313
Aguilar Amat Prior, M. 3.111, 3.119
Ahlm, S. 3.337
Ahmadi, M.E. 2.116
Ahmed, N. 2.307
Ahmed, S.N. 2.342, 3.260
Ahn, Y. 2.183
Ahronowitz, I. 3.312
Aiguabella, M. 2.243
Akalan, N. 1.147
Akamatsu, N. 1.341
Akiyama, T. 1.062, 2.083
Akman, C. 1.068, 1.125, 1.187, 1.371, 2.030
Al Hammadi, F.H. 1.295
Al Neaimi, O. 1.295
Al Saadi, T.M. 1.295
Al-Kaylani, M. 2.262
Alabousi, A. 3.323
Alaghband, Y. 3.034
Alan, S. 1.147
Albertson, A. 1.005
Albrecht, M. 1.225
Aldenkamp, A.P. 1.374
Alduligan, M. 1.079, 2.064
Alehan, F. 1.245, 2.187
Alekar, S. 1.257
Alessi, R. 3.262, 3.279
Alexander, H.K. 2.002
Alexander, R.P. 1.322
Alexandre, V. 2.147
Alexandre Jr., V. 2.023
Alexopoulos, A. 1.091, 1.177, 1.179, 1.184, 1.326, 2.038, 2.073, 2.078, 2.086, 2.087, 3.027, 3.131, 3.215, 3.220
Alfaro, C.T. 1.099
Alfirevic, A. 3.315
Alhusaini, S. 3.301, 3.317
Ali, I. 2.069
Ali, K. 2.058
Ali Taha, H.M. 1.295
Alkonyi, B. 3.173
Allen, C. 2.212
Allen, P. 2.094
Allison, K. 2.361
Almaraz, C. 1.175
Almas, M. 1.261, 1.275
Almehdar, A. 2.138
Almeida, E. 2.023
Almeida, J.P. 1.327
Almubarak, S.A. 2.065
Alonso, M.A. 2.246
Alonso, N.B. 2.241
Alonso-Vanegas, M. 2.259, 3.164B, B.01
Alore, P.L. 1.231
Alshekhlee, A. 2.336
Altenmüller, D.M. 1.138
Althaus, A.L. 3.342
Altman, N. 3.185
Alur, S. 2.308
Aluri, J. 2.192
Alves-Leon, S.V. 2.107
Amaro Jr, E. 1.327
Amarreh, I.G. 2.098
Amrom, D.R. 3.291, 3.292
Anand, A. 1.200
Anang, J. 2.347
Anaya, J. 1.225
Andermann, E. 3.291, 3.292
Andermann, F. 2.039, 3.291, 3.292
Andersen, D. 2.015
Anderson, A. 1.007, 1.034, 1.053, 2.030, 3.023
Anderson, C.T. 2.008, 2.247
Anderson, K. 1.330
Anderson, M. 1.045
Anderson, W.S. 1.048, 1.110
Andersson-Roswall, L. 1.318
Ando, N. 2.132
Andrade, A. 1.149
Andrade, C.S. B.08
Andrade, D. 2.232
Andrade, E. 2.145
Andrade-Valença, L.P. 2.032, 2.033
Andreasson, K. 1.015
Andrews, N. 3.239
Andriola, M. 1.303, 1.314, 2.202, 3.123
Anschel, D.J. 3.284
Antony, A.R. 2.081
Aparicio Calvo, J. 3.233
Apelian, R.G. 1.173
Appendino, J. 3.135
Arai, H. 3.025, 3.100, 3.216, 3.365
Arain, A.M. 2.337, 3.275, 3.283
Arantes, P.R. 1.327
Araujo, D. 3.358
Ardesch, J. 1.142
Argentoni-Baldochi, M. 2.303, 2.304, 2.309, 2.272
Argumosa, E.V. 2.216
Argyelan, M. 2.089, 2.316
Arias, J. 1.063
Arisi, G. 3.018, 3.032, 3.361
Arnamwong, A. 2.325
Arndt, D. 2.301, C.05
Arnold, S. 1.149, 2.206, 2.299
Aronica, E. 1.027
Arrington, D.K. 1.069
Arshad, S.T. 1.101
Arshadmansab, M.F. 1.051
Arsnow, C. 3.237
Arsov, T. 3.294, 3.295, 3.297
Arthur, T. 2.276
Artsy, E. 2.213
Arya, K. 2.234
Aryasova, I.K. 2.007
Asano, E. 1.106, 1.124, 1.143, 1.108
Asano, K. 3.216
Asato, M.R. 1.360
Assirati, J.A. 2.003, 3.358
Atac, B. 2.187
Ataya, N. 2.289
Ataç, B. 1.245
Atkinson, M. 1.226
Aubert, S. 1.132
August-Schmidt, L. 3.240
Aungst, S. 1.006
Aurlien, D. 3.136
Aurora, J. 1.339
Austin, J.K. 1.358, 3.261
Auvin, S. 2.174, 2.236
Avakyan, G. 1.282
Avellán, A.M. 2.216
Avison, W. 3.336
Avoli, M. 3.353, 3.356
Aylett, S. 3.095
Ayoubian, L. 1.109, 1.121
Azar, N. 2.162, 3.275
Azevedo, A.M. 2.241
Azevedo, C.J. 1.101
Azhar, F. 1.048, 1.110

B

Baayen, J.C. 1.027, 2.085
Baba, K. 2.060
Baba, M. 2.054
Babb, T.L. 3.343
Babtain, F. 2.039
Bachmann, T. 2.175
Badjatia, N. 1.174
Bae, A. 3.284
Baer, K. 3.303
Bagary, M. 3.288
Bai, X. 1.150, 3.176, 3.195, 3.212
Bailey, J. 3.322
Bailey, R. 2.048
Baillet, S. 3.232
Bainbridge, J.L. 2.159
Bair, L. 1.365, 1.378
Baird, A. 2.127
Baisch, T. 3.141
Baise, C. 2.272, 2.303, 2.304, 2.309
Baker, G. 1.297, 1.299, 1.312, 3.263, 3.274, C.07
Baker, J. 2.185
Bakken, S. 3.329
Balaji, K.R. 3.147
Balakirsky, S. 1.225
Balanya, C. 2.184
Baldwin, M. 1.155
Balestri, M. 3.137
Ballout, N. 1.209
Bamps, Y. 2.358, 2.362
Bangalore-Vittal, N. 3.275
Banks, S. 1.323, 1.324
Bankstahl, J.P. 3.033, 3.158
Bankstahl, M. 3.033, 3.158
Bao, M. 3.128
Baptiste, S.L. 3.068
Bar-Yosef, O. 1.359
Baram, T.Z. 3.034, 3.341
Barba, A.L. 1.158
Barba, D. 2.116
Barbaro, N. 3.229
Barber, A. 2.154
Barber, J. 3.335
Barcia, G. 1.163
Barker, G. 3.175
Barker-Cummings, C. 3.304
Barkley, G.L. 2.049
Barkmeier, D. 1.086, 2.052, 2.244
Barlow, K. 2.122
Barnard, L. 3.164
Barnerias, C. 1.163
Barnes, G.N. 3.348
Baron, J. 2.338
Barr, W.B. 1.389, 3.248, 3.250
Barrios, L. 2.310
Barron, D. 3.203
Barsottini, O. 1.076
Bartfeld, E. 2.025
Bartolomei, F. 1.132
Basehore, H. 3.293
Bastianelli, L.V. 3.244, 3.276
Bateman, L.M. 3.259
Battacharyya, S. 3.202
Battaglia, G. 3.015
Bauer, G. 1.160
Bauer, P.P. 2.108
Baulac, M. 3.177
Baumann, R.J. 2.360
Baumgart, S. 1.079, 2.064
Baumgartner, J. 2.079, 2.287, 3.115
Bausch, S.B. 1.246
Bautista, J. 3.131
Baxter, N. 1.299
Baybis, M. 2.008
Baykan, B. 1.164
Bayly, M.A. 3.292, 3.294, 3.295
Bazan, N.G. A.04
Bazil, C. 2.057, 3.250, 3.334
Bealer, S.L. 3.243
Beaton, A. 2.285
Beaulieu, C. 1.322, 2.122, 2.141
Bebek, N. 1.164
Becerra, J. 1.309, 2.184
Becker, A.J. 1.031
Beckhaus, M. 1.167
Becske, T. 1.389
Beghi, E. 3.142, C.03
Begley, C.E. 1.188, 2.362, 2.365
Begnaud, J. 2.217
Beige, A. 2.206
Bekersky, I. 1.259
Bell, W. 3.155
Bellerose, J. 1.323, 1.324
Bello-Espinosa, L. 2.122
Ben Mabrouk, F. 3.054
Ben Mahmoud, S. 3.159
Ben-Zeev, B. 1.092

Benbadis, S. 1.350, 1.356
Benes, S.C. 2.188
Benge, J.F. 1.346
Benke, T.A. 1.049
Benn, E. 1.369, C.03
Bennet, K. 3.055
Bennett-Back, O. 2.077
Benoist, J.F. 2.236
Benyhe, S. 3.164B
Berdichevsky, Y. 1.248
Berg, A. 1.154, 1.369, 3.250, 3.253, 3.254, 3.337
Berg, M.J. 3.129
Berg, R. 1.080
Berger, B. 3.096
Bergey, G.K. 1.119, 1.136
Bergin, A. 1.301, 2.227, 2.239
Bergin, P.S. 3.142
Bergo, F. 2.126
Bergqvist, C. 2.224
Bergstrand, S. 2.088
Berkovic, S.F. 1.157, 3.045, 3.292, 3.294, 3.295, 3.297, 3.363, B.02
Berkowitz, A.L. 2.360
Berl, M.M. 3.191, 3.192, 3.224
Berman, R. 1.377, 3.176, 3.195, 3.212
Bermeo, A.C. 1.081
Bernard, C. 3.341
Bernard, P.B. 1.049
Bernard, T.J. 1.191
Bernasconi, A. 2.102, 2.121,
Bernasconi, N. 2.109, 2.125
Bernhardt, B.C. 2.102, 2.109, 2.121, 2.125
Berquin, P. 2.174
Berrettini, W. 3.037, 3.293
Berry, A. 2.159
Berry, G.T. 3.014
Berth, W. 3.238
Bertheussen, K.H. 2.175
Bertram, E.H. 3.022, 3.357
Besio, W. 3.067
Betting, L.E. 2.110, 2.111, 2.126
Bezuyen, A. 2.016
Bhasyal, C. 3.162
Bhatt, A.B. 2.040, 2.359, 3.152
Bhattacharjee, M.B. 1.053
Bhupalam, R. 3.139
Bianchi, A. 3.313
Bianchin, M.M. 3.112, 3.244, 3.245, 3.276
Bibbiani, F. 2.192
Bickel, S. 2.089, 2.263, 2.316, 3.213
Bienvenu, T. 3.294, 3.296
Bierbower, S.M. 3.349
Bilevicius, E. 3.307
Bilgin, C. 1.336
Bin, J. 3.146
Binder, J.R. 2.108
Bindra, T. 3.123
Binelli, S. 3.318
Bingaman, W. 2.006, 2.034, B.05
Binns, D. 3.170
Birch, R. 1.156
Birnbaum, A.K. 1.321
Bissler, J. 1.260
Bissonette, G.B. 3.060
Bisulli, F. 3.313, 3.318
Biton, V. 1.254, 1.259, 1.271, 1.277, 1.278
Bitra, R.K. 2.363
Bizzo, B. 2.107
Blackman, M. 2.018, 3.241
Blackmon, K. 3.248
Blair, R. 1.009
Blaise, J.H. 2.210
Blake, S. 2.168
Blatt, I. 1.092
Blount, J. 2.010, 2.139, B.07
Bluemcke, I. 1.335, 2.279
Blum, A. 2.248
Blum, D. 1.242, 1.287, 1.289, 2.153, 3.046
Blumenfeld, H. 1.150, 1.225, 1.240, 1.377, 1.382, 3.162, 3.176, 3.195, 3.212, 3.354
Boddaert, N. 1.163
Bodden, C. 2.079
Bodmann, B. 1.050
Bogacz, A. 2.024
Bogojevich, L. 3.097
Bohlmann, K. 3.078
Boison, D. 1.019, 3.001, 3.003, 3.046, A.03
Bold, G. 1.391
Boles, B. 3.204
Bollineni, A. 2.069
Bomben, V. 2.001
Bonaventi, C. 1.313
Bonelli, S. 2.106
Bonilha, L. 2.099
Boniver, C. 3.318
Bonnett, L.J. 3.132
Boon, P. 1.252, 2.072, 2.075, 2.214, 3.063, 3.066, 3.070
Boop, F. 2.293
Boor, R. 1.286
Bordey, A. 3.002
Bordson, C. 2.014
Borghs, S. 1.262
Borgulya, G. 3.317
Boro, A. 2.047
Borsodi, A. 3.164B
Bortel, A. 3.353
Boshuisen, K. 1.298
Bosnjak, J. 2.166
Boss-Williams, K.A. 3.052
Botega, N.J. 2.345
Botti, B. 2.339
Bouilleret, V. 3.170
Boulanger, Y. 1.207
Boulware, M.J. 2.172, 2.176, 2.179
Bourel, E. 2.174
Bourgeois, B. 1.083, 1.088, 1.301, 2.227, 3.209
Bourguignon, M. 2.072
Bouthillier, A. 1.207, 2.267
Bouvier, G. 2.267
Bowen, S. 1.366
Bower, M. 1.093, 1.130, 3.055
Bower, R.S. 2.315
Bower Baca, C. 3.254
Boyd, P. 2.192
Boyd, S.G. 1.162
Boyer, K. 2.050
Boyle, G. 3.317
Bozorg, A. 1.350, 1.356, 3.267, 3.285
Braams, O.B. 2.097
Bradfield, J. 3.293
Bradley, C.A. 3.104
Braga, P. 2.024
Bragatti, J.A. 3.112, 3.244, 3.245, 3.276
Bragin, A. 1.037
Branco Germiniani, F.M. 3.281
Brand, E.J. 2.008
Brar, S. 3.001
Braun, K.P. 1.298, 2.061, 2.097
Brazdil, M. 1.237, 2.249, 3.201
Breier, J. 2.100
Breier, J.I. 1.384
Brennan, B. 1.391
Brennan, P. 3.317
Brenner, R.P. 2.040
Breschi, G. 3.040
Brewster, A. 1.007, 1.053
Brickel, N. 1.272
Briffa-Mirabella, S.A. 3.277
Brill, J. 1.002, 3.339
Brinkmann, B. 1.130, 3.055, 3.171
Britto, L.R. 1.044
Britton, J. 2.062, 2.356
Briyal, S. 1.041
Brna, P.M. 2.334
Brna, P. 2.273
Brodie, M. 1.253, 1.315, C.03
Brody, D.L. 1.014
Bromley, R. 1.297, 1.299, 1.312
Bronson, S.L. 3.340
Brooks, B.L. 1.368, 1.370, 2.122
Brooks, D.J. 3.202
Brooks-Kayal, A. C.05
Brooks-Kayal, A.R. 1.012
Brown, C.P. 1.111
Brown, E. 1.112, 1.143
Brown, P.C. 3.206
Brown, S. 1.353
Browning, N. C.07
Brownstone, R.M. 1.218
Brundage, R. 1.285, 2.190
Brunelle, F. 1.163
Brunklaus, A. 1.156
Brázdil, M. 1.213
Bubrick, E. 3.081, 3.089
Buchanan, G.F. 3.010
Buchanan, T. 2.159
Buchanan, T.M. 1.094, 2.071
Buchhalter, J. 1.203, 2.021, 3.304
Buchlis, J. 3.237
Buckmaster, P.S. 1.055
Budzyn, D. 2.326
Buelow, J.M. 2.011
Buentjen, J. 2.319
Buffel, I. 1.252
Bujarski, K.A. 1.101, 2.305, 2.312
Bujarski, K. 1.325
Bulacio, J. 1.390, 2.073, 2.092, B.05
Bulaj, G. 2.164
Bullock, C. 3.113
Bulteau, C. 2.297
Bunch, M.E. 2.250
Buono, R.J. 3.037, 3.293
Burakgazi, E. 2.008
Burakgazi-Dalkilic, E. 3.143
Burattini, J. 2.272, 2.303, 2.304, 2.309
Burcet, J. 1.309
Burch, V. 3.095
Burdette, D. 1.254, 1.291, 1.293
Burger, C. 1.244
Burgess, R. 2.073, 2.078, 2.086, 2.087
Burke, C.J. 3.294
Burkhart, G. 2.167
Burneo, J. 1.165, 1.168, 1.306, 2.245, 2.340, 3.085, 3.142, 3.323
Busch, R. 1.326, 1.351, 1.363, 1.366
Busolin, G. 3.313, 3.318
Butler, T. 3.248
Buttinelli, C. 3.174
Byars, A. 1.358, 2.276, 3.261

C

Caboclo, L. 1.076, 1.232, 2.241, 2.251, 2.275
Cadotte, A. 1.056, 2.145, 3.031
Cain, V. 2.337
Calcaneo, J.D. 2.216
Calderbank, R. 1.299
Calhoun, S. 3.258
Caliebe, A. 3.309
Callanan, M. 2.247
Calvo Boixet, A. 3.233
Camarinho, M. 2.023
Camfield, C.S. 1.197, C.01
Camfield, P.R. 1.197, C.01
Campbell, M. 3.336
Campos, M.G. 3.188
Camposano, S.E. 3.178
Canevini, M.P. 1.066, 1.205, 1.357
Cano, A. 1.309
Canpolat, S. 2.189
Cansu, A. 2.189
Caplan, R. 1.364, 1.365, 1.378, 2.135, 3.253, 3.254
Caporro, M. 3.174
Cappabianco, F. 2.126
Cardoner, N. 2.243
Cardoso, I. 3.077
Cardoso, M.F. 2.107
Care, M.M. 2.221
Carlotti Jr, C.G. 2.003, 3.358
Carlson, C. 1.150, 1.345, 1.389, 2.123, 2.250, 2.254, 3.068, 3.074, 3.184, 3.248
Carlson, H. 2.122
Carlson, S. 2.150
Carmichael, D.W. 3.189
Carney, P. 2.145, 3.157, 3.235
Carney, P.R. 1.056, 3.031, 3.172
Carney, P.W. 1.157
Carpenter, A. 2.047
Carpenter, J.L. 1.095
Carranza, D. 3.294
Carrete, H.J. 2.251
Carrete Jr, H. 1.076, 1.232, 2.275
Carrette, E. 2.072, 2.214, 3.070
Carreño, M. 1.180, 2.352
Carreño Martínez, M. 3.233
Carrington, B. 1.247
Carrithers, J. 2.179

Case, M. 3.346
Cash, S. 1.042, 1.078, 1.099, 1.332, 2.360
Cassidy, C. 2.030
Castana, L. 1.066, 3.015
Castano, A.M. 1.049
Castañeda-Gonzáles, C. 3.366
Castañer, S. 2.243
Castillo, E. 1.384, 2.079, 2.082, 2.115, 2.287
Castillo, R. 3.122
Castillo Montoya, C. 2.259, B.01
Castro, A. 2.023
Castro, B.M. 1.327
Castro, L.H. 1.172, 1.327, 3.234
Catterall, W. 1.032, 3.026
Cavalheiro, E.A. 3.028
Cavalleri, G. 3.301, 3.317
Cavazos, J. 2.150, 2.357, 3.011, 3.247
Caylor, L. 3.335
Ceja Moreno, H. 1.282
Cendes, F. 2.110, 2.111, 2.126, 2.322, 3.028, 3.306, 3.307
Centeno, M. 3.175
Centeno, R. 1.076, 1.232, 2.241, 2.251, 2.275
Cerminara, C. 2.204
Cervenka, M. 1.136, 3.280
Cha, B. 1.227
Chachua, T. 3.012, 3.048, 3.049
Chae, J. 2.280, 3.120
Chakraborty, P.K. 3.173
Chambers, J.D. 3.363
Chan, V.W. 3.087
Chander, R. 1.107
Chandra, S. 1.059
Chang, B.S. 1.129
Chang, E. 2.163, 3.229
Chang, J. 2.036
Chang, S. 3.055
Chang, T. 1.079, 2.064, 3.083
Chang, Y. 3.154
Chansakul, C. 2.022
Chapieski, L. 1.371
Chapieski, M. 2.030
Chapin, J. 1.326, 1.351
Chapman, K.E. 1.069, 2.219, 3.138
Chapple, K. 2.355
Charchaflieh, J. 3.068
Chari, G. 2.234, 3.114
Chatten, J.B. 1.123
Chaudhary, F. 3.275
Chaudhary, N. 1.059
Chauvel, P. 1.132
Chavez, L. 3.164B
Chaytor, N. 1.349, 3.335
Chen, C. 1.113, 3.148
Chen, D.K. 1.346
Chen, H.X. 3.013
Chen, J.W. 1.113
Chen, J. 2.217
Chen, L. 1.133
Chen, L.S. 2.252
Chen, M. 2.053
Chen, T. B.05
Chen, T.T. 2.001
Chen, V. 1.188
Chen, X. 1.155
Cheng, J. 1.225
Cheng, M. 2.248
Cheong, I. 2.120
Cherian, P.J. 1.070
Cherry, S.V. 2.201
Cherubini, P.A. 3.244, 3.245, 3.276
Chervovena, I. 1.308
Cheung, C. 3.229
Cheyne, D. 2.083, 2.277
Chez, M.G. 3.079
Chiavacci, R. 3.293
Chien, J. 1.075, 1.117
Chiesa, V. 1.205, 1.357,
Chifari, R. 1.313
Chihara, Y. 3.364
Chin, R. 2.351, C.08
Chiron, C. 2.174
Chitty, J. 3.095
Cho, B. 2.280
Cho, J. 1.173
Cho, K. 1.208
Cho, Y. 1.193, 1.208
Choi, B.S. 2.270, 3.206
Choi, H. 2.350, 3.030, 3.311, 3.314, 3.329
Choi, J. 1.209, 3.120
Choi, N. 1.120
Chong, J. 2.328, 2.341
Chorostecki, J. 3.343
Chou, S.H. 3.092
Chow, U. 2.210
Chowdhury, F. 1.114
Chrastina, J. 2.249
Christensen, J. C.06
Christophe, C. 3.291
Chuang, S. 2.077
Chuang, S. 2.277
Chuang, S.C. 3.351
Chuang, S.H. 2.074, 2.083
Chugani, D.C. 3.173
Chugani, H. 1.124, 1.316, 2.101, 2.282, 3.164A, 3.165, 3.173
Chung, H. 1.035, 1.379
Chung, J.M. 1.386
Chung, K. 2.177
Chung, M. 1.377
Chung, S. 1.258, 1.263, 1.265, 2.029, 2.036, 2.161, 2.253, 3.096, 3.146
Chung, S.K. 3.303
Chung, S.S. 1.214, 1.282, 2.022, 2.151, 2.355
Chunn, S. 2.174
Chupin, M. B.06
Cianci, V. 3.313
Cibula, J. 2.028, 2.145
Ciechanowski, P. 2.362, 3.335
Ciernik, M. 2.020
Cilio, M.R. 3.137
Cipriani, C. 2.163
Claassen, J. 1.174
Clancy, R.R. 1.080
Clarin, D. 2.137
Clark, A. 1.285, 2.190
Clark, C. C.08
Clark, D. 2.302
Clark, N.M. 2.017, 2.362
Clarke, D. 1.206, 2.080, 2.137, 2.293
Claus, S. 2.096
Clayton Smith, J. 1.297, 1.299, C.07
Cleary, D. 2.078
Cleary, R. 1.251, 3.014
Clemenceau, S. 1.042
Clinckers, R. 3.070
Cloostermans, M.C. 1.071
Cloyd, J. 1.259, 1.279, 1.285, 2.190, 3.129
Cmejla, R. 3.053
Coan, A. 2.111, 2.126
Cock, H.R. 3.287
Codina, M. 1.309, 2.184
Cohen, J. 1.209
Cohen, M. C.07
Cohen, M.J. 2.270
Cohn, A. 2.203, 2.160
Colciaghi, F. 3.015
Cole, A. 1.078, 1.332, 2.146, 3.266
Collins, R.L. 1.346
Colonnelli, M. 2.300, 3.116
Coman, D. 3.162
Comi, A.M. 3.042
Compton, R. 3.109
Concha, L. 1.322, 2.141
Cong, X. 3.250
Connelly, J. 2.209
Connelly, L. 3.107
Connolly, E.S. 1.174
Conry, J. 1.281,1.283, 2.284, 3.298
Consalvo, D.E. 3.144
Constable, R.T. 1.339, 3.162, 3.176, 3.195, 3.199, 3.212
Constable, T. 3.190, 3.211
Constantinou, J.E. 2.266
Contreras, D. 3.065
Contreras, G. 2.235
Cook, D.J. 3.084
Cook, M.J. 1.273
Coppola, G. 1.270, 1.286, 2.195, 3.313, 3.318
Coquillette, M. 3.162
Cornet, M. 2.191
Cortez, M. 3.135
Cosgrove, G.R. 2.146
Cossette, P. 2.267, 3.293, 3.322
Costa, A. 2.126
Costa, A.L. 2.322
Costa, L.V. 2.275
Costas, K. 2.227, 2.239
Costello, D. 1.078
Coughlin, D. 3.362, A.06
Coutin-Churchman, P.E. 1.133
Covolan, L. 3.028
Cox, K. 3.328
Craig, A. 1.279
Craigie, S.M. 3.325
Cramer, J. 1.262
Crawford, T. C.07
Crepeau, A. 2.036, 3.096, 3.138
Crino, P.B. 2.008
Crippa, A.C. 3.281, 3.289
Crisp, E.D. 2.163
Critchley, D.J. 2.192
Crockford, G.P. 3.314
Crone, N.E. 1.054, 1.136
Cross, J.H. 1.162, 1.373, 2.300, 3.095, 3.116
Crumrine, P. 2.197
Cruz, Y. 1.012
Cuberas, G. 3.226
Cuccaro, M.L. 3.249
Cuellar-Herrera, M. 3.164B
Cui, L. 3.193, 3.223
Cukiert, A. 2.272, 2.304, 2.303, 2.309
Cukiert, C. 2.272, 2.303, 2.304, 2.309
Culberson-Brown, P. 2.270
Cunningham, H. 2.209
Cunnington, M.C. 2.157
Curatolo, N. 2.236
Curia, G. 3.035
Curry, D. 1.053
Cushion, T.D. 3.303
Cvitanovic Sojat, L. 2.166
Czech, T. 1.160
Czuczwar, S.J. 2.148

D

D'Amour, J. 3.050
D'Ambrosio, R. 2.257, 3.035
D'Amour, J. 3.044
D'Andrea Meira, I. 2.107
D'Giano, C. 2.310
D'Souza, W. 3.142, 1.273
Dabaj, I. 3.117
Dabbs, K. 2.098, 2.103, 2.113, 2.124
Dagenais, E. 2.267
Dahlin, M. 1.286, 2.152
Dal Pizzol, A. 3.244, 3.245, 3.276
Dale, A.M. 2.116
Damiano, J.A. 3.297
Dan, B. 3.291
Danek, A. 1.228
Daniels, T. 1.284
Danielson, N. 1.150, 1.225, 3.162, 3.176, 3.195
Dantzig, A. 2.348
Danzer, S. 3.340
Darke, K. 3.140
Das, R.R. 2.193
Dastjerdi, M. 2.093
Dauwe, I. 1.252, 3.063
Davies, J.S. 3.303
Davies, M.J. 3.260
De Backer, M. 1.262
De Bellis, M. 2.129
de Curtis, M. 1.008, 1.022, 1.116, 3.040
De Falco, F. 3.318
de Haan, M. 1.373
De Herdt, V. 1.252, 2.214, 3.070
De Jonghe, P. 3.294
De La Cruz, E. 1.024
de la Loge, C. 1.305
de Lange, E.C. 3.161
de Marinis, A. 3.269
de Paola, L. 3.281, 3.289
De Tiege, X. 2.072
de Vos, C.C. 1.071, 1.142
de Vos, M. 1.070, 1.144
de Weerd, A. 1.142
De Witt Hamer, P.C. 2.085
de-Haan, M. 1.372
Deacon, C. 2.264
Dean, J.C. 2.212

Dean, P. 1.367
Dean, S. 2.354
DeBassio, W.A. 2.051
Deblaere, K. 2.072, 2.214
Deburchgraeve, W. 1.070
Deconinck, N. 3.291
Deep, A. 2.029, 2.253, 2.355
Deepak, K.K. 1.059
Dees, D. 3.113
DeGiorgio, A. 1.249, 3.149
DeGiorgio, C. 1.249, 3.080, 3.149, 3.240
deGrauw, T.J. 1.358, 3.261
Dehpour, A.R. 2.149
Deisseroth, K. 3.339
Del Balzo, F. 2.204, 3.137
del Campo, J. 1.306
Del Claro Hopker, C. 3.281, 3.289
Delalande, O. 2.297
Delanoe, C. 2.174
Delanty, N. 3.301, 3.317
Delargy, H. 2.192
Delazer, M. 1.160, 3.182
Delgado-Escueta, A.V. 3.322
Delios, A.M. 3.152
DeLorenzo, R. 1.009, 1.047, 3.133
Demarin, V. 2.166, 2.256
Dempsey, J. 2.027
Denny, M. 3.097
Depondt, C. 3.301
Depositario-Cabacar, D.T. 2.284
Dergalust, S. 3.076
DeRossett, S.E. 1.272, 1.277, 1.293
Derry, P. 1.353
Derry, R. 2.017
Desai, T. 3.295
Desalvo, M.N. 1.225
Desguerre, I. 1.163
Deshpande, L. 1.047, 1.009
Desso, T. 1.249
Detyniecki, K. 1.225, 1.382
Deuschl, G. 3.197
deVeber, G. 3.135
Devi, S. 1.307
Devinsky, O. 1.150, 2.123, 2.283, 3.068, 3.074, 3.184, 3.248, 3.250
Dewar, S. 2.076
Dewolfe, J. 1.159, 2.268, B.07
Dezsi, G. 1.240
Dhaliwal, H. 1.333
Dhall, R. 2.355
Dhamne, S. 2.228
Dhir, A. 3.051
Dholakia, S. 2.019
Di Bonaventura, C. 3.313, 3.318
Dias, R.A. 3.259
Dibb-Hajj, S. 3.298
Dibbens, L.M. 3.292, 3.294, 3.295, 3.320
Dichter, M.A. 1.001
Dickens, D.L. 1.311, 3.222
Diehl, B. 1.326, 3.189, 2.094
Dilorio, C.K. 2.358, 2.362
Dilipkumar, S. 1.200
Dinetz, E. 1.209
Ding, L. 3.222
Ding, X. 3.158
Diniz, P.B. 2.142, 3.236
Diniz, P.R. 2.119, 2.134
Dinkelacker, V. 3.177
Diosy, D. 1.168
DiSano, M. 2.100
Diwakar, M. 3.193, 3.223
Dlugos, D. 1.080, 1.186, 2.047, 3.293
Dobesberger, J. 1.160, 1.268, 3.182
Dobyns, W.B. 3.291
Doescher, J.S. 2.282
Dogan, A. 2.143
Doherty, C.P. 3.317
Doherty, M. 1.342
Doi, T. 3.364
Dole, A. 3.282
Domingos, C.J. 3.281, 3.289
Donadío, M. 2.310
Donaire Pedraza, A. 3.233
Donath, V. 2.020
Donevan, S. 1.238
Dong, Y. 1.246
Donlon, S. 1.258, 2.151, 2.161, 2.294
Donnelly, M. 1.080
Donner, E.J. 1.062, 1.359, 3.087
Dooley, J.M. 2.334
Doreswamy, M. 2.194, 2.207
Dorfmuller, G. 2.297
Doring, T. 2.107
Doss, J. 1.361
Doss, R. 3.257
Doss, R.C. 1.337, 3.255
Doty, P. 1.262, 1.263, 1.265
Doucette, H. 3.081
Douglass, L.M. 2.051
Dourado, A. 1.061
Douw, L. 2.085
Doyle, G.A. 3.037
Doyle, W. 1.150, 2.283, 3.074
Drake, J. 1.062, 2.077
Drake, K. 2.313, 2.341, 3.206, 2.328
Drane, D.L. 3.180
Drazkowski, J. 1.212, 2.332, 2.363, 3.331
Driscoll, V. 2.223, 2.229, 2.237
Drislane, F. 3.073
Druga, R. 3.344
Drummond, R. 1.283
Du, C. 3.352
Dube, C. 3.034, 3.341
Dubeau, F. 1.121, 2.013, 2.032, 2.033, 2.039, 3.168, 3.214, 3.291
Dubinsky, S. 1.188
DuBois, J. 2.123, 3.248
Duchowny, M. 1.367, 2.273, 3.185, 3.196
Duckrow, R. 1.225, 1.382
Dudek, F.E. 1.317A, 3.057
Duempelmann, M. 1.102
Duffy, K. 1.171
Dugan, P. 2.254
Duh, M. 2.211, C.04
Duke, E.S. 3.191, 3.192, 3.224
Dulac, O. 1.163
Dulay, M.F. 1.381
Dulla, C. 1.002
Dumont, G.A. 1.128
Dümpelmann, M. 1.138, 2.035
Duncan, D. 1.026
Duncan, J. 1.156, 3.175
Duncan, J.S. 2.106
Dunn, D.W. 1.358, 3.261
Dunn, M.E. 2.282
Dunoyer, C. 2.273, 3.196
Dupont, S. 3.177
Duran, A. 1.194
Duran, F. 2.235
Durand, D.M. A.01
Durbhakula, S. 2.320
Durnford, A. 2.285
Duron, R. 3.322
Dustin, I. 3.224, 3.230
Dutta, S. 2.198
Dutton, S. 3.300
Dworetzky, B. 1.110, 1.151, 1.199, 2.213, 2.360, 3.081, 3.089, 3.092, 3.209, 3.324
Dyken, M.E. 3.238
Dzhafarova, N. 2.202, 3.123
Dzhala, V. 1.010, 1.248
Dziura, J. 3.250

E

Eastman, C.L. 3.035
Eberly, L. 2.344
Ebersole, J. 1.098, 1.155, 2.042
Ebersole, S. 1.155
Ebert, A. 1.228
Ebner, A. 2.319
Edelbroek, P.M. 3.162
Edlbeck, A. 2.233
Edwards, A.L. 2.365
Edwards, J.C. 2.099
Edwards, S.E. 3.140
Eeg-Olofsson, O. 1.383
Egeo, G. 3.313, 3.318
Egerton, A. 3.202
Eidelman, O. 2.008
Einhaus, S. 2.293
Eisenschenk, S. 2.028, 2.145
Eitel, H. 2.279
Ekstein, D. 2.228
Ekstrand, J.J. 3.057
EL Khashab, M. 2.314
El Tahry, R. 1.252, 3.070
El-Hayek, Y. 3.352
Elam, M. 2.088
Elgavish, R.A. 2.268, B.07
Elger, C. 1.145, 1.146, 1.152, 1.274
Elia, M. 3.313, 3.318
Eliashiv, D. 1.386, 2.076
Elices, E. 2.352
Elisevich, K. 2.049, 2.266
Ellens, D.J. 1.150
Elliott, I.M. 1.062
Elliott, J.O. 1.181
Elliott, R.E. 3.074
Ellmore, T. 2.100, 2.112
Ellsworth, K. 1.360
Elsen, F.P. 2.004
Eltze, C.M. 1.373
Elwan, S. 1.177, 2.034
Elwes, R.D. 1.114
Elzawahry, H. 2.201
Emerson, R.G. 2.057, 3.050
Emmady, P. 1.064
Enamandram, S. 1.225, 1.382
Enatsu, R. 2.034, 2.092
Endziniene, M. 1.292
Engel Jr, J. 1.037
England, P.M. 1.006
Engle, D.M. 2.078
Englot, D.J. 1.150, 3.354
Engman, E. 1.318
Enoki, H. 2.066
Entz, L. 2.089, 3.213, 2.316
Eom, S. 1.379
Epps, S. 3.052
Erdem, R. 1.245, 2.187
Erdheim, D.R. 2.215, 3.351
Ergene, E. 3.187
Ericson, E.J. 1.189
Erisken, S. 1.035
Ermolinsky, B.S. 1.051
Erol, I. 1.245, 2.187
Ervin, C. 2.329
Escandon, A. 1.329
Escandon-Sandino, A. 2.203
Escayg, A. 3.300
Escorsi-Rosset, S.R. 2.119
Eskandar, E. 1.078, 1.332
Espinosa, P.S. 2.360
Ess, K. 1.170
Esser, M. 3.036
Etienne, M. 2.350
Ettinger, A. 2.165, 2.329
Eubank, E. 2.217
Eun, B. 1.379, 3.016
Eun, S. 1.379
Evankovich, K. 1.371
Evans, A. 3.228
Evans, J. 2.320

F

Fagan, A. 3.317
Fahimi, M. 2.335
Fahlstrom, R. 2.047, 2.155, 3.316
Faingold, C.L. 3.017
Faith, A. 1.115
Falcone, N.M. 2.360
Falcón Falcón, C. 3.233
Falip, M. 1.180, 2.243, 1.309
Famelart, M. 1.247
Fang, J. 3.323
Fanselow, E.E. 2.220
Farfel, G.M. 1.288
Farheen, A. 2.363
Farias, S.T. 3.259
Faris, P. 2.354
Farooque, P. 1.225, 1.382
Fasano, R.E. 3.192
Fastenau, P.S. 1.358, 3.261
Faught, E. 1.216, 1.263, 1.265, 1.294, 2.167, 2.211, 2.329, C.04
Faulkner, C. 3.340
Fay, T. 1.333, 1.362, 2.018
Fedder, W.N. 3.330
Feddersen, B. 1.228
Federico, P. 1.195, 2.186, 3.088, 3.124, 3.327
Fee, D. 2.360
Fehnel, S.E. 2.329
Felber, S. 1.160, 3.182
Feletti, F. 2.147
Feliciano, D. 3.002
Fender, J.S. 3.035

Fenoglio-Simeone, K.A. 1.250
Ferguson, L. 1.363
Ferguson, P.L. 3.273
Ferlazzo, E. 3.313
Fernandes, P.T. 2.345
Fernandez, S. 1.180, 1.309, 2.243
Ferrand Sorbets, S. 2.297
Ferrari, P. 2.277
Ferrari, T.P. 1.232
Ferraro, T. 3.037, 3.293
Ferrier, C. 1.077, 2.063
Ferro, M. 3.336
Fertig, E. 1.096, 1.307, 1.347, 2.314, 3.268, 3.271
Fessler, A. 3.256
Feucht, M. 1.160
Feurst, D. 2.052
Fields, M. 1.082
Fiest, K. 2.018
Filho, G.M. 2.241
Filiano, J.J. 1.166
Finardi, A. 3.015
Finegersh, A. 3.224
Finnerty, G.T. 3.053
Finnerty, M. 2.237
Finsterwalder, K. 3.309
Fiol, M.E. 2.361
Fiore, L.A. 1.340, 1.343
Fiorito Grafman, M. 1.328
Fisch, B. 1.220
Fischer, A. B.02
Fisher, R. 2.025, 2.247, 2.269
Fitzgerald, E. 3.029, A.08
Fitzgerald, T. 1.114
Fitzsimons, M. 3.317
Flink, R. 3.093
Floden, D. 1.351
Flom, P. 2.254
Florea, O. 3.169, 3.231
Florence, G. 1.028
Flores, J.A. 3.308
Fluiter, K. 1.027
Flynn, C. 3.341
Foerch, P. 1.247
Fohlen, M. 2.297
Foldvary-Schaefer, N. 3.131, 3.239
Fonseca, N. 3.082
Foote, S. 3.195
Forbes, G.H. 1.156
Forcelli, P. 3.038
Forcier, M. 3.337
Ford, S. 2.068
Foresti, M. 3.018, 3.032, 3.361
Forster, C. 2.272, 2.303, 2.304, 2.309
Fortuny, R. 2.243
Fossas, P. 1.309
Foster, B. 2.093
Foster, M.S. 2.012
Fountain, N.B. 1.161, 1.204, 2.343
Fountas, K. 2.255
Fowler, K.M. 1.151
Fox, C. 1.186
Fox, P. 3.203
Foxe, J.J. 1.122
Franaszczuk, P.J. 1.048, 1.054, 1.136
Francione, S. 1.066, 1.116
Franco, E. 3.326
Francois, C. 1.225
Franke, A. 3.309
Franz, D. 1.260, 1.296, 1.300, 2.009, 2.221, 2.271, 3.218
Frasca, A. 3.015
Fraser, C.L. 3.156
Fraser, R.T. 2.362, 2.365, 3.335
Frazier, T. 1.326
Fredholm, B.B. 1.019
Freeman, W.D. 2.180
Fregni, F. 2.216
Freilich, E. 3.083, 3.298
Freitas-Lima, P. 2.147
French, C.R. 1.241
French, J. 1.253, 1.271, 1.274, 1.292, 2.123, 2.250, 2.254, 2.329, 3.068, 3.143, 3.184, 3.248, 3.293
Frey, L. 3.125, A.05
Frey, M. 3.097
Frey, S. 3.164
Fried, A. 2.314
Friedman, D. 1.188, 3.044, 3.050
Friedman, D.B. 2.366
Friedman, D.E. 3.150
Friedman, L. 2.171
Friedman, L.K. 1.057
Friedo, A. 3.078
Froklage, F.E. 3.161
Frontera, A. 1.350, 1.356
Frost, H. 1.329
Frost, M.D. 2.282
Fu, C. 1.170
Fucic, A. 2.166
Fuentes, D. 1.340, 1.343, 1.380
Fuerst, D. 1.086, 1.112, 2.244
Fuerst, D.R. 2.127
Fujii, M. 2.311
Fujimoto, A. 1.131, 2.066, 2.074, 2.324
Fujioka, H. 2.311
Fujita, M. 3.230
Fujitani, S. 2.060
Fujiwara, H. 2.084, 2.271, 1.065
Fukasawa, T. 2.132
Fukuda, M. 1.224, 3.151
Fuller, K. 1.273
Fulton, S. 2.293
Fumanal, S. 2.184
Fureman, B. 2.327
Furman, K. 3.354
Fuseau, E. 1.264
Fusegi, K. 3.216

G

Gadhoumi, K. 1.103
Gadre, G. 1.200
Gaelic, S.E. 1.166
Gage, N. 1.386
Gaillard, W. 1.095, 1.360, 2.284, 2.335, 3.061, 3.191, 3.192, 3.224, 3.298
Gajewski, B. 3.107
Galanopoulou, A.S. 2.158
Gale, K. 2.068, 2.156, 3.038
Gale-Ross, R.M. 2.127
Gallagher, A. 3.178
Gallentine, W. 2.289
Gallentine, W.B. 1.223, 2.129, 2.185
Galvez, M. 2.023, 3.188
Galvin, S. 1.238
Galvis-Alonso, O.Y. 3.358
Gambardella, A. 3.318
Gandhi, S. 2.234
Gangisetty, O. 1.041, 1.011
Gao, L. 1.083
Garcia, I. 1.051
Garcia, P. 3.229, B.03
Garcia-Williams, A. 2.365
García, M. 2.182
Gardella, E. 1.357, 1.066
Gardner, D.A. 1.166
Garrido, E.R. 1.051
Garzon, E. 3.112
Garzon, Y.R. 2.360
Gaspard, N. 2.041
Gasparetto, E.L. 2.107
Gaspari, A.P. 3.281, 3.289
Gati, J. 3.163
Gattaz, W. 3.251, 3.308, 3.321
Gattone, J. 3.097
Gavrilovici, C. 1.243
Gawlowicz, J. 1.282
Gay, C. 2.021
Gdynia, H.J. 3.299
Gecz, J. 3.295
Gedela, S. 2.197
Geib, V. 3.084
Geier, C. 1.360
Geiger, J.D. 1.019
Gelfand, M.J. 2.271, 3.218
Geller, E. 2.339, 3.074
Geng, Y. 2.042
Gentry, W. 2.150
Gerard, E. 1.189, 1.231, 3.153
Gerber, P. 3.138
Gerber-Gore, P. 2.330
Germiniani, F.M. 3.289
Ghacibeh, G. 1.307, 2.314
Ghadersohi, S. 3.102
Ghasemi, A. 2.149
Ghasemi, M. 2.149
Ghatan, S. 1.084, 2.274, 3.130,
Ghearing, G.R. 3.152
Gholipour, T. 3.214
Ghosh, S. 2.046
Giacino, J.T. 1.225
Giagante, B. 3.144
Giallonardo, A.T. 3.313, 3.318
Giard, N. 2.267
Gibbs, S.A. 1.207
Gidal, B. 3.129
Gielissen, K. 3.006
Gil-Nagel, A. 1.291, 1.293, 2.352
Gilani, O. 3.250
Gilbert, J.R. 3.249
Gilbert, K. 1.325, 2.305, 2.312
Gilbert, T. 3.350
Gilioli, R. 3.028
Gill, J. 3.098
Gill, S. 3.275, 3.283
Gillard, M. 1.247
Gillen, R.W. 1.158
Giller, C. 1.320, 2.313
Gilliam, F.G. 3.134
Gillogly, C. 2.231
Giordano, S. 1.261, 1.275
Girard, H.M. 2.116
Girvin, J.P. 2.245
Giza, C.C. 1.194
Gjergja Juraski, R. 2.166
Gjerstad, L. 3.136
Glauser, T. 1.058, 2.276
Gleason, K. 1.151, 3.324
Glessner, J. 3.293
Gluckman, B.J. 3.047
Gnatkovsky, V. 1.008, 1.116
Go, C. 2.077, 2.083, 3.121
Go, C.Y. 1.062
Go, M. 1.153
Godoy, J. 3.077
Godwin, D. 3.204, 3.228
Goellner, E. 2.245
Goerss, S. 3.055
Gois, J.O. 1.343
Gokyigit, A. 1.164
Goldberg, K.X. 3.262
Goldberg-Stern, H. 1.274
Goldenberg, N.A. 1.191
Goldman, A.M. 2.001
Goldman, S. 2.072
Goldsmith, I. 2.145
Goldstein, D. 3.301
Goldstein, D.B. 3.290
Goli, S. 1.159
Golomb, J.D. 1.150
Gomez, C.H. 1.029
Gong, G. 2.122
Gonsales, M.C. 3.310
Gonzalez, J. 1.101, 2.092, 2.203
Gonzalez, M. 3.056
Gonzalez, M.I. 1.012
Gonzalez Giraldez, B. 1.175
Gonzalez Reiley, S.G. 3.114
Gonzalez-Martinez, J. 2.006, 2.073, B.05
Gonzalez-Nosti, M. 1.384
Gonzalez-Victores, J.A. 1.336
González Nosti, M. 2.115
González-Aragón, M.F. 1.099, 2.216
Goodkin, H.P. 2.048
Goodman, J.H. 2.215, 3.351
Goodman, R. 3.362
Gooty, V. 1.221, 2.336
Goradia, D. 2.101
Gordillo Espinoza, J. B.01
Gordon, A. 1.150
Gordon, K.E. 2.334
Gorji, A. 1.036
Gorter, J.A. 1.027
Gotman, J. 1.103, 1.107, 1.109, 1.121, 2.032, 2.033, 2.039, 3.168, 3.194, 3.214, 3.353
Gotwald, T. 1.160, 3.182
Gouras, P. 2.196
Govaert, P. 1.070
Govindan, R.M. 2.101, 3.164A
Goyal, M. 2.286
Goyal, S. 1.074
Grabenstatter, H. 1.012
Grade, M. 2.332
Graf, W. 1.387
Granner, M.A. 3.238

Grant, G. 2.289
Grant, S. 3.293
Grasse, D. 1.013
Graus, F. 1.180
Gray, W.P. 2.285
Greco, F. 3.137
Greenberg, D. 3.048
Gregoire, M.C. 3.170
Gregory, T.D. 2.012
Greiner, H. 1.296, 1.300
Gressens, P. 2.236
Grieff, A.N. 1.342
Grier, M.D. 1.033
Griesemer, D.A. 2.193
Griessenauer, C. 1.159
Grillo, Y. 2.203
Grinnon, S. 2.327
Groppa, S. 3.197
Gross, D. 1.322, 2.141, 2.307, 2.342, 3.260
Grossman, A. 1.329
Grossman, R.G. 1.381
Gruber-Baldini, A. 1.330
Gu, F. 1.050
Gu, W. 2.001
Guan, Y. 3.075
Guekht, A.B. 2.007
Guerin, A. 2.211
Guerra, M.P. 2.287, 3.115
Guerreiro, C.A. 2.110
Guerreiro, M.M. 1.380, 3.310
Guerrero, R. 1.175
Guilhoto, L. 1.301, 2.023
Guimarães, C.A. 1.380
Guimarães, M.D. 2.251
Guiot, M.C. 2.003
Gulley, M. 3.081
Gulyaeva, N.V. 2.007
Guo, D. 1.014
Guo, J. 1.377, 3.176, 3.195, 3.212
Guo, Y. 3.293
Gupta, A. 2.031
Gupta, D. 2.075
Gupta, P. 1.185
Gupta, R. 2.169, 2.199
Gurbani, S. 2.135, 1.364
Gurgen, S.G. 2.189
Gurr, S. 2.302
Gusev, E.I. 2.007
Gustafson, M. 1.255
Gutierrez-Colina, A.M. 1.080
Guzman, F. 2.298
Guzmán, L. 3.226
Gómez-Abad, C. 1.175
Gürses, C. 1.164

H

Haas, K. 1.033, 2.059
Haberlandt, E. 1.160
Hablitz, J.J. 1.005
Hader, W. 1.333, 1.362, 2.122
Hafez Abdelmoity, A. 2.223, 2.229, 2.237
Haginoya, K. 2.044
Hagler, D.R. 3.248
Hagler, Jr., D.J. 2.116
Haglund, M.M. 3.156
Hahn, C. 1.100, 1.304
Haibei, L. 3.250
Hain, H. 1.238
Hakimian, S. 2.257
Hakonarson, H. 3.293
Haldar, A. 2.043, 2.050, 2.133
Halford, J. 1.075, 1.117, 1.229, 2.099
Halgren, E. 2.116, 2.123, 3.184, 3.248
Hall, A.S. 3.115
Hall, J. 2.039, 2.242
Hall, S. 1.254, 1.277, 1.290
Hall, V. 3.273
Hallböök, T. 2.088
Hallinan, B. 1.058
Haltiner, A.M. 1.342
Halvorsen, M.B. 2.172, 2.176, 2.179
Hama, T. 1.344
Hamad, A.A. 2.275
Hamad, A.P. 1.232
Hämäläinen, M. 3.207, 3.209
Hamani, C. 2.232
Hamberger, M.J. 1.345
Hamera, E. 3.107
Hamid, H. 1.150, 1.225, 1.382, 3.250
Hamilton, M. 3.085
Hamiwka, L. 1.378, 3.294, 1.365
Hammeke, T.A. 2.108
Hammers, A. 3.202
Hammond, C.L. 3.303
Hammond, J. 1.272, 1.291, 1.293
Hammond, N. 3.107
Hamrahian, A. 1.326
Han, J.H. 2.280
Hancock, E. 3.140
Handler, M. 2.290, 2.301
Haneef, Z. 3.174, 3.179, 3.219
Hanna, J. 1.311
Hannah, M. 3.253
Hannan, S. 2.300, 3.116
Hanson, A. 1.195, 2.186, 3.088, 3.124, 3.327
Hantus, S. 1.302, 2.078, 3.131, B.05
Hara, K. 1.344, 2.054, 2.067, 2.265
Hara, M. 2.054, 2.067
Harden, C. 1.151, 1.257, 1.329, 2.160, 2.203, 3.103
Hardy, B. 1.279
Hardy, R. 1.279
Hargus, N.J. 3.357
Hari, K. 1.226
Harini, C. 2.205
Harkness, W. 2.300, 3.095, 3.116
Harms, S. 2.344
Harner, R.N. 1.123
Harnod, T. 1.104
Harrison, A. 2.139
Harrison, S. 3.095
Hartley-McAndrew, M. 2.231
Harvey, A.S. 1.157, 3.296
Hasebroock, K. A.05
Hasegawa, H. 2.055
Hasulak, N.R. 2.215
Hauser, W.A. 2.335, 2.350, 3.304, 3.311, 3.314, C.03
Haut, J. 1.363, 1.366
Haward, C. 1.328
Hawes-Ebersole, S. 1.098, 2.042
Hawkins-Taylor, C.E. 1.321
Hawley, J. 2.168
Hayman-Abello, B. 1.353
Hayman-Abello, S. 1.353
Hazra, A. 1.050
He, B. 3.171, 3.183, 3.210, 3.221
He, Q. 1.269
Heath, C. 2.284
Hebb, A.O. 2.257
Hecimovic, H. 2.256
Heck, C. 2.128, 2.252, C.02
Heckemann, R.A. 3.202
Hecox, K. 1.140
Heffer-Rahn, P. 2.285
Heida, J. 1.023
Heiman, G.A. 2.350
Heimans, J.J. 2.085
Heinze, H.J. 2.319
Heinzen, E. 3.290, 3.301
Helbig, I. 3.309
Helmers, S.L. 2.211
Hemasilpin, N. 2.084
Hempel, A. 1.337, 1.388
Hemza, J. 2.249
Hendrikse, N.H. 3.161
Hendriksen, J. 1.374
Hengen, K. 3.004
Henry, J.C. 3.256
Henry, T. 1.219, 2.190, B.06
Heo, K. 1.193, 1.208, 3.090
Herman, S. 3.073
Hermann, B. 1.360, 2.098, 2.103, 2.113, 2.124, 2.135, 3.264
Hermanova, M. 2.249
Hernandez-Ronquillo, L. 1.097
Heron, S.E. 3.320
Herren, L. 1.365, 1.378
Herrington, L.L. 1.033
Herzog, A.G. 1.151
Hesdorffer, D.C. 1.369, C.03
Hetherington, H.P. 1.178
Hetherington, S. 1.271
Hewett, J.A. 1.015
Hewett, S.J. 1.015
Heyes, M. 1.067
Hickman, E. 1.202
Hicks, R.J. 3.170
Higo, T. 3.025, 3.100, 3.365
Hilario-Gomez, C. 1.016
Hillebrand, A. 2.085
Hira, J.S. 2.263
Hirata, M. 2.317
Hirsch, E. 1.290
Hirsch, L.J. 1.174, 2.196
Hirvonen, J. 3.230
Hiyoshi, T. 1.210
Hmaimess, G. 3.117
Hnojcikova, M. 2.278
Ho, Y. 3.302
Hochman, D.W. 3.156
Hoechstetter, K. 1.106
Hoerth, M.T. 1.212, 2.332
Hoerth, M. 3.331
Hoffmann, J.M. 1.152
Hogan, R.E. 3.167
Holder, D. 2.197, 2.288
Holland, D. 2.116
Holland, K. 2.276, 3.340
Holland, M. 2.326
Holland-Bouley, K. 1.065, 2.221, 2.271, 2.292, 3.218
Holmes, G.L. 1.030, 1.043, 1.101, 1.166, 1.192, 1.385, 3.041
Holmes, M. 1.118, 1.126, 1.139, 1.391, 2.257, 3.350
Holthausen, H. 1.286, 2.279
Hong, K. 3.154
Hong, S.B. 2.090
Hong, S.H. 1.090
Hong, Z. 1.292
Honnorat, J. 1.247
Hope, O. 2.100, 2.115
Hopfengärtner, R. 1.094
Hopp, J.L. 1.330
Hori, T. 3.145
Horigome, Y. 1.211, 3.019
Horn, P. 2.271, 3.218
Horstmann, M. 1.145
Hoshida, T. 2.323
Hoshimi, K. 2.317
Hou, C. 3.293
Howes, O.D. 3.202
Hrachovy, R.A. 1.346
Hrncir, Z. 3.196
Hsin, Y. 1.104
Hsu, D. 2.098, 2.113
Hsu, M. 2.098
Hsu, S. 3.148
Hu, B. 3.172
Hu, J. 3.165
Hu, S.Q. 1.130
Hua, J. 2.244
Huang, M. 3.193, 3.223
Huang, S. 3.352
Huberfeld, G. 1.042
Hudson, J.L. 1.135, 1.137
Huganir, R.L. 3.029
Hughes, G. B.05
Huguenard, J.R. 1.002, 1.039, 3.339
Huh, S. 2.239
Huiskamp, G. 1.077, 2.063
Huisman, M.C. 3.161
Huitt, T.W. 3.204
Hunegs, L. 2.327
Hunt, R.F. 3.345
Hunter, E. 3.107
Huntsman, M.M. 3.270
Hunyadi, B. 1.144
Hurwitz, S. 2.213, 3.324
Husain, A. 1.263, 1.265, 2.194, 2.207
Husaini, B. 2.337
Husaini, H. 1.307, 3.268, 3.271
Husk, G. 1.209
Hussain, A. 1.209
Hussain, S.A. 3.099
Hussein, A. 3.130
Hussein, A.M. 2.225, 3.110, 3.217
Hussein, Z. 1.264
Hutchison, A. 1.225
Hutchison, J. 1.100, 1.304
Hutchison, R. 3.163
Hwang, H. 3.120, 3.146
Hwang, S. 2.089, 2.316, 3.213
Hwang, S.T. 2.263

Hwang, W. 3.086
Hwang, Y. 2.280, 3.120
Hyang, L.W. 1.225
Hyder, F. 3.162, 3.354
Hyland, K. 1.223

I

Iacobas, D. 1.057
Iacobas, S. 1.057
Iasemidis, L.D. 1.115
Ibrahim, I. 2.058
Ichord, R.N. 1.080
Igbokwe, E. 2.146
Ihle, M. 1.061
Ilmura, Y. 3.025, 3.100
Iino, H. 2.054, 2.067
Ikeda, H. 1.210, 1.211, 1.233, 3.118, 3.118
Ikegami, M. 1.211, 1.233
Imai, K. 1.211, 1.233, 2.083, 3.118
Imoto, H. 2.311
Indic, P. 1.134
Ing, K. 1.225
Innis, R.B. 3.230
Inoue, Y. 1.210, 1.211, 1.233, 2.060, 3.019, 3.118
Ionita-Laza, I. 3.302
Iragui, V. 1.190, 2.116, 3.109
Irislimane, M. 2.264
Irwin, B. 1.312
Isaeva, O. 1.030
Ishihara, N. 2.132
Isojarvi, J. 1.263, 1.265
Isojärvi, J. 1.305
Ivanez Mora, V. 3.119
Ivaturi, S. 2.008
Ivañez Mora, V. 3.111
Ives, J. 3.164
Ivicevic Bakulic, T. 2.166
Ivy, A. 3.034
Iwasaki, M. 2.044, 2.087, 3.069
Iyagba, B. 1.188
Iyer, A. 1.027
Iyer, P. 3.317
Iyer, R.V. 1.186
Izadyar, S. 1.346
Izawa, A. 3.227

J

Jackson, G.D. 1.157, B.02
Jackson, M. 3.014, 3.029, A.08
Jacobs, J. 1.102, 1.107, 2.033, 2.035
Jacoby, A. 3.263, 3.274
Jafari, B. 3.102
Jahnke, H. 3.138
Jahodova, A. 3.196
Jain, S. 2.089, 3.213, 3.242
Jain, S.K. 2.316
Jain, S.V. 1.222
Jalin, C. 2.297
James, G.A. 3.180
Janousek, J. 2.154
Jansen, F. 2.061, 2.097
Jansen, L.A. 2.002
Janssen, M.J. 3.038
Jarrar, R. 1.203, 2.021
Jaryal, A. 1.059
Javidan, M. 1.128
Jawa, R. 1.033
Jayakar, P. 1.367, 2.273, 3.185, 3.196
Jee, H. 1.227
Jefferys, J.G. 3.053
Jeha, L. B.05
Jehi, L. 1.351, 3.131, 3.252, 3.272
Jenkins, P.D. 2.255
Jensen, A.L. A.01
Jensen, F. 1.016, 1.017, 1.025, 1.029, 1.251, 2.228, 3.014, 3.029, A.08
Jeong, M. 1.276
Jeradeh Boursoulian, L. 1.170
Jette, N. 1.195, 2.186, 2.250, 3.088, 3.124, 3.246, 3.332, 3.333, 3.327
Jetter, G.M. 2.150
Jetté, N. 2.354
Ji, K. 3.086
Ji, L. 3.157, 3.235
Jiang, H. 3.157, 3.172, 3.235
Jiang, R. 3.235, 3.157
Jin, K. 2.073, 2.086
Jin, Y. 3.347
Jin, Z. 1.045
Jirsch, J. 3.260, 2.342
Jiruska, P. 3.053
Jobst, B. 1.101, 1.325, 2.024, 2.305, 2.312
Johnson, A. 3.140
Johnson, C.S. 1.358, 3.261
Johnson, E.K. 3.335
Johnson, F.R. 2.165
Johnson, J. 2.356
Johnson, M.E. 1.256, 1.267
Johnson, S. 3.004
Johnson, S.E. 1.135, 1.137
Johnston, J. 3.303
Johnston, M.V. 3.042
Jomphe, M. 3.292
Jonas, R. 2.051
Jones, C. 3.338
Jones, J. 2.124
Jones, J.E. 3.264
Jones, J.M. 3.298
Jones, M.V. 3.004
Jones, N. 1.240
Jones-Gotman, M. 1.323, 1.324, 3.208
Jonsson, P. 1.383
Joo, E. 2.090, 3.086
Jorge, C.L. 1.327
Jorgensen, A. 3.315
Jorgensen, J. 3.259
Joseph, A. A.08
Joseph, J.R. 1.266
Joshi, S.M. 1.236
Josic, K. 1.050
Jouny, C.C. 1.119, 1.136
Judd, L. 2.201
Juhasz, C. 1.106, 1.108, 1.112, 1.124, 1.143, 2.101, 3.165, 3.173
Juncadella, M. 1.180, 2.243
Jung, K. 2.349
Jung, S. 1.031, 1.120
Jurjuck, R. 2.023
Juul, H. 1.001

K

Kadam, S.D. 3.042
Kaffka, J. 3.338
Kahlenberg, C.A. 2.305
Kaido, T. 2.295
Kajiwara, K. 2.311
Kakisaka, Y. 2.086, 2.087
Kaku, M. 1.314
Kalamangalam, G. 1.089, 2.100, 3.181
Kalayjian, L. 2.252, C.07
Kaleyias, J. 1.083
Kalitzin, S. 2.096
Kalman, C. 1.351
Kalume, F. 3.026
Kalume, F.K. 1.032
Kamada, T. 3.020
Kamberakis, K. 3.311
Kandratavicius, L. 2.003
Kaneko, Y. 2.295
Kang, B.H. 1.090
Kang, H. 1.084, 1.120, 1.379, 2.291
Kang, H.C. 2.230, 3.101
Kang, J. 1.090, 1.153
Kang, T. 3.030
Kania, B. 2.233
Kankirawatana, P. 2.010, 2.139
Kanner, A. 1.081, 2.329, 3.097, 3.265, 3.269, C.07
Kanner, H.R. 3.265
Kansagra, S.M. 1.223, 2.185, 2.289
Kansal, L. 1.190
Kanter, J. 1.331, 1.334, 1.348, 3.268
Kaplan, D.L. A.03
Kaplan, H. 3.337
Kar, J.K. 3.186
Karaagaç, N. 1.198
Karakis, I. 3.266
Karcher, G. 3.159
Karkar, K. 3.286
Karli Oguz, K. 1.147
Kashyape, P. 3.095
Kasper, K.C. 2.177
Kassab, M.Y. 2.359
Kasteleijn Nolst-Trenite, D.G. 1.271, 2.198, A.02
Katki, K. 1.023, 3.032, 3.361
Kato, A. 2.317
Katsifis, A. 3.170
Katzan, I. 3.131
Kauffman, M.A. 3.144
Kaulas, H. 1.095, 2.284
Kaur, M. 2.181
Kavalir, M. 3.107
Kawai, K. 1.141
Kawai, M. 1.085
Kawamura, M. 1.341
Kawata, K. 2.323
Kay, E. 1.197
Kayali, M. 2.217
Kayyali, H.R. 2.223, 2.226, 2.229
Kearney, J. 3.021
Keating, B. 3.293
Keating, J.G. 1.001
Keator, C. 1.191
Keininger, D. 1.305
Keller, A. 2.122
Keller, C. 2.089, 3.213
Keller, L. 1.201
Kelley, S.D. 3.267
Kelly, C. 3.213
Kelly, K. 1.075, 1.117, 1.258, 1.315, 2.151, 2.161, 2.294, 3.008, 3.127
Kemp, R. 3.106
Kendirli, M.T. 3.022
Kennedy, C. 3.140
Kennedy, R.E. B.04
Kenyon, A. 2.335
Kerber, K. 1.102, 2.035
Kerling, F. 1.387
Kern, R. 1.075, 1.117
Kernitsky, L. 3.133
Kerr, P. 2.013
Kerrigan, J.F. 1.069, 2.005, 2.219, 3.138, 3.347
Kershenovich, A. 2.257
Kessler, S. 1.080, 2.224, 2.279
Kettani, H. 2.162
Khan, M. 3.334
Khan, O. 1.101, 2.163
Kharidia, J. 1.242
Khatamian, Y. 3.194
Khodabakhsh, K. 1.316
Khoury, J. 1.212
Kihara, A.H. 1.044
Killory, B. 1.377, 3.162, 3.176, 3.195, 3.212
Kim, C. 3.293
Kim, D. 2.218, 2.349
Kim, D.H. 3.065
Kim, D.S. 3.101
Kim, D.Y. 2.183, 2.219
Kim, D. 2.258
Kim, H. 1.379, 2.010, 2.125, 2.139, 2.291
Kim, H.D. 3.101
Kim, H. 2.102, 3.120
Kim, I. 3.055
Kim, K. 2.280, 3.120
Kim, M. 1.227, 3.016
Kim, M.J. 1.090
Kim, O.J. 3.090
Kim, P. 2.252
Kim, P.E. 2.128
Kim, S. 1.120, 1.379, 2.114, 2.280, 3.120, 3.146
Kim, S.H. 3.101
Kim, S.O. 3.090
Kim, T. 3.045
Kim, W. 1.193
Kim, W.S. 1.072
Kim, Y. 1.120, 3.146
Kim, Y.I. 2.140
Kim, Y.M. 2.208
Kimberlin, D.W. 2.010
Kimble, C. 3.055
King, J.A. 3.222
King-Stephens, D. 1.176
Kingsley, P. 2.316, 3.213
Kinjo, E.R. 1.044
Kink, R. 3.328
Kira, J. 3.020
Kirkham, F.J. 2.285
Kirmani, B. 2.163, 3.122, 3.203, 1.105
Kirton, A. 2.122

Király, M. 2.004, 3.054
Kishima, H. 2.317
Kiyota, G. 2.029, 2.253
Klaas, P. 1.363, 1.366
Klassen, B. 1.195, 2.186, 3.124
Klassen, T.L. 2.001
Kleefuss-Lie, A.A. 1.152
Kleeman, E. 3.034
Kleen, J. 1.385
Klein, B. 2.164
Klein, G. 1.345, 2.316
Klein, K.M. 3.296
Klein, P. 1.016, 1.017, 1.025, 1.029, 1.278, 2.154, 3.029
Kleinschmidt-Demasters, B.K. 2.301
Klinkenberg, S. 1.374
Kluger, G. 1.270, 1.286, 2.195
Knape, K. 3.160, A.07
Knaus, H.G. 1.051
Knight, R. 3.229
Knowlton, R. 2.254, 2.268, 3.186, B.07
Knox, J. 3.332, 3.333
Knupp, K. 1.191, 2.290
Ko, D. 1.173, 2.252
Ko, S. 1.174
Ko, T. 1.276
Kobau, R. 2.362
Kobayakawa, M. 1.341
Kobayashi, E. 2.003, 3.166, 3.208
Kobayashi, J. 3.087
Kobayashi, S. 1.169
Kochen, S.S. 3.144
Kocvarova, J. 2.249
Kodangattil Narayanan, J. 1.036
Koepp, M. 3.175, 3.202
Koga, S. 1.108
Kogan, A. 2.202
Koh, S. 1.026, 1.035, 2.301, 3.016, 2.290
Kohler, S. 2.088, 2.168
Koizumi, H. 2.311
Koka, K. 3.067
Kokes, U. 1.164
Komaki, H. 3.126
Komarek, V. 3.196
Kominami, S. 1.169
Kondo, A. 2.060
Kondo, S. 3.145
Kondratyev, A. 2.068, 2.156
Koo, D. 3.086
Kopec, L. 3.133
Koppelstaetter, F. 1.160, 3.182
Koranda, J.L. 2.210
Korinthenberg, R. 2.035
Korman, B.M. 1.367
Kornips, B. 2.075
Korzeniewska, A. 1.136
Kosaras, B. 1.016, 1.029, 1.251, 3.014
Kossoff, E. 2.230
Kotagal, P. 1.177, 1.196
Kothare, S. 1.083, 1.088, 1.091, 1.179, 1.221, 1.301, 2.133, 2.193, 2.195, 2.336
Kotloski, R.J. 1.235
Koubeissi, M.Z. 2.091, 2.336
Koudijs, S.M. 2.097
Koutsogiannopoulos, S. 2.013
Kovac, S. 2.094
Kovach, K. 1.342
Kozitza, R.L. 2.129
Kral, J.G. 3.068
Kramer, M.A. 1.003
Kransz, N.E. 3.342
Krassman, C. 3.333
Krauss, G. 1.151, 1.271, 1.274, 1.280, 1.292
Krawiecki, N. 2.168
Kreisl, W.C. 3.230
Kriegstein, A.R. 3.007
Kriel, R. 1.285, 2.190
Krishnamurthy, K.B. 3.073
Kroll, J. 2.170, 2.178
Kron, M.M. 3.342
Kroner, B. 2.335, 3.061
Krongthong, W. 1.215, 2.325
Krsek, P. 3.196
Krueger, D. 1.296, 1.300, 2.009, 2.221
Krumholz, A. 1.330
Krusienski, D.J. 1.135, 3.071
Kršek, P. 3.185
Kuba, R. 1.237, 2.249, 1.213
Kubota, Y. 2.092
Kubova, H. 3.039, 3.344
Kubu, C. 1.326
Kuchukhidze, G. 1.160, 1.268, 3.182
Kuczynski, E. 3.082
Kudernatsch, M. 2.279
Kudr, M. 3.196
Kuester, G. 3.188
Kulandaivel, K. 1.192, 2.305, 2.312
Kulikova, R. 1.307
Kumar, D. 1.274, 1.280
Kumari, V. 3.175
Kunii, N. 1.141
Kunz, W. 3.299
Kuratani, J. 2.117, 3.200
Kurelowech, L. 1.386
Kurth, C. 1.201
Kurths, J. 1.028
Kurzbuch, K. 1.387
Kuzniecky, R. 2.123, 3.068, 3.184, 3.248
Kwan, P. 1.267
Kwan, S.Y. 3.148
kwon, E. 2.291
Kwon, O. 1.120
Kwon, S. 1.379

L

La Briola, F. 1.357
La Neve, A. 3.318
Laban, O. 1.096, 1.347, 1.348, 2.314
Laban-Grant, O. 3.268
Labar, D. 2.306
Labiner, D.M. 2.328, 2.341
Lachhwani, D. 3.220
Lacuey, N. 3.225, 3.226
Ladowski, D.S. 1.323
Ladrón de Guevara, D. 3.188
Lafeuille, M.H. C.04
LaFrance, W. 3.269
LaFrancois, J. 3.044, 3.050
Lagrange, A. 1.033, 1.170
Lai, Y. 1.034
Lainey, E. 2.167
Lajeunesse, P. 1.217
Lakeman, F. 2.010
Lamar, C. 3.155
Lamb, J.G. 3.359
Lambrakis, C. 1.096
Lambrecht, L. 2.172, 2.176, 2.179
Lammertsma, A.A. 3.161
Lancman, G. 1.319
Lancman, M. 1.096, 1.307, 1.328, 1.331, 1.334, 1.347, 1.348, 1.352, 2.314, 3.268
Lane, S. 3.263, 3.274
Lanfermann, H. 3.158
Lang, C. 3.105
Langan, Y. C.03
Langer, J.E. 2.343
Langfitt, J. 3.250, 3.256
Lanphier, E. 1.364
Laoprasert, P. 2.290, 2.301
Larch, J. 1.160, 3.182, 1.268
Lardizabal, D. 2.019
LaRoche, S. 1.075, 2.201
Larsen, J.P. 3.136
Lassiter, T.F. 2.194, 2.207
Lassonde, M. 3.169, 3.231
Lau, E.W. 3.170
LaViolette, P. 2.130, 3.232
Law, M. 2.128
Lawrence, K. 3.297
Lawson, A. 1.247
Lax, I.D. 1.359
Laxer, K. 2.120, B.03
Lay Ergun, E. 1.147
Lazow, S. 2.312
Le, N. 1.302
Leach, J. 2.009, 2.271
Lebedeva, A.V. 2.007
Lecointe, C. 2.236
Lee, B. 1.193, 1.208
Lee, B.I. 3.090
Lee, E. 1.276
Lee, E.M. 1.090
Lee, G. 2.313
Lee, G.P. 1.320, 2.270
Lee, H. 2.114
Lee, H.W. 1.382, 3.090
Lee, I. 3.146
Lee, J. 1.347, 1.379, 2.114, 2.213, 2.291, 3.120
Lee, J.K. 1.090
Lee, J.L. 1.096
Lee, J.S. 3.101
Lee, J.W. 3.092
Lee, J.Y. 2.090
Lee, K. 1.065, 1.093, 1.174, 2.271, 2.276, 2.292, 3.218
Lee, K.H. 3.055, 3.186
Lee, M. 1.206, 1.208
Lee, M.R. 2.270
Lee, M. 1.193
Lee, R. 3.223
Lee, R.R. 3.193
Lee, S. 2.150, 3.091
Lee, S.A. 1.090, 3.090
Lee, S.I. 2.090
Lee, S.K. 2.258
Lee, S.M. 3.090
Lee, S.W. 2.036
Lee, S. 2.349
Lee, Y. 1.154
Leeman, B. 1.332
Leemans, A. 2.097
Lefebvre, P. C.04
Legarda, M.S. 2.068
LeGros, B. 1.073, 2.041, 2.072, 3.142
Lehericy, S. B.06
Lehmkuhle, M.J. 3.057
Lehnertz, K. 1.145, 1.146
Lehnhoff, L.L. 1.214
Lehéricy, S. 3.177
Leibson, C.L. 3.304
Leijten, F. 1.077, 2.063
Leite, C.C. 3.234, B.08
Leite, J.P. 2.003, 2.119, 2.134, 2.142, 3.236, 3.358
Lekovic, G.P. 2.005
Leland, M.M. 3.058, 3.160, A.07
LeMaire, A.W. 1.346
Lemieux, L. 3.189
Lena, T.S. 1.354
Lenartowicz, A. 3.174, 3.179, 3.219
Lenck-Santini, P.J. 3.041
Lenck-Santini, P.P. 1.043, 1.385
Lepkin, A. A.05
Lepore, F. 3.169, 3.231
Leppik, I. 1.257, 1.279, 1.285, 1.321, 2.190, 2.344
Lerario, M. 2.008
Lerche, H. 3.299
Lerdlum, S. 2.260
Lerner, A. 2.128
Lerner, J.T. 1.194, 3.099
Leroy, R.F. 1.254, 1.277, 1.290
Lesage, F. 3.169, 3.231
Lesser, R. 3.280
Leung, L.S. 3.163
Leurgans, S.E. 1.081
Levan, P. 2.035
LeVanQuyen, M. 1.061
Leventer, R.J. B.02
Leveque, M. 1.132
Levin, H.S. 3.150
Levitt, J. 1.364, 2.135
Levy, R. 2.021, 2.338
Lew, F. 1.055
Lew, S.M. 2.004
Lewine, J.D. 3.205
Lewis, D. 2.289
Li, C.S. 3.259
Li, G. 3.347
Li, H. 2.069
Li, K. 1.035
Li, L.M. 2.345
Li, P. 3.102
Li, S. 2.344
Li, T. 1.019, A.03
Li, X. 3.150
Li, Y. 3.014
Li, Y.F. 3.348
Li, Z. 1.384, 2.079, 2.082, 2.115
Liang, L.P. 1.060
Libenson, M.H. 1.182, 2.043
Librizzi, L. 1.022, 3.040
Lie, O.V. 1.072
Liew, C. 3.224
Lillis, K. 1.003

Lim, B. 1.120, 3.120
Lim, S.C. 2.140
Lim Fat, M. 2.333
Lim-arune, C. 2.325
Lima, J. 2.209
Limbrick, D. 2.296
Limond, J. 2.285
Lin, J. 2.113, 2.103, 2.105
Lin, K. 2.023
Lin, S.J. 3.052
Lin, T.C. 3.259
Lin, Y.Y. 3.148
Lina, J.M. 1.103
Lineweaver, T. 1.363
Liporace, J. 1.151, C.07
Lippman Bell, J. 1.017, 1.025
Liscak, R. 2.104
Litt, B. 3.065
Little, A.S. 3.138
Little, J.G. 3.243
Liu, C. 2.252
Liu, H. 3.178, 3.209
Liu, L.C. 3.256
Liu, M. 1.322, 2.141, 2.354, 3.246
Liu, W. 2.198, 3.187
Liu, X. 1.135, 3.067
Liu, Y.C. 3.087
Liu, Z. 2.145
Lo, M. 1.104
Lo, W. 3.293
Lo Russo, G. 1.066
Locharernkul, C. 1.215, 2.260, 2.325
Locicero-Casazza, B. 1.314
Loddenkemper, T. 1.074, 1.083, 1.088, 1.091, 1.110, 1.179, 1.221, 1.301, 2.133, 2.195, 2.228, 2.336, 3.089
Lodi, M. 1.313
Loeb, J. 1.086, 2.052, 2.244
Lofti, N. 3.053
Logan, W.J. 1.359
Lohoff, F. 3.037, 3.293
Lombardi, F. 1.205
Londero, R.G. 3.244, 3.245
Longo, D. 3.137
Look, M. 3.034
Lopes da Silva, F. 2.096
Lopes-Cendes, I. 2.111, 3.028, 3.306, 3.307, 3.310
Lopez-Gomariz, E. 2.182
Lopez-Trigo, J. 2.182
Lorent, S. 1.073
Lorenzo, C. 3.226
Loring, D. B.03, C.07
LoRusso, G. 3.015
Lotarski, S. 1.238
Lotze, T.E. 1.068, 1.187
Lowe, H. 3.087
Lowe, M. 1.329, 2.160, 2.203, 3.103
Lowerison, M. 1.195, 2.186, 3.088, 3.124
Lozano, A.M. 2.232
Lu, S. 1.256, 1.267, 1.282, 1.284
Lu, Y. 3.183, 3.221
Luan, G. 3.075, 3.128
Lubarr, N. 3.130
Lubin, F.D. 1.018
Lucas, M. 3.041
Luders, H. 2.091
Ludvig, N. 3.068
Luef, G. 2.175
Lugo, J.N. 1.007, 3.023
Luk, M.E. 2.180
Luna, B. 1.360
Lundgren, J. 2.088
Lupica, K. 2.209
Lupski, J.R. 2.001
Lusardi, T.A. 3.003
Luszczki, J.J. 2.148
Luther, N. 2.306
Lutz, G.J. A.06
Lutz, M.T. 1.355
Luu, P. 3.350
Lux, A. 3.140
Lykens, N.M. A.06
Lynch, E. 1.296, 1.300
Lynch, T. 1.158
Lyons, P. 3.104
Lyra, K.P. 3.234
Lytle, N. 3.003
Léonard, M. 2.191
Lévesque, M. 3.353
Löscher, W. 3.033, 3.158
Lüders, H.O. 2.262
Lüders, J. 2.262
Lüders, R. 2.262

M

Ma, C. 3.088
Ma, D. 3.249
Ma, H. 1.024
Mabe, M. 1.206
MacAllister, W.S. 1.368, 1.370
Macchiarulo, S. 3.048
Maccotta, L. 3.167
Macdonald, E.A. 2.348
MacDonald, J. 3.328
Machan, J.T. 3.269
Machatha, S.G. 1.269
Maciunas, R.J. 2.091
Macken, M. 1.189, 1.231, 3.153
Macklin, E.A. 1.332
MacLusky, N.J. 3.044, 3.050
Macrodimitris, S. 1.195, 2.186, 2.018, 3.088, 3.124, 3.332, 3.333,
Madder Joaquim, M.J. 3.281, 3.289
Madikians, A. 1.194
Madsen, J. 1.074, 1.088, 3.089, 3.209
Maehara, T. 1.344, 2.054, 2.067, 2.265
Maertens, P.M. 1.171, 3.113
Maganti, R. 2.022, 2.036, 2.253, 3.096
Maglajlija, V. 2.094
Maglakelidze, G. 3.048
Maguire, S. 3.317
Maia, D.F. B.08
Maia, J. 1.242
Maier, G. 1.242
Mail, M. 1.010
Majid, A. 2.359
Malacrida, S. 3.313
Malak, R. 1.333
Maldonado, L.B. 2.216
Malheiros, J.M. 3.028
Malikova, H. 2.104
Malkin, M. 2.209
Malla, R. 3.203
Malmgren, K.A. 1.318
Malone, A.G. 1.181
Malone, S. 2.302, 3.196
Malow, B. 2.059
Malpe, C. 2.037
Malphrus, A. 1.371, 2.030
Manco-Johnson, M. 1.191
Mancuso, J. 1.057
Mandelstam, S.A. B.02
Manfro, G.G. 3.276
Mangan, K.P. 3.004
Manganaro, S. 1.083, 1.088
Mangano, F. 2.276
Mangano, F.T. 1.065, 2.271, 2.292, 3.218
Mangeshkar, P. 2.221
Mangubat, E.Z. 3.064
Mani, R. 2.247
Manjunath, R. 2.329, C.04, 2.165
Mansour, H.G. 3.117
Manza, P. 1.225
Manzanarez Colin, M.C. 3.366
Manzee, A. 2.196
Marawar, R.A. 2.181
Marchesini, R.B. 3.028
Marchini, M. 3.318
Marcuccilli, C. 2.004, 3.054
Marcuse, L.V. 1.082
Marecek, R. 3.201
Mareci, T. 1.056, 2.145
Mares, P. 3.005, 3.039, 3.344
Marfeo, A. 1.150
Mari, F. 1.103, 1.107, 1.121, 2.032, 2.033
Mariani, P. 2.272, 2.303, 2.304, 2.309
Marie, P.Y. 3.159
Marinas, A. 2.352
Marino, S. 1.285, 1.321
Markowitz, G.J. 3.042
Marsh, R. 1.093, 2.315
Marsh, S. 1.127
Marsh, W. 3.055
Marson, A. 3.315
Marson, T.G. 3.132
Martin, B.S. 3.270
Martin, K.C. 3.244, 3.245, 3.276
Martin, M.G. 1.172
Martinez, A. 3.224
Martinez, E. 1.220
Martinez, R.C. 2.203
Martini, M. 1.146
Martinos, M. 1.372, C.08
Martins, H. 2.023, 2.241
Martins, M. 2.023
Martuzzi, R. 3.199
Martz, G. 1.135, 1.137
Maru, N.K. 1.229
Maruta, Y. 2.311
Marx, C. 1.068, 1.187
Marín-Léon, L. 2.345
Masino, S. 1.019, 2.210
Maskali, F. 3.159
Mason, K. 2.049
Mason, S.M. 3.255, 3.257
Massager, N. 2.072
Massagli, M.P. 1.305
Massaro, A. 1.079, 2.064
Massot, A. 1.175
Masuko, A. 2.023
Mateus, N. 2.023
Matheisel, A. 1.230
Mathews, W.H. 2.268
Mathieu, D. 2.264
Maton, B. 3.196
Matos, A.H. 3.028
Matsuda, A. 2.054, 2.067
Matsuda, K. 2.060
Matsui, H. 1.344
Matsumoto, J. 1.194, 3.099
Matsuo, F. 2.056, 2.071
Matsushima, E. 2.054, 2.067
Matsuura, M. 1.344, 2.054, 2.067, 2.265
Matthews, W.H. B.07
Mattingly, M. 1.350, 1.356
Mattis, J. 3.339
Matzner, B. 1.348
Maurer-Morelli, C. 3.306, 3.307
Mawer, G. 1.297, 1.299
Mayer, S.A. 1.174
Mayer, T. 1.225, 1.355
Mayo, J. 3.191
Mayorga, A.M. 1.099
Mays, V. 2.047
Mazarati, A.M. 1.021, 3.024
Mazurkiewicz-Beldzinska, M. 1.230
McArthur, D.L. 1.194
McAuley, J.W. 3.105
McBrian, D.K. 1.307
McCarthy, D. 2.213
McClain, C. 1.083
McClelland, S. 3.341
McCloskey, C. 2.326
McCloskey, D. 3.277
McCormack, M. 3.301
McCoy, B. 1.100, 1.304, 3.121
McDaniel, S.S. 2.222
McDermott, D. 3.106
McDonald, C.R. 2.116, 3.248
McDonald, W.S. 1.039
McEvoy, A. 2.094, 3.189
McGill, M. 3.184
McGillivray, G. B.02
McGinnity, C.J. 3.202
McGoldrick, P.E. 1.084, 2.026, 2.274, 3.130
McGovern, R. 3.362
McGregor, A. 2.137, 2.293
Mckenzie, B. 1.083
McKenzie, F. 3.295
McKhann, G. 3.362
McKhann II, G.M. 1.004
McLachlan, R. 1.165, 1.168, 1.243, 1.353
McMahon, J.M. 3.294
McManis, M. 2.080
McMullan, W.J. B.03
McShea, C. 1.263, 1.265, 1.282
Meador, K.J. 1.332, B.03, C.07
Meaney, J. 3.317
Mecarelli, O. 3.313, 3.318
Medani, K. 3.089
Medveczky, G. 3.068

Medvedev, A. 3.067
Mehta, A. 1.345, 2.089, 2.263, 2.316, 3.213
Meier, M. 3.158
Meisler, M. 3.298
Mekaroonkamol, P. 1.215
Melching, L. 1.142
Mello, C.F. 1.051
Mello, V. 2.272, 2.303, 2.304, 2.309
Melot, C. 2.041
Men, C. 1.225
Mendiratta, A. 3.329
Mendonça, A. 2.023
Menendez, J. 2.254
Mentch, F. 3.293
Mercer, E. 3.333
Mercier, M.R. 1.122
Merschhemke, M. 1.256, 1.267
Mertz, J.C. 1.003
Mesa, T. 3.077
Mesquita, S. 2.023
Messenheimer, J. 2.157
Metcalf, C.S. 2.164
Metcalfe, A. 3.327
Meurs, A. 1.252, 2.072, 2.214, 3.070
Meyer, F. 1.093, 2.315, 3.055
Meyerand, M.E. 2.098
Miao, L. 1.161
Miao, Y. 3.165
Micallef, C. 2.106
Michelsen, K.A. 3.063
Michelucci, R. 3.313, 3.318
Michotte, Y. 3.070
Micic, V. 1.196, 2.030
Mifsud, J. 2.027
Mihara, T. 2.060
Mihaylova, T. 2.052
Mihaylova, T.G. 1.086
Mikati, M. 1.223, 2.129, 2.185, 2.289
Mikell, C. 3.362
Mikl, M. 3.201
Mikula, I. 2.166
Miles, L. 2.271
Miles, R. 1.042
Miller, I. 3.185, 3.196
Miller, J. 1.349, 2.091
Miller, J.H. 3.186
Miller, J.W. 1.072, 2.257, 3.335
Miller, K. 1.247, 2.047
Miller, P. 3.149, 3.240
Miller, S. 1.026, 1.216
Miller, S.R. B.07
Miller, W. 2.011
Miller-Horn, J. 1.314, 1.303
Millett, D. 1.173, 2.252
Milligan, H. 2.218
Milligan, T. 3.081
Milteer, W. 3.139
Min, L.L. 2.110
Min Ju, K. 3.090
Minasyan, G.R. 1.123
Mine, J. 1.211
Mintzer, S. 2.320, 1.308
Miozzo, M. 1.345
Miranda, M.J. 2.230
Miranda, S. 1.320, 2.270, 2.313, 3.206, 3.224, 3.230
Miravet, E. 1.309
Mireles, P.S. 2.045
Miro, J. 1.180, 1.309
Mirro, E.A. 1.176
Mirsattari, S. 1.165, 1.168, 3.163
Miró, J. 2.243
Mishagina, N. C.04
Mishra, A.M. 3.162, 3.354
Misiewicz, S. 3.319
Miskov, S. 2.166
Mitchell, A.J. 3.287
Mittal, A. 1.303
Mittal, S. 1.086, 1.112, 2.052, 2.244, 3.173
Miyajima, M. 2.054, 2.067
Miyata, H. 3.145
Moddel, G. 1.036
Modur, P. 3.139
Moeller, F. 3.197
Moeller, J. 2.057
Mogal, Z. 3.142
Mogami, M. 1.233
Mogami, Y. 1.211
Mogensen, M. 2.128
Mohamed, I. 2.122, 2.277
Mohamed, I.S. 1.362
Moharir, M. 3.135
Moien-Afshari, F. 1.097
Molins, A. 1.309
Mollet, L. 1.252, 3.070
Molthoff, C.F. 3.161
Monin, P. 3.159
Monrad, P. 2.278
Montanye, J. 1.101
Monteiro, M.R. 2.003
Montenegro, M.A. 3.310
Montouris, G. 1.257, 3.266
Moon, B. 2.177
Moon, W. 2.129
Moore, E.L. 1.271
Moosa, A.N. 2.031
Mora, J. 2.243
Moreland, S. 3.125
Moreno, L.M. 2.150
Morgan, L. 2.357, 3.286
Morgan, V.L. 3.198
Morgan, W. 2.028
Morita, M. 1.078
Morland, T.B. 1.225
Moroz, E. 1.037
Morris, D. 1.359
Morris, G. 2.170, 2.178
Morrison, C. 1.345, 1.389
Morrow, J. 1.312
Morse, C. 3.230
Morse, R.P. 1.101, 1.166, 2.312
Morsi, A. 3.074
Morton, L.D. 3.133
Morya, E. 1.044
Moschetta, S. 1.340, 1.343
Moseley, B.D. 2.356
Moses, D.L. 2.330
Mosher, G.L. 1.269
Mosher, J. 2.073, 2.078, 2.086, 2.087
Mossey, J. 3.258
Motelow, J.E. 1.150, 3.354
Mothersill, I. 3.141
Mounaim, F. 3.062
Moussalli, M. 2.310
Moxon, K.A. 1.013
Moya, P. 3.077
Mrela, C. 2.355
Mtchedlishvili, Z. 3.008
Mudigoudar, B.D. 2.234
Mueller, A. 1.270, 1.286
Mueller, K. 1.262
Mueller, S. 2.120, B.03
Mueller, W. 2.108, 2.130, 3.232
Muhle, H. 3.309
Mukaida, S. 1.233
Mullen, S. 3.297
Muller, P. 2.228
Mulley, J. 3.320
Mulley, J.C. 3.292, 3.294, 3.295
Mullins, J.G. 3.303
Mumford, J. 3.179, 3.219
Mundy, J. 3.341
Mungall, D. 3.122
Munger Clary, H. 2.350
Munian Govindan, R. 2.131
Munuera, J. 3.226
Murakami, T. 2.323
Murashima, Y. 3.059
Murphy, B.L. 3.340
Murphy, M. 1.199, 1.273
Murphy, W. 1.195, 2.186, 3.088, 3.124
Murro, A. 1.320, 2.255, 2.270, 2.313, 3.206
Musilova, K. 1.213
Musson, C. 3.330
Musto, A.E. A.04
Muthugovindan, D. 3.280
Muthuraman, M. 3.197
Muzik, O. 1.112, 3.173
Muzyka, I. 2.223, 2.229
Myers, D.E. 3.170
Myers, L. 1.319, 1.328, 1.331, 1.334, 1.347, 1.348, 1.352, 3.268
Myers, O. 1.220
Myers, S. 1.056
Myles, S.T. 2.118
Myles, T. 1.333
Müller, M. 1.036

N

Nabbout, R. 1.163
Nadasdy, Z. 1.105
Nadkarni, V. 1.080
Naduvil Valappil, A. 1.390
Naeije, G. 1.073
Nagarajan, L. 2.046
Nagasawa, T. 1.106, 1.108, 1.112, 1.124, 1.143
Nagoro, T. 2.132
Nair, D. 1.390, 2.037, 2.092, 3.131
Najm, I. 1.184, 1.326, 1.351, 1.390, 2.006, 2.034, 2.073, 2.086, 2.092, 3.027, 3.131, 3.220, 3.252, 3.326, B.05
Nakagawa, E. 2.295, 3.126
Nakaji, P. 3.138
Nakajima, M. 3.025, 3.100, 3.365
Nakamura, F. 2.060
Nakano, M. 3.216
Nakasato, N. 2.044, 3.069
Nakase, H. 2.323
Nakata, T. 2.132
Nam, S. 1.379, 2.208
Nanbu, S. 2.077
Nancy, M. 3.187
Narayana, K. 2.363
Narayana, S. 3.058, 3.160
Narayanan, J. 1.134, 3.098
Nariai, H. 1.124
Nariai, T. 2.265
Naritoku, D.K. 1.278
Narurkar, M. 2.192
Nash, K.B. 3.312
Nashef, L. 1.114
Nasim, M.M. 2.263
Nathwani, N.B. 2.215
Natola, M.A. 1.101, 2.024
Natsume, J. 2.102, 2.132
Nau, K. 2.180
Naugle, R. 1.326
Navarre, W. 1.231
Nawarawong, N. 1.360
NEAD Study Group, A. C.07
Nebieridze, N. 3.355
Negishi, M. 3.162, 3.176, 3.190, 3.195, 3.199, 3.211, 3.212
Nehamkin, S. 2.091
Nehlig, A. 3.159
Nei, M. 2.308, 2.320
Neilman, V. 2.123
Neiman, E.S. 2.363
Nelson, J.T. 3.181
Neme-Mercante, S. 3.131
Nemes, A. 3.027
Nesbitt, G. 2.047
Netto, C.B. 3.112
Newey, C.R. 3.215
Newman, M. 1.151
Newmark, M. 1.188
Newton, H. 2.209
Newton, R. 3.140
Ng, Y. 1.283, 2.219, 2.253, 2.294
Ng, Y.T. 1.317
Nguyen, D. 1.207, 2.264, 2.267, 3.062, 3.169, 3.231
Nguyen, J. 2.177
Nguyen, N. 1.050
Nguyen, V.V. 3.076
Nicita, F. 2.204
Nickels, K. 1.148, 2.278, 2.346, 2.353, 2.356
Nicolai, J. 1.374
Nilsson, L. C.03
Nishimura, K. 3.025
Nishimura, M. 1.038
Nissenkorn, A. 1.092
Nkinin, S. 1.058
No, Y. 3.091
Noachtar, S. 1.228, 1.336
Nobile, C. 3.313, 3.318
Nobili, P. 3.015
Noe, K. 1.212, 2.331, 2.332, 3.331
Noebels, J.L. 2.001
Noel, D. 2.220
Nolan, K. 1.197
Nomura, S. 2.311
Noor, N. 1.087
Nordgren, R.E. 1.101, 1.166
Nordli, D.R. 1.154, 3.337

Norrington, J. 3.095
Nov, E. 3.035
Novak, E. 3.272
Novak, Z. 2.249
Novotney, C.A. 3.068
Novotny, E. 2.117, 3.176, 3.195, 3.199, 3.200, 3.212
Nowack, W.J. 3.107
Nunes, T. 1.289
Nunn, A. 1.225
Nwaubani, A. 2.051
Nygaard, H.B. 3.043

O

O'Brien, C. 3.125
O'Brien, T. 1.240, 3.170
O'Callaghan, F.J. 3.140
O'Connor, G. 3.301
O'Connor, S.E. 2.233
O'Donovan, C. 1.235, 2.045, 3.155, 3.204, 3.228
O'Dwyer, R. 2.006, 3.027
O'Laughlin, K. 3.324
O'Mahony, E. 1.182
O'Muirchearthaigh, J. 3.175
O'Reilly, H. 1.373
O'Riordan, K. 1.244
Oakley, J.C. 1.032, 1.072, 3.026
Obeid, M. 1.310
Obermeyer, T. 3.309
Ochi, A. 1.062, 1.100, 2.074, 2.077, 2.083, 2.277
Oddo, S.A. 3.144
Odenkirchen, J. 2.327
Offord, J. 1.238
Ogden, P. 2.225
Ogg, R.J. 2.080
Ogiwara, I. 3.019
Oguro, K. 3.059, 3.227
Ohkura, H. 3.025
Ohman, I. 2.152
Ohno, K. 2.265
Ohta, K. 2.054, 2.067
Ohtani, H. 3.019
Oitment, C. 1.376
Ojemann, J. 2.002, 2.117, 2.257, 3.180, 3.200
Ojha, B.C. 3.186
Ojopi, E.B. 3.308, 3.321
Ojukwu, N. 1.188
Okamoto, H. 2.074
Okanishi, T. 2.066
Okumura, A. 1.224
Okura, H. 3.365, 3.216
Oleynick, J.U. 3.037
Oliveira, E. 2.322, 3.082
Oliveira, M.A. 3.244, 3.245, 3.276
Oliveira, M.C. 1.172
Oliveira, M.S. 1.051
Olivier, A. 2.039
Olsen, J. C.06
Olsson, I. 3.093
Onat, F.Y. 3.022
Ono, T. 2.158
Onufriev, M.V. 2.007
Op de beeck, M. 2.072
Orozco, A. 2.177
Orozco, S. 2.246
Orozco-Suarez, S. 3.164B
Orta, D.S. 1.099, 2.216
Ortiz, E. 2.360
Ortiz, L. 2.014
Ortler, M. 1.160
Osawa, S. 2.044, 3.069
Osborne, J.P. 3.140
Oshino, S. 2.317
Osiowy, K. 3.332
Oslejskova, H. 2.249
Osorio, I. 3.107
Ossenblok, P. 2.075
Oster, J.M. 2.146
Osting, S.M. 3.006
Ostrander, B.E. 2.338
Otaduy, M.C. 3.234, B.08
Otaduy, M.G. 1.327
Otani, S. 1.211
Otayza, F. 3.188
Otis, S. 1.386
Otoul, C. 1.278
Otsubo, H. 1.062, 1.100, 2.074, 2.077, 2.083, 2.277, 3.135
Otsuki, T. 2.295
Ottman, R. 3.290, 3.302, 3.311, 3.314, 3.304
Ouellette, E. 2.341
Ouyang, B. 1.081
Overvliet, G. 1.374
Owens, J. 2.030
Ozkara, C. 1.198

P

Pacheco, L. 1.051
Pacheco, O. 2.360
Pacia, S. 3.250
Padmanabhan, A. 1.360
Pai, D. 2.244
Paige, A.L. 1.096, 2.268, 3.186, B.07
Pak, A. 3.284
Pakhdikian, M.C. 3.034
Pakhomov, S.V. 1.321
Palacios Escalona, S. 3.366
Palau, J. 2.182
Palmer, G.M. 3.156
Palumbo, L. 2.046
Pan, J.W. 1.178
Pan, Y. 1.052
Pan, Y.Z. 1.020
Pang, T. 3.073
Panjarat, J. 1.215
Pannek, H.W. 2.319
Panuccio, G. 3.356
Paolicchi, J. 1.222, 1.234, 2.012, 2.059
Papanastassiou, A.M. 2.318
Papanicolaou, A. 1.384, 2.079, 2.082, 2.115
Papetti, L. 2.204
Para, M.F. 1.181
Paradis, P. C.04
Pardalos, P. 1.075, 1.117
Pardo, C. 3.188
Parekh, M. 1.056, 2.145
Parent, J.M. 3.342
Pargeon, K. 2.196, 3.329
Parikh, G. 3.138
Parisé, H. C.04
Park, E.J. 3.234
Park, H. 3.091
Park, J. 3.154
Park, K. 1.120, 2.290
Park, Y. 2.270, 2.313
Park, Y.D. 1.320, 2.255, 3.206
Parker, H. 2.183
Parker, P. 1.315
Parkerson, K. 1.110, 3.092
Parrent, A.G. 2.245
Parrish, R.R. 1.018
Partlo, L. 1.333
Parvizi, J. 2.095, 1.183, 2.093
Pascher, B. 2.279
Pascoal, V.D. 3.028
Pascual-Leone, A. 2.228
Pasini, E. 3.313, 3.318
Pastori, C. 1.116
Patankar, C. 3.105
Patay, Z. 2.137
Patel, A. 2.180
Patel, M. 1.060
Patel, M.K. 3.357
Patel, N. 3.352
Patel, R.H. 2.116
Pati, S. 2.029, 2.253, 2.294, 2.355
Patil, V. 1.053
Patterson, C. 2.197
Patterson, E. 1.279
Pauli, E. 1.335, 1.387
Paulson, K. 3.056
Pavkovic, I. 2.282
Payne, E. 1.304
Paz, J.T. 1.039
Pazourkova, M. 2.249
Pearl, D. 2.209
Pearl, P. 2.284
Pearl, P.L. 3.298
Pedley, T.A. 3.311
Pegenius, G. 2.088
Peguero, N. 3.114
Peixoto-Santos, J.E. 3.358
Peljto, A.L. 3.304
Pellock, J. 2.167
Peltzer, J. 3.107
Pennell, P. 1.151, C.07
Penovich, P. 1.311, 3.257
Pequinot, E. 1.308
Peragut, J. 1.132
Pereda, P. 2.024
Pereira, F. 2.111, 2.126
Pereira, L. 2.147
Pereira, T. 1.028, 3.028
Pereira, V.C. 2.107
Perez Cardenas, S. B.01
Pericak-Vance, M.A. 3.249
Perilla, J.R. 1.136
Perkins, F. 2.137, 2.293
Perkins, F.F. 2.080
Perkins, S.M. 1.358, 3.261
Perrine, K. 1.319, 1.329, 1.331, 1.347, 3.271
Perrine, K.R. 1.122
Perry, M.S. 1.206, 2.168
Perucca, E. 2.147
Perucca, P. 3.134
Pestana Knight, E.M. 1.236
Peterka, D.S. 3.072
Peters, A. 1.336
Petersen, C.B. C.06
Peterson, J. 1.238
Petre, C. 2.310
Petrosyan, R. 3.341
Petrou, S. 3.004, 3.045, 3.363
Peugh, L.D. 2.002
Peyre, S. 3.081
Pham, L.A. 3.076
Phatak, V. 1.349
Phi, J. 2.280
Philip, S. 2.169, 2.199
Phillipps, G. 3.110
Phillips, L. 3.104
Phillips, N. 2.080
Piantino, J. 3.217
Piazzini, A.J. 1.357
Picard, R. 1.074
Pichon, B. 3.291
Pico, G. 1.309
Pieper, T. 2.279
Pierre, M. 3.292
Pieters, T. 2.100
Pike, V.W. 3.230
Pillai, J. 3.258
Pillay, N. 1.195, 1.306, 1.333, 2.118, 2.186, 3.088, 3.124
Pineda, E. 3.024, 1.021
Pinette, K. 1.287
Pinto, A.L. 2.281
Pinto, A.R. 1.088
Piperidou, C. 3.266
Pipkin, J.D. 1.269
Pirmohamed, M. 3.315
Pita, I. 1.063
Pitruzzello, A.M. 3.061
Pitsch, J. 1.031
Pittau, F. 3.214, 3.168
Pittman, Q. 3.036
Plans, G. 2.243
Plueger, M.D. 2.029
Pociecha, J. 2.310
Pockett, S. 1.391
Poduri, A. 2.227, 3.290, 3.291
Poh, M. 1.074
Pohlmann-Eden, B. 1.167, 3.084
Poliakov, A. 2.117, 3.200
Politsky, J. 1.067, 1.096, 1.331
Pollard, H.B. 2.008
Pollard, J. 2.008
Pollard, J.P. 3.143
Pollard, J.R. 2.247
Polli, R.S. 3.028
Polovitz, K.A. 3.108
Poma, R. 3.164
Pomata, H. 2.310
Pong, A.W. 1.310
Poolos, N.P. 1.031
Pop, J. 3.080, 3.240
Popli, G.S. 2.281
Popova, M.S. 2.007
Porcel, J. 2.352
Pornsriniyom, D. 3.239
Porter, R. 1.277, 1.293, 2.355
Potter, W. 1.244
Pouliot, P. 3.169, 3.231
Pouliot, W.A. 1.317A
Poulsen, D. 3.001

Poulter, M.O. 1.243
Poupon, C. 3.177
Poussier, S. 3.159
Poveda, A. 3.050
Poveda-Ramos, A. 3.044
Powell, A.D. 3.053
Powell, E. 3.060
Pozner, C.N. 3.081
Prabhu, S. 2.133
Prasad, A.N. 3.305
Prasad, C. 3.305
Prasad, M. 3.105
Pressler, R.M. 1.162
Preto, P.M. 3.310
Price, A.V. 2.299
Price, M. 1.330
Prince, D.A. 1.039
Pritchard, E.M. A.03
Pritchard, P.B. 1.217
Privitera, M. 3.129, 3.293, C.07
Prochazka, T. 2.104
Progesterone Trial Study Group 1.151
Provenzale, J.M. 2.129
Pruess, T. 2.164
Pujar, S. 2.351
Pulitano, P. 3.318
Pun, R.Y. 3.340
Pung, C. 2.116
Purcaro, M.J. 1.150, 1.225
Pushchinska, G. 3.123
Pérez, S. 2.259

Q

Qian, S. 1.155
Qian, Y. 1.007
Quach, M. 1.111, 1.125, 2.030
Quan, H. 2.354, 3.246
Quebedeaux, T.M. A.04
Qui, H. 3.293
Quigg, M. 1.135, 1.137, 2.048
Quigley, S. 1.186
Quinn, B.T. 2.123, 3.248
Quint, P. 1.386
Quintana, M. 3.225

R

Rabinowitz, D. 3.316
Radman, T. 3.050
Radtke, R. 3.301
Raedt, R. 1.252, 2.214, 3.063, 3.066, 3.070
Raethjen, J. 3.197
Raffo, E. 3.159
Rafiuddin, A. 2.171
Raghavan, M. 2.108, 2.130, 3.232
Rahey, S. 1.218
Rahman, A. 1.019, 3.046
Rahme, R. 2.267
Rakhade, S. 1.016, 3.029
Ramachandran Nair, R. 1.375, 2.070
Ramakrishnan, V. 3.133
Ramanathan, M. 2.231
Ramantani, G. 1.138
Ramirez, M. 3.114
Ramon, C. 1.118, 1.126, 1.139
Rampling, J. 3.287
Rampp, S. 1.094
Ramsay, R.E. 2.198
Rand, S.D. 2.130
Rankin, P. 3.095
Rankin, S.J. 1.308
Rao, M. 2.359
Raol, Y.H. 1.012, 1.040
Raposo, N.R. 3.251
Rarick, J. 1.279
Rask, K. 2.168
Rasmussen, J. 2.170, 2.178
Raspall, M. 1.309
Rastogi, R.G. 1.317, 2.294
Rathakrishnan, R. 2.058
Ratnapriya, R. 1.200
Rauchenzauner, M. 2.175
Rausch, G. 3.149
Ravizza, T. 1.022
Ray, C. 2.338
Raymond, A.A. 3.142
Reavey, E. 1.156
Reddi, J.M. A.06
Reddy, D. 1.011, 1.041
Reed, R. 2.198
Rees, M.I. 1.338, 3.303
Regis, J. 1.132
Regnier-Golanov, A. 1.246
Rego, C. 2.107
Reid, A. 2.354, 3.036
Reid, C.A. 3.045
Reijneveld, J.C. 2.085
Reimer, R.J. 1.002
Reinsberger, C. 1.074, 1.110, 1.199, 3.092,
Rekate, H.L. 2.005
Rekow, V. 1.349
Rektor, I. 1.213, 1.237, 2.249, 3.201
Rektorova, I. 3.201
Rembao Bojórquez, D. 3.366
Remedio, V. 2.326
Remi, J. 1.336
Rensing, N.R. 2.222
Resnick, T. 1.367, 2.273, 3.196
Resor, Jr, S.R. 2.196
Reutlinger, C. 3.309
Rey, G. 1.367
Reyes, C. 3.298
Rezvanian, E. 1.126, 1.139
Rho, J. 2.183, 2.218, 2.219
Riano Barros, D.A. 3.202
Ricciardi Ciocchini, A. 2.184
Richard, G.R. 3.041
Richards, D.A. 3.340
Richards, K. 1.206
Richardson, K. 1.325
Richardson, M. 1.114, 3.142, 3.175
Richerson, G.B. 3.010
Richmond, J. 2.302
Rieder, C.R. 3.112
Rigby, M. 3.333
Rigdon, G.C. 1.271
Riggeal, B. 2.028
Rigon, L. 3.318
Riley, J. 2.103, 2.105, 2.113
Riley, K.O. 2.268, B.07
Rimkus, C.M. 3.234
Rinehardt, E. 1.350, 1.356
Ris-Hilgersom, I.H. 2.085
Risse, G.L. 1.337, 1.388
Ristic, A.J. 1.184, 3.220
Ritaccio, A. 1.158, 2.181
Ritch, P. 2.163
Ritter, F.J. 1.255, 1.361, 2.282
Ritzl, E.K. 3.192
Riviello, J. 1.068,1.125, 1.187, 1.371, 2.030
Riviello, Jr, J.J. 1.111
Rizk, M. 2.247
Roberts, D. 2.024, 2.305, 2.312
Roberts, J. 3.327, 3.332
Robertson, C.R. 2.164
Robertson, D. 3.285
Robertson, S. B.02
Robinson, A.A. 2.059
Robinson, J.L. 3.203
Robinson, S. 2.286
Robles Irizarry, L. 2.209
Rocha, L. 2.246, 3.164B, 3.366
Rockoff, M. 1.083
Rode, D.L. 3.072
Roden, W.H. 2.002
Rodgers-Neame, N. 1.350, 1.356
Rodionov, R. 3.189
Rodriguez, R. 2.298
Rogawski, M.A. 3.051
Rogemond, V. 1.247
Rogers, B.P. 3.198
Rogers, J.A. 3.065
Rogers, S. 2.150
Rogier, J. 2.296
Rojas, G. 3.188
Roman, C.T. 1.369
Romantseva, L. 2.225
Romeo, A. 1.313
Ronan, A. 3.295
Ronan, L. 3.317
Ronen, G.M. 1.375
Roopra, A. 1.244
Roper, S.N. 3.009, 3.013
Rosa-Neto, P. 2.003, 3.166, 3.208
Rosales, S.J. 2.357
Rose, D. 1.065, 2.084, 2.271
Rose, S. 1.098
Roselt, P. 3.170
Rosenberger, L.R. 3.191
Rosendo, J. 2.352
Rosenkranz, K. 3.189
Rosenstone, S. 2.361
Rosset, S. 2.134
Rossi, M.A. 3.064, 3.205
Rosso, L. 3.202
Rostasy, K. 1.160
Rotenberg, A. 1.221, 2.228
Rothermel, R. 1.106, 1.108, 1.112, 1.143
Rothkopf, Z. 1.067
Rothman, S. 3.072
Rotim, K. 2.256
Rouits, E. 1.278
Rouleau, I. 2.267
Rovba, L. C.04
Rovira, A. 3.225, 3.226
Rovira, R. 3.226
Rovner, M. 3.265
Rowley, J. 3.166, 3.208
Rowley, N. 3.359
Royston, S.E. 2.394
Rozhkov, L. 2.271, 3.218
Rozzelle, C. 2.010, 2.139
Rubens, E. 1.122, 2.306
Rubio-Donnadieu, F. 2.259
Rubí Sureda, S. 3.233
Ruch, A. 3.361
Rudd, G.D. 1.284
Rudenko, V. 2.171
Ruiz, S.E. 3.037
Rupar, C.A. 3.305
Rusch, M.D. 3.269
Ruskin, D.N. 2.210
Russek, S.J. 1.012
Rutecki, P. 1.020, 1.052, 1.244, 2.124
Rutherford, D. 2.018
Rutka, J. 1.062, 2.077
Ruzzo, E.K. 3.290
Ryan, K. 1.060
Rydenhag, B. 3.093
Ryu, H. 3.030
Ryzi, M. 2.249
Rzezak, P. 1.380
Rémi, J. 1.228
Ríos, L. 3.188

S

Saag, K. 3.338
Sabater, L. 1.180
Sabesan, S. 1.115, 1.127
Sabolek, H.R. 1.042
Sabsevitz, D.S. 2.108
Sackellares, J.C. 1.075, 1.117, 2.028
Sadiq, S. 2.354
Sadler, R. 1.218
Safford, M. 3.338
Sagar, S. 1.283
Sagyhan, A. 1.057
Sahaya, K. 2.019
Sahin, M. 1.260
Sahmoud, T. 1.260, 2.221
Sahota, P.K. 2.019
Said, R.R. 1.149
Sainz, V. 2.235
Saito, N. 1.141
Saito, T. 2.311
Saito, Y. 3.126
Saiz, A. 1.180
Sajko, T. 2.256
Sakai, S. 3.019
Sakamoto, A. 2.119, 2.134, 2.142, 2.147, 2.275, 3.236, 3.306
Sakuma, H. 3.126
Salam, M. 1.087
Salam, M.T. 3.062
Salamon, N. 2.076
Salanova, V. 1.176, 2.269
Salas-Puig, J. 2.352
Salas-Puig, X. 3.225, 3.226
Sales, F. 1.061
Salinas, F.S. 3.058, 3.160, A.07
Salmon, C.E. 2.119, 2.134, 2.142, 3.236
Salom, A. 2.360
Salvadó, M. 3.226
Salzberg, M. 1.240
Sam, M. 3.155
Samson, S. 3.177
Samuels, P. 3.105

Samuelson, T.M. 2.211
Samuelsson, H. 1.318
San Juan, D. B.01
San Luciano, M. 3.266
Sanchez, R. 1.023
Sandau, U.S. 3.001, 3.046
Sander, J.S. C.03
Sandhu, J. 3.260
Sandison, E. 2.340
Sandra, S. 1.155
Sane, S.A. 2.363
Saneto, R. 2.117, 3.200
Sanford, N. 3.208
Sanganahalli, B.G. 3.354
Sankar, R. 1.021, 3.024, 3.099
Santamarina, E. 3.225, 3.226
Santin, J. 3.077
Santos, A.C. 2.119, 2.134, 2.142, 3.236, 3.358
Santos, R.O. 3.306, 3.307
Sanz, R. 1.175
Saposnik, G. 3.323
Saragiotto da Silva, M.S. 3.307
Sarco, D. 2.050
Sarda, S.P. 2.211
Saria, H.Y. 1.089
Sarkis, R. 1.351
Sarria, S. 3.225, 3.226
Sasaki, M. 2.295, 3.126
Satishchandra, P. 3.147
Satishchnadra, P. 1.200
Sato, S. 3.192, 3.224
Saul, K. 3.056
Sauro, K. 3.332, 3.333
Save, S. 1.195, 2.186, 3.124
Savjani, R. 3.203
Sawan, M. 3.062
Sawchuk, R. 3.129
Saygi, S. 1.245, 2.187
Sazgar, M. 3.102
Saúde, A.V. 2.126
Scafidi, J. 3.083
Scandiuzzi, R.C. 3.358
Scanlon, C. 2.120, 3.317, B.03
Scaramelli, A. 2.024
Schachter, S. 1.332, 3.073, 3.293
Schaefer, K. 1.226
Schaffer, S.G. 2.316
Scharfman, H. 3.044, 3.050, 3.362
Schauwecker, P. 3.360
Scheff, S.W. 3.345
Scheffer, I.E. 1.157, 3.294, 3.295, 3.296, 3.297, B.02
Scheuer, T. 1.032, 3.026
Schevon, C. 1.150, 3.050
Schiemann-Delgado, J. 1.278, 1.282
Schiff, S.J. 3.047
Schilhabel, M. 3.309
Schmainda, K.M. 2.130
Schmidt, J.M. 1.174
Schmitt, F.C. 2.319
Schneider, C. 3.346
Schoenberg, M. 1.350, 1.356
Schoenfeld, J. 2.238
Scholl, E.A. 2.164
Scholtz, H. 2.235
Schomer, D.L. 3.073
Schoonheim, M.M. 2.085
Schousboe, A. 3.359
Schrader, D.V. 2.121
Schreiber, J.M. 1.095
Schroeder, C. 3.050
Schuele, S. 1.189, 3.153
Schuele, S.U. 1.231
Schultz, R. 1.266, 1.371, 2.030
Schulze-Bonhage, A. 1.102, 1.138, 2.035, 1.061
Schusse, C. 2.151, 2.161
Schusse, S. 1.258
Schwabe, M.J. 1.140
Schwartz, I.V. 3.112
Schwartz, T.H. 1.024, 1.122, 2.306
Schwebel, C.L. 3.037
Scott, C. 2.094
Scott, J. 2.118
Scott, M. 1.083
Scott, R. 1.043, 1.325, 1.372, 1.373, 1.385, 2.351, 3.041, C.08
Secolin, R. 3.306, 3.307
Sedigh-Sarvestani, M. 3.047
Segalovich, M. 2.310
Sehgal, S. 2.069
Seidel, W.T. 1.345
Seidenberg, M. 2.103, 2.113, 2.124, 3.264
Selenica, M.B. 2.364
Selimbeyoglu, A. 2.095
Sell, E. 2.333
Selvitelli, M. 3.073
Selwa, L.M. 2.365
Selznick, L. 3.104
Senties-Madrid, H. 2.259
Seo, D. 3.086
Seo, J. 1.065, 2.271, 2.276, 2.292, 3.218
Serafini, R. 2.049
Sergott, R. 1.294, 2.167
Serin, M. 2.189
Serkova, N. A.05
Serrano, E. 1.329, 2.160, 2.203, 3.103
Serratosa, J. 1.175, 1.292, 2.352
Setchell, K. 1.058
Sethi, N. 2.053, 2.306
Setoain Perego, X. 3.233
Seyal, M. 3.259
Sha, Z. 1.219, B.06
Shafaroodi, H. 2.149
Shafer, P.O. 2.025
Shah, A. 1.086, 1.112, 1.226, 2.052, 2.244
Shah, N.S. 3.328
Shahidi Zandi, A. 1.128
Shaikh, S. 1.254, 1.277, 1.290, 1.291
Shallcross, R. 1.312
Shamy, M.C. 1.150
Shang, E. 3.048
Shapiro, L. 3.018, 3.032, 3.361
Shapiro, M.S. 3.349
Sharan, A. 2.308, 2.320
Sharifi-Hannauer, P. 3.099
Sharma, A. 2.355
Sharma, R. 1.100
Sharma, S. 2.070
Shatzmiller, R.A. 1.173
Shaw, D. 2.117, 3.200
Shaw, S. 2.252
Shazadi, K. 3.315
Shegog, R. 1.188, 2.362
Shellhaas, R. 1.236, 2.047
Shellock, F.G. 2.128
Sherman, A. 2.223, 2.229
Sherman, E. 1.333, 1.368, 2.018
Sherman, E.M. 1.370, 2.122
Sherman, E.S. 1.362
Sheth, R. 2.113, 2.124
Sheth, S. 1.078, 1.332
Shi, L. 3.334
Shiau, D. 1.075, 1.117
Shiau, D.S. 3.008
Shields, D. 2.167
Shields, W.D. 3.099
Shigematsu, H. 1.211, 1.233
Shigeto, H. 3.020
Shih, J.J. 1.135, 3.071
Shih, Y.H. 3.148
Shimazaki, K. 3.059
Shimojima, K. 1.211
Shin, D. 1.021, 3.024, 3.030, 3.090
Shinnar, S. 3.250
Shiroishi, M. 2.128
Shishido, T. 3.118
Shklyar, I. 1.225
Shneker, B.F. 1.181
Shon, Y.M. 2.140
Shorey, J. 3.061
Shrestha, A. 3.125
Shuangshoti, S. 2.260
Shulman, D. 2.331
Shulman, L. 1.330
Shurtleff, H. 3.200
Siddarth, P. 1.364, 2.135
Sidenius, P.C. C.06
Siebzehnrubl, F.A. 3.013
Siegel, S. 3.348
Sikora, M.A. B.06
Silander, H. 3.093
Sills, G.J. 3.315
Silva, M.S. 3.306
Silva Cunha, J.P. 1.336
Silvado, C.E. 3.281, 3.289
Silveira, D.C. 1.177, 3.131, 3.272
Silverberg, A. 3.074
Sim, T.B. 2.058
Simakajornboon, N. 3.242
Simeone, T.A. 1.239
Sinclair, D.B. 2.307
Singer, J. 1.088
Singh, H. 2.302
Singh, J. 2.118
Singh, P. 2.337, 3.275
Singh, S.P. 2.081
Sinha, S. 3.147
Siniatchkin, M. 3.197
Sinsioco, C. 2.053
Sirven, J. 1.212, 2.332, 2.355, 3.331
Sisodiya, S. 3.295, 3.301
Skidmore, C. 1.308, 2.320
Skinner, F. 1.051
Skinner, H.J. 2.028
Slater, J. 1.384, 2.079, 2.082, 2.100, 2.115
Sleiman, P. 3.293
Smith, B. 2.326
Smith, B.J. 2.266
Smith, B.N. 3.345
Smith, D.R. 3.042
Smith, E. 1.083
Smith, E.C. 1.223
Smith, G.G. 3.037
Smith, G. 3.273
Smith, J. 2.313
Smith, J.R. 1.320, 2.255, 2.270
Smith, K. 2.091
Smith, M. 1.376, 2.167, 2.169, 2.199, 3.330, 3.359
Smith, M.A. 1.165, 1.168
Smith, M.D. 2.164
Smith, M.L. 2.138
Smith, P.E. 1.338, 3.303
Smith, S. 1.045, 2.094
Smith, T.M. 3.334
Smolders, I. 3.070
Smyth, M. 2.296
Snape, D.A. 3.263, 3.274
Snead III, O.C. 1.062, 2.074, 2.077, 2.083, 2.138, 2.277
Snyder, T. 1.322
So, N. 1.184, 2.034, 3.131, 3.220, B.05
Soares-da-Silva, P. 1.242, 1.287, 1.289, 2.153
Sofia, V. 3.318
Soldati, M. 3.137
Solomon, G. 2.053
Soltesz, I. 3.346
Song, H. 3.030
Song, H.K. 3.090
Song, T. 3.193, 3.223
Song, Y. 2.162, 2.337, 3.275, 3.283
Sonmezturk, H.H. 3.094, 3.198
Sood, S. 1.106, 1.108, 1.112, 1.124, 1.143, 2.101, 3.164A, 3.173
Sosunov, A.A. 1.004, 3.362
Sotero de Menezes, M. 2.238
Soto, A. 2.235
Soto-Salgado, M. 1.063
Soucy, J.P. 1.207, 3.166
Soul, J.S. 3.014
Souza, A.C. 3.244, 3.245, 3.276
Souza, L. 1.076, 1.232
Soylemezoglu, F. 1.147
Spalding, W. 1.287
Spalice, A. 3.137, 2.204
Spanaki, M.V. 2.266
Spanaki-Varelas, M. 2.326
Spann, M. 1.377, 3.176, 3.195
Speechley, K. 3.325, 3.336
Spencer, D.C. 1.176
Spencer, D.D. 1.150, 1.178, 1.339, 2.318, 3.190, 3.199, 3.211
Spencer, S. 1.150, 3.250
Sperling, M. 1.151, 1.288, 1.308, 2.308, 2.320, 3.250, 3.293
Spiegel, R. 2.202, 3.123
Spire, W. 2.024
Spitz, M.C. 2.159, 3.125
Spray, D. 1.057
Squillacote, D. 1.274, 1.292, 1.280
Sreenivasan, A. 1.225

Srikijvilaikul, T. 2.260
Sripankaew, K. 2.325
St-Hilaire, J. 2.267
St. Louis, E.K. 3.238
St.Germaine, C. 3.246
Staba, R. 3.240
Stafstrom, C. 2.113
Staley, K. 1.003, 1.010, 1.042, 1.248
Stam, C.J. 2.061, 2.085
Stamoulis, C. 1.129
Staniek, M. 1.146
Stapleton-Kotloski, J. 3.204
Starky, M. 3.260
Stead, M. 1.093, 1.130, 3.055
Stebbins, G.T. 3.097
Steber, D. 2.170, 2.178
Stefan, H. 1.094, 1.335, 1.387
Stefanello, S. 2.345
Steger-May, K. 2.296
Stein, M. 3.205
Steinborn, B. 1.230
Steindler, D.A. 3.013
Steinhoff, B.J. 1.201
Steinmetz, P.N. 1.202, 2.005
Stengel, B. 2.108
Stepanenko, A.Y. 2.007
Stepanichev, M.Y. 2.007
Stephani, U. 3.197, 3.309
Stephen, L.J. 1.315
Stern, J. 2.076, 3.174, 3.179, 3.219
Steven, D.A. 2.245, 3.085
Stevens, G. 2.209
Stevens, S.J. 2.263
Stewart, K. 3.001
Stewart, M. 3.325
Stewart, T.H. 3.035
Stickland, S.M. 2.270
Stock, D. 1.281
Stockis, A. 1.278
Stojic, A. 3.131
Stoll, S.C. 2.017
Stolle, J. 1.283
Stott, L. 2.308, 2.320
Stoub, T.R. 2.136, 3.205
Stout, A. 2.327
Straub, H. 3.078
Strenkowski, B. 1.238
Striano, P. 1.286, 3.313, 3.318
Striano, S. 3.313, 3.318
Strickland, S. 1.320, 2.313, 3.206
Strittmatter, S.M. 3.043
Strobel, A. 3.347
Strom, L. 2.159, 3.106, 3.125
Strubé, D. 3.061
Strupp, J.P. B.06
Stuelpnagel, C. 1.286
Stufflebeam, S. 3.178, 3.207, 3.209
Stödberg, T. 3.294
Su, T. 3.002
Sudarsanam, A. 2.199, 2.169
Suddes, M. 3.333
Sueiras, M. 3.226
Suffczynski, P. 1.054
Sugai, K. 2.295, 3.126
Sugano, H. 3.025, 3.100, 3.216, 3.365
Sugiyama, I. 2.083
Suh, S. 3.030
Sullivan, J. 2.047, 3.312
Suls, A. 3.294
Sun, D. 1.052, 3.006
Sun, F.T. 2.215
Sun, H. A.08
Sun, W. 3.020
Surbeck, W. 2.267
Surgenor, S.D. 1.101
Susul, U. 1.186
Sutula, T.P. 1.052, 3.006
Suwaroporn, S. 2.325
Suzuki, M. 2.311
Suzuki, N. 3.178, 3.209, 3.207
Suzuki, Y. 1.233
Svalheim, S. 2.175
Svendsen, K. 2.344
Swann, J. 1.038, 1.053, 3.023
Swanson, S.J. 2.108
Swarte, R.M. 1.070
Swartz, K. 2.360
Sweeney, C. 2.329
Sweetman, M. 2.017
Swenson, B. 1.219
Swenson, N. 1.074
Swiercz, W.B. 1.042
Swint, C. 2.168
Syed, T.U. 2.336
Sykora, P. 1.237
Sylverberg, A. 2.283
Symms, M. 2.106, 3.175
Synder, T. 3.260
Synowiec, A. 3.127
Syvänen, S. 3.161
Szabo, C.A. 2.357, 3.058, 3.160, 3.286, A.02, A.07
Szeliga, C. 1.194, 3.099
Sziklas, V. 1.323, 3.208
Szmuda, M. 1.230
Sánchez, J.C. 2.352

T

Tabb, K. 3.052
Tafreshi, R. 1.128
Taher, Y. 1.096, 1.347
Takahashi, A. 2.295
Takahashi, H. 1.211, 1.344
Takahashi, T. 3.216
Takahashi, Y. 1.211, 1.233, 3.019, 3.118, 3.151
Takase, K. 3.020
Takayama, R. 1.211, 3.118, 1.233
Takeoka, M. 2.050, 2.227, 2.281
Takumi, I. 1.169
Talani, M. 3.292
Talathi, S.S. 1.056, 3.031
Talib, L.L. 3.251
Tallent, M.K. A.06
Talos, D. A.08
Tammaa, M. 3.275
Tampieri, D. 3.291
Tamura, K. 2.323
Tanaka, M. 3.322
Tanaka, N. 3.178, 3.207, 3.209
Tanaka, Y. 2.265
Tandon, N. 2.100, 2.112, 2.261
Taneja, A. 1.185
Tang, H.M. 3.068
Tani, H. 1.002
Tanner, A. 2.262
Tannús, A. 3.028
Tao, J. 1.098, 1.155, 2.042
Tapsell, L. 2.331
Tarquinio, D.C. 2.051
Tarrant, S. 2.227, 2.239
Tatum, W.O. 2.180, 2.364, 3.278
Taub, K.S. 2.224
Taubøll, E. 3.136, 2.175
Taussig, D. 2.297
Tavares, C. 2.023
Tavorath, R. 1.260
Tcheng, T.K. 2.215
Tecoma, E. 1.190, 2.116, 3.109
Tedeschi, H. 2.322
Teive, H.A. 3.289
Teleb, M. 2.036
Tellez-Zenteno, J.F. 1.097, 2.347
Temkin, N.R. 3.335
Templeton, D. 1.264
Tenney, J. 2.084
Tepmongkol, S. 2.260
Terada, K. 2.060
Teramoto, A. 1.169
Terranova, P. 1.205
Terwilliger, R. 1.360
Tesar, G. 1.326, 3.131, 3.282
Tesar, G.E. 3.252, 3.326
Tesfaye, M. 3.192
Teucher, U. 2.015
Thadani, V. 1.101, 1.325, 2.081, 2.305, 2.312
Thaler, A. 3.143
Thampratankul, L. 3.242
Thapalia, U. 1.085
The EPGP Senior Investigators 2.047, 2.155, 3.316
The RNS System Investigators C.02
The SANTE Study 2.269
Thennarasu, K. 3.147
Theodore, W.H. 3.192, 3.224, 3.230
Theofilas, P. 3.001
Thesen, T. 2.123, 3.184, 3.248
Thiele, E.A. 3.178
Thio, L.L. 2.222, 2.296
Thivard, L. 3.177
Thomas, E.A. 3.363
Thomas, F.S. 1.220
Thomas, R.H. 1.338, 3.303
Thome-Souza, S. 3.082
Thompson, N. 2.362, 2.365, 3.107
Thompson, P. 3.175
Thompson, S.J. 1.307
Thompson, S.M. 1.006
Thomson, A. 1.274
Thomé-Souza, S. 3.321
Thorburn, D.R. 3.294
Thordstein, M. 2.088
Thornton, N. 3.241
Thrasher, S.L. 1.339
Thurman, D.J. 2.335
Tillema, J.M. 2.009
Tingley, E. 3.095
Tinuper, P. 3.313, 3.318
Titiz, A.S. 1.043
Titus, J. 2.296
Todd, W. 2.172, 2.176, 2.179
Toepser, C.S. 1.146
Toguri, J. 1.189
Tokoglu, F. 3.190
Tolbert, D. 1.259
Toledo, M. 1.309, 3.226, 3.225
Tolstykh, G. 3.011, 3.247
Tombul, T. 2.143
Tomcik, J. 3.201
Tominaga, T. 2.044, 3.069
Toms, N. 2.094
Tomson, T. C.03
Topcu, M. 1.147
Topjian, A.A. 1.080
Torres, C.M. 3.112, 3.244, 3.245, 3.276
Torres, F.R. 2.111
Torres, R. 2.128
Torres-Corzo, J.G. 2.298
Torri, S. 1.294
Tosun, D. 2.120
Tottori, T. 2.060
Towne, A. 3.133
Tran, T. 3.280
Tran, Y. 1.086, 2.052, 2.244
Trandafir, C. 1.317A
Trayanov, S. 2.170, 2.178
Treiman, D.M. 1.127, 1.202, 2.029
Tremblay, J. 3.169, 3.231
Trinka, E. 1.160, 1.268, 3.182
Tripathi, M. 1.059
Triplett, W. 2.145
Tripp, K. 1.287, 1.289, 2.153
Tripputi, M. C.05
Tristán Agundis, M.F. 3.366
Trobliger, R. 1.352
Trombin, F. 1.008
Tryba, A.K. 2.004, 3.054
Tsai, J. 1.288
Tsang, S. 2.196
Tsiakiri, A. 3.266
Tsiouris, A.J. 2.306
Tsuchida, T. 1.079, 2.064, 2.284, 3.083, 3.298
Tsuji, S. 1.341
Tsukerman, S. 2.156
Tu, B. 1.174
Tuchman, R. 3.249
Tuchscherer, V. 2.124
Tucker, D. 3.350
Tudor, C. 2.221
Tudur Smith, C. 3.132
Tupal, S. 3.017
Turanli, G. 1.147
Turkheimer, F.E. 3.202
Turner, K. 1.357
Tuxhorn, I. 1.196, 1.366
Tyrlikova, I. 1.237, 2.249
Tyrlíková, I. 1.213
Tytgat, D. 2.191
Tzu, W.H. 3.308

U

Uchida, C. 1.076
Ueda, Y. 3.364
Uematsu, M. 2.044
Ugarnes, G. 2.310
Ugorec, I. 1.067

Ugurbil, K. B.06
Uhl, J.D. 3.340
Uiterwaal, C.S. 1.298
Umeoka, S. 2.060
Unal, O. 2.143
Unnwongse, K. 1.326, 2.038
Unterberger, I. 1.160, 1.268, 3.182
Upchurch, K. 2.076
Ura, H. 1.169
Uribe, S. 3.077
Ursitti, F. 2.204
Usami, K. 1.141
Usui, K. 2.060
Usui, N. 2.060
Uysal, S. 1.221
Uysal, U. 2.048, 1.161
Uzan, M. 1.198

V

Vaiciene-Magistris, N. 1.280
Vaidya, C.J. 3.191
Valderrábano, M. 1.034
Valdez, J. 2.177
Vale, F. 1.350, 1.356
Valenca, L. 1.121
Valencerina, S. 2.128
Valencia, J. 2.177
Valente, K. 1.340, 1.343, 1.380, 3.082, 3.251, 3.262, 3.279, 3.308, 3.321, B.08
Valeriano, J. 1.075, 3.127
Valerio, R.M. 1.327
Valero-Fonseca, J. 1.222
Valino, H. 1.194
Valle, A. 1.044
van 't Klooster, M.A. 1.077, 2.063
Van Bogaert, P. 2.072
van Breemen, M.S. 2.061
van Campen, J.S. 2.097
Van Cott, A.C. 2.040
Van de Moortele, P.F. B.06
van Dellen, E. 2.085
Van der Perren, C. 1.247
van Diessen, E. 2.061
Van Dycke, A. 1.252, 2.214, 3.063
Van Gompel, J. 2.315
Van Gompel, J.J. 3.055
Van Hirtum-Das, M. 1.194
Van Houdt, P. 2.075
Van Huffel, S. 1.070, 1.144
van Lambalgen, H.C. 1.142
van Leeuwen, J. 1.374
Van Luijtelaar, G. 2.075, 3.162
Van Ness, P.C. 1.176, 1.185
van Nieuwenhuizen, O. 1.298, 2.061, 2.097
Van Nieuwenhuyse, B. 3.066
Van Nuffelen, M. 2.041
Van Paesschen, W. 1.144
Van Poppel, K. 2.137
Van Putten, M. 1.071, 1.142
van Rijn, T. 3.162
Van Roost, D. 2.072, 2.214
van Schoonhoven, J. 1.142
van Vliet, E. 1.027
Vandendriessche, A. 1.247
Vanderhaeghen, P. 3.063
Vanegas, F. 1.007, 1.034
Vanegas, M.A. 1.099
VanLandingham, K. 1.291, 2.329
VanMeter, J. 3.191
Vannasing, P. 3.169, 3.231
Vannatta, K. 1.365, 1.378
Vanzulli, I. 1.022
Varadkar, S. 2.300, 3.116
Varma, R. 2.197
Varrin-Doyer, M. 1.247
Vasoli, V.M. 3.304
Vasquez, B. 2.360
Vassar, S. 3.254
Vazquez, C. 2.310
Vazquez, G. 1.319, 2.361
Vedolin, L. 3.112
Veerapandiyan, A. 1.223, 2.185
Vega, C. 1.377, 1.382, 3.176, 3.195
Velasco, A. 3.164B
Velasco, F. 3.164B
Velasco, T.R. 2.119, 2.134, 2.142, 3.236, 3.306
Velayudam, K. 1.234
Velez, A. 3.286
Velez-Ruiz, N. 1.078
Velis, D. 2.096
Velisek, L. 3.012, 3.049, 3.355, 3.048
Veliskova, J. 3.012, 3.048, 3.049, 3.355
Vendrame, M. 1.083, 1.091, 1.110, 1.221, 1.301, 2.195, 1.179
Venkatasubramanian, A. 1.186
Ventura, N. 2.107
Ver Hoef, L.W. 2.268, B.04, B.07
Verdru, P. 1.284
Verhaert, K. 1.373
Verity, C. 3.140
Verley, D.R. 3.035
Verma, A. 1.085, 1.381
Verma, J. 2.200
Versavel, M. 1.242, 1.287, 1.289, 2.153
Vestal, M. 1.377, 3.162, 3.176, 3.195, 3.212
Vestergaard, M. C.06
Vezina, L.G. 2.284
Vezzani, A. 3.015, 1.022
Vicenttis, S. 1.343
Vicini, S. 3.038
Vickrey, B.G. 3.250, 3.254
Vidal, R. 3.113
Vidal-Dourado, M. 2.023
Vigeland, L. 3.065
Vignoli, A. 1.205, 1.357
Vilanova, L.C. 1.232, 2.275
Vilela, J. 2.107
Villalobos-Nieto, R. 2.298
Villanueva, V. 1.292, 2.182, 2.352
Villarreal, S. 2.261
Villeda, J. 2.246
Villeda Hernandez, J. 3.366
Vincent, J.L. 1.073
Vincentiis, S. 3.251, 3.262, 3.279, 3.308
Viner, K.M. 1.320
Viri, M. 1.313
Visser, G.H. 1.070
Vivash, L.E. 3.170
Viventi, J. 3.065
Vives, K. 1.150, 2.318
Vles, J.S. 1.374
Vo, E.B. 3.278
Voets, N.L. 2.125
Vogelsong, B. 1.253
Voges, J. 2.319
Vogt, H. 3.141
Vojtech, Z. 2.104
Vollmar, C. 3.175
Von Allmen, G. 2.079, 2.115, 2.287
von Oertzen, T.J. 3.287
von Spiczak, S. 3.295, 3.309
Von Stuelpnagel, C. 1.270
VonAllmen, G. 3.115
Vonck, K. 1.252, 2.072, 2.214, 3.063, 3.066, 3.070
Voskuyl, R.A. 3.161
Vreijling, J. 1.027
Vulliemoz, S. 3.189
Vymazal, J. 2.104

W

Wadadekar, T. 1.050
Wadman, W. 3.063, 3.066, 3.070
Wagner, J.L. 3.273
Wagner, M.T. 1.217
Wait, S. 2.005
Walcutt, I.A. 2.240
Walczak, T. 3.250, C.03
Waldbaum, S. 1.060
Walker, E. 2.358
Walker, J. 2.284, 3.192
Walker, L. 3.073
Walker, M. 2.094, 3.189
Wallace, G. 3.296
Wallace, M.C. 3.084
Walser, G. 1.160, 1.268, 3.182
Walsh, C.A. 3.291
Walzer, M. 1.259
Wang, D.D. 3.007
Wang, G. 3.210, 3.221
Wang, H. 2.123
Wang, I. 2.087
Wang, K. 2.280, 3.293
Wang, L. 3.067
Wang, M. 2.217
Wang, S. 1.034
Wang, X. 3.184
Wang, Y. 3.314
Wang, Z.I. 2.086, 3.215
Wanichakorn, N. 1.215
Wannamaker, B.B. 3.273
Ware, R.E. 3.170
Warner, L.N. 1.031
Warner, M. 3.200
Warren, C. 1.130
Wasade, V.S. 2.266
Wassmer, E. 2.169, 2.199
Watanabe, A. 1.169
Watanabe, E. 3.059, 3.227
Watanabe, K. 2.132
Watanabe, M. 2.054
Watanabe, S. 1.344, 2.054, 2.067
Waterhouse, E. 3.133
Watson, C. 2.127
Watts, L.T. 3.349
Waxman, S.G. 3.298
Weber, Y. 3.299
Weber-Byars, A. 2.221
Wechapinan, T. 1.079, 2.064
Wedel, R. 3.290, 3.311
Wehbeh, R. 3.237
Wehner, T. 2.038
Wei, X. 2.122
Weigel, D. 1.094
Weil, A.G. 2.267
Weiner, D. 1.209
Weiner, M. 2.120
Weiner, M.W. B.03
Weinshenker, D. 3.052
Weinstock, A. 2.231, 3.237
Weinstock-Guttman, B. 3.237
Weiss, J.M. 3.052
Weiss, S. 1.062, 3.121
Weitlauf, C. 1.033
Welsh, A. 2.030
Welty, T. 3.129
Wen, X. 1.055
Wendling, F. 1.132
Wennberg, R. 1.354, 2.232
Wesche, D. 1.259, 1.294, 2.167
Westall, C. 3.121
Westenbroek, R. 1.032, 3.026
Wetjen, N. 2.278
Whang, K. 1.227
Whayman, M. 2.192
Wheatley, M. 2.307
Wheless, J. 2.137, 2.293, 3.328
White, C. 3.303
White, H.S. 2.164, 3.359
White, J. 1.003, 2.190
Whitman, L.A. 1.389
Whitney, A. 2.285
Wicks, P. 1.305
Widdess-Walsh, P. 2.339
Widjaja, E. 2.077, 2.083, 2.138, 2.277
Wiebe, S. 1.195, 1.333, 2.118, 2.122, 2.186, 2.354, 3.088, 3.124, 3.246, 3.327
Wiemer-Kruel, A. 2.230
Wijesekara, D.S. 1.162
Wilder-Smith, E.P. 2.058
Wilfong, A. 1.260, 1.266, 1.371, 2.030, 2.200
Wilke, C. 3.171
Wilke, J. 2.183
Williams, A.C. 1.345
Williams, F.B. B.04
Williams, H.E. 3.288
Williams, J.T. A.02, A.07
Williams, K. 1.203
Williams, L.N. 2.062
Williams, S. 1.005, 2.197
Williamson, P.R. 3.132
Willmore, J. 3.364
Willner, A.P. 3.277
Winawer, M. 3.314, 3.316, 3.319
Winchester, S.A. 1.223, 2.185
Winczewska-Wiktor, A. 1.230
Windhorst, A.D. 3.161
Winkler, P. 2.279
Winoske, K. 3.023
Winstanley, F.S. 1.339
Winston, G. 2.106
Winter, B. 3.055

Wirrell, E. 1.148, 2.278, 2.315, 2.346, 2.353, 2.356, 3.241
Wodrich, D. 2.021
Wojcik, J. 3.056
Wolf, S.M. 1.084, 2.026, 2.274, 3.130
Wolff, C. 1.247
Wolgamuth, B. 3.272
Wolgemuth, D. 3.048
Wong, C. 3.215, 3.220
Wong, C.H. 1.184
Wong, J.B. 3.329
Wong, M. 1.204, 2.222, 1.014, 1.046
Wong, P.K. 2.065
Wong, R.K. 3.351
Wong-Kisiel, L. 2.353
Wood, R.L. 1.338
Worrell, G. 1.093, 1.130, 2.315, 3.055, 3.171, 3.183, 3.210, 3.221
Wright, C. 2.163
Wright, H.H. 3.249
Wright, T. 3.121
Wu, C. 3.352
Wu, E.X. 1.385
Wu, G. 3.215, 3.220
Wu, H.C. 1.143
Wu, J. 3.099, 3.347
Wu, J.Y. 1.133, 1.194
Wu, T. 2.036
Wu, X. 3.362, 1.004
Wyckhuys, T. 1.252, 2.214, 3.063, 3.066, 3.070
Wyllie, E. 1.091

X

Xiao, B. 1.225
Xu, H. 3.008
Xu, J. 3.060
Xu, L. 1.045
Xu, M. 3.187
Xuan, Y. 3.165

Y

Yacubian, E. 1.076, 1.232, 2.023, 2.251, 2.275
Yacubian, E.T. 2.241
Yadava, G. 3.110
Yalcin, A. 3.164B
Yalnizoglu, D. 1.147
Yamada, K.A. 2.222
Yamaguchi, M. 2.060
Yamakawa, K. 3.019
Yamakawa, T. 2.311, 2.321
Yamamoto, H. 3.151, 1.224
Yamamoto, T. 1.131, 1.211, 2.066, 2.283, 2.324
Yamano, M. 1.341
Yamazaki, M. 1.131, 2.066, 2.324
Yamazoe, T. 2.066, 2.324
Yandora, K. 3.127
Yang, H. 1.274, 1.292
Yang, J. 3.341
Yang, J.C. 2.165
Yang, L. 1.150, 1.225, 1.382, 3.183, 3.221, 3.171
Yang, X.F. 3.072
Yap, E. 1.225
Yasuda, C. 2.110, 2.111, 2.126, 2.322, 3.306
Yaun, A. 2.284
Yavuz Demiray, D. 1.198
Yeates, K. 1.365, 1.378
Yee, A. 3.056
Yee, A.S. 3.056
Yeh, H. 3.174, 3.179, 3.219
Yen, D.J. 3.148
Yendle, S.C. 3.296
Yeni, N. 1.198
Yerys, B.E. 3.191
Yildirim, M. 2.189
Yin, H. 3.340
Ying, Z. 2.006
Yiu, C.H. 3.148
Yogarajah, M. 2.106
Yokoi, S. 2.132
Yokota, H. 3.059, 3.227
Yokota, T. 2.066
Yoong, M. 1.372, C.08
Yoshimine, T. 2.317
Yoshor, D. 1.053
Youatt, E. 2.017
Yu, F. 3.338
Yu, H. 3.148
Yu, J. 3.154
Yu, L. 1.150
Yuan, Z. 3.157, 3.172, 3.235
Yudovin, S. 1.194
Yuen, A.W. 2.240
Yum, M. 1.276, 3.012, 3.049
yun, Y. 1.090
Yung, I. 1.098, 2.042
Yuste, R.M. 3.072

Z

Zaatreh, M. 1.307, 2.314
Zaborowsky, A. 3.164
Zagardo, M. 3.187
Zak, M. 3.087
Zamarian, L. 1.160
Zambrelli, E. 1.357
Zamel, K. 2.188
Zangaladze, A. 2.320
Zaninoto, A.L. 1.232
Zarei Mahmoodabadi, S. 2.138
Zarkou, S. 2.332
Zaroff, C. 1.328, 1.334
Zarowski, M. 1.179, 1.091
Zaveri, H.P. 1.150
Zawadzki, L. 2.290
Zayachkivsky, A. 3.057
Zelleke, T. 2.284
Zelmann, R. 1.107, 1.121, 2.032, 2.033,
Zeng, L.H. 1.014
Zhang, B. 1.046
Zhang, F. 2.001
Zhang, G. 3.156
Zhang, H. 1.150, 3.221, 3.293, 3.342
Zhang, K. 1.023
Zhang, L. 3.352
Zhang, Q. 3.157, 3.172
Zhang, S. 3.139, 3.284
Zhang, W. 1.337, 3.058
Zhang, W.B. 3.222
Zhang, X. 3.211
Zhang, Y. 3.230
Zhao, J. 3.031
Zhao, M. 1.024
Zhou, C. 1.017, 1.025, 3.029
Zhou, F. 3.009, 3.013
Zhou, J. 3.157, 3.172, 3.235
Zhu, J. 1.292, 1.330
Zhu, M. 3.222
Ziburkus, J. 1.050
Zielinski, D. 3.097
Zijlmans, M. 1.077, 1.107, 2.063
Zimin, L.G. 2.321
Zimmerman, M.B. 3.238
Zimmerman, R.S. 1.212
Zimmermann, M. 2.107
Ziobro, J.M. 1.047
Zitron, I. 3.173
Zolkowska, D. 3.051
Zorzetto, D. 3.289
Zou, G. 3.325
Zsurka, G. 3.299
Zubera, A. 2.263
Zuberi, S.M. 1.156
Zummo, J. 2.153
Zurolo, E. 1.027

CAMELICE Authors

Alcantara-Gonzalez, D. 3.367
Alonso Vanegas, M. 3.376
Alonso, M. 3.386
Alvarez-Alamilla, J. 3.369
Arellano Montellano, E.I. 3.370
Arrazola-Cortez, E. 3.375
Avalos-Plata, R. 3.383
Avecilla-Ramírez, G. N. 3.382
Barragan Perez, E. 3.370, 3.377
Barrera-Reséndiz, J. E. 3.382
Berenguer-Sánchez, M.J. 3.371, 3.372, 3.376
Campos Villarreal, O. 3.376
Cejudo-Tejeda, M.A. 3.379
Chávez, L., 3.368
Colin-Ramírez, E. 3.384
Conde, R. 3.384
Corsi-Cabrera, M 3.369
Cuellar Herrera, M. 3.368
del Río, I. 3.369
Díaz-Torres, M.A. 3.373
Domínguez Herz, C.R. 3.374
Espinoza-López, D.A. 3.381
Estañol, B. 3.372, 3.376
Estañol-Vidal B. 3.371
Fernández-Aguilar, M. 3.373
Fernández-Bouzas, A. 3.382
Florán, B. 3.367
Garcia, B. 3.374
García, C. 3.374
García-Briseño, A. 3.383
García-Ramos G. 3.371, 3.372, 3.376
González Orizaga, I. M. 3.376
González-Fernández N. 3.379
González-Gómez, R. 3.375
Guevara-Guzmán R. 3.379
Gutiérrez-Manjarrez F.A. 3.371, 3.372, 3.376
Harmony, T. 3.382
Hernandez Hernandez, M. 3.377
Herrera-Mora, P. 3.383
Jiménez-Domínguez, E.O. 3.381
Juárez-Martínez, E. 3.375
Maldonado-Torres, G. 3.375
Marcos Ortega, J. 3.380
María Núñez, J. 3.380
Marquez Chuquimia, C.S. 3.377
Martínez de la Escalera, D. 3.382
Martínez-Juárez, I.E. 3.373, 3.381
Mendez –Quintal C. 3.379
Montes De Oca, M. 3.380
Montes Lahuerta, C.A. 3.378
Morán-Molina, S. 3.373
Moreno-Araujo U.R. 3.379
Moreno-Avellán, A. 3.381
Nuche, A. 3.384
Nuche-Bricaire, A. 3.380
Núñez, J., 3.368, 3.384, 3.385
Nuñez-de la Vega, J.M. 3.379
Núñez-Orozco, L. 3.375
Orozco, S., 3.368, 3.386
Ortiz, R. 3.374
Paz, C. 3.374
Piquet-Uscanga, Y.O. 3.381
Plascencia-Alvarez, N. 3.375
Porras-Katz, E. 3.382
Ricardo-Garcell, J. 3.382
Rocha, L. 3.367, 3.368, 3.386
Ruiz-García, M. 3.383
Sandoval-Pacheco, R. 3.383
Sentíes-Madrid, H. 3.371, 3.372, 3.376
Severiano-Pérez P. 3.379
Soto Cabrera, E. 3.376
Soto, F. 3.374
Teyes, N. 3.374
Trejo, D. 3.380
Trejo-Martínez, D. 3.369, 3.384
Valencia- Solís, E. 3.382
Vazquez, D. 3.380, 3.385
Velasco, A. L. 3.368, 3.369, 3.379, 3.384, 3.385
Velasco, F. 3.368, 3.384, 3.385
Velasco-Monroy, A.L. 3.380
Villeda Hernandez, J. 3.386
Zavala Ferrer, F. 3.376

Leader Level

Special thanks to...

Pfizer Inc.

for supporting:

- ILAE Symposium
- PEC Symposium
- National EpiFellows Awards
- Exhibit

Leader Level

Special thanks to...

UCB, Inc.

for supporting:

- Hot Topics Symposium
- Merritt-Putnam Symposium
- Annual Course
- Itinerary Planner
- Program Book ads – 2
- President's Reception
- Nurse Awards
- Young Investigator Awards
- Scientific Exhibit
- Exhibit

ucb

THE EPILEPSY COMPANY™

Partner Level

Special thanks to...

GlaxoSmithKline

for supporting:

- The AES Annual Meeting
- Exhibit

Partner Level

Special thanks to...

Sunovion Pharmaceuticals Inc.

for supporting:

- AET Symposium
- Scientific Exhibit (All Day)
- Special Interest Group (2)
- Exhibit
- Lunch in Exhibit Hall (Saturday)

Supporter Level

Special thanks to...

Lundbeck

for supporting:

- Cyber Café in Exhibit Hall
- Scientific Exhibit
- Special Interest Group (2)
- Exhibit
- Product Training Pavilion

Supporter Level

Special thanks to...

Eisai Inc.

for supporting:

- Program Book Ad
- Merritt-Putnam Symposium
- Scientific Exhibit
- Exhibit

Contributor Level

Special thanks to...

Nihon Kohden America, Inc.

for supporting:

- Auction of Video EEG for Lennox and Lombroso/Spencer Research Trusts
- Exhibit

NIHON KOHDEN

Contributor Level

Special thanks to...

Medtronic, Inc.

for supporting:

- Junior Investigator Awards
- Scientific Exhibit

Medtronic
Alleviating Pain · Restoring Health · Extending Life

Contributor Level

Special thanks to...

Cyberonics, Inc.

for supporting:

- Plenary II Symposium
- Scientific Exhibit
- Exhibit

VNS THERAPY™ VAGUS NERVE STIMULATION

Contributor Level

Special thanks to...

Questcor Pharmaceuticals, Inc.

for supporting:

- Special Interest Group
- Scientific Exhibit
- Exhibit

QUESTCOR®

Advocate Level

Special thanks to...

Novartis Pharmaceuticals Corporation

for supporting:

- Product Training Pavilion
- Exhibit

NOVARTIS

Grass Technologies

for supporting:

- Auction of Video EEG for Lennox and Lombroso/Spencer Research Trusts
- Exhibit

GRASS TECHNOLOGIES
An Astro-Med, Inc. Subsidiary

Analyze Direct

for supporting:

- Exhibit

AnalyzeDirect
Visualization and Analysis Software

Care Fusion

for supporting:

- Exhibit

CareFusion

Compumedics Limited

for supporting:

- Exhibit

COMPUMEDICS
'Defining *Life's* Signals'

Elekta

for supporting:

- Exhibit

ELEKTA

Natus Medical

for supporting:

- Exhibit

natus

Supernus Pharmaceuticals, Inc.

for supporting:

- Cyber Café
- Coffee Break

Supernus® Pharmaceuticals

Patron Level

Special thanks to...

Optima Neuroscience

for supporting:

- Auction of EEG Review Software License IdentEvent™ for Lennox and Lombroso/Spencer Research Funds
- Exhibit

PMT Corporation

for supporting:

- Exhibit

Ad Tech Medical Instrument Corp.

for supporting:

- Exhibit

Blackrock Microsystems

for supporting:

- Exhibit

Cadwell Laboratories

for supporting:

- Exhibit

Epilepsy Foundation

for supporting:

- Exhibit

Electrical Geodesics, Inc.

for supporting:

- Exhibit

AES 64th Annual Meeting

The American Epilepsy Society (AES) is one of 98 Chapters of the International League Against Epilepsy (ILAE). The Annual Meeting of the American Epilepsy Society is the largest meeting and exhibition in the world of those who share the common scientific and clinical interests of epilepsy and clinical neurophysiology. Each year close to 4,000 attendees gather who are dedicated to improving the quality of life for those afflicted with epilepsy. This meeting is the top forum to examine common concerns and to gain insight from leading authorities.

Mission Statement

The American Epilepsy Society promotes research and education for professionals dedicated to the prevention, treatment and cure of epilepsy.

Target Audience

Basic / fundamentals: Those new to epilepsy treatment or whose background is limited, e.g. students, residents, general physicians, general neurologists and neurosurgeons, other professionals in epilepsy care, administrators.

Intermediate: Epilepsy fellows, epileptologists, epilepsy neurosurgeons, "mid-level" providers with experience in epilepsy care (e.g., advanced practice nurses, nurses, physician assistants), neuropsychologists, psychiatrists, basic and translational researchers.

Advanced: Symposium will address highly technical or complex topics (e.g., neurophysiology, advanced imaging techniques, advanced treatment modalities including surgery).

Policy on Commercial Support and Conflict of Interest

The American Epilepsy Society maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the AES provide in-depth presentations that are fair, balanced, independent and scientifically rigorous. All faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to the activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentations. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Faculty disclosure will be made available through syllabus materials and faculty presentations.

Disclosure of Unlabeled / Unapproved Uses

This educational program may include references to the use of products for indications not approved by the FDA. These discussions are noted on the faculty's disclosure forms as well as during their presentations. Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any other manufacturers of pharmaceuticals.

Abstracts

Abstracts from the 2010 Annual Meeting are available on the AES website.

Accreditation

The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to offer continuing medical education for physicians.

Insurance, Liabilities

The American Epilepsy Society cannot be held responsible for any personal injury, loss, damage, accident to private property or additional expenses incurred as a result of delays or changes in air, rail, sea, road, or other services, strikes, sickness, weather, acts of terrorism and any other cause. All participants are encouraged to make their own arrangements for health and travel insurance.

Credit Designation

Selected AES programs are approved for continuing education units (CEUs). Pharmacists will be required to complete evaluations for each program attended.

Physicians: The American Epilepsy Society designates this educational activity for a maximum of 34.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credits commensurate with the extent of their participation in the activity.

Nurses: Continuing education credit will be provided through physician CME credit. Some state nursing boards accept physician CMEs. For specific questions, contact your state board of nursing. Nursing CE credit is available for the Professionals in Epilepsy Care symposium and the Fundamentals Symposium. To successfully complete either program and receive 2.5 Nursing Contact Hours, please complete and return the paper evaluation form to the volunteers at the door or the main registration desk at the conclusion of the program. You will receive your CE certificate in exchange for a completed form.

Pharmacists: The University of Minnesota, College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

These knowledge-based activities provide up to 27.5 contact hours (2.75 CEUs). Following attendance, completion of the activity evaluation and verification of attendance, participants will be provided an electronic statement of credit.

International Credits: The American Medical Association has determined that non-U.S. licensed physicians who participate in this CME activity are eligible for *AMA PRA Category 1 Credit*™.

CME Certificates and Medical Education Evaluator®

The Medical Education Evaluator® allows attendees to self-manage the process of completing course evaluations, tracking credits and printing out the appropriate certificate for either *AMA PRA Category 1 Credits*™, CE or ACPE pharmacy statement of credits.

Log on to the Evaluator via the AES website. Once you are on the Evaluator, you will be asked to enter your AES ID # and password. The certificate(s) are saved to your personal account page which is cumulative. You may print the certificate(s) in PDF format at any time.

To help support this process, attendees who want CME will be asked to pay $35 before January 15 and $50 after January 15.

The online Evaluator will be left open through February 28, 2011, so you must complete the evaluations and credit tracking by that date.

By completing this information online, attendees greatly assist the Council on Education and Annual Meeting Committee with important needs assessment data whereby the AES can further plan and address educational gaps to meet the needs of our learners.

A meeting attendance certificate will be available for international meeting attendees at the registration desk.

Syllabus

Syllabi for the educational symposia are available on the AES website and are available to print. Paper handouts will not be provided.

Audience Response System

AES will be utilizing the Audience Response System (ARS) in the sessions noted below. A limited number of keypads will be available to attendees. Faculty members will have an ARS question as part of their presentation with a multiple-choice answer. The ARS will allow for interactive audience participation and well as real time, immediate feedback to enhance the learning environment and ensure that we are meeting the learning objectives set forth for each symposium.

Saturday, December 4	Presidential Symposium	1:45 p.m. - 4:15 p.m.
	Antiepileptic Therapy Symposium (AET)	5:30 p.m. - 7:15 p.m.
Sunday, December 5	Annual Course	8:45 a.m. - 5:15 p.m.
Monday, December 6	Merritt-Putnam Symposium	9:00 a.m.- Noon

Commercial Exhibits (page 69)

The Exhibit Hall is an integral part of the learning experience. Attendees will have an ideal opportunity to learn about the latest in pharmaceuticals, publications, scientific equipment, and technology relevant to the fields of epilepsy and neurophysiology. Please check the AES website for an updated listing of exhibiting companies and organizations. To ensure safety and security, no children, strollers, carriages, wheeled luggage or wheeled briefcases will be allowed in the Exhibit Hall during exhibit hours.

Saturday, December 4	11:30 a.m. - 6:00 p.m.
Sunday, December 5	11:00 a.m. - 6:00 p.m.
Monday, December 6	11:00 a.m. - 4:00 p.m.

Scientific Exhibits (page 22)

The American Epilepsy Society has adopted and approved guidelines for industry-sponsored scientific exhibits at the Annual Meeting. Scientific Exhibits differ from traditional poster presentations in that a broad range of material can be presented as a collection of topics, such as results of various clinical trials, or a thematic presentation of one aspect of drug development. Scientific Exhibits will be displayed on two days, Sunday, December 5 and Monday, December 6.

Cyber Café (page 14)

Convention Center – Hall A, Street Level

The Cyber Café will be available at the Convention Center during Exhibit Hall hours with e-mail and Internet access. You will also be able to complete the course evaluations and obtain your CME certificate online via the Cyber Café.

Language

The official language of the Annual Meeting is English. No simultaneous translation is available.

Photography and Recording of Programs

The American Epilepsy Society strictly prohibits all photography (flash, digital, or otherwise), audio and/or videotaping during the Annual Meeting. Equipment will be confiscated. Photographs taken during this meeting by the AES may be used in any of the Society's communications and materials in the furtherance of the organization's goals and purposes.

Press Room

Convention Center – Room 101B, Street Level

The American Epilepsy Society Press Room offers press releases, biographies, fact sheets, scientific abstracts, and other resources for journalists reporting on epilepsy study reports and educational presentations at this meeting. The AES staffs the on-site Press Room and works with journalists to develop stories, connect with experts and presenters, and research facts and information. Sponsors and exhibitors are encouraged to submit relevant press releases and media kits for on-site Press Room display and distribution. For more information, contact Peter Van Haverbeke at pvanhaverbeke@aesnet.org.

There will be a press briefing held on Monday, December 6 at 11:00 a.m.

In addition, there will be mini press briefings in the Press Room through out the meeting.

Friday, December 3	7:30 a.m. - 7:00 p.m.
Saturday, December 4	7:30 a.m. - 6:00 p.m.
Sunday, December 5	7:30 a.m. - 6:00 p.m.
Monday, December 6	7:30 a.m. - 6:00 p.m.
Tuesday, December 7	7:30 a.m. - 3:00 p.m.

Program Changes

AES can not assume liability for any changes in the program due to external or unforeseen circumstances.

Hotel Information

Early Departure Policy

Guests who check out of the hotel prior to their scheduled departure date will be charged a penalty of one night's room rate and tax.

San Antonio Marriott Rivercenter (Headquarters Hotel)
101 Bowie Street, San Antonio, Texas 78205
Telephone: 210.223.1000

San Antonio Marriott Riverwalk
889 East Market Street, San Antonio, Texas 78205
Telephone: 210.224.4555

Grand Hyatt San Antonio
600 East Market Street, San Antonio, Texas 78205
Telephone: 210.224.1234

Hilton Palacio Del Rio
200 South Alamo Street, San Antonio, Texas 78205
Telephone: 210.222.1400

La Quinta Inn Convention Center Hotel
303 Blum Street, San Antonio, TX 78205
Telephone: 210.222.9181

Meeting Location

Henry B. Gonzalez Convention Center
200 E. Market Street, San Antonio, TX 78205

Business Center – The UPS Store

A full-service business center is located on the Street Level of the Convention Center. For more information please call 210.258.8950 or e-mail: store4180@theupsstore.com.

No Smoking Policy

For the comfort and health of all attendees, smoking is not permitted at any AES functions. This includes educational sessions, meetings and all food functions. Both the Convention Center and Marriott are 100% smoke-free facilities.

Meeting Attire

AES promotes casual business attire for the duration of the Annual Meeting. Consider bringing a light jacket or sweater to Annual Meeting activities since meeting room temperatures and personal comfort levels vary.

Information for International Travelers

Consulates and Embassies

All international embassies from other countries to the United States are located in Washington, D.C. There are a number of international embassy branch offices, called consulates, located in Texas. If your country does not have a consulate in Texas, call directory information in Washington, D.C. (phone: 202.555.1212) for the number of your national embassy.

Gratuities

Gratuities are not automatically added to the bill, except in some cases for large groups. Waiters and waitresses are usually given 15% to 20% of the bill. Taxi drivers usually receive 15% of the fare and doormen, skycaps and porters are normally tipped $1 per bag.

Show Us Your Badge

Present your Annual Meeting badge at participating establishments while in San Antonio, including the airport, and receive a discount or free offer. Pick up a "Show Us Your Badge" booklet at registration for a complete listing of participating restaurants and nightlife establishments.

Registration & Security

The American Epilepsy Society is committed to providing a secure meeting environment. A formal security plan is in place with the Security Department at the Convention Center. All meeting attendees will be required to produce government-issued photo identification prior to receiving their badge and registration materials. Appropriate badges must be worn at all times while in attendance at the meeting and are required for admittance to all meeting activities. Special security procedures are also in place for exhibition materials and all deliveries to the AES meeting.

Safety and Security Information

First Aid Station

Outside Entrance to Ballroom A - AES Registration

The following security measures have been designed to further enhance your personal and professional safety.

- Pick up any Convention Center house phone located in the facility and dial 210.207.7773. In addition, there phones located throughout the facility that will connect you directly to the security department. Uniformed Convention Center employees have radios and are ready to assist you. Advise the dispatcher of the exact location within the Convention Center.

  We respectfully request that you do NOT call 911 directly.
- An EMT will be on duty in the Convention Center throughout the meeting.
- A government-issued photo identification is required to receive a badge and to replace a lost badge.
- Convention Center Security may randomly check packages and bags at the Convention Center entrances, meeting rooms and in the Exhibit Hall.
- You will be asked to always clearly display your name badge and to use only approved entrances and exits to the Convention Center.
- Appropriate badges will be required to enter all educational sessions, Poster Sessions, the Exhibit Hall and meetings. Due to safety and fire regulations, doors will be closed to all session rooms that fill to capacity.
- Throughout the meeting, you will notice a presence of security staff to monitor the safety of all participants.
- Do not leave unattended packages (i.e., briefcases, laptops, purses, etc.) in any area of the Convention Center or hotel.
- Please report any suspicious activity to security staff or to the AES registration desk staff.

General Safety Tips

- Remove your badge once you leave the meeting facilities.
- Carry important telephone numbers with you.
- Do not display or carry large amounts of cash.
- Walk in groups, especially at night.
- Lock your hotel room door.
- Always verify hotel room repair or service calls.
- Do not disclose your room number to anyone.
- Never give your personal information (credit card, room number, etc.) over the phone; instead, go to the front desk if the hotel calls with questions.

Contact Information

American Epilepsy Society
342 North Main Street
West Hartford, CT 06117-2507

Phone: 860.586.7505
Meeting Fax: 860.586.7550
E-mail: info@aesnet.org
Website: www.AESNET.org

Join AES

The American Epilepsy Society invites you to join one of the oldest neurological professional organizations in the United States. The AES seeks to promote interdisciplinary communications, scientific investigation, and exchange of clinical information about epilepsy. Members include clinicians, scientists, and other professionals interested in seizure disorders, representing both pediatric and adult aspects of epilepsy.

AES members receive benefits that include: discounted fees for subscriptions to scientific journals and discounted registration to the AES Annual Meeting; opportunities to apply for funding your research, participate in the Society through committee membership, and network with national and international colleagues.

Membership and Registration Rates – To qualify for member rates on-site:

Membership Renewal – Current members
Dues must have been renewed and paid in full by **Friday, October 29, 2010, 11:59 p.m. ET** to have qualified for the discounted member registration rate.

Membership Application – New members
Membership application, sponsor statement, and payment must have been received by **Friday, October 29, 2010, 11:59 p.m. ET** to have qualified for the discounted member registration rate.

Speaker Ready Room and Photos

Location: *Convention Center – Room 101A, Street Level*

Speakers need to have photos taken for repurposing of symposia on the AES website. All faculty PowerPoint presentations have already been uploaded through the AES Faculty Development Room. All speakers must stop by to reconfirm their presentation with an audio visual technician.

Friday, December 3 ..... 8:00 a.m. - 6:00 p.m.
Saturday, December 4 ..... 8:00 a.m. - 6:00 p.m.
Sunday, December 5 ..... 8:00 a.m. - 6:00 p.m.
Monday, December 6 ..... 8:00 a.m. - 6:00 p.m.
Tuesday, December 7 ..... 8:00 a.m. - 11:00 a.m.

3RD BIENNIAL NORTH AMERICAN REGIONAL EPILEPSY CONGRESS PARTICIPANTS

2011

AMERICAN EPILEPSY SOCIETY

65TH ANNUAL MEETING

BALTIMORE, MD

BALTIMORE CONVENTION CENTER

December 2 – 6, 2011

MEETING HIGHLIGHTS

- **CME Symposia and Lectures**
- **Platform Sessions**
- **Poster Sessions**
- **Commercial Exhibits**
- **Special Interest Group Meetings**

Future Annual Meeting Dates

2012
San Diego, CA
San Diego Convention Center
November 30 – December 4

2013
Washington, D.C.
Washington Convention Center
December 6 – 10

2014
Seattle, WA
Washington State Convention and Trade Center
December 5 – 9

2015
Philadelphia, PA
Pennsylvania Convention Center
December 4 – 8

2016
Houston, TX
George R. Brown Convention Center
December 2 – 6

THE EPILEPSY COMPANY™

COMMITTED to serving the needs of the epilepsy community

EpilepsyAdvocate™
Strength in numbers™

Epilepsy Advocate Program

epilepsy classroom™

Epilepsy Classroom

UCB FAMILY EPILEPSY SCHOLARSHIP PROGRAM™

UCB Family Epilepsy Scholarship Program

Canine Assistants

Canine Assistants Program

H.O.P.E. Mentoring Program™
Helping Other People with Epilepsy

H.O.P.E. Mentoring Program

Recognizing

SUZANNE BERRY

For 20 years of dedicated service at the American Epilepsy Society

THE EPILEPSY COMPANY™

EPILEPSY FOUNDATION®
Not another moment lost to seizures

Printed in U.S.A. KX1086-0910

PLEASE VISIT US AT BOOTH #301

Our commitment to ongoing research and patient support programs **STANDS STRONG.**

VIMPAT®

VIMPAT® (lacosamide) CV

tablets
injection
oral solution

Visit www.vimpat.com